

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
27 July 2006 (27.07.2006)

PCT

(10) International Publication Number
WO 2006/079068 A2

(51) International Patent Classification:
A61K 48/00 (2006.01)

(21) International Application Number:
PCT/US2006/002441

(22) International Filing Date: 20 January 2006 (20.01.2006)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/646,099 20 January 2005 (20.01.2005) US

(71) Applicant (for all designated States except US): UNIVER-
SITY OF ROCHESTER [US/US]; 601 ELMWOOD AV-
ENUE, Box Ott, Rochester, New York 14642 (US).

(72) Inventor; and

(75) Inventor/Applicant (for US only): KYRKANIDES,
Stephanos [US/US]; 625 Elmwood Ave., Rochester, New
York 14620 (US).

(74) Agents: HUIZENGA, David et al.; Needle & Rosenberg,
P.C., Suite 1000, 999 Peachtree Street, Atlanta, GA 30309-
3915 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,
GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,
KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV,
LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI,
NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG,
SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US,
UZ, VC, VN, YU, ZA, ZM, ZW.


(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM,
ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI,
FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT,
RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA,
GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— without international search report and to be republished
upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

(54) Title: COMPOSITIONS AND METHODS FOR STUDYING AND TREATING INFLAMMATORY DISEASES AND DIS-
ORDERS



(57) Abstract: Disclosed are compositions and methods that can be used in the treatment of diseases and disorders caused, exacer-
bated or otherwise affected by inflammation.

COMPOSITIONS AND METHODS FOR STUDYING AND TREATING INFLAMMATORY DISEASES AND DISORDERS

I. CROSS-REFERENCE TO RELATED APPLICATIONS

1. This application claims benefit of U.S. Provisional Application No. 60/646,099 filed January 20, 2005, which is hereby incorporated herein by reference in its entirety.

II. BACKGROUND

2. There are a number of diseases and disorders related to inflammation, as well as a number of pathways and molecules related to inflammation. Disclosed are methods of treating inflammatory disease using compositions and methods identified herein.

III. SUMMARY

3. In accordance with the purposes of this invention, as embodied and broadly described herein, this invention, in one aspect, relates to vector constructs that can be used to inhibit inflammation and treat subjects with inflammatory disease.

4. Disclosed are methods and compositions related to polypeptides, nucleic acids, vectors, cells, transgenic animals for the study and treatment of inflammatory diseases and disorders, and methods of making and using thereof.

IV. BRIEF DESCRIPTION OF THE DRAWINGS

5. The accompanying drawings, which are incorporated in and constitute a part of this specification, illustrate several embodiments and together with the description illustrate the disclosed compositions and methods.

6. Figure 1 shows IL-1 β^{XAT} – an excisionally activated transgene. IL-1 β^{XAT} is a bicistronic gene comprised of the cytomegalovirus promoter (CMV), followed by a “floxed” transcriptional termination cassette (►STOP►), the human IL-1 RA peptide secretion signal (ss) fused to the mature human IL-1 β ORF (ssIL-1 β), the reporter lacZ gene and the bovine growth hormone poly A mRNA tail (pA). An internal ribosomal entry signal facilitates translation and expression of the second ORF, lacZ, at approximately 45% of the first ORF.

7. Figure 2 shows Cre-mediated activation of the inducible IL-1 β^{XAT} transgene. The IL-1 β^{XAT} gene was transfected into the murine fibroblast NIH 3T3 cell line. Transient expression of Cre recombinase following co-transfection of the expression vector pRc/CMV-CreWT resulted in IL-1 β^{XAT} activation and higher levels of IL-1 β mRNA detected by RT-PCR, as well as lacZ expression assessed by X-gal histochemistry (10X). Control conditions included (a) plain NIH 3T3 cells, as well as (b) cells co-transfected with IL-1 β^{XAT} and (c) the pRc/CMV- backbone

vector, which displayed background levels of IL-1 β and lacZ expression presumably due to minimal spontaneous read-through from the strong CMV promoter.

8. Figure 3 shows CrePr induces loxP-directed IL-1 β^{XAT} excisional recombination and gene activation. The IL-1 β^{XAT} gene was transiently transfected into 293HGLVP/CrePr cells and the expression of IL-1 β and lacZ were evaluated following RU486 (10⁻⁷ M) administration. (A) Activation of Cre recombinase by RU486 resulted in up-regulation of both IL-1 β and lacZ mRNA as assessed by RT-PCR. For demonstration purposes, an IL-1 β standard curve (1 μ g -10⁻⁵ μ g) is included in this panel. (B) Concomitantly, significantly higher levels of secreted IL-1 β protein were found in the supernatant media of RU486-treated cells as assessed by ELISA for human IL-1 β . (C) The expression of the reporter gene β -galactosidase was also confirmed by Xgal histochemistry: naïve cells present only minimal levels of background staining, whereas addition of RU486 in the culture media resulted in significant increase in the number of X-gal positive cells. (D) IL-1 β^{XAT} excisional DNA recombination was confirmed by PCR of genomic DNA extracts from cells treated with plain growth media as well as media containing RU486 (10⁻⁷M) using a primer set (UP & LP) that flanked the ►STOP► sequence. PCR amplification of cells under plain media yielded a full-length product (~3Kb), indicative of a dormant IL-1 β^{XAT} state. In contrast, RU486-treated cells yielded a PCR product of 1Kb in size, indicative of DNA recombination and excision of the ►STOP► cassette.

9. Figure 4 shows IL-1 β^{XAT} activation results in expression of biologically potent IL-1 β cytokine. The biological potency of the transgene-derived IL-1 β cytokine was evaluated in vitro as follows. Murine fibroblasts were treated with conditioned media collected from cultured NIH 3T3 cells that had been previously transfected with Cre-induced IL-1 β^{XAT} as described in Figure 2 above (co-transfection with the pRc/CMV-creWT vector). COX-2 transcript levels were measured as previously described in the target cells (murine fibroblasts) and was employed as a measure of IL-1 β biological potency. Conditioned media were incubated with the neutralizing antibodies for 2 hours at 37°C prior to addition to target cells. (A) Conditioned medium collected from naïve NIH 3T3 cells (containing <3.9 pg/mL hIL-1 β as determined by ELISA) were placed on murine fibroblasts, which in turn showed low levels of murine COX-2 mRNA. Moreover, (B) conditioned medium from NIH 3T3 cells transfected with IL-1 β^{XAT} + pRc/CMV-backbone vector (contained <3.9 pg/mL hIL-1 β) also showed low levels of murine COX-2 mRNA. In contrast, (C) conditioned medium from IL-1 β^{XAT} + pRc/CMV- CreWT transfected NIH 3T3 cells (1 ng/mL hIL-1 β) significantly induced COX-2 mRNA in the target cells; (D) pre-incubation of the conditioned medium with a control rabbit IgG antibody (5 μ g/mL IgG1

isotype) had minimal effects on COX-2 regulation. However, (E) pre-incubation of the conditioned medium with a rabbit anti- hIL-1 β (5 μ g/mL IgG1) antibody attenuated the COX-2 induction. (F) Positive control: additional of human recombinant IL-1 β (1 ng/mL+ 5 μ g IgG1 isotype). (G) human recombinant IL-1 β pre-incubated with 5 μ g/mL neutralizing antibody. Results are shown as fold induction of COX-2 mRNA relative to group A. In conclusion, this experiment demonstrated that activation of the IL-1 β^{XAT} gene results in production of biologically potent IL-1 β and subsequently up-regulation of the inducible COX-2. (N=3). *p<0.05; S.E.M.

10. Figure 5 shows IL-1 β induces inflammation-related genes. The effects of IL-1 β were evaluated in vitro utilizing primary rat endothelial cell cultures as a representative rodent cell type. In this experiment, murine IL-1 β (10ng/mL) was administered to cultured primary cells, and subsequently examined for the regulation of several inflammation-related genes at the transcript level over the course of 72 hours. These molecules include (A) the inducible isoform of cyclooxygenase (COX-2), intercellular adhesion molecule-1 (ICAM-1) and monocyte chemoattractant protein-1 (MCP-1), as well as (B) the collagenase-A (MMP-2) and -B (MMP-9). Panel (C) depicts enzyme activity levels of MMP-2 and MMP-9 as evaluated by zymography.

11. Figure 6 shows Cre-mediated activation of the COLL1- IL1 β^{XAT} gene. The 3.6 Kb promoter of the A1 chain of pro-collagen I gene, which has been shown to target gene expression in bone and cartilage, drove the expression of the IL-1 β^{XAT} gene in NIH 3T3 stable cell line following transfection with the pRc/CMV-CreWT vector and infection with the HIV(Cre) virus. Panel (A) depicts transfection (+) of such a stable cell line with pRc/CMV-CreWT, leading to expression of human IL-1 β expression concomitantly with Cre recombinase as detected by RT-PCR. In contrast, untreated cells (-) were characterized by the absence of IL-1 β and Cre recombinase. Panel (B) depicts similar IL-1 β and Cre expression as assessed by RT-PCR following infection of the COLL1-IL1 β^{XAT} cell line with the HIV(Cre) virus. The presence of IL-1 β^{XAT} in the cells was confirmed by PCR as shown.

12. Figure 7 shows COLL1A1-IL-1 β^{XAT} transgenic mice. Two series of micro-injections yielded 3 strong candidate transgenic COLL1A1-IL-1 β^{XAT} mouse lines: #4, #11 and #12. This figure depicts PCR amplification of the transgene using a set of primers that also amplify the endogenous murine IL-1 β gene at low levels. Transgene transmission was examined in the offspring of #4, 11 and 12 transgenic founders. F2 mice were bilaterally injected with FIV(cre) into the knee joint and are being monitored weekly for changes in locomotive behavior and

mass. c=control; 4, 11, 12, 13, 14 = Transgenic mouse lines; + = PCR positive control; - = PCR primers control.

13. Figure 8 shows mRNA knockdown by siRNA. siRNA knockdown of mRNA's encoding genes of the Prostaglandin E2 inflammatory pathway. NIH3T3's were transfected under standard condition with 100-200 nM chemically synthesized siRNA species and total RNA was collected 60 hrs later. mRNA knockdown was determined using QRT-PCR. Western immunoblotting was used to demonstrate siRNA knockdown of cPGES, mPGES, COX-2, and COX-1 protein. NIH3T3 cells were transfected with 200 nM of chemically synthesized siRNA complementary to the cPGES, mPGES, COX-2, and COX-1, and total protein collected 60 hrs later. Samples were probed with an anti-mouse cPGES, mPGES, COX-2, and COX-1 antibody, respectively.

14. Figure 9 shows behavioral changes in Col1-IL1 β^{XAT} mice after injection of FIV(Cre) in the knees. A group of Col1-IL1 β^{XAT} transgenic mice (N=3) received a single intra-articular injection of 10^6 infectious particles of FIV(Cre) in the right and left knees at 2 months of age. In addition, a second group of mice (N=3) received saline injection and served as controls. During a session, each mouse was videotaped for 1 hour. The tape was then transferred digitally to a computer and analyzed in 20 periods of 3 minutes each. The duration of each mouse displaying grooming and licking was recorded and summed as seconds. The analysis of the behaviors was made by an investigator who was blind to the animal group assignment. Statistical analysis was performed by t-Test. Error bars = SEM. *= $P < 0.05$.

15. Figure 10 shows locomotive deterioration in Col1-IL1 β^{XAT} mice after injection of FIV(Cre) in the knees. Four groups of mice (N=3) were evaluated in terms of locomotive behavior by the rotarod appliance (Columbus Instruments, Columbus OH) and the lapse time until the mice fell off the rotating cylinder (20 rpm) was recorded. The mice were evaluated over a period of 8 weeks following the intra-articular injections (8 wks – 16 wks of age).

16. Figure 11 shows FIV(Cre) injection in the knee of Col1-IL1 β^{XAT} mice resulted in transgene induction. Immunocytochemical detection of the reporter gene β -galactosidase was employed to confirm the activation of the Col1-IL1 β^{XAT} transgene by FIV(Cre) in this mouse model using antibodies raised against β -galactosidase and Cre recombinase. (A) FITC-conjugated immuno-detection of β -galactosidase, (B) Texas Red-conjugated immunodetection of Cre recombinase, and (C) B/W image of the same microscopic field. (D) Overlap of panels A+B, and (E) overlap of panels A+B+C demonstrating co-expression of β -galactosidase and Cre

recombinase in vivo (solid arrows). All images were captured at a magnification of 20X.

“m”=meniscus; “a”=articular surface; “T”=intra-articular space.

17. Figure 12 shows arthritic changes in the knee joint of $\text{Col1-IL1}\beta^{\text{XAT}}$ mice following injection of FIV(Cre). (A) H&E staining of a knee section harvested from a 4 month old $\text{Col1-IL1}\beta^{\text{XAT}}$ transgenic mouse injected with FIV(Cre) revealed the formation of fibrillations (solid arrow) and of an articular lip (open arrow). In contrast, (B) a transgenic mouse that received the control vector FIV(GFP) did not develop such anatomic aberrations. (C) Alcian blue / orange semi-quantitative evaluation showed a decrease in cartilage and bone density in the $\text{Col1-IL1}\beta^{\text{XAT}}$ +FIV(Cre) knees compared to (D) controls. Moreover, increased cloning along with thickening of the articular surfaces was observed in the experimental animals (indicated by small arrows).

18. Figure 13 shows brain inflammation in $\text{Col1-IL1}\beta^{\text{XAT}}$ mice following injection of FIV(Cre) in the knee and TMJ. Eight weeks after FIV(Cre) injection in the knee and TMJ of $\text{Col1-IL1}\beta^{\text{XAT}}$ mice the brain was evaluated for activation of microglia and astrocytes by immunocytochemistry. (A) Using a monoclonal antibody raised against the MHC-class II antigen, the presence of activated microglia was detected in the brain. In contrast, control animals did not display any MHC-II positive cells. (C) Larger magnification of panel A. (B) There was lack of astrocyte activation in the brains of these animals as assessed by glial fibrillary acidic protein (GFAP). (D) Larger magnification of panel B.

19. Figure 14 shows arthritis-like changes in the TMJ of $\text{Col1-IL1}\beta^{\text{XAT}}$ mice after intra-articular injection of FIV(Cre). Eight weeks after FIV(Cre) injection in the TMJ of $\text{Col1-IL1}\beta^{\text{XAT}}$ mice anatomic aberrations of the joint were evaluated by semi-quantitative Alcian blue – orange G histochemistry. (A) TMJ section from an inactive $\text{Col1-IL1}\beta^{\text{XAT}}$ mouse depicting the condylar head as well as the meniscus. In comparison, (B) a TMJ section harvested from a $\text{Col1-IL1}\beta^{\text{XAT}}$ mouse injected with FIV(Cre) in the TMJ. (C) Larger magnification of the identified area of panel A. (D) Larger magnification of the identified area of panel B.

20. Figure 15 shows the inflammatory cascade and strategic targets in the cascade for gene and protein therapies. Figure 13, shows inhibition of $\text{IL-1}\beta$'s biologic activity by a neutralizing antibody. (A) Conditioned medium collected from naïve NIH 3T3 cells were placed on murine fibroblasts, which in turn showed low levels of murine COX-2 mRNA. (B) Conditioned medium from NIH 3T3 cells transfected with $\text{IL-1}\beta^{\text{XAT}}$ + pRc/CMV- backbone vector also showed low levels of murine COX-2 mRNA. In contrast, (C) conditioned medium from $\text{IL-1}\beta^{\text{XAT}}$ + pRc/CMV-CreWT transfected NIH 3T3 cells significantly induced COX-2

mRNA in the target cells; (D) preincubation of the conditioned medium with a control rabbit IgG antibody (5 ng/mL IgG1 isotype) had minimal effects on COX-2 regulation. However, (E) pre-incubation of the conditioned medium with a rabbit anti- IL1 β (5 ng/mL IgG1) antibody attenuated the COX-2 induction. (F) Positive control: addition of human recombinant IL-1 β (1 ng/mL+ 5 ng IgG1 isotype). (G) human recombinant IL-1 β pre-incubated with 5 ng/mL neutralizing antibody. Results are shown as fold induction of COX-2 mRNA relative to group A.

21. Figure 16 shows inhibition of IL-1 β 's biologic activity by a neutralizing antibody. (A) Conditioned medium collected from naïve NIH 3T3 cells were placed on murine fibroblasts, which in turn showed low levels of murine COX-2 mRNA. (B) Conditioned medium from NIH 3T3 cells transfected with IL-1 β^{XAT} + pRc/CMV- backbone vector also showed low levels of murine COX-2 mRNA. In contrast, (C) conditioned medium from IL-1 β^{XAT} + pRc/CMV-CreWT transfected NIH 3T3 cells significantly induced COX-2 mRNA in the target cells; (D) preincubation of the conditioned medium with a control rabbit IgG antibody (5 ng/mL IgG1 isotype) had minimal effects on COX-2 regulation. However, (E) pre-incubation of the conditioned medium with a rabbit anti- IL1 β (5 ng/mL IgG1) antibody attenuated the COX-2 induction. (F) Positive control: addition of human recombinant IL-1 β (1 ng/mL+ 5 ng IgG1 isotype). (G) human recombinant IL-1 β pre-incubated with 5 ng/mL neutralizing antibody. Results are shown as fold induction of COX-2 mRNA relative to group A.

22. Figure 17 shows FIV(IL1ra) successfully transduces cells with a gene expressing IL-1ra receptor antagonist. FIV(IL1ra) was constructed as depicted in panel A and confirmed by restriction enzyme analysis depicted in panel B. FIV(IL1ra) was then tested in vitro; IL1ra expression was evaluated in murine NIH 3T3 cells infected with this virus at the mRNA and protein levels. (C) RT-PCR analysis of infected cells demonstrated the expression of IL1ra mRNA. In contrast, naïve cells did not display any IL1ra expression. The housekeeping gene G3PDH was also employed. (D) IL1ra protein level in the media of infected cells was assessed by ELISA. Infection of cells by FIV(IL1ra) resulted in therapeutic IL1ra levels (>30 μ g/mL). In contrast, FIV(gfp) and naïve cells did not express IL1ra.

V. DETAILED DESCRIPTION

23. The disclosed method and compositions can be understood more readily by reference to the following detailed description of particular embodiments and the Example included therein and to the Figures and their previous and following description.

24. Before the present compounds, compositions, articles, devices, and/or methods are disclosed and described, it is to be understood that they are not limited to specific synthetic

methods or specific recombinant biotechnology methods unless otherwise specified, or to particular reagents unless otherwise specified, as such can, of course, vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only and is not intended to be limiting.

A. Definitions

25. As used in the specification and the appended claims, the singular forms "a," "an" and "the" include plural referents unless the context clearly dictates otherwise. Thus, for example, reference to "a pharmaceutical carrier" includes mixtures of two or more such carriers, and the like.

26. Ranges can be expressed herein as from "about" one particular value, and/or to "about" another particular value. When such a range is expressed, another embodiment includes from the one particular value and/or to the other particular value. Similarly, when values are expressed as approximations, by use of the antecedent "about," it will be understood that the particular value forms another embodiment. It will be further understood that the endpoints of each of the ranges are significant both in relation to the other endpoint, and independently of the other endpoint. It is also understood that there are a number of values disclosed herein, and that each value is also herein disclosed as "about" that particular value in addition to the value itself. For example, if the value "10" is disclosed, then "about 10" is also disclosed. It is also understood that when a value is disclosed that "less than or equal to" the value, "greater than or equal to the value" and possible ranges between values are also disclosed, as appropriately understood by the skilled artisan. For example, if the value "10" is disclosed the "less than or equal to 10" as well as "greater than or equal to 10" is also disclosed. It is also understood that throughout the application, data is provided in a number of different formats, and that this data, represents endpoints and starting points, and ranges for any combination of the data points. For example, if a particular data point "10" and a particular data point 15 are disclosed, it is understood that greater than, greater than or equal to, less than, less than or equal to, and equal to 10 and 15 are considered disclosed as well as between 10 and 15.

27. In this specification and in the claims which follow, reference will be made to a number of terms which shall be defined to have the following meanings:

28. "Optional" or "optionally" means that the subsequently described event or circumstance may or may not occur, and that the description includes instances where said event or circumstance occurs and instances where it does not.

29. "Primers" are a subset of probes which are capable of supporting some type of enzymatic manipulation and which can hybridize with a target nucleic acid such that the enzymatic manipulation can occur. A primer can be made from any combination of nucleotides or nucleotide derivatives or analogs available in the art which do not interfere with the enzymatic manipulation.

30. "Probes" are molecules capable of interacting with a target nucleic acid, typically in a sequence specific manner, for example through hybridization. The hybridization of nucleic acids is well understood in the art and discussed herein. Typically a probe can be made from any combination of nucleotides or nucleotide derivatives or analogs available in the art.

31. Throughout this application, various publications are referenced. The disclosures of these publications in their entireties are hereby incorporated by reference into this application in order to more fully describe the state of the art to which this pertains. The references disclosed are also individually and specifically incorporated by reference herein for the material contained in them that is discussed in the sentence in which the reference is relied upon.

B. Compositions and Methods

32. Disclosed are the components to be used to prepare the disclosed compositions as well as the compositions themselves to be used within the methods disclosed herein. These and other materials are disclosed herein, and it is understood that when combinations, subsets, interactions, groups, etc. of these materials are disclosed that while specific reference of each various individual and collective combinations and permutation of these compounds can not be explicitly disclosed, each is specifically contemplated and described herein. For example, if a particular vector is disclosed and discussed and a number of vector components including the promoters are discussed, each and every combination and permutation of promoters and other vector components and the modifications that are possible unless specifically indicated to the contrary. Thus, if a class of molecules A, B, and C are disclosed as well as a class of molecules D, E, and F and an example of a combination molecule, A-D is disclosed, then even if each is not individually recited each is individually and collectively contemplated meaning combinations, A-E, A-F, B-D, B-E, B-F, C-D, C-E, and C-F are considered disclosed. Likewise, any subset or combination of these is also disclosed. Thus, for example, the sub-group of A-E, B-F, and C-E would be considered disclosed. This concept applies to all aspects of this application including, but not limited to, steps in methods of making and using the disclosed compositions. Thus, if there are a variety of additional steps that can be performed it is understood that each of these

additional steps can be performed with any specific embodiment or combination of embodiments of the disclosed methods.

1. Inflammatory Disease

33. Provided herein are compositions, including polypeptides, nucleic acids, vectors, and cells, that can be used in the study and treatment of inflammatory diseases and disorders. Inflammation is a localized protective reaction of tissue to irritation, injury, or infection, characterized by pain, redness, swelling, and sometimes loss of function. As used herein, "inflammatory disorder" or "inflammatory disease" refers to any condition, disease or disorder wherein inflammation is involved, such as the sustained or chronic inflammation that occurs when tissues are injured by viruses, bacteria, trauma, chemicals, heat, cold or any other harmful stimulus. Irritation or discomfort can result from inflammation in a mammal due to, for example, skin inflammation, eye inflammation, gut inflammation or the like. Further, it is generally believed that chronic inflammation can increase the risk to develop other disease or ailment, such as osteoarthritis, autoimmune disease, cancer or the like.

34. In one aspect, the provided compositions and methods relate to the study and treatment of arthritis. Arthritis as a disease can include many different disorders and symptoms and can affect many parts of the body. Arthritis typically causes pain, loss of movement and sometimes swelling. Arthritis is actually a term used for a set of more than 100 current medical conditions. Arthritis is most commonly associated with older individuals, but can start as early as infancy. Some forms affect people in their young-adult years. A common aspect among arthritic conditions is that they affect the musculoskeletal system and specifically the joints - where two or more bones meet. Arthritis-related joint problems can include pain, stiffness, inflammation and damage to joint cartilage (the tough, smooth tissue that covers the ends of the bones, enabling them to glide against one another) and surrounding structures. Such damage can lead to joint weakness, instability and visible deformities depending on the location of joint involvement. Many of the arthritic conditions are systemic, in that they affect the whole body. In these diseases, arthritis can cause damage to virtually any bodily organ or system, including the heart, lungs, kidneys, blood vessels and skin.

35. Some different types of arthritis are Osteoarthritis, Rheumatoid arthritis, Gout, Ankylosing spondylitis, Juvenile arthritis, Systemic lupus erythematosus (lupus), Scleroderma, and Fibromyalgia. Osteoarthritis is a degenerative joint disease in which the cartilage that covers the ends of bones in the joint deteriorates, causing pain and loss of movement as bone begins to rub against bone. It is the most prevalent form of arthritis. Rheumatoid arthritis is an

autoimmune disease in which the joint lining becomes inflamed as part of the body's immune system activity. Rheumatoid arthritis is one of the most serious and disabling types, affecting mostly women. Gout affects mostly men. It is usually the result of a defect in body chemistry. This painful condition most often attacks small joints, especially the big toe. Fortunately, gout almost always can be completely controlled with medication and changes in diet. Ankylosing spondylitis is a type of arthritis that affects the spine. As a result of inflammation, the bones of the spine grow together. Juvenile arthritis is a general term for all types of arthritis that occur in children. Children can develop juvenile rheumatoid arthritis or childhood forms of lupus, ankylosing spondylitis or other types of arthritis. Systemic lupus erythematosus (lupus) is a disorder that can inflame and damage joints and other connective tissues throughout the body. Scleroderma is a disease of the body's connective tissue that causes a thickening and hardening of the skin. Fibromyalgia is a disorder in which widespread pain affects the muscles and attachments to the bone. It affects mostly women.

36. In another aspect, the provided compositions and methods relate to the study and treatment of neuroinflammation. Neuroinflammation, characterized by activated microglia and astrocytes and local expression of a wide range of inflammatory mediators, is a fundamental reaction to brain injury, whether by trauma, stroke, infection, or neurodegeneration. This local tissue response is surely part of a repair and restorative process. Yet, like many inflammatory conditions in peripheral diseases, neuroinflammation can contribute to the pathophysiology of CNS disorders. For example, in Alzheimer's disease (AD), glial-driven inflammatory responses to A β deposition are thought to promote neurodegeneration, as evidenced by the extent of neuroinflammation in AD, increased risk for AD with certain polymorphisms of proinflammatory cytokine genes, and reduction in disease risk for individuals taking nonsteroidal anti-inflammatory drugs (NSAIDs).

37. Considered herein is the use of the provided compositions and methods relate to the study and treatment of any inflammatory disease. Thus, the provided compositions and methods relate to the study and treatment of inflammatory bowel disease. The provided compositions and methods relate to the study and treatment of chronic dermatological disorders.

38. A particular advantage of the provided compositions and methods is the herein described ability to deliver inflammatory mediators, and the disclosed modulators thereof, to the brain by means of peripheral administration. For example, FIV vectors are disclosed herein that can deliver the herein disclosed nucleic acids to target sites within the subject. The disclosed FIV constructs can be delivered systemically by injection into the circulation or locally by injection

into the target site, such that either method of administration can result in the delivery of the nucleic acid to cells in the brain, such as, for example, microglia or astrocytes. The use of FIV vectors to deliver nucleic acids or transgenes to the brain following systemic administration is described in Patent Cooperation Treaty Application No. PCT/US03/13672 and U.S. Provisional Patent Application No. 10/781,142, which are herein incorporated by reference in their entirety as they related to this teaching. Thus, neural inflammatory disorders, as disclosed herein, can be treated through delivery of an inflammatory mediator, as discussed herein, via, for example, injection in the joint of the subject. In addition, inflammatory conditions related to bone and/or joints can be treated by injection into the joint or through system injection or IP injection as discussed herein.

2. Inflammatory mediator

39. Inflammatory diseases such as arthritis and neuroinflammation can be treated in part by inhibiting the expression or activity of an inflammatory mediator. An inflammatory mediator, as used herein, refers to a protein that modulates inflammation and includes, for example, cytokines (e.g., IL-1 β) prostaglandins (e.g., prostaglandin E₂ (PGE₂)), prostaglandin synthases (e.g., COX-1, COX-2, cPGES, and mPGES), and modulators thereof.

a) Interleukin-1

40. An example of an inflammatory mediator is interleukin-1 (IL-1). IL-1 is a potent immunomodulating cytokine that exists as two principal isoforms, IL-1 α and IL-1 β . These two molecules show significant divergence in sequence and have somewhat different roles with IL-1 α generally thought to be involved in direct cell:cell communication, whereas IL-1 β is secreted. Nevertheless, these two molecules act through the same membrane-associated receptor known as IL-1 receptor type 1 (IL-1R1) to promote a proinflammatory signaling cascade that includes the activation of NF κ B and MAP kinases [Rothwell, N.J. and G.N. Luheshi. Trends Neurosci. (2000) 23:618-625].

41. At least two molecules have been identified that antagonize the effects of IL-1. IL-1 receptor antagonist (IL-1ra) competes for receptor binding, and IL-1 receptor type 2 (IL-1R2), which lacks an intracellular domain, is thought to serve as a decoy receptor [Rothwell, N.J. and G.N. Luheshi. Trends Neurosci. (2000) 23:618-625]. Expression of each of these molecules is regulated. The contribution of IL-1 to an inflammatory response therefore depends on the relative balance of expression between these family members [Arend, W.P. Cytokine & Growth Factor Rev. (2002) 13:323-340]. In one example, the mature form of IL-1 β is attached to the

secretion signal from IL-1 α , which is the same sequence as the secretion signal sequence of IL-1 β .

42. Lavage and explant studies from normal and osteoarthritic cartilage support the contention that cytokines are up regulated in disease states. Specifically, Moos et al. [Moos V, et al. (1999) J Rheumatol 26:870-9] have demonstrated that cartilage from knee or hip joints in 10 patients with osteoarthritis (OA) compared to controls demonstrated cytokines, including IL-1 β that are up regulated in OA cartilage. Shin et al. [Shin S-j, et al. (2003) J Appl Physiol.; 95:308-13] examined the influence of mechanical stress on matrix turnover in the meniscus in the presence of IL-1 β to determine the role of nitric oxide (NO) in these processes. Stimulation of proteoglycan release in response to compression was dependent on NOS2 regardless of the presence of IL-1. These findings suggest that IL-1 can modulate the effects of mechanical stress on extracellular matrix turnover through a pathway that is dependent on NO. Joosten et al. [Joosten LA, et al (1999) J Immunol; 163:5049-55] have demonstrated that blocking of IL-1 is a cartilage and bone protective therapy in destructive arthritis, whereas the TNF-alpha antagonist has little effect on tissue destruction. Webb et al. [Webb GR, et al. (1998) Osteoarthritis & Cartilage 6:167-76] demonstrated that OA synovium supernatants contained higher concentrations of interleukin-1 beta (IL-1 β) and interleukin-6 (IL-6) than normal synovial supernatants and neutralizing antibodies to these cytokines either partially or totally abrogated the ability of the OA supernatants to increase chondrocyte p55 TNF-R expression. These results suggest that IL-1 and IL-6 produced by OA synovium contribute to the progression of the disease by rendering chondrocytes more susceptible to stimulation by catabolic cytokines. Smith et al. [Smith MD, et al. (1997) J Rheumatol 24:365-71] examined the production of IL-1 α , IL-1 β and TNF α in synovial membranes from patients with OA, irrespective of the degree of articular cartilage damage. They suggest that chronic inflammatory changes with production of proinflammatory cytokines are a feature of synovial membranes from patients with early OA, with the most severe changes seen in patients at the time of joint replacement surgery. This low grade synovitis results in the production of cytokines that can contribute to the pathogenesis of OA.

43. Although both isoforms of IL-1 are made in brain, most work has focused on the role of IL-1 β . Principally produced by microglia, IL-1 β is rapidly induced following CNS injury. IL-1 β affects many cellular targets, including astrocytes, neurons, and endothelial cells. In these cells, IL-1 up-regulates cytokines and chemokines, induces the expression of cell surface adhesion molecules and matrix metalloproteases, and stimulates cell proliferation [St Pierre, B.A., et al. Effects of cytokines on CNS cells: glia, in: (Ed.) Ransohoff, R.M., E.N. Beveniste,

Cytokines and the CNS, CRC Press, Boca Raton, (1996) pp. 151-168]. Moreover, it has been demonstrated that IL-1 β induces COX-2 in brain astrocytes, leading to production of the proinflammatory prostaglandin PGE₂ [O'Banion, M.K., *et al.* Neurochem. (1996) 66:2532-2540]. Taken together, the myriad effects of IL-1 on multiple brain cell types suggest a critical role for IL-1 family members in coordinating brain neuroinflammatory responses.

44. The profound influence of IL-1 on neuroinflammation and its ubiquitous expression in conditions ranging from frank brain trauma to neurodegenerative disease suggests that it might contribute to CNS injury [Rothwell, N.J. and G.N. Luheshi. Trends Neurosci. (2000) 23:618-625]. This appears to be the case. For example, IL-1 β is induced in experimental models of stroke [Minami, M., K. *et al.* J. Neurochem. (1992) 58:390-392] and infusion of IL-1 β exacerbates damage whereas treatment with IL-1ra or IL-1 blocking antibodies significantly attenuates tissue injury [Loddick, S.A. and N.J. Rothwell. J. Cereb. Blood Flow Metab. (1996) 16:932-940 and Yamasaki, Y., N. Matsuura, H. Shozuhara, H. Onodera, Y. Itoyama and K. Kogure. Stroke (1995) 26:676-681]. Similarly, ischemic injury is significantly attenuated in interleukin-1 converting enzyme deficient mice [Friedlander, R.M., *et al.* J. Exp. Med. (1997) 185:933-940]. As another example, GFAP directed expression of a human IL-1ra transgene attenuates edema, cytokine production and neurological deficits in a murine model of closed head injury [Tehrani, R., S. *et al.* J. Neurotrauma (2002) 19:939-951]. Finally, studies of penetrating brain injury in mice lacking the type 1 IL-1 receptor showed dramatic attenuation in microglial activation, leukocyte infiltration, and astrocyte activation [Basu, A., *et al.* J. Neurosci. (2002) 22:6071-6082]. Expression of numerous inflammatory mediators, including vascular cell adhesion molecule-1, several cytokines, and COX-2 was also greatly reduced in the IL-1R1 knockout mice, indicating that the IL-1 signaling pathway is essential for glial activation and the neuroinflammatory response. However, short-term infusion and viral delivery systems do not provide chronic stimuli and the genetic knockout systems are complicated by potential compensatory changes during development.

b) cyclooxygenase COX

45. Another example of an inflammatory mediator is the enzyme cyclooxygenase (COX). Cyclooxygenase is the principal target of non-steroidal anti-inflammatory drugs (NSAIDs), which are a mainstay of treatment for many inflammatory conditions. Cyclooxygenase catalyzes the first step in the conversion of arachidonic acid to prostanoids, a group of potent lipid mediators acting in diverse physiological processes.

46. Cyclooxygenase is known to exist in two isoforms: COX-1, which in many tissues appears to be constitutively expressed and responsible for homeostatic production of prostanoids, and COX-2, which is often referred to as the “inducible” isoform since its expression is rapidly modulated in response to diverse stimuli such as growth factors, cytokines, and hormones [O'Banion MK, et al. (1991). *J Biol Chem* 266: 23261-7; O'Banion MK, et al. (1992). *Proc Natl Acad Sci U.S.A.* 89:4888-92]. The distinction between these two COX isoforms, the roles they play, and the actions of prostanoids have been previously reviewed [Vane JR, et al. (1998). *Annu. Rev. Pharmacol. Toxicol.* 38:97-120; Smith, WL, et al. (2000). *Annu Rev Biochem* 69:145-82].

47. Interest in selectively inhibiting production of PGE₂, the principle inflammatory prostanoid, has been heightened by recognition of at least two PGE₂ synthase isoforms that are reportedly coupled to distinct COX isoforms. More specifically, a membrane-associated isoform (mPGES) is functionally coupled to COX-2, whereas a cytosolic enzyme (cPGES) appears to be linked to a COX-1-dependent production of PGE₂ (Tanioka et al. 2000; Murakami et al., 2000). Although cellular localization can play some role, functional coupling is largely a factor of expression patterns: as with COX-2, mPGES is dramatically upregulated by proinflammatory stimuli, whereas cPGES is constitutively expressed in cell systems examined to date (Jackobson et al., 1999; Stichtenoth et al., 2001; Han et al., 2002). In addition, COX-2 and mPGES are coordinately upregulated in a rat model of adjuvant arthritis (Mancini et al., 2001).

3. Inhibition

48. Provided herein are compositions that act to modulate an activity of an inflammatory mediator. “Activity,” as used herein, refers to any function or process of a composition disclosed herein and includes, for example, transcription, translation, post-translational modification, translocation, homophilic or heterophilic binding, secretion, endocytosis, or degradation. Disclosed therefore are compositions that inhibit one or more activities of an inflammatory mediator provided herein. These compositions are referred to herein as inflammatory mediator inhibitors. Inhibition or a form of inhibition, such as inhibit or inhibiting, as used herein means to restrain or limit. Reduce or a form of reduce, such as reducing or reduces, as used herein, means to diminish, for example in size or amount. It is understood that wherever one of inhibit or reduce is used, unless explicitly indicated otherwise, the other can also be used. For example, if something is referred to as “inhibited,” it is also considered referred to as “reduced.”

a) knockdown of gene expression

49. The activity of an inflammatory mediator can be modulated at the gene expression level. The disclosed inflammatory mediator inhibitor can be a gene expression inhibitor. Methods of targeting gene expression are generally based on the sequence of the gene to be targeted. Disclosed are any such methods that can be applied to the targeted knockdown of an inflammatory mediator. By "knockdown" is meant a decrease in detectable mRNA expression. Nucleic acids are generally used to knockdown gene expression and generally comprise a sequence capable of hybridizing to the target sequence, such as mRNA. Examples of such functional nucleic acids include antisense molecules, ribozymes, triplex forming nucleic acids, external guide sequences (EGS), and small interfering RNAs (siRNA).

50. Antisense molecules are designed to interact with a target nucleic acid molecules through either canonical or non-canonical base pairing. The interaction of the antisense molecule and the target molecule is designed to promote the destruction of the target molecule through, for example, RNaseH mediated RNA-DNA hybrid degradation. Alternatively the antisense molecule is designed to interrupt a processing function that normally would take place on the target molecule, such as transcription or replication. Antisense molecules can be designed based on the sequence of the target molecule. Numerous methods for optimization of antisense efficiency by finding the most accessible regions of the target molecule exist. Exemplary methods would be in vitro selection experiments and DNA modification studies using DMS and DEPC. It is preferred that antisense molecules bind the target molecule with a dissociation constant (k_d) less than or equal to 10^{-6} , 10^{-8} , 10^{-10} , or 10^{-12} . A representative sample of methods and techniques which aid in the design and use of antisense molecules can be found in the following non-limiting list of United States patents: 5,135,917, 5,294,533, 5,627,158, 5,641,754, 5,691,317, 5,780,607, 5,786,138, 5,849,903, 5,856,103, 5,919,772, 5,955,590, 5,990,088, 5,994,320, 5,998,602, 6,005,095, 6,007,995, 6,013,522, 6,017,898, 6,018,042, 6,025,198, 6,033,910, 6,040,296, 6,046,004, 6,046,319, and 6,057,437. However, the effect of iRNA or siRNA or their use is not limited to any type of mechanism.

51. Disclosed herein are any antisense molecules designed as described above based on the sequences for the herein disclosed inflammatory mediators. Examples of antisense sequences are disclosed herein for IL-1 α (SEQ ID NO:70), IL-1 β (SEQ ID NO:71), COX-1 (SEQ ID NO:72), COX-2 (SEQ ID NO:73), cPGES (SEQ ID NO:74), and mPGES (SEQ ID NO:75).

52. Ribozymes are nucleic acid molecules that are capable of catalyzing a chemical reaction, either intramolecularly or intermolecularly. Ribozymes are thus catalytic nucleic acid.

It is preferred that the ribozymes catalyze intermolecular reactions. There are a number of different types of ribozymes that catalyze nuclease or nucleic acid polymerase type reactions which are based on ribozymes found in natural systems, such as hammerhead ribozymes, (for example, but not limited to the following United States patents: 5,334,711, 5,436,330, 5,616,466, 5,633,133, 5,646,020, 5,652,094, 5,712,384, 5,770,715, 5,856,463, 5,861,288, 5,891,683, 5,891,684, 5,985,621, 5,989,908, 5,998,193, 5,998,203, WO 9858058 by Ludwig and Sproat, WO 9858057 by Ludwig and Sproat, and WO 9718312 by Ludwig and Sproat) hairpin ribozymes (for example, but not limited to the following United States patents: 5,631,115, 5,646,031, 5,683,902, 5,712,384, 5,856,188, 5,866,701, 5,869,339, and 6,022,962), and tetrahymena ribozymes (for example, but not limited to the following United States patents: 5,595,873 and 5,652,107). There are also a number of ribozymes that are not found in natural systems, but which have been engineered to catalyze specific reactions *de novo* (for example, but not limited to the following United States patents: 5,580,967, 5,688,670, 5,807,718, and 5,910,408). Preferred ribozymes cleave RNA or DNA substrates, and more preferably cleave RNA substrates. Ribozymes typically cleave nucleic acid substrates through recognition and binding of the target substrate with subsequent cleavage. This recognition is often based mostly on canonical or non-canonical base pair interactions. This property makes ribozymes particularly good candidates for target specific cleavage of nucleic acids because recognition of the target substrate is based on the target substrates sequence. Representative examples of how to make and use ribozymes to catalyze a variety of different reactions can be found in the following non-limiting list of United States patents: 5,646,042, 5,693,535, 5,731,295, 5,811,300, 5,837,855, 5,869,253, 5,877,021, 5,877,022, 5,972,699, 5,972,704, 5,989,906, and 6,017,756.

53. Disclosed herein are any ribozymes designed as described above based on the sequences for the herein disclosed inflammatory mediators. Hammerhead ribozymes can cleave RNA substrates at for example, a 5'-GUC-3' sequence, cleaving the mRNA immediately 3' to the GUC site. Engineered hammerhead ribozymes, which cleave at a different sequence are known and disclosed, for example, in the patents disclosed herein, and are incorporated by reference. A hammerhead ribozyme is typically composed of three parts. The first part is a region which will hybridize to the sequence 5' of the GUC recognition site, and can be called a first hybridization arm. A second part consists of a core catalytic domain of the hammerhead ribozyme, and typically has the sequence ^{3'}CAAAGCAGGAGUGCCUGAGUAGUC^{5'} (SEQ ID NO:82). Variations on this sequence are known and are herein disclosed and incorporated by reference, for example, in the patents disclosed herein. A third part consists of sequence capable

or hybridizing to the sequence immediately 3' to the GUC cleavage site, and can be called a second hybridization arm. The hybridization arms can be any length allowing binding to the substrate, such as, from 3-40 nucleotides long, 5-30 nucleotides long, 8-20, nucleotides long and 10-15 nucleotides long, as well as any length up to 50 nucleotides. As an example, hammerhead ribozymes can be designed by identifying a nucleic acid triplet GUC within the mRNA target sequence, and then identifying the appropriate hybridizing arms as discussed herein to the catalytic core as discussed herein. Examples of hammerhead ribozyme sequences are disclosed herein for IL-1 α (SEQ ID NO:76), IL-1 β (SEQ ID NO:77), COX-1 (SEQ ID NO:78), COX-2 (SEQ ID NO:79), cPGES (SEQ ID NO:81), and mPGES (SEQ ID NO:80), but it is understood that others are also disclosed as discussed herein. Furthermore, using assays as discussed herein, one can test a given ribozyme (or any functional nucleic acid, such as an siRNA or antisense) for its level of activity, both in vitro and in vivo.

54. Triplex forming functional nucleic acid molecules are molecules that can interact with either double-stranded or single-stranded nucleic acid. When triplex molecules interact with a target region, a structure called a triplex is formed, in which there are three strands of DNA forming a complex dependant on both Watson-Crick and Hoogsteen base-pairing. Triplex molecules are preferred because they can bind target regions with high affinity and specificity. It is preferred that the triplex forming molecules bind the target molecule with a k_d less than 10^{-6} , 10^{-8} , 10^{-10} , or 10^{-12} . Representative examples of how to make and use triplex forming molecules to bind a variety of different target molecules can be found in the following non-limiting list of United States patents: 5,176,996, 5,645,985, 5,650,316, 5,683,874, 5,693,773, 5,834,185, 5,869,246, 5,874,566, and 5,962,426.

55. External guide sequences (EGSs) are molecules that bind a target nucleic acid molecule forming a complex, and this complex is recognized by RNase P, which cleaves the target molecule. EGSs can be designed to specifically target a RNA molecule of choice. RNase P aids in processing transfer RNA (tRNA) within a cell. Bacterial RNase P can be recruited to cleave virtually any RNA sequence by using an EGS that causes the target RNA:EGS complex to mimic the natural tRNA substrate. (WO 92/03566 by Yale, and Forster and Altman, Science 238:407-409 (1990)). Similarly, eukaryotic EGS/RNase P-directed cleavage of RNA can be utilized to cleave desired targets within eukaryotic cells. (Yuan et al., Proc. Natl. Acad. Sci. USA 89:8006-8010 (1992); WO 93/22434 by Yale; WO 95/24489 by Yale; Yuan and Altman, EMBO J 14:159-168 (1995), and Carrara et al., Proc. Natl. Acad. Sci. (USA) 92:2627-2631 (1995)). Representative examples of how to make and use EGS molecules to facilitate cleavage of a

variety of different target molecules are found in the following non-limiting list of United States patents: 5,168,053, 5,624,824, 5,683,873, 5,728,521, 5,869,248, and 5,877,162.

56. Gene expression can also be effectively silenced in a highly specific manner through RNA interference (RNAi). This silencing was originally observed with the addition of double stranded RNA (dsRNA) (Fire, A., et al. (1998) *Nature*, 391, 806-811) (Napoli, C., et al. (1990) *Plant Cell* 2, 279-289) (Hannon, G.J. (2002) *Nature*, 418, 244-251). Once dsRNA enters a cell, it is cleaved by an RNase III-like enzyme, Dicer, into double stranded small interfering RNAs (siRNA) 21-23 nucleotides in length that contains 2 nucleotide overhangs on the 3' ends (Elbashir, S.M., et al. (2001) *Genes Dev.*, 15:188-200) (Bernstein, E., et al. (2001) *Nature*, 409, 363-366) (Hammond, S.M., et al. (2000) *Nature*, 404:293-296). In an ATP dependent step, the siRNAs become integrated into a multi-subunit protein complex, commonly known as the RNAi induced silencing complex (RISC), which guides the siRNAs to the target RNA sequence (Nykanen, A., et al. (2001) *Cell*, 107:309-321). At some point the siRNA duplex unwinds, and it appears that the antisense strand remains bound to RISC and directs degradation of the complementary mRNA sequence by a combination of endo and exonucleases (Martinez, J., et al. (2002) *Cell*, 110:563-574). However, the effect of iRNA or siRNA or their use is not limited to anytype of mechanism.

57. Short Interfering RNA (siRNA) is a double-stranded RNA that can induce sequence-specific post-transcriptional gene silencing, thereby decreasing or even inhibiting gene expression. In one example, an siRNA triggers the specific degradation of homologous RNA molecules, such as mRNAs, within the region of sequence identity between both the siRNA and the target RNA. For example, WO 02/44321 discloses siRNAs capable of sequence-specific degradation of target mRNAs when base-paired with 3' overhanging ends, herein incorporated by reference for the method of making these siRNAs. Sequence specific gene silencing can be achieved in mammalian cells using synthetic, short double-stranded RNAs that mimic the siRNAs produced by the enzyme dicer (Elbashir, S.M., et al. (2001) *Nature*, 411:494-498) (Ui-Tei, K., et al. (2000) *FEBS Lett* 479:79-82). siRNA can be chemically or *in vitro*-synthesized or can be the result of short double-stranded hairpin-like RNAs (shRNAs) that are processed into siRNAs inside the cell. Synthetic siRNAs are generally designed using algorithms and a conventional DNA/RNA synthesizer. Suppliers include Ambion (Austin, Texas), ChemGenes (Ashland, Massachusetts), Dharmacon (Lafayette, Colorado), Glen Research (Sterling, Virginia), MWB Biotech (Eschersberg, Germany), Prologix (Boulder, Colorado), and Qiagen (Ventspils, The Netherlands). siRNA can also be synthesized *in vitro* using kits such as Ambion's *SILENCER*

siRNA CONSTRUCTION KIT. Disclosed herein are any siRNA designed as described above based on the sequences for the herein disclosed inflammatory mediators. Examples of siRNA include: COX-1 (SEQ ID NOs:47-52), COX-2 (SEQ ID NOs:53-58), cPGES (SEQ ID NOs:41-46), and mPGES (SEQ ID NO:59).

58. The production of siRNA from a vector is more commonly done through the transcription of a shRNA. Kits for the production of vectors comprising shRNA are available, such as for example Imgenex's GeneSuppressor Construction Kits and Invitrogen's BLOCK-iT inducible RNAi plasmid and lentivirus vectors. Disclosed herein are any shRNA designed as described above based on the sequences for the herein disclosed inflammatory mediators. Examples of shRNA primer sequences are disclosed for COX-1 (SEQ ID NOs:64-65), COX-2 (SEQ ID NOs:66-67), cPGES (SEQ ID NOs:60-61), and mPGES (SEQ ID NO:62-63).

b) Inhibition of Binding

59. Another activity of an inflammatory mediator that can be targeted is homophilic and heterophilic binding to other molecules, such as, for example, receptors. Thus, the inflammatory mediator inhibitor can be a ligand binding inhibitor. Methods for inhibiting the binding of a protein to its receptor can, for example, be based on the use of molecules that compete for the binding site of either the ligand or the receptor.

60. Thus, a ligand binding inhibitor can be, for example, a polypeptide that competes for the binding of a receptor without activating the receptor. Likewise, a ligand binding inhibitor can be a decoy receptor that competes for the binding of ligand. Such a decoy receptor can be a soluble receptor (e.g., lacking transmembrane domain) or it can be a mutant receptor expressed in a cell but lacking the ability to transduce a signal (e.g., lacking cytoplasmic tail). Antibodies specific for either a ligand or a receptor can also be used to inhibit binding. The ligand binding inhibitor can also be naturally produced by a subject. Alternatively, the inhibitory molecule can be designed based on targeted mutations of either the receptor or the ligand.

61. Thus, as an illustrative example, the ligand binding inhibitor can be IL-1 receptor antagonist (IL-1ra). The ligand binding inhibitor can also be a polypeptide comprising a fragment of IL-1ra, wherein the fragment is capable of binding IL-1R1. ligand binding inhibitor can further be IL-1R2, which is a soluble form of the receptor that can compete for IL-1 binding. The ligand binding inhibitor can further be a polypeptide comprising a fragment of IL-1R1. The IL-1R1 fragment can lack the cytoplasmic tail, which includes the Toll/interleukin-1(IL-1) receptor (TIR) domain (amino acids 384-528 of SEQ ID NO:8). The fragment of IL-1R1 can lack the amino acids corresponding to the transmembrane domain.

4. Antibodies

Antibodies specific for inflammatory mediators or their receptors can be used herein. For example, disclosed for use in the provided compositions and methods are neutralizing antibodies specific for IL-1 β or IL-1 receptor, or nucleic acids encoding said antibodies.

(1) Antibodies Generally

The term "antibodies" is used herein in a broad sense and includes both polyclonal and monoclonal antibodies. In addition to intact immunoglobulin molecules, also included in the term "antibodies" are fragments or polymers of those immunoglobulin molecules, and human or humanized versions of immunoglobulin molecules or fragments thereof, as long as they are chosen for their ability to interact with inflammatory mediators or their receptors such that inflammatory mediators is inhibited from interacting with its receptor. The antibodies can be tested for their desired activity using the *in vitro* assays described herein, or by analogous methods, after which their *in vivo* therapeutic and/or prophylactic activities are tested according to known clinical testing methods.

The term "monoclonal antibody" as used herein refers to an antibody obtained from a substantially homogeneous population of antibodies, i.e., the individual antibodies within the population are identical except for possible naturally occurring mutations that may be present in a small subset of the antibody molecules. The monoclonal antibodies herein specifically include "chimeric" antibodies in which a portion of the heavy and/or light chain is identical with or homologous to corresponding sequences in antibodies derived from a particular species or belonging to a particular antibody class or subclass, while the remainder of the chain(s) is identical with or homologous to corresponding sequences in antibodies derived from another species or belonging to another antibody class or subclass, as well as fragments of such antibodies, as long as they exhibit the desired antagonistic activity (See, U.S. Pat. No. 4,816,567 and Morrison et al., Proc. Natl. Acad. Sci. USA, 81:6851-6855 (1984)).

The disclosed monoclonal antibodies can be made using any procedure which produces mono clonal antibodies. For example, disclosed monoclonal antibodies can be prepared using hybridoma methods, such as those described by Kohler and Milstein, Nature, 256:495 (1975). In a hybridoma method, a mouse or other appropriate host animal is typically immunized with an immunizing agent to elicit lymphocytes that produce or are capable of producing antibodies that will specifically bind to the immunizing agent. Alternatively, the lymphocytes may be immunized in vitro, e.g., using the HIV Env-CD4-co-receptor complexes described herein.

The monoclonal antibodies may also be made by recombinant DNA methods, such as those described in U.S. Pat. No. 4,816,567 (Cabilly et al.). DNA encoding the disclosed monoclonal antibodies can be readily isolated and sequenced using conventional procedures (e.g., by using oligonucleotide probes that are capable of binding specifically to genes encoding the heavy and light chains of murine antibodies). Libraries of antibodies or active antibody fragments can also be generated and screened using phage display techniques, e.g., as described in U.S. Patent No. 5,804,440 to Burton et al. and U.S. Patent No. 6,096,441 to Barbas et al.

In vitro methods are also suitable for preparing monovalent antibodies. Digestion of antibodies to produce fragments thereof, particularly, Fab fragments, can be accomplished using routine techniques known in the art. For instance, digestion can be performed using papain. Examples of papain digestion are described in WO 94/29348 published Dec. 22, 1994 and U.S. Pat. No. 4,342,566. Papain digestion of antibodies typically produces two identical antigen binding fragments, called Fab fragments, each with a single antigen binding site, and a residual Fc fragment. Pepsin treatment yields a fragment that has two antigen combining sites and is still capable of cross-linking antigen.

The fragments, whether attached to other sequences or not, can also include insertions, deletions, substitutions, or other selected modifications of particular regions or specific amino acids residues, provided the activity of the antibody or antibody fragment is not significantly altered or impaired compared to the non-modified antibody or antibody fragment. These modifications can provide for some additional property, such as to remove/add amino acids capable of disulfide bonding, to increase its bio-longevity, to alter its secretory characteristics, etc. In any case, the antibody or antibody fragment must possess a bioactive property, such as specific binding to its cognate antigen. Functional or active regions of the antibody or antibody fragment may be identified by mutagenesis of a specific region of the protein, followed by expression and testing of the expressed polypeptide. Such methods are readily apparent to a skilled practitioner in the art and can include site-specific mutagenesis of the nucleic acid encoding the antibody or antibody fragment. (Zoller, M.J. Curr. Opin. Biotechnol. 3:348-354, 1992).

As used herein, the term "antibody" or "antibodies" can also refer to a human antibody and/or a humanized antibody. Many non-human antibodies (e.g., those derived from mice, rats, or rabbits) are naturally antigenic in humans, and thus can give rise to undesirable immune responses when administered to humans. Therefore, the use of human or humanized antibodies

in the methods serves to lessen the chance that an antibody administered to a human will evoke an undesirable immune response.

(2) Human antibodies

The disclosed human antibodies can be prepared using any technique. Examples of techniques for human monoclonal antibody production include those described by Cole et al. (*Monoclonal Antibodies and Cancer Therapy*, Alan R. Liss, p. 77, 1985) and by Boerner et al. (*J. Immunol.*, 147(1):86-95, 1991). Human antibodies (and fragments thereof) can also be produced using phage display libraries (Hoogenboom et al., *J. Mol. Biol.*, 227:381, 1991; Marks et al., *J. Mol. Biol.*, 222:581, 1991).

The disclosed human antibodies can also be obtained from transgenic animals. For example, transgenic, mutant mice that are capable of producing a full repertoire of human antibodies, in response to immunization, have been described (see, e.g., Jakobovits et al., *Proc. Natl. Acad. Sci. USA*, 90:2551-255 (1993); Jakobovits et al., *Nature*, 362:255-258 (1993); Bruggermann et al., *Year in Immunol.*, 7:33 (1993)). Specifically, the homozygous deletion of the antibody heavy chain joining region (J(H)) gene in these chimeric and germ-line mutant mice results in complete inhibition of endogenous antibody production, and the successful transfer of the human germ-line antibody gene array into such germ-line mutant mice results in the production of human antibodies upon antigen challenge. Antibodies having the desired activity are selected using Env-CD4-co-receptor complexes as described herein.

(3) Humanized antibodies

Antibody humanization techniques generally involve the use of recombinant DNA technology to manipulate the DNA sequence encoding one or more polypeptide chains of an antibody molecule. Accordingly, a humanized form of a non-human antibody (or a fragment thereof) is a chimeric antibody or antibody chain (or a fragment thereof, such as an Fv, Fab, Fab', or other antigen-binding portion of an antibody) which contains a portion of an antigen binding site from a non-human (donor) antibody integrated into the framework of a human (recipient) antibody.

To generate a humanized antibody, residues from one or more complementarity determining regions (CDRs) of a recipient (human) antibody molecule are replaced by residues from one or more CDRs of a donor (non-human) antibody molecule that is known to have desired antigen binding characteristics (e.g., a certain level of specificity and affinity for the target antigen). In some instances, Fv framework (FR) residues of the human antibody are replaced by corresponding non-human residues. Humanized antibodies may also contain

residues which are found neither in the recipient antibody nor in the imported CDR or framework sequences. Generally, a humanized antibody has one or more amino acid residues introduced into it from a source which is non-human. In practice, humanized antibodies are typically human antibodies in which some CDR residues and possibly some FR residues are substituted by residues from analogous sites in rodent antibodies. Humanized antibodies generally contain at least a portion of an antibody constant region (Fc), typically that of a human antibody (Jones et al., *Nature*, 321:522-525 (1986), Reichmann et al., *Nature*, 332:323-327 (1988), and Presta, *Curr. Opin. Struct. Biol.*, 2:593-596 (1992)).

Methods for humanizing non-human antibodies are well known in the art. For example, humanized antibodies can be generated according to the methods of Winter and co-workers (Jones et al., *Nature*, 321:522-525 (1986), Riechmann et al., *Nature*, 332:323-327 (1988), Verhoeven et al., *Science*, 239:1534-1536 (1988)), by substituting rodent CDRs or CDR sequences for the corresponding sequences of a human antibody. Methods that can be used to produce humanized antibodies are also described in U.S. Patent No. 4,816,567 (Cabilly et al.), U.S. Patent No. 5,565,332 (Hoogenboom et al.), U.S. Patent No. 5,721,367 (Kay et al.), U.S. Patent No. 5,837,243 (Deo et al.), U.S. Patent No. 5,939,598 (Kucherlapati et al.), U.S. Patent No. 6,130,364 (Jakobovits et al.), and U.S. Patent No. 6,180,377 (Morgan et al.).

(4) Administration of antibodies

Administration of the antibodies can be done as disclosed herein. Nucleic acid approaches for antibody delivery also exist. The broadly neutralizing anti xxx antibodies and antibody fragments can also be administered to patients or subjects as a nucleic acid preparation (e.g., DNA or RNA) that encodes the antibody or antibody fragment, such that the patient's or subject's own cells take up the nucleic acid and produce and secrete the encoded antibody or antibody fragment. The delivery of the nucleic acid can be by any means, as disclosed herein, for example.

C. Compositions

62. Disclosed herein are constructs capable of inhibiting an activity of an inflammatory mediator. In one aspect, the constructs are vectors comprising a nucleic acid, wherein the nucleic acid encodes for the inhibitor. The nucleic acids of the constructs can be based on the sequence of an inflammatory mediator.

1. Inflammatory Mediators – Sequences

63. The disclosed constructs can comprise a nucleic acid based on the sequence of IL-1 alpha. The nucleic acid sequence can be based on the sequence of human IL-1 alpha. An

example of a nucleic acid encoding human IL-1 alpha is SEQ ID NO:1, Accession No. NM_000575.

64. The disclosed constructs can comprise a nucleic acid based on the sequence of IL-1 beta. The nucleic acid sequence can based on the sequence of human IL-1 beta. An example of a nucleic acid encoding human IL-1 beta is SEQ ID NO:2, Accession No. NM_000576.

65. The disclosed constructs can comprise a nucleic acid based on the sequence of IL-1ra. The nucleic acid sequence can based on the sequence of human IL-1ra. An example of a nucleic acid encoding human IL-1ra is SEQ ID NO:5, Accession No. NM_173842.

66. The disclosed constructs can comprise a nucleic acid based on the sequence of IL-1R1. The nucleic acid sequence can based on the sequence of human IL-1RA. An example of a nucleic acid encoding human IL-1R1 is SEQ ID NO:8, Accession No. NM_000877.

67. The disclosed constructs can comprise a nucleic acid based on the sequence of IL-1R2. The nucleic acid sequence can based on the sequence of human IL-1R2. An example of a nucleic acid encoding human IL-1R2 is SEQ ID NO:9, Accession No. NM_173343.

68. The disclosed constructs can comprise a nucleic acid based on the sequence of COX-1. The nucleic acid sequence can based on the sequence of human COX-1. An example of a nucleic acid encoding human COX-1 is SEQ ID NO:10, Accession No. M59979.

69. The disclosed constructs can comprise a nucleic acid based on the sequence of COX-2. The nucleic acid sequence can based on the sequence of human COX-2. An example of a nucleic acid encoding human COX-2 (SEQ ID NO:11, Accession No. NM_000963).

70. The disclosed constructs can comprise a nucleic acid based on the sequence of mPGES. The nucleic acid sequence can based on the sequence of human mPGES. An example of a nucleic acid encoding human mPGES is SEQ ID NO:12, Accession No. NM_004878.

71. The disclosed constructs can comprise a nucleic acid based on the sequence of cPGES. The nucleic acid sequence can based on the sequence of human cPGES/p23. An example of a nucleic acid encoding human cPGES/p23 is SEQ ID NO:13, Accession No. L24804.

72. Disclosed herein is a functional nucleic acid wherein the nucleic acid can inhibit the expression of a mediator of inflammation. Also disclosed herein is a construct comprising a nucleic acid encoding the functional nucleic acid operably linked to an expression control sequence. The functional nucleic acid can comprise an siRNA. The siRNA can be derived from the nucleic acid sequence for COX-1 (SEQ ID NO:10). Thus, the siRNA can have the nucleic acid sequence SEQ ID NO:47, 48, 49, 50, 51, or 52. The siRNA can be derived from the nucleic

acid sequence for COX-2 (SEQ ID NO:11). Thus, the siRNA can have the nucleic acid sequence SEQ ID NO:53, 54, 555, 56, 57, or 58. The siRNA can be derived from the nucleic acid sequence for mPGES (SEQ ID NO:12). Thus, the siRNA can have the nucleic acid sequence SEQ ID NO:59. The siRNA can be derived from the nucleic acid sequence for cPGES (SEQ ID NO:13). Thus, the siRNA can have the nucleic acid sequence SEQ ID NO:41,,42, 43, 44, 45, or 46.

73. Disclosed herein is a construct comprising a nucleic acid encoding a polypeptide operably linked to an expression control sequence, wherein the polypeptide can inhibit the binding of IL-1 to IL-1R1. The polypeptide can comprise IL-1ra. The polypeptide can have the amino acid sequence SEQ ID NO:38. The polypeptide can comprise a fragment of IL-1ra. The polypeptide can have at least 70%, 75%, 80%, 85%, 90%, 95% identity to the amino acid sequence SEQ ID NO:38. The nucleic acid can comprise the sequence SEQ ID NO:5. The nucleic acid encode a polypeptide that with at least 70%, 75%, 80%, 85%, 90%, 95% identity to the nucleic acid sequence SEQ ID NO:5. Also disclosed are nucleic acids that can hybridize under stringent conditions, or other conditions, as described herein, with the nucleic acid sequence SEQ ID NO:5.

74. The polypeptide can comprise a fragment of IL-1R1, wherein the fragment is capable of binding IL-1 and wherein the fragment has a reduced ability to activate a signal cascade. It is understood that one skilled in the art can readily determine the ability of a polypeptide to bind IL-1 or activate a signal cascade using standard biochemical and molecular genetics techniques and reagents. As an example, the fragment can be a truncation lacking the transmembrane domain. Wherein the transmembrane domain has not been identified, it is understood that one skilled in the art can estimate the approximate location of this domain based on the amino acid sequence using, for example, hydrophobicity plots. As another example, the fragment can lack part of the cytoplasmic tail, which includes the Toll/interleukin-1(IL-1) receptor (TIR) domain (amino acids 384-528 of SEQ ID NO:8). The polypeptide can have the amino acid sequence SEQ ID NO:39. The polypeptide can have at least 70%, 75%, 80%, 85%, 90%, 95% identity to the amino acid sequence SEQ ID NO:39. The nucleic acid can comprise the sequence SEQ ID NO:8. The nucleic acid encode a polypeptide that with at least 70%, 75%, 80%, 85%, 90%, 95% identity to the nucleic acid sequence SEQ ID NO:8. Also disclosed are nucleic acids that can hybridize under stringent conditions, or other conditions, as described herein, with the nucleic acid sequence SEQ ID NO:8.

75. The polypeptide can comprise IL-1R2. The polypeptide can have the amino acid sequence SEQ ID NO:40. The polypeptide can comprise a fragment of IL-1R2, wherein the fragment is capable of binding IL-1 and wherein the fragment has a reduced ability to activate a signal cascade. The polypeptide can have at least 70%, 75%, 80%, 85%, 90%, 95% identity to the amino acid sequence SEQ ID NO:40. The nucleic acid can comprise the sequence SEQ ID NO:9. The nucleic acid encode a polypeptide that with at least 70%, 75%, 80%, 85%, 90%, 95% identity to the nucleic acid sequence SEQ ID NO:9. Also disclosed are nucleic acids that can hybridize under stringent conditions, or other conditions, as described herein, with the nucleic acid sequence SEQ ID NO:9.

76. The herein disclosed polypeptides can further comprise a secretion signal. The secretion signal can be the IL-1ra secretion signal sequence, which is the same sequence as the secretion signal sequence of IL-1 β . Thus, the secretion signal can comprise the polypeptide sequence SEQ ID NO:14. The secretion signal can be encoded by nucleic acid sequence SEQ ID NO:68.

77. The disclosed constructs can be integrated into a vector delivery system. Thus, disclosed are vectors comprising the nucleic acids provided herein. The expression control sequence is generally a promoter. The promoter can be any promoter, such as those discussed herein.

78. Targeted and global delivery of the constructs provided herein is also disclosed. Disclosed is a pseudotyped feline immunodeficiency virus (FIV) for global transgene delivery. Stable expression of the therapeutic gene aids prolonged restoration of the genetic anomaly enhancing treatment efficacy and contributing to long-term therapeutic outcomes. One of the backbone FIV systems disclosed herein is set forth in Poeschla EM, et al., Nature Medicine 4: 354-357. (1998). For example, disclosed herein is stable expression of the reporter gene *lacZ* for over 3 months in mice following perinatal systemic FIV(*lacZ*) administration.

79. A model system for the study of these constructs is the IL-1 β exisionally activated transgenic (XAT) mouse (IL-1 β^{XAT}) and variations thereof. Variations include the use of tissue specific promoters such as in for example the COLL1A1-IL-1 β^{XAT} mouse. This mouse model is the subject of U.S. Patent Application No. 60/627,604, which is herein incorporated by reference in its entirety for teachings related to the disclosed mouse models. This mouse model allows for the induction of localized inflammation based on the delivery of a Cre recombinase expression vector such as FIV(Cre) to the target site. For example, the delivery of FIV(Cre) to the joints of the COLL1A1-IL-1 β^{XAT} mouse can induce inflammation to model arthritis. This mouse model

can thus be used to, for example, test or optimize the effects of the provided constructs on arthritis. Also disclosed herein is the ability of FIV vectors to deliver any of the herein provided nucleic acids or transgenes to the brain of a subject following injection of the vector into either the circulation or joints. Thus, the IL-1 β ^{XAT} and variations thereof can be used as a model of neuroinflammation following delivery of FIV(Cre) into the circulation or joints.

2. Nucleic acids

80. There are a variety of molecules disclosed herein that are nucleic acid based, including for example the nucleic acids that encode, for example, IL-1ra as well as any other proteins disclosed herein, as well as various functional nucleic acids. The disclosed nucleic acids are made up of for example, nucleotides, nucleotide analogs, or nucleotide substitutes. Non-limiting examples of these and other molecules are discussed herein. It is understood that for example, when a vector is expressed in a cell, that the expressed mRNA will typically be made up of A, C, G, and U. Likewise, it is understood that if, for example, an antisense molecule is introduced into a cell or cell environment through for example exogenous delivery, it is advantageous that the antisense molecule be made up of nucleotide analogs that reduce the degradation of the antisense molecule in the cellular environment.

a) Nucleotides and related molecules

81. A nucleotide is a molecule that contains a base moiety, a sugar moiety and a phosphate moiety. Nucleotides can be linked together through their phosphate moieties and sugar moieties creating an internucleoside linkage. The base moiety of a nucleotide can be adenin-9-yl (A), cytosin-1-yl (C), guanin-9-yl (G), uracil-1-yl (U), and thymine-1-yl (T). The sugar moiety of a nucleotide is a ribose or a deoxyribose. The phosphate moiety of a nucleotide is pentavalent phosphate. A non-limiting example of a nucleotide would be 3'-AMP (3'-adenosine monophosphate) or 5'-GMP (5'-guanosine monophosphate).

82. A nucleotide analog is a nucleotide which contains some type of modification to either the base, sugar, or phosphate moieties. Modifications to nucleotides are well known in the art and would include for example, 5-methylcytosine (5-me-C), 5-hydroxymethyl cytosine, xanthine, hypoxanthine, and 2-aminoadenine as well as modifications at the sugar or phosphate moieties.

83. Nucleotide substitutes are molecules having similar functional properties to nucleotides, but which do not contain a phosphate moiety, such as peptide nucleic acid (PNA). Nucleotide substitutes are molecules that will recognize nucleic acids in a Watson-Crick or Hoogsteen manner, but which are linked together through a moiety other than a phosphate

moiety. Nucleotide substitutes are able to conform to a double helix type structure when interacting with the appropriate target nucleic acid.

84. It is also possible to link other types of molecules (conjugates) to nucleotides or nucleotide analogs to enhance for example, cellular uptake. Conjugates can be chemically linked to the nucleotide or nucleotide analogs. Such conjugates include but are not limited to lipid moieties such as a cholesterol moiety. (Letsinger et al., Proc. Natl. Acad. Sci. USA, 1989,86, 6553-6556),

85. A Watson-Crick interaction is at least one interaction with the Watson-Crick face of a nucleotide, nucleotide analog, or nucleotide substitute. The Watson-Crick face of a nucleotide, nucleotide analog, or nucleotide substitute includes the C2, N1, and C6 positions of a purine based nucleotide, nucleotide analog, or nucleotide substitute and the C2, N3, C4 positions of a pyrimidine based nucleotide, nucleotide analog, or nucleotide substitute.

86. A Hoogsteen interaction is the interaction that takes place on the Hoogsteen face of a nucleotide or nucleotide analog, which is exposed in the major groove of duplex DNA. The Hoogsteen face includes the N7 position and reactive groups (NH2 or O) at the C6 position of purine nucleotides.

b) Sequences

87. There are a variety of sequences related to, for example, IL-1ra as well as any other protein disclosed herein that are disclosed on Genbank, and these sequences and others are herein incorporated by reference in their entireties as well as for individual subsequences contained therein.

88. A variety of sequences are provided herein and these and others can be found in Genbank, at www.pubmed.gov. Those of skill in the art understand how to resolve sequence discrepancies and differences and to adjust the compositions and methods relating to a particular sequence to other related sequences. Primers and/or probes can be designed for any sequence given the information disclosed herein and known in the art.

c) Primers and probes

89. Disclosed are compositions including primers and probes, which are capable of interacting with the genes disclosed herein. In certain embodiments the primers are used to support DNA amplification reactions. Typically the primers will be capable of being extended in a sequence specific manner. Extension of a primer in a sequence specific manner includes any methods wherein the sequence and/or composition of the nucleic acid molecule to which the primer is hybridized or otherwise associated directs or influences the composition or sequence of

the product produced by the extension of the primer. Extension of the primer in a sequence specific manner therefore includes, but is not limited to, PCR, DNA sequencing, DNA extension, DNA polymerization, RNA transcription, or reverse transcription. Techniques and conditions that amplify the primer in a sequence specific manner are preferred. In certain embodiments the primers are used for the DNA amplification reactions, such as PCR or direct sequencing. It is understood that in certain embodiments the primers can also be extended using non-enzymatic techniques, where for example, the nucleotides or oligonucleotides used to extend the primer are modified such that they will chemically react to extend the primer in a sequence specific manner. Typically the disclosed primers hybridize with the nucleic acid or region of the nucleic acid or they hybridize with the complement of the nucleic acid or complement of a region of the nucleic acid.

3. Sequence similarities

90. It is understood that as discussed herein the use of the terms homology and identity mean the same thing as similarity. Thus, for example, if the use of the word homology is used between two non-natural sequences it is understood that this is not necessarily indicating an evolutionary relationship between these two sequences, but rather is looking at the similarity or relatedness between their nucleic acid sequences. Many of the methods for determining homology between two evolutionarily related molecules are routinely applied to any two or more nucleic acids or proteins for the purpose of measuring sequence similarity regardless of whether they are evolutionarily related or not.

91. In general, it is understood that one way to define any known variants and derivatives or those that might arise, of the disclosed genes and proteins herein, is through defining the variants and derivatives in terms of homology to specific known sequences. This identity of particular sequences disclosed herein is also discussed elsewhere herein. In general, variants of genes and proteins herein disclosed typically have at least, about 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99 percent homology to the stated sequence or the native sequence. Those of skill in the art readily understand how to determine the homology of two proteins or nucleic acids, such as genes. For example, the homology can be calculated after aligning the two sequences so that the homology is at its highest level.

92. Another way of calculating homology can be performed by published algorithms. Optimal alignment of sequences for comparison can be conducted by the local homology algorithm of Smith and Waterman Adv. Appl. Math. 2: 482 (1981), by the homology alignment

algorithm of Needleman and Wunsch, J. Mol Biol. 48: 443 (1970), by the search for similarity method of Pearson and Lipman, Proc. Natl. Acad. Sci. U.S.A. 85: 2444 (1988), by computerized implementations of these algorithms (GAP, BESTFIT, FASTA, and TFASTA in the Wisconsin Genetics Software Package, Genetics Computer Group, 575 Science Dr., Madison, WI), or by inspection.

93. The same types of homology can be obtained for nucleic acids by for example the algorithms disclosed in Zuker, M. *Science* 244:48-52, 1989, Jaeger et al. *Proc. Natl. Acad. Sci. USA* 86:7706-7710, 1989, Jaeger et al. *Methods Enzymol.* 183:281-306, 1989 which are herein incorporated by reference for at least material related to nucleic acid alignment. It is understood that any of the methods typically can be used and that in certain instances the results of these various methods can differ, but the skilled artisan understands if identity is found with at least one of these methods, the sequences would be said to have the stated identity, and be disclosed herein.

94. For example, as used herein, a sequence recited as having a particular percent homology to another sequence refers to sequences that have the recited homology as calculated by any one or more of the calculation methods described above. For example, a first sequence has 80 percent homology, as defined herein, to a second sequence if the first sequence is calculated to have 80 percent homology to the second sequence using the Zuker calculation method even if the first sequence does not have 80 percent homology to the second sequence as calculated by any of the other calculation methods. As another example, a first sequence has 80 percent homology, as defined herein, to a second sequence if the first sequence is calculated to have 80 percent homology to the second sequence using both the Zuker calculation method and the Pearson and Lipman calculation method even if the first sequence does not have 80 percent homology to the second sequence as calculated by the Smith and Waterman calculation method, the Needleman and Wunsch calculation method, the Jaeger calculation methods, or any of the other calculation methods. As yet another example, a first sequence has 80 percent homology, as defined herein, to a second sequence if the first sequence is calculated to have 80 percent homology to the second sequence using each of calculation methods (although, in practice, the different calculation methods will often result in different calculated homology percentages).

4. Hybridization/selective hybridization

95. The term hybridization typically means a sequence driven interaction between at least two nucleic acid molecules, such as a primer or a probe and a gene. Sequence driven interaction means an interaction that occurs between two nucleotides or nucleotide analogs or nucleotide

derivatives in a nucleotide specific manner. For example, G interacting with C or A interacting with T are sequence driven interactions. Typically sequence driven interactions occur on the Watson-Crick face or Hoogsteen face of the nucleotide. The hybridization of two nucleic acids is affected by a number of conditions and parameters known to those of skill in the art. For example, the salt concentrations, pH, and temperature of the reaction all affect whether two nucleic acid molecules will hybridize.

96. Parameters for selective hybridization between two nucleic acid molecules are well known to those of skill in the art. For example, in some embodiments selective hybridization conditions can be defined as stringent hybridization conditions. For example, stringency of hybridization is controlled by both temperature and salt concentration of either or both of the hybridization and washing steps. For example, the conditions of hybridization to achieve selective hybridization can involve hybridization in high ionic strength solution (6X SSC or 6X SSPE) at a temperature that is about 12-25°C below the T_m (the melting temperature at which half of the molecules dissociate from their hybridization partners) followed by washing at a combination of temperature and salt concentration chosen so that the washing temperature is about 5°C to 20°C below the T_m . The temperature and salt conditions are readily determined empirically in preliminary experiments in which samples of reference DNA immobilized on filters are hybridized to a labeled nucleic acid of interest and then washed under conditions of different stringencies. Hybridization temperatures are typically higher for DNA-RNA and RNA-RNA hybridizations. The conditions can be used as described above to achieve stringency, or as is known in the art. (Sambrook et al., *Molecular Cloning: A Laboratory Manual*, 2nd Ed., Cold Spring Harbor Laboratory, Cold Spring Harbor, New York, 1989; Kunkel et al. *Methods Enzymol.* 1987:154:367, 1987 which is herein incorporated by reference for material at least related to hybridization of nucleic acids). A preferable stringent hybridization condition for a DNA:DNA hybridization can be at about 68°C (in aqueous solution) in 6X SSC or 6X SSPE followed by washing at 68°C. Stringency of hybridization and washing, if desired, can be reduced accordingly as the degree of complementarity desired is decreased, and further, depending upon the G-C or A-T richness of any area wherein variability is searched for. Likewise, stringency of hybridization and washing, if desired, can be increased accordingly as homology desired is increased, and further, depending upon the G-C or A-T richness of any area wherein high homology is desired, all as known in the art.

97. Another way to define selective hybridization is by looking at the amount (percentage) of one of the nucleic acids bound to the other nucleic acid. For example, in some

embodiments selective hybridization conditions would be when at least about, 60, 65, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100 percent of the limiting nucleic acid is bound to the non-limiting nucleic acid. Typically, the non-limiting primer is in for example, 10 or 100 or 1000 fold excess. This type of assay can be performed at under conditions where both the limiting and non-limiting primer are for example, 10 fold or 100 fold or 1000 fold below their k_d , or where only one of the nucleic acid molecules is 10 fold or 100 fold or 1000 fold or where one or both nucleic acid molecules are above their k_d .

98. Another way to define selective hybridization is by looking at the percentage of primer that gets enzymatically manipulated under conditions where hybridization is required to promote the desired enzymatic manipulation. For example, in some embodiments selective hybridization conditions would be when at least about, 60, 65, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100 percent of the primer is enzymatically manipulated under conditions which promote the enzymatic manipulation, for example if the enzymatic manipulation is DNA extension, then selective hybridization conditions would be when at least about 60, 65, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100 percent of the primer molecules are extended. Preferred conditions also include those suggested by the manufacturer or indicated in the art as being appropriate for the enzyme performing the manipulation.

99. Just as with homology, it is understood that there are a variety of methods herein disclosed for determining the level of hybridization between two nucleic acid molecules. It is understood that these methods and conditions can provide different percentages of hybridization between two nucleic acid molecules, but unless otherwise indicated meeting the parameters of any of the methods would be sufficient. For example if 80% hybridization was required and as long as hybridization occurs within the required parameters in any one of these methods it is considered disclosed herein.

100. It is understood that those of skill in the art understand that if a composition or method meets any one of these criteria for determining hybridization either collectively or singly it is a composition or method that is disclosed herein.

5. Delivery of the compositions to cells

101. The herein disclosed nucleic acids can be delivered to cells or cells in a subject. There are a number of compositions and methods which can be used to deliver nucleic acids to

cells, either *in vitro* or *in vivo*. These methods and compositions can largely be broken down into two classes: viral based delivery systems and non-viral based delivery systems. For example, the nucleic acids can be delivered through a number of direct delivery systems such as, electroporation, lipofection, calcium phosphate precipitation, plasmids, viral vectors, viral nucleic acids, phage nucleic acids, phages, cosmids, or via transfer of genetic material in cells or carriers such as cationic liposomes. Appropriate means for transfection, including viral vectors, chemical transfectants, or physico-mechanical methods such as electroporation and direct diffusion of DNA, are described by, for example, Wolff, J. A., et al., *Science*, 247, 1465-1468, (1990); and Wolff, J. A. *Nature*, 352, 815-818, (1991). Such methods are well known in the art and readily adaptable for use with the compositions and methods described herein. In certain cases, the methods will be modified to specifically function with large DNA molecules. Further, these methods can be used to target certain diseases and cell populations by using the targeting characteristics of the carrier.

a) Nucleic acid based delivery systems

Transfer vectors can be any nucleotide construction used to deliver genes into cells (e.g., a plasmid), or as part of a general strategy to deliver genes, e.g., as part of recombinant retrovirus or adenovirus (Ram et al. *Cancer Res.* 53:83-88, (1993)).

As used herein, plasmid or viral vectors are agents that transport the disclosed nucleic acids, such as, for example, the IL-1ra, COX-1 siRNA, COX-2 siRNA, cPGES siRNA, or mPGES siRNA constructs into the cell without degradation and include a promoter yielding expression of the disclosed sequences in the cells into which it is delivered. In some embodiments the vectors for the IL-1ra, COX-1 siRNA, COX-2 siRNA, cPGES siRNA, or mPGES siRNA constructs are derived from a virus, retrovirus, or lentivirus. Viral vectors can be, for example, Adenovirus, Adeno-associated virus, Herpes virus, Vaccinia virus, Polio virus, AIDS virus, neuronal trophic virus, Sindbis and other RNA viruses, including these viruses with the HIV backbone, and lentiviruses. Also preferred are any viral families which share the properties of these viruses which make them suitable for use as vectors. Retroviruses include Murine Maloney Leukemia virus, MMLV, and retroviruses that express the desirable properties of MMLV as a vector. Retroviral vectors are able to carry a larger genetic payload, i.e., a transgene, such as, the disclosed IL-1ra, COX-1 siRNA, COX-2 siRNA, cPGES siRNA, or mPGES siRNA constructs or marker gene, than other viral vectors, and for this reason are a commonly used vector. However, they are not as useful in non-proliferating cells. Adenovirus

vectors are relatively stable and easy to work with, have high titers, and can be delivered in aerosol formulation, and can transfect non-dividing cells. Pox viral vectors are large and have several sites for inserting genes, they are thermostable and can be stored at room temperature. A preferred embodiment is a viral vector, which has been engineered so as to suppress the immune response of the host organism, elicited by the viral antigens. Preferred vectors of this type will carry coding regions for Interleukin 8 or 10.

Viral vectors can have higher transaction (ability to introduce genes) abilities than chemical or physical methods to introduce genes into cells. Typically, viral vectors contain, nonstructural early genes, structural late genes, an RNA polymerase III transcript, inverted terminal repeats necessary for replication and encapsidation, and promoters to control the transcription and replication of the viral genome. When engineered as vectors, viruses typically have one or more of the early genes removed and a gene or gene/promotor cassette is inserted into the viral genome in place of the removed viral DNA. Constructs of this type can carry up to about 8 kb of foreign genetic material. The necessary functions of the removed early genes are typically supplied by cell lines which have been engineered to express the gene products of the early genes in *trans*.

(1) Retroviral Vectors

A retrovirus is an animal virus belonging to the virus family of Retroviridae, including any types, subfamilies, genus, or tropisms. Retroviral vectors, in general, are described by Verma, I.M., Retroviral vectors for gene transfer. In Microbiology-1985, American Society for Microbiology, pp. 229-232, Washington, (1985), which is incorporated by reference herein. Examples of methods for using retroviral vectors for gene therapy are described in U.S. Patent Nos. 4,868,116 and 4,980,286; PCT applications WO 90/02806 and WO 89/07136; and Mulligan, (Science 260:926-932 (1993)); the teachings of which are incorporated herein by reference.

A retrovirus is essentially a package which has packed into it nucleic acid cargo. The nucleic acid cargo carries with it a packaging signal, which ensures that the replicated daughter molecules will be efficiently packaged within the package coat. In addition to the package signal, there are a number of molecules which are needed in *cis*, for the replication, and packaging of the replicated virus. Typically a retroviral genome, contains the gag, pol, and env genes which are involved in the making of the protein coat. It is the gag, pol, and env genes which are typically replaced by the foreign DNA that it is to be transferred to the target cell.

Retrovirus vectors typically contain a packaging signal for incorporation into the package coat, a sequence which signals the start of the gag transcription unit, elements necessary for reverse transcription, including a primer binding site to bind the tRNA primer of reverse transcription, terminal repeat sequences that guide the switch of RNA strands during DNA synthesis, a purine rich sequence 5' to the 3' LTR that serve as the priming site for the synthesis of the second strand of DNA synthesis, and specific sequences near the ends of the LTRs that enable the insertion of the DNA state of the retrovirus to insert into the host genome. The removal of the gag, pol, and env genes allows for about 8 kb of foreign sequence to be inserted into the viral genome, become reverse transcribed, and upon replication be packaged into a new retroviral particle. This amount of nucleic acid is sufficient for the delivery of a one to many genes depending on the size of each transcript. It is preferable to include either positive or negative selectable markers along with other genes in the insert.

Since the replication machinery and packaging proteins in most retroviral vectors have been removed (gag, pol, and env), the vectors are typically generated by placing them into a packaging cell line. A packaging cell line is a cell line which has been transfected or transformed with a retrovirus that contains the replication and packaging machinery, but lacks any packaging signal. When the vector carrying the DNA of choice is transfected into these cell lines, the vector containing the gene of interest is replicated and packaged into new retroviral particles, by the machinery provided in cis by the helper cell. The genomes for the machinery are not packaged because they lack the necessary signals.

(2) Adenoviral Vectors

The construction of replication-defective adenoviruses has been described (Berkner et al., J. Virology 61:1213-1220 (1987); Massie et al., Mol. Cell. Biol. 6:2872-2883 (1986); Haj-Ahmad et al., J. Virology 57:267-274 (1986); Davidson et al., J. Virology 61:1226-1239 (1987); Zhang "Generation and identification of recombinant adenovirus by liposome-mediated transfection and PCR analysis" BioTechniques 15:868-872 (1993)). The benefit of the use of these viruses as vectors is that they are limited in the extent to which they can spread to other cell types, since they can replicate within an initial infected cell, but are unable to form new infectious viral particles. Recombinant adenoviruses have been shown to achieve high efficiency gene transfer after direct, in vivo delivery to airway epithelium, hepatocytes, vascular endothelium, CNS parenchyma and a number of other tissue sites (Morsy, J. Clin. Invest. 92:1580-1586 (1993); Kirshenbaum, J. Clin. Invest. 92:381-387 (1993); Roessler, J. Clin.

Invest. 92:1085-1092 (1993); Moullier, *Nature Genetics* 4:154-159 (1993); La Salle, *Science* 259:988-990 (1993); Gomez-Foix, *J. Biol. Chem.* 267:25129-25134 (1992); Rich, *Human Gene Therapy* 4:461-476 (1993); Zabner, *Nature Genetics* 6:75-83 (1994); Guzman, *Circulation Research* 73:1201-1207 (1993); Bout, *Human Gene Therapy* 5:3-10 (1994); Zabner, *Cell* 75:207-216 (1993); Caillaud, *Eur. J. Neuroscience* 5:1287-1291 (1993); and Ragot, *J. Gen. Virology* 74:501-507 (1993)). Recombinant adenoviruses achieve gene transduction by binding to specific cell surface receptors, after which the virus is internalized by receptor-mediated endocytosis, in the same manner as wild type or replication-defective adenovirus (Chardonnet and Dales, *Virology* 40:462-477 (1970); Brown and Burlingham, *J. Virology* 12:386-396 (1973); Svensson and Persson, *J. Virology* 55:442-449 (1985); Seth, et al., *J. Virol.* 51:650-655 (1984); Seth, et al., *Mol. Cell. Biol.* 4:1528-1533 (1984); Varga et al., *J. Virology* 65:6061-6070 (1991); Wickham et al., *Cell* 73:309-319 (1993)).

A viral vector can be one based on an adenovirus which has had the E1 gene removed and these virions are generated in a cell line such as the human 293 cell line. In another preferred embodiment both the E1 and E3 genes are removed from the adenovirus genome.

(3) Adeno-associated viral vectors

Another type of viral vector is based on an adeno-associated virus (AAV). This defective parvovirus is a preferred vector because it can infect many cell types and is nonpathogenic to humans. AAV type vectors can transport about 4 to 5 kb and wild type AAV is known to stably insert into chromosome 19. Vectors which contain this site specific integration property are preferred. An especially preferred embodiment of this type of vector is the P4.1 C vector produced by Avigen, San Francisco, CA, which can contain the herpes simplex virus thymidine kinase gene, HSV-tk, and/or a marker gene, such as the gene encoding the green fluorescent protein, GFP.

In another type of AAV virus, the AAV contains a pair of inverted terminal repeats (ITRs) which flank at least one cassette containing a promoter which directs cell-specific expression operably linked to a heterologous gene. Heterologous in this context refers to any nucleotide sequence or gene which is not native to the AAV or B19 parvovirus.

Typically the AAV and B19 coding regions have been deleted, resulting in a safe, noncytotoxic vector. The AAV ITRs, or modifications thereof, confer infectivity and site-specific integration, but not cytotoxicity, and the promoter directs cell-specific expression.

United States Patent No. 6,261,834 is herein incorporated by reference for material related to the AAV vector.

The vectors of the present invention thus provide DNA molecules which are capable of integration into a mammalian chromosome without substantial toxicity.

The inserted genes in viral and retroviral usually contain promoters, and/or enhancers to help control the expression of the desired gene product. A promoter is generally a sequence or sequences of DNA that function when in a relatively fixed location in regard to the transcription start site. A promoter contains core elements required for basic interaction of RNA polymerase and transcription factors, and can contain upstream elements and response elements.

(4) Lentiviral vectors

102. The vectors can be lentiviral vectors, including but not limited to, SIV vectors, HIV vectors or a hybrid construct of these vectors, including viruses with the HIV backbone. These vectors also include first, second and third generation lentiviruses. Third generation lentiviruses have lentiviral packaging genes split into at least 3 independent plasmids or constructs. Also vectors can be any viral family that share the properties of these viruses which make them suitable for use as vectors. Lentiviral vectors are a special type of retroviral vector which are typically characterized by having a long incubation period for infection. Furthermore, lentiviral vectors can infect non-dividing cells. Lentiviral vectors are based on the nucleic acid backbone of a virus from the lentiviral family of viruses. Typically, a lentiviral vector contains the 5' and 3' LTR regions of a lentivirus, such as SIV and HIV. Lentiviral vectors also typically contain the Rev Responsive Element (RRE) of a lentivirus, such as SIV and HIV.

(a) *Feline immunodeficiency viral vectors*

One type of vector that the disclosed constructs can be delivered in is the VSV-G pseudotyped Feline Immunodeficiency Virus system developed by Poeschla *et al.* (1998). This lentivirus has been shown to efficiently infect dividing, growth arrested as well as post-mitotic cells. Furthermore, due to its lentiviral properties, it allows for incorporation of the transgene into the host's genome, leading to stable gene expression. This is a 3-vector system, whereby each confers distinct instructions: the FIV vector carries the transgene of interest and lentiviral apparatus with mutated packaging and envelope genes. A vesicular stomatitis virus G-glycoprotein vector (VSV-G; Burns *et al.*, 1993) contributes to the formation of the viral envelope *in trans*. The third vector confers packaging instructions *in trans* (Poeschla *et al.*,

1998). FIV production is accomplished *in vitro* following co-transfection of the aforementioned vectors into 293-T cells. The FIV-rich supernatant is then collected, filtered and can be used directly or following concentration by centrifugation. Titers routinely range between $10^4 - 10^7$ bfu/ml..

(5) Packaging vectors

As discussed above, retroviral vectors are based on retroviruses which contain a number of different sequence elements that control things as diverse as integration of the virus, replication of the integrated virus, replication of un-integrated virus, cellular invasion, and packaging of the virus into infectious particles. While the vectors in theory could contain all of their necessary elements, as well as an exogenous gene element (if the exogenous gene element is small enough) typically many of the necessary elements are removed. Since all of the packaging and replication components have been removed from the typical retroviral, including lentiviral, vectors which will be used within a subject, the vectors need to be packaged into the initial infectious particle through the use of packaging vectors and packaging cell lines. Typically retroviral vectors have been engineered so that the myriad functions of the retrovirus are separated onto at least two vectors, a packaging vector and a delivery vector. This type of system then requires the presence of all of the vectors providing all of the elements in the same cell before an infectious particle can be produced. The packaging vector typically carries the structural and replication genes derived from the retrovirus, and the delivery vector is the vector that carries the exogenous gene element that is preferably expressed in the target cell. These types of systems can split the packaging functions of the packaging vector into multiple vectors, e.g., third-generation lentivirus systems. Dull, T. et al., "A Third-generation lentivirus vector with a conditional packaging system" *J. Virol* 72(11):8463-71 (1998)

Retroviruses typically contain an envelope protein (env). The Env protein is in essence the protein which surrounds the nucleic acid cargo. Furthermore cellular infection specificity is based on the particular Env protein associated with a typical retrovirus. In typical packaging vector/delivery vector systems, the Env protein is expressed from a separate vector than for example the protease (pro) or integrase (in) proteins.

(6) Packaging cell lines

The vectors are typically generated by placing them into a packaging cell line. A packaging cell line is a cell line which has been transfected or transformed with a retrovirus that contains the replication and packaging machinery, but lacks any packaging signal. When the

vector carrying the DNA of choice is transfected into these cell lines, the vector containing the gene of interest is replicated and packaged into new retroviral particles, by the machinery provided in cis by the helper cell. The genomes for the machinery are not packaged because they lack the necessary signals. One type of packaging cell line is a 293 cell line.

(7) Large payload viral vectors

Molecular genetic experiments with large human herpesviruses have provided a means whereby large heterologous DNA fragments can be cloned, propagated and established in cells permissive for infection with herpesviruses (Sun et al., *Nature genetics* 8: 33-41, 1994; Cotter and Robertson, *Curr Opin Mol Ther* 5: 633-644, 1999). These large DNA viruses (herpes simplex virus (HSV) and Epstein-Barr virus (EBV), have the potential to deliver fragments of human heterologous DNA > 150 kb to specific cells. EBV recombinants can maintain large pieces of DNA in the infected B-cells as episomal DNA. Individual clones carried human genomic inserts up to 330 kb appeared genetically stable. The maintenance of these episomes requires a specific EBV nuclear protein, EBNA1, constitutively expressed during infection with EBV. Additionally, these vectors can be used for transfection, where large amounts of protein can be generated transiently in vitro. Herpesvirus amplicon systems are also being used to package pieces of DNA > 220 kb and to infect cells that can stably maintain DNA as episomes.

Other useful systems include, for example, replicating and host-restricted non-replicating vaccinia virus vectors.

b) Non-nucleic acid based systems

103. The disclosed compositions can be delivered to the target cells in a variety of ways. For example, the compositions can be delivered through electroporation, or through lipofection, or through calcium phosphate precipitation. The delivery mechanism chosen will depend in part on the type of cell targeted and whether the delivery is occurring for example in vivo or in vitro.

104. Thus, in addition to the disclosed nucleic acids or vectors, the compositions can comprise, for example, lipids such as liposomes, such as cationic liposomes (e.g., DOTMA, DOPE, DC-cholesterol) or anionic liposomes. Liposomes can further comprise proteins to facilitate targeting a particular cell, if desired. Administration of a composition comprising a compound and a cationic liposome can be administered to the blood afferent to a target organ or inhaled into the respiratory tract to target cells of the respiratory tract. Regarding liposomes, see, e.g., Brigham et al. *Am. J. Resp. Cell. Mol. Biol.* 1:95-100 (1989); Felgner et al. *Proc. Natl.*

Acad. Sci USA 84:7413-7417 (1987); U.S. Pat. No. 4,897,355. Furthermore, the compound can be administered as a component of a microcapsule that can be targeted to specific cell types, such as macrophages, or where the diffusion of the compound or delivery of the compound from the microcapsule is designed for a specific rate or dosage.

105. In the methods described above which include the administration and uptake of exogenous DNA into the cells of a subject (i.e., gene transduction or transfection), delivery of the compositions to cells can be via a variety of mechanisms. As one example, delivery can be via a liposome, using commercially available liposome preparations such as LIPOFECTIN, LIPOFECTAMINE (GIBCO-BRL, Inc., Gaithersburg, MD), SUPERFECT (Qiagen, Inc. Hilden, Germany) and TRANSFECTAM (Promega Biotec, Inc., Madison, WI), as well as other liposomes developed according to procedures standard in the art. In addition, the disclosed nucleic acid or vector can be delivered *in vivo* by electroporation, the technology for which is available from Genetronics, Inc. (San Diego, CA) as well as by means of a SONOPORATION machine (ImaRx Pharmaceutical Corp., Tucson, AZ).

106. The materials may be in solution, suspension (for example, incorporated into microparticles, liposomes, or cells). These may be targeted to a particular cell type via antibodies, receptors, or receptor ligands. The following references are examples of the use of this technology to target specific proteins to tumor tissue (Senter, et al., *Bioconjugate Chem.*, 2:447-451, (1991); Bagshawe, K.D., *Br. J. Cancer*, 60:275-281, (1989); Bagshawe, et al., *Br. J. Cancer*, 58:700-703, (1988); Senter, et al., *Bioconjugate Chem.*, 4:3-9, (1993); Battelli, et al., *Cancer Immunol. Immunother.*, 35:421-425, (1992); Pietersz and McKenzie, *Immunolog. Reviews*, 129:57-80, (1992); and Roffler, et al., *Biochem. Pharmacol.*, 42:2062-2065, (1991)). These techniques can be used for a variety of other specific cell types. Vehicles such as "stealth" and other antibody conjugated liposomes (including lipid mediated drug targeting to colonic carcinoma), receptor mediated targeting of DNA through cell specific ligands, lymphocyte directed tumor targeting, and highly specific therapeutic retroviral targeting of murine glioma cells *in vivo*. The following references are examples of the use of this technology to target specific proteins to tumor tissue (Hughes et al., *Cancer Research*, 49:6214-6220, (1989); and Litzinger and Huang, *Biochimica et Biophysica Acta*, 1104:179-187, (1992)). In general, receptors are involved in pathways of endocytosis, either constitutive or ligand induced. These receptors cluster in clathrin-coated pits, enter the cell via clathrin-coated vesicles, pass through an acidified endosome in which the receptors are sorted, and then either recycle to the cell surface, become stored intracellularly, or are degraded in lysosomes. The internalization

pathways serve a variety of functions, such as nutrient uptake, removal of activated proteins, clearance of macromolecules, opportunistic entry of viruses and toxins, dissociation and degradation of ligand, and receptor-level regulation. Many receptors follow more than one intracellular pathway, depending on the cell type, receptor concentration, type of ligand, ligand valency, and ligand concentration. Molecular and cellular mechanisms of receptor-mediated endocytosis has been reviewed (Brown and Greene, DNA and Cell Biology 10:6, 399-409 (1991)).

107. Nucleic acids that are delivered to cells which are to be integrated into the host cell genome, typically contain integration sequences. These sequences are often viral related sequences, particularly when viral based systems are used. These viral intergration systems can also be incorporated into nucleic acids which are to be delivered using a non-nucleic acid based system of deliver, such as a liposome, so that the nucleic acid contained in the delivery system can be come integrated into the host genome.

108. Other general techniques for integration into the host genome include, for example, systems designed to promote homologous recombination with the host genome. These systems typically rely on sequence flanking the nucleic acid to be expressed that has enough homology with a target sequence within the host cell genome that recombination between the vector nucleic acid and the target nucleic acid takes place, causing the delivered nucleic acid to be integrated into the host genome. These systems and the methods necessary to promote homologous recombination are known to those of skill in the art.

c) In vivo/ex vivo

109. As described above, the compositions can be administered in a pharmaceutically acceptable carrier and can be delivered to the subject's cells *in vivo* and/or *ex vivo* by a variety of mechanisms well known in the art (e.g., uptake of naked DNA, liposome fusion, intramuscular injection of DNA via a gene gun, endocytosis and the like).

110. If *ex vivo* methods are employed, cells or tissues can be removed and maintained outside the body according to standard protocols well known in the art. The compositions can be introduced into the cells via any gene transfer mechanism, such as, for example, calcium phosphate mediated gene delivery, electroporation, microinjection or proteoliposomes. The transduced cells can then be infused (e.g., in a pharmaceutically acceptable carrier) or homotopically transplanted back into the subject per standard methods for the cell or tissue type. Standard methods are known for transplantation or infusion of various cells into a subject.

6. Expression systems

The nucleic acids that are delivered to cells typically contain expression controlling systems. For example, the inserted genes in viral and retroviral systems usually contain promoters, and/or enhancers to help control the expression of the desired gene product. A promoter is generally a sequence or sequences of DNA that function when in a relatively fixed location in regard to the transcription start site. A promoter contains core elements required for basic interaction of RNA polymerase and transcription factors, and may contain upstream elements and response elements.

a) Viral Promoters and Enhancers

Preferred promoters controlling transcription from vectors in mammalian host cells can be obtained from various sources, for example, the genomes of viruses such as: polyoma, Simian Virus 40 (SV40), adenovirus, retroviruses, hepatitis-B virus and most preferably cytomegalovirus, or from heterologous mammalian promoters, e.g. beta actin promoter. The early and late promoters of the SV40 virus are conveniently obtained as an SV40 restriction fragment which also contains the SV40 viral origin of replication (Fiers et al., *Nature*, 273: 113 (1978)). The immediate early promoter of the human cytomegalovirus is conveniently obtained as a HindIII E restriction fragment (Greenway, P.J. et al., *Gene* 18: 355-360 (1982)). Of course, promoters from the host cell or related species also are useful herein.

Enhancer generally refers to a sequence of DNA that functions at no fixed distance from the transcription start site and can be either 5' (Laimins, L. et al., *Proc. Natl. Acad. Sci.* 78: 993 (1981)) or 3' (Lusky, M.L., et al., *Mol. Cell Bio.* 3: 1108 (1983)) to the transcription unit. Furthermore, enhancers can be within an intron (Banerji, J.L. et al., *Cell* 33: 729 (1983)) as well as within the coding sequence itself (Osborne, T.F., et al., *Mol. Cell Bio.* 4: 1293 (1984)). They are usually between 10 and 300 bp in length, and they function in cis. Enhancers function to increase transcription from nearby promoters. Enhancers also often contain response elements that mediate the regulation of transcription. Promoters can also contain response elements that mediate the regulation of transcription. Enhancers often determine the regulation of expression of a gene. While many enhancer sequences are now known from mammalian genes (globin, elastase, albumin, α -fetoprotein and insulin), typically one will use an enhancer from a eukaryotic cell virus for general expression. Preferred examples are the SV40 enhancer on the late side of the replication origin (bp 100-270), the cytomegalovirus early promoter enhancer, the polyoma enhancer on the late side of the replication origin, and adenovirus enhancers.

The promoter and/or enhancer can be specifically activated either by light or specific chemical events which trigger their function. Systems can be regulated by reagents such as tetracycline and dexamethasone. There are also ways to enhance viral vector gene expression by exposure to irradiation, such as gamma irradiation, or alkylating chemotherapy drugs.

In certain embodiments the promoter and/or enhancer region can act as a constitutive promoter and/or enhancer to maximize expression of the region of the transcription unit to be transcribed. In certain constructs the promoter and/or enhancer region be active in all eukaryotic cell types, even if it is only expressed in a particular type of cell at a particular time. A preferred promoter of this type is the CMV promoter (650 bases). Other preferred promoters are SV40 promoters, cytomegalovirus (full length promoter), and retroviral vector LTR.

Expression vectors used in eukaryotic host cells (yeast, fungi, insect, plant, animal, human or nucleated cells) can also contain sequences necessary for the termination of transcription which could affect mRNA expression. These regions are transcribed as polyadenylated segments in the untranslated portion of the mRNA encoding tissue factor protein.

The 3' untranslated regions also include transcription termination sites. It is preferred that the transcription unit also contain a polyadenylation region. One benefit of this region is that it increases the likelihood that the transcribed unit will be processed and transported like mRNA. The identification and use of polyadenylation signals in expression constructs is well established.

It is preferred that homologous polyadenylation signals be used in the transgene constructs. In certain transcription units, the polyadenylation region is derived from the SV40 early polyadenylation signal and consists of about 400 bases. It is also preferred that the transcribed units contain other standard sequences alone or in combination with the above sequences improve expression from, or stability of, the construct.

111. In certain embodiments the promoters are constitutive promoters. This can be any promoter that causes transcription regulation in the absence of the addition of other factors. Examples of this type of promoter are the CMV promoter and the beta actin promoter, as well as others discussed herein. In certain embodiments the promoter can consist of fusions of one or more different types of promoters. For example, the regulatory regions of the CMV promoter and the beta actin promoter are well known and understood, examples, of which are disclosed herein. Parts of these promoters can be fused together to, for example, produce a CMV-beta actin fusion promoter, such as the one shown in SEQ ID NO:18. It is understood that this type of promoter has a CMV component and a beta actin component. These components can function

independently as promoters, and thus, are themselves considered beta actin promoters and CMV promoters. A promoter can be any portion of a known promoter that causes promoter activity. It is well understood that many promoters, including the CMV and Beta Actin promoters have functional domains which are understood and that these can be used as a beta actin promoter or CMV promoter. Furthermore, these domains can be determined. For example, SEQ ID NO:s 15-33 display a number of CMV promoters, beta actin promoters, and fusion promoters. These promoters can be compared, and for example, functional regions delineated, as described herein. Furthermore, each of these sequences can function independently or together in any combination to provide a promoter region for the disclosed nucleic acids.

112. The promoters can also be non-constitutive promoters, such as cell specific promoters. These are promoters that are turned on at specific time in development or stage or a particular type of cell, such as a cardiac cell, or neural cell, or a bone cell. Some examples of cell specific promoters are, the neural enolase specific promoter (NSE), the procollagen promoters COL1A1 (SEQ ID NO:35) and COL2A1 (SEQ ID NO:36), the CD11b promoter (PBMC-microglia/macrophage/monocyte specific) (SEQ ID NO:69), and the glial specific glial fibrillary acetic protein (GFAP) promoter (SEQ ID NO:34).

113. It is understood that the recombinant systems can be expressed in a tissue-specific manner. It is understood that tissue specific expression can occur due to the presence of a tissue-specific promoter. Typically, proteins under control of a tissue-specific promoter are transcribed when the promoter becomes active by virtue of being present in the tissue for which it is specific. Therefore, all cells can encode for a particular gene without global expression. As such, labeled proteins can be shown to be present in certain tissues without expression in other nearby tissues that could complicate results or expression of proteins in tissues where expression is detrimental to the host. Disclosed are methods wherein the cre recombinase is under the control of the EIIA promoter, a promoter specific for breast tissue, such as the WAP promoter, a promoter specific for ovarian tissue, such as the ACTB promoter, or a promoter specific for bone tissue, such as osteocalcin. Any tissues specific promoter can be used. Promoters specific for prostate, testis, and neural are also disclosed. Examples of some tissue-specific promoters include but are not limited to MUC1, EIIA, ACTB, WAP, bHLH-EC2, HOXA-1, Alpha-fetoprotein (AFP), opsin, CR1/2, Fc- γ -Receptor 1 (Fc- γ -R1), MMTVD-LTR, the human insulin promote, Pdha-2. For example, use of the AFP promoter creates specificity for the liver. Another example, HOXA-1 is a neuronal tissue specific promoter, and as such, proteins expressed under the control of HOXA-

1 are only expressed in neuronal tissue. Sequences for these and other tissue-specific promoters are known in the art and can be found, for example, in Genbank, at www.pubmed.gov.

b) Markers

114. The viral vectors can include nucleic acid sequence encoding a marker product. This marker product is used to determine if the gene has been delivered to the cell and once delivered is being expressed. Preferred marker genes are the *E. Coli lacZ* gene, which encodes β -galactosidase, and green fluorescent protein.

115. In some embodiments the marker can be a selectable marker. Examples of suitable selectable markers for mammalian cells are dihydrofolate reductase (DHFR), thymidine kinase, neomycin, neomycin analog G418, hygromycin, and puromycin. When such selectable markers are successfully transferred into a mammalian host cell, the transformed mammalian host cell can survive if placed under selective pressure. There are two widely used distinct categories of selective regimes. The first category is based on a cell's metabolism and the use of a mutant cell line which lacks the ability to grow independent of a supplemented media. Two examples are: CHO DHFR- cells and mouse LTK- cells. These cells lack the ability to grow without the addition of such nutrients as thymidine or hypoxanthine. Because these cells lack certain genes necessary for a complete nucleotide synthesis pathway, they cannot survive unless the missing nucleotides are provided in a supplemented media. An alternative to supplementing the media is to introduce an intact DHFR or TK gene into cells lacking the respective genes, thus altering their growth requirements. Individual cells which were not transformed with the DHFR or TK gene will not be capable of survival in non-supplemented media.

116. The second category is dominant selection which refers to a selection scheme used in any cell type and does not require the use of a mutant cell line. These schemes typically use a drug to arrest growth of a host cell. Those cells which have a novel gene would express a protein conveying drug resistance and would survive the selection. Examples of such dominant selection use the drugs neomycin, (Southern P. and Berg, P., J. Molec. Appl. Genet. 1: 327 (1982)), mycophenolic acid, (Mulligan, R.C. and Berg, P. Science 209: 1422 (1980)) or hygromycin, (Sugden, B. et al., Mol. Cell. Biol. 5: 410-413 (1985)). The three examples employ bacterial genes under eukaryotic control to convey resistance to the appropriate drug G418 or neomycin (geneticin), xgpt (mycophenolic acid) or hygromycin, respectively. Others include the neomycin analog G418 and puramycin.

c) Post transcriptional regulatory elements

117. The disclosed vectors can also contain post-transcriptional regulatory elements. Post-transcriptional regulatory elements can enhance mRNA stability or enhance translation of the transcribed mRNA. An exemplary post-transcriptional regulatory sequence is the WPRE sequence isolated from the woodchuck hepatitis virus. [Zufferey R, et al., J Virol; 73:2886-92 (1999)]. Post-transcriptional regulatory elements can be positioned both 3' and 5' to the exogenous gene, but it is preferred that they are positioned 3' to the exogenous gene.

d) Transduction efficiency elements

118. Transduction efficiency elements are sequences that enhance the packaging and transduction of the vector. These elements typically contain polypurine sequences. An example of a transduction efficiency element is the ppt-cts sequence that contains the central polypurine tract (ppt) and central terminal site (cts) from the HIV-1 pSG3 molecular clone (SEQ ID NO:1 bp 4327 to 4483 of HIV-1 pSG3 clone).

e) 3' untranslated regions

119. Expression vectors used in eukaryotic host cells (yeast, fungi, insect, plant, animal, human or nucleated cells) may also contain sequences necessary for the termination of transcription which could affect mRNA expression. These 3' untranslated regions are transcribed as polyadenylated segments in the untranslated portion of the mRNA encoding the exogenous gene. The 3' untranslated regions also include transcription termination sites. The transcription unit also can contain a polyadenylation region. One benefit of this region is that it increases the likelihood that the transcribed unit will be processed and transported like mRNA. The identification and use of polyadenylation signals in expression constructs is well established. Homologous polyadenylation signals can be used in the transgene constructs. In an embodiment of the transcription unit, the polyadenylation region is derived from the SV40 early polyadenylation signal and consists of about 400 bases. Transcribed units can contain other standard sequences alone or in combination with the above sequences improve expression from, or stability of, the construct.

7. Peptides

a) Protein variants

120. Disclosed herein are constructs comprising nucleic acids that encode polypeptides. As discussed herein, there can be numerous variants of each of these polypeptides, such as IL-1ra, that are herein contemplated. In addition, to the known functional proteins that are disclosed, such as IL-1ra, there are also derivatives of these proteins which also function in

the disclosed methods and compositions. Protein variants and derivatives are well understood to those of skill in the art and in can involve amino acid sequence modifications. For example, amino acid sequence modifications typically fall into one or more of three classes: substitutional, insertional or deletional variants. Insertions include amino and/or carboxyl terminal fusions as well as intrasequence insertions of single or multiple amino acid residues. Insertions ordinarily will be smaller insertions than those of amino or carboxyl terminal fusions, for example, on the order of one to four residues. Immunogenic fusion protein derivatives, such as those described in the examples, are made by fusing a polypeptide sufficiently large to confer immunogenicity to the target sequence by cross-linking in vitro or by recombinant cell culture transformed with DNA encoding the fusion. Deletions are characterized by the removal of one or more amino acid residues from the protein sequence. Typically, no more than about from 2 to 6 residues are deleted at any one site within the protein molecule. These variants ordinarily are prepared by site specific mutagenesis of nucleotides in the DNA encoding the protein, thereby producing DNA encoding the variant, and thereafter expressing the DNA in recombinant cell culture. Techniques for making substitution mutations at predetermined sites in DNA having a known sequence are well known, for example M13 primer mutagenesis and PCR mutagenesis. Amino acid substitutions are typically of single residues, but can occur at a number of different locations at once; insertions usually will be on the order of about from 1 to 10 amino acid residues; and deletions will range about from 1 to 30 residues. Deletions or insertions preferably are made in adjacent pairs, i.e. a deletion of 2 residues or insertion of 2 residues. Substitutions, deletions, insertions or any combination thereof can be combined to arrive at a final construct. The mutations must not place the sequence out of reading frame and preferably will not create complementary regions that could produce secondary mRNA structure. Substitutional variants are those in which at least one residue has been removed and a different residue inserted in its place. Such substitutions generally are made in accordance with the following Tables 1 and 2 and are referred to as conservative substitutions.

TABLE 1: Amino Acid Abbreviations

Amino Acid	Abbreviations	
Alanine	Ala	A
allosoleucine	AlIe	
Arginine	Arg	R
asparagine	Asn	N
aspartic acid	Asp	D
Cysteine	Cys	C
glutamic acid	Glu	E
Glutamine	Gln	Q
Glycine	Gly	G
Histidine	His	H
Isoleucine	Ile	I

Leucine	Leu	L
Lysine	Lys	K
phenylalanine	Phe	F
proline	Pro	P
pyroglutamic acid	pGlu	
Serine	Ser	S
Threonine	Thr	T
Tyrosine	Tyr	Y
Tryptophan	Trp	W
Valine	Val	V

TABLE 2: Amino Acid Substitutions

Original Residue Exemplary Conservative Substitutions,
others are known in the art.

Ala	Ser
Arg	Lys; Gln
Asn	Gln; His
Asp	Glu
Cys	Ser
Gln	Asn, Lys
Glu	Asp
Gly	Pro
His	Asn; Gln
Ile	Leu; Val
Leu	Ile; Val
Lys	Arg; Gln
Met	Leu; Ile
Phe	Met; Leu; Tyr
Ser	Thr
Thr	Ser
Trp	Tyr
Tyr	Trp; Phe
Val	Ile; Leu

121. Substantial changes in function or immunological identity are made by selecting substitutions that are less conservative than those in Table 2, i.e., selecting residues that differ more significantly in their effect on maintaining (a) the structure of the polypeptide backbone in the area of the substitution, for example as a sheet or helical conformation, (b) the charge or hydrophobicity of the molecule at the target site or (c) the bulk of the side chain. The substitutions which in general are expected to produce the greatest changes in the protein properties will be those in which (a) a hydrophilic residue, e.g. seryl or threonyl, is substituted for (or by) a hydrophobic residue, e.g. leucyl, isoleucyl, phenylalanyl, valyl or alanyl; (b) a cysteine or proline is substituted for (or by) any other residue; (c) a residue having an electropositive side chain, e.g., lysyl, arginyl, or histidyl, is substituted for (or by) an electronegative residue, e.g., glutamyl or aspartyl; or (d) a residue having a bulky side chain, e.g.,

phenylalanine, is substituted for (or by) one not having a side chain, e.g., glycine, in this case, (e) by increasing the number of sites for sulfation and/or glycosylation.

122. For example, the replacement of one amino acid residue with another that is biologically and/or chemically similar is known to those skilled in the art as a conservative substitution. For example, a conservative substitution would be replacing one hydrophobic residue for another, or one polar residue for another. The substitutions include combinations such as, for example, Gly, Ala; Val, Ile, Leu; Asp, Glu; Asn, Gln; Ser, Thr; Lys, Arg; and Phe, Tyr. Such conservatively substituted variations of each explicitly disclosed sequence are included within the mosaic polypeptides provided herein.

123. Substitutional or deletional mutagenesis can be employed to insert sites for N-glycosylation (Asn-X-Thr/Ser) or O-glycosylation (Ser or Thr). Deletions of cysteine or other labile residues also may be desirable. Deletions or substitutions of potential proteolysis sites, e.g. Arg, is accomplished for example by deleting one of the basic residues or substituting one by glutamyl or histidyl residues.

124. Certain post-translational derivatizations are the result of the action of recombinant host cells on the expressed polypeptide. Glutamyl and asparagyl residues are frequently post-translationally deamidated to the corresponding glutamyl and asparyl residues. Alternatively, these residues are deamidated under mildly acidic conditions. Other post-translational modifications include hydroxylation of proline and lysine, phosphorylation of hydroxyl groups of seryl or threonyl residues, methylation of the o-amino groups of lysine, arginine, and histidine side chains (T.E. Creighton, *Proteins: Structure and Molecular Properties*, W. H. Freeman & Co., San Francisco pp 79-86 [1983]), acetylation of the N-terminal amine and, in some instances, amidation of the C-terminal carboxyl.

125. It is understood that one way to define the variants and derivatives of the disclosed proteins herein is through defining the variants and derivatives in terms of homology/identity to specific known sequences. For example, SEQ ID NO:5 sets forth a particular sequence of IL-1ra and SEQ ID NO:9 sets forth a particular sequence of a IL-1R2 protein. Specifically disclosed are variants of these and other proteins herein disclosed which have at least, 70% or 75% or 80% or 85% or 90% or 95% homology to the stated sequence. Those of skill in the art readily understand how to determine the homology of two proteins. For example, the homology can be calculated after aligning the two sequences so that the homology is at its highest level.

126. Another way of calculating homology can be performed by published algorithms. Optimal alignment of sequences for comparison can be conducted by the local homology algorithm of Smith and Waterman *Adv. Appl. Math.* 2: 482 (1981), by the homology alignment algorithm of Needleman and Wunsch, *J. Mol. Biol.* 48: 443 (1970), by the search for similarity method of Pearson and Lipman, *Proc. Natl. Acad. Sci. U.S.A.* 85: 2444 (1988), by computerized implementations of these algorithms (GAP, BESTFIT, FASTA, and TFASTA in the Wisconsin Genetics Software Package, Genetics Computer Group, 575 Science Dr., Madison, WI), or by inspection.

127. The same types of homology can be obtained for nucleic acids by for example the algorithms disclosed in Zuker, M. *Science* 244:48-52, 1989, Jaeger et al. *Proc. Natl. Acad. Sci. USA* 86:7706-7710, 1989, Jaeger et al. *Methods Enzymol.* 183:281-306, 1989 which are herein incorporated by reference for at least material related to nucleic acid alignment.

128. It is understood that the description of conservative mutations and homology can be combined together in any combination, such as embodiments that have at least 70% homology to a particular sequence wherein the variants are conservative mutations.

129. As this specification discusses various proteins and protein sequences it is understood that the nucleic acids that can encode those protein sequences are also disclosed. This would include all degenerate sequences related to a specific protein sequence, i.e. all nucleic acids having a sequence that encodes one particular protein sequence as well as all nucleic acids, including degenerate nucleic acids, encoding the disclosed variants and derivatives of the protein sequences. Thus, while each particular nucleic acid sequence may not be written out herein, it is understood that each and every sequence is in fact disclosed and described herein through the disclosed protein sequence. It is also understood that while no amino acid sequence indicates what particular DNA sequence encodes that protein within an organism, where particular variants of a disclosed protein are disclosed herein, the known nucleic acid sequence that encodes that protein in the particular organism from which that protein arises is also known and herein disclosed and described.

130. It is understood that there are numerous amino acid and peptide analogs which can be incorporated into the disclosed compositions. For example, there are numerous D amino acids or amino acids which have a different functional substituent than the amino acids shown in Table 1 and Table 2. The opposite stereo isomers of naturally occurring peptides are disclosed, as well as the stereo isomers of peptide analogs. These amino acids can readily be incorporated into polypeptide chains by charging tRNA molecules with the amino acid of choice and

engineering genetic constructs that utilize, for example, amber codons, to insert the analog amino acid into a peptide chain in a site specific way (Thorson et al., *Methods in Molec. Biol.* 77:43-73 (1991), Zoller, *Current Opinion in Biotechnology*, 3:348-354 (1992); Ibba, *Biotechnology & Genetic Engineering Reviews* 13:197-216 (1995), Cahill et al., *TIBS*, 14(10):400-403 (1989); Benner, *TIB Tech*, 12:158-163 (1994); Ibba and Hennecke, *Bio/technology*, 12:678-682 (1994) all of which are herein incorporated by reference at least for material related to amino acid analogs).

131. Molecules can be produced that resemble peptides, but which are not connected via a natural peptide linkage. For example, linkages for amino acids or amino acid analogs can include $\text{CH}_2\text{NH--}$, $\text{--CH}_2\text{S--}$, $\text{--CH}_2\text{--CH}_2\text{--}$, --CH=CH-- (cis and trans), $\text{--COCH}_2\text{--}$, $\text{--CH(OH)CH}_2\text{--}$, and $\text{--CHH}_2\text{SO--}$ (These and others can be found in Spatola, A. F. in *Chemistry and Biochemistry of Amino Acids, Peptides, and Proteins*, B. Weinstein, eds., Marcel Dekker, New York, p. 267 (1983); Spatola, A. F., *Vega Data* (March 1983), Vol. 1, Issue 3, *Peptide Backbone Modifications* (general review); Morley, *Trends Pharm Sci* (1980) pp. 463-468; Hudson, D. et al., *Int J Pept Prot Res* 14:177-185 (1979) ($\text{--CH}_2\text{NH--}$, $\text{CH}_2\text{CH}_2\text{--}$); Spatola et al. *Life Sci* 38:1243-1249 (1986) ($\text{--CH H}_2\text{--S--}$); Hann J. *Chem. Soc Perkin Trans. I* 307-314 (1982) (--CH--CH-- , cis and trans); Almquist et al. *J. Med. Chem.* 23:1392-1398 (1980) ($\text{--COCH}_2\text{--}$); Jennings-White et al. *Tetrahedron Lett* 23:2533 (1982) ($\text{--COCH}_2\text{--}$); Szelke et al. *European Appln*, EP 45665 CA (1982): 97:39405 (1982) ($\text{--CH(OH)CH}_2\text{--}$); Holladay et al. *Tetrahedron Lett* 24:4401-4404 (1983) ($\text{--C(OH)CH}_2\text{--}$); and Hruby *Life Sci* 31:189-199 (1982) ($\text{--CH}_2\text{--S--}$); each of which is incorporated herein by reference. A particularly preferred non-peptide linkage is $\text{--CH}_2\text{NH--}$. It is understood that peptide analogs can have more than one atom between the bond atoms, such as b-alanine, g-aminobutyric acid, and the like.

132. Amino acid analogs and analogs and peptide analogs often have enhanced or desirable properties, such as, more economical production, greater chemical stability, enhanced pharmacological properties (half-life, absorption, potency, efficacy, etc.), altered specificity (e.g., a broad-spectrum of biological activities), reduced antigenicity, and others.

133. D-amino acids can be used to generate more stable peptides, because D amino acids are not recognized by peptidases and such. Systematic substitution of one or more amino acids of a consensus sequence with a D-amino acid of the same type (e.g., D-lysine in place of L-lysine) can be used to generate more stable peptides. Cysteine residues can be used to cyclize or attach two or more peptides together. This can be beneficial to constrain peptides into particular

conformations. (Rizo and Gierasch Ann. Rev. Biochem. 61:387 (1992), incorporated herein by reference).

8. Pharmaceutical carriers/Delivery of pharmaceutical products

134. The compositions disclosed herein can also be administered *in vivo* in a pharmaceutically acceptable carrier. By "pharmaceutically acceptable" is meant a material that is not biologically or otherwise undesirable, i.e., the material can be administered to a subject, along with the nucleic acid or vector, without causing any undesirable biological effects or interacting in a deleterious manner with any of the other components of the pharmaceutical composition in which it is contained. The carrier would naturally be selected to minimize any degradation of the active ingredient and to minimize any adverse side effects in the subject, as would be well known to one of skill in the art.

135. The compositions can be administered orally, parenterally (e.g., intravenously), by intramuscular injection, by intraperitoneal injection, transdermally, extracorporeally, topically or the like, including topical intranasal administration or administration by inhalant. As used herein, "topical intranasal administration" means delivery of the compositions into the nose and nasal passages through one or both of the nares and can comprise delivery by a spraying mechanism or droplet mechanism, or through aerosolization of the nucleic acid or vector. Administration of the compositions by inhalant can be through the nose or mouth via delivery by a spraying or droplet mechanism. Delivery can also be directly to any area of the respiratory system (e.g., lungs) via intubation. The exact amount of the compositions required will vary from subject to subject, depending on the species, age, weight and general condition of the subject, the severity of the allergic disorder being treated, the particular nucleic acid or vector used, its mode of administration and the like. Thus, it is not possible to specify an exact amount for every composition. However, an appropriate amount can be determined by one of ordinary skill in the art using only routine experimentation given the teachings herein.

136. Parenteral administration of the composition, if used, is generally characterized by injection. Injectables can be prepared in conventional forms, either as liquid solutions or suspensions, solid forms suitable for solution or suspension in liquid prior to injection, or as emulsions. A more recently revised approach for parenteral administration involves use of a slow release or sustained release system such that a constant dosage is maintained. See, e.g., U.S. Patent No. 3,610,795, which is incorporated by reference herein.

137. The materials can be in solution, suspension (for example, incorporated into microparticles, liposomes, or cells). These can be targeted to a particular cell type via

antibodies, receptors, or receptor ligands. The following references are examples of the use of this technology to target specific proteins to tumor tissue (Senter, et al., *Bioconjugate Chem.*, 2:447-451, (1991); Bagshawe, K.D., *Br. J. Cancer*, 60:275-281, (1989); Bagshawe, et al., *Br. J. Cancer*, 58:700-703, (1988); Senter, et al., *Bioconjugate Chem.*, 4:3-9, (1993); Battelli, et al., *Cancer Immunol. Immunother.*, 35:421-425, (1992); Pietersz and McKenzie, *Immunolog. Reviews*, 129:57-80, (1992); and Roffler, et al., *Biochem. Pharmacol.*, 42:2062-2065, (1991)). Vehicles such as "stealth" and other antibody conjugated liposomes (including lipid mediated drug targeting to colonic carcinoma), receptor mediated targeting of DNA through cell specific ligands, lymphocyte directed tumor targeting, and highly specific therapeutic retroviral targeting of murine glioma cells *in vivo*. The following references are examples of the use of this technology to target specific proteins to tumor tissue (Hughes et al., *Cancer Research*, 49:6214-6220, (1989); and Litzinger and Huang, *Biochimica et Biophysica Acta*, 1104:179-187, (1992)). In general, receptors are involved in pathways of endocytosis, either constitutive or ligand induced. These receptors cluster in clathrin-coated pits, enter the cell via clathrin-coated vesicles, pass through an acidified endosome in which the receptors are sorted, and then either recycle to the cell surface, become stored intracellularly, or are degraded in lysosomes. The internalization pathways serve a variety of functions, such as nutrient uptake, removal of activated proteins, clearance of macromolecules, opportunistic entry of viruses and toxins, dissociation and degradation of ligand, and receptor-level regulation. Many receptors follow more than one intracellular pathway, depending on the cell type, receptor concentration, type of ligand, ligand valency, and ligand concentration. Molecular and cellular mechanisms of receptor-mediated endocytosis has been reviewed (Brown and Greene, *DNA and Cell Biology* 10:6, 399-409 (1991)).

a) Pharmaceutically Acceptable Carriers

138. The compositions, including antibodies, can be used therapeutically in combination with a pharmaceutically acceptable carrier.

139. Suitable carriers and their formulations are described in *Remington: The Science and Practice of Pharmacy* (19th ed.) ed. A.R. Gennaro, Mack Publishing Company, Easton, PA 1995. Typically, an appropriate amount of a pharmaceutically-acceptable salt is used in the formulation to render the formulation isotonic. Examples of the pharmaceutically-acceptable carrier include, but are not limited to, saline, Ringer's solution and dextrose solution. The pH of the solution is preferably from about 5 to about 8, and more preferably from about 7 to about 7.5. Further carriers include sustained release preparations such as semipermeable matrices of solid

hydrophobic polymers containing the antibody, which matrices are in the form of shaped articles, e.g., films, liposomes or microparticles. It will be apparent to those persons skilled in the art that certain carriers may be more preferable depending upon, for instance, the route of administration and concentration of composition being administered.

140. Pharmaceutical carriers are known to those skilled in the art. These most typically would be standard carriers for administration of drugs to humans, including solutions such as sterile water, saline, and buffered solutions at physiological pH. The compositions can be administered intramuscularly or subcutaneously. Other compounds will be administered according to standard procedures used by those skilled in the art.

141. Pharmaceutical compositions can include carriers, thickeners, diluents, buffers, preservatives, surface active agents and the like in addition to the molecule of choice. Pharmaceutical compositions can also include one or more active ingredients such as antimicrobial agents, antiinflammatory agents, anesthetics, and the like.

142. The pharmaceutical composition can be administered in a number of ways depending on whether local or systemic treatment is desired, and on the area to be treated. Administration can be topically (including ophthalmically, vaginally, rectally, intranasally), orally, by inhalation, or parenterally, for example by intravenous drip, subcutaneous, intraperitoneal or intramuscular injection. The disclosed antibodies can be administered intravenously, intraperitoneally, intramuscularly, subcutaneously, intracavity, or transdermally.

143. Preparations for parenteral administration include sterile aqueous or non-aqueous solutions, suspensions, and emulsions. Examples of non-aqueous solvents are propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable organic esters such as ethyl oleate. Aqueous carriers include water, alcoholic/aqueous solutions, emulsions or suspensions, including saline and buffered media. Parenteral vehicles include sodium chloride solution, Ringer's dextrose, dextrose and sodium chloride, lactated Ringer's, or fixed oils. Intravenous vehicles include fluid and nutrient replenishers, electrolyte replenishers (such as those based on Ringer's dextrose), and the like. Preservatives and other additives can also be present such as, for example, antimicrobials, anti-oxidants, chelating agents, and inert gases and the like.

144. Formulations for topical administration can include ointments, lotions, creams, gels, drops, suppositories, sprays, liquids and powders. Conventional pharmaceutical carriers, aqueous, powder or oily bases, thickeners and the like could be necessary or desirable.

145. Compositions for oral administration include powders or granules, suspensions or solutions in water or non-aqueous media, capsules, sachets, or tablets. Thickeners, flavorings, diluents, emulsifiers, dispersing aids or binders could be desirable..

146. Some of the compositions can be administered as a pharmaceutically acceptable acid- or base- addition salt, formed by reaction with inorganic acids such as hydrochloric acid, hydrobromic acid, perchloric acid, nitric acid, thiocyanic acid, sulfuric acid, and phosphoric acid, and organic acids such as formic acid, acetic acid, propionic acid, glycolic acid, lactic acid, pyruvic acid, oxalic acid, malonic acid, succinic acid, maleic acid, and fumaric acid, or by reaction with an inorganic base such as sodium hydroxide, ammonium hydroxide, potassium hydroxide, and organic bases such as mono-, di-, trialkyl and aryl amines and substituted ethanolamines.

b) Therapeutic Uses

147. Effective dosages and schedules for administering the compositions can be determined empirically, and making such determinations is within the skill in the art. The dosage ranges for the administration of the compositions are those large enough to produce the desired effect in which the symptoms of disorder are affected. The dosage should not be so large as to cause adverse side effects, such as unwanted cross-reactions, anaphylactic reactions, and the like. Generally, the dosage will vary with the age, condition, sex and extent of the disease in the patient, route of administration, or whether other drugs are included in the regimen, and can be determined by one of skill in the art. The dosage can be adjusted by the individual physician in the event of any counterindications. Dosage can vary, and can be administered in one or more dose administrations daily, for one or several days. Guidance can be found in the literature for appropriate dosages for given classes of pharmaceutical products. For example, guidance in selecting appropriate doses for antibodies can be found in the literature on therapeutic uses of antibodies, e.g., Handbook of Monoclonal Antibodies, Ferrone et al., eds., Noyes Publications, Park Ridge, N.J., (1985) ch. 22 and pp. 303-357; Smith et al., Antibodies in Human Diagnosis and Therapy, Haber et al., eds., Raven Press, New York (1977) pp. 365-389. A typical daily dosage of the antibody used alone might range from about 1 $\mu\text{g/kg}$ to up to 100 mg/kg of body weight or more per day, depending on the factors mentioned above.

148. Following administration of a disclosed composition, such as a vector, for treating, inhibiting, or preventing inflammation, the efficacy of the therapeutic vector can be assessed in various ways well known to the skilled practitioner. For instance, one of ordinary skill in the art will understand that a composition, such as a vector, disclosed herein is

efficacious in treating or inhibiting inflammation in a subject by observing that the composition reduces inflammation.

9. Animals

149. Provided herein are transgenic animals comprising germline transmission of any of the vectors or nucleic acids provided herein. In one aspect, the transgenic animal provided herein is an excision activated transgenic (XAT) animal. The disclosed transgenic animals can have temporally and spatially regulated transgene expression (Brooks, AI, et al. 1991. *Nature Biotech* 15:57-62; Brooks, AI, et al. 1999. *Neuroreport* 10:337-344; Brooks, AI, et al. 2000. *Proc Natl Acad Sci USA* 97:13378-13383) of an inflammation element. It is understood that where the transgenic animal comprises a nucleic acid comprising a recombination site, as disclosed herein, delivery of a recombinase, such as Cre recombinase to cells within the provided transgenic animal will result in the expression of the inflammatory modulator, e.g., IL-1 β , IL-1ra, COX-2, within those cells.

150. By a "transgene" is meant a nucleic acid sequence that is inserted by artifice into a cell and becomes a part of the genome of that cell and its progeny. Such a transgene can be (but is not necessarily) partly or entirely heterologous (e.g., derived from a different species) to the cell. The term "transgene" broadly refers to any nucleic acid that is introduced into an animal's genome, including but not limited to genes or DNA having sequences which are perhaps not normally present in the genome, genes which are present, but not normally transcribed and translated ("expressed") in a given genome, or any other gene or DNA which one desires to introduce into the genome. This can include genes which are normally present in the nontransgenic genome but which one desires to have altered in expression, or which one desires to introduce in an altered or variant form. A transgene can include one or more transcriptional regulatory sequences and any other nucleic acid, such as introns, that can be necessary for optimal expression of a selected nucleic acid. A transgene can be as few as a couple of nucleotides long, but is preferably at least about 50, 100, 150, 200, 250, 300, 350, 400, or 500 nucleotides long or even longer and can be, e.g., an entire genome. A transgene can be coding or non-coding sequences, or a combination thereof. A transgene usually comprises a regulatory element that is capable of driving the expression of one or more transgenes under appropriate conditions. By "transgenic animal" is meant an animal comprising a transgene as described above. Transgenic animals are made by techniques that are well known in the art. The disclosed nucleic acids, in whole or in part, in any combination, can be transgenes as disclosed herein.

151. Disclosed are animals produced by the process of transfecting a cell within the animal with any of the nucleic acid molecules disclosed herein. Disclosed are animals produced by the process of transfecting a cell within the animal any of the nucleic acid molecules disclosed herein, wherein the animal is a mammal. Also disclosed are animals produced by the process of transfecting a cell within the animal any of the nucleic acid molecules disclosed herein, wherein the mammal is mouse, rat, rabbit, cow, sheep, pig, or primate.

152. The disclosed transgenic animals can be any non-human animal, preferably a non-human mammal (e.g. mouse, rat, rabbit, squirrel, hamster, rabbits, guinea pigs, pigs, micro-pigs, prairie dogs, baboons, squirrel monkeys and chimpanzees, etc), bird or an amphibian, in which one or more cells contain heterologous nucleic acid introduced by way of human intervention, such as by transgenic techniques well known in the art. The nucleic acid is introduced into the cell, directly or indirectly, by introduction into a precursor of the cell, such as by microinjection or by infection with a recombinant virus. The disclosed transgenic animals can also include the progeny of animals which had been directly manipulated or which were the original animal to receive one or more of the disclosed nucleic acids. This molecule can be integrated within a chromosome, or it can be extrachromosomally replicating DNA. For techniques related to the production of transgenic animals, see, inter alia, Hogan et al (1986) *Manipulating the Mouse Embryo--A Laboratory Manual* Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y., 1986).

153. Animals suitable for transgenic experiments can be obtained from standard commercial sources such as Charles River (Wilmington, Mass.), Taconic (Germantown, N.Y.), and Harlan Sprague Dawley (Indianapolis, Ind.). For example, if the transgenic animal is a mouse, many mouse strains are suitable, but C57BL/6 female mice can be used for embryo retrieval and transfer. C57BL/6 males can be used for mating and vasectomized C57BL/6 studs can be used to stimulate pseudopregnancy. Vasectomized mice and rats can be obtained from the supplier. Transgenic animals can be made by any known procedure, including microinjection methods, and embryonic stem cells methods. The procedures for manipulation of the rodent embryo and for microinjection of DNA are described in detail in Hogan et al., *Manipulating the Mouse Embryo* (Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y., 1986), the teachings of which are generally known and are incorporated herein.

154. Transgenic animals can be identified by analyzing their DNA. For this purpose, for example, when the transgenic animal is an animal with a tail, such as rodent, tail samples (1 to 2 cm) can be removed from three week old animals. DNA from these or other samples can

then be prepared and analyzed, for example, by Southern blot, PCR, or slot blot to detect transgenic founder (F (0)) animals and their progeny (F (1) and F (2)). The present invention further provides transgenic non-human animals that are progeny of crosses between a transgenic animal of the invention and a second animal. Transgenic animals can be bred with other transgenic animals, where the two transgenic animals were generated using different transgenes, to test the effect of one gene product on another gene product or to test the combined effects of two gene products.

155. The provided compositions can be evaluated using a mouse model of arthritis. As prolonged expression of IL-1 β in the joint can lead to the development of arthrosis similar to that seen in arthritis patients, disclosed is a mouse model of arthritis based on prolonged, low level intra-articular transgenic expression of IL-1 β . The role of IL-1 β , TNF α and other inflammatory mediators, such as prostanoids, are well recognized in the pathogenesis of arthritis. The two most commonly forms of arthritis are osteoarthritis (OA), which affects about 80%-90% of all adults over the age of 65, and rheumatoid arthritis (RA), which affects approximately 1% of the general U.S. population. Although distinct differences exist between OA and RA, both appear to develop secondary to a pro-inflammatory cascade. Previous animal models have proven valuable in studying arthritis and testing novel therapies, including the model of methylated bovine serum albumin/IL-1 β , intra-articular administration of IL-1 β , constitutive intra-articular expression of IL-1 β following ex vivo transfer of genetically engineered synoviocytes, as well as the TNF α transgenic mouse model. The aforementioned IL-1 β models are based on the direct administration of a deleterious agent, whereas the TNF α transgenic mouse is based on the prolonged expression of TNF α in vivo and has thus far yielded valuable insight on the role of TNF α in the development of arthritis. However, as with the majority of transgenic mice, TNF α transgenesis is susceptible to uncontrolled and uncharacterized developmental compensatory changes.

156. The provided mouse model is based on a method (somatic mosaic analysis) utilizing a germline transmitted recombinational substrate containing a dormant transcription unit and somatic gene transfer of a viral vector that expresses Cre recombinase that "activates" the gene of interest. IL-1 β excisionally activated transgenic (IL-1 β^{XAT}) mice, and variations thereof, have been generated using this method. The provided mouse model is the subject of U.S. Patent Application No. 60/627,604, which is herein incorporated by reference in its entirety. This mouse model allows for the induction of localized inflammation based on the delivery of a Cre recombinase expression vector such as FIV(Cre) to the target site. Variations include the use of

cell or tissue specific promoters such as in for example the COL1A1-IL-1 β^{XAT} mouse. For example, the delivery of FIV(Cre) to, for example, the joints of the COL1A1-IL-1 β^{XAT} mouse can induce inflammation to model arthritis. This mouse model can thus be used to, for example, test or optimize the effects of the provided constructs on arthritis. As another example, delivery of FIV(Cre) to the circulation or joint of the COL1A1-IL-1 β^{XAT} mouse can induce inflammation in the brain to model, for example, Alzheimer's disease.

157. IL1 β^{XAT} regulation is controlled in a temporal (time) and spatial (location) fashion by the Cre/loxP molecular genetic method utilizing (1) a germline transmitted recombinational substrate (e.g. COL1A1-IL1 β^{XAT}) containing a dormant transcription unit and (2) somatic gene transfer of a viral vector that expresses Cre recombinase which "activates" the gene of interest. Thus, these mice can be used herein to induce IL-1 β constitutive expression in the joints (e.g., knee) of mice. As an example, localized transgene activation, i.e., IL-1 β , can be accomplished in IL-1 β^{XAT} mice by the intracapsular injection of FIV(Cre), a lentivirus capable of transducing soft and hard tissues of joints, to the area of interest, and subsequent recombinational excision of the ►STOP► cassette leading to gene transcription. Recombination-mediated gene "activation" permanently alters the genetic constitution of infected cells thus allowing chronic IL-1 β synthesis. The COL1A1 promoter can further be used to target gene expression to chondrocytes, osteocytes and fibroblasts, making this transgenic mouse available for the study of arthritis in any joint of interest. This promoter has been shown to target gene expression in bone and cartilage and was cloned in the IL-1 β^{XAT} gene in place of the CMV promoter (Figure 1): (COL1A1-IL1 β^{XAT}) COL1A1 => ►STOP► ssIL1 β – IRES – lacZ

158. COL2 is another suitable promoter. This transgene has been constructed and tested in a murine NIH 3T3 stable cell line following expression of Cre recombinase by the transient transfection of the pRc/CMV-CreWT expression vector or after infection by the lentiviral vector FIV(Cre).

159. The somatic gene transfer of the recombinase, such as Cre can be performed using any type of vector system producing the recombinase. However, in certain embodiments, the vector system is a self inactivating vector system, wherein the promoter, for example, of the recombinase is flanked by recombination sites so that upon production of the recombinase, the recombinase will down regulate its own production. The delivery vectors for the recombinase can be CRE mediated.

160. For example, activation of the dormant $\text{COLL1-IL1}\beta^{\text{XAT}}$ can be mediated by the transfer of Cre recombinase to the area of interest (e.g. knee) via a self-inactivating Cre feline immunodeficiency virus FIV(Cre). The effects of this FIV vector system have been previously examined using the reporter gene lacZ (β -galactosidase) in mice that received intra-articular injections of a viral solution [Kyrkanides S, *et al.* (2004). *J Dental Res* 83: 65-70], wherein transduction of soft (articular disc) and hard (cartilage) TMJ tissues was demonstrated. The FIV(Cre)vector has been constructed by cloning a loxP-flanked ("floxed") nlsCre cassette in the place of the lacZ gene; the nuclear localization signal (nls) was fused to the *cre* open reading frame by PCR and subsequently cloned into the TOPO 2.1 vector (Invitrogen) per manufacturer's instructions employing a custom-made floxed cloning cassette. The reason for developing a self-inactivating *cre* gene is based on a recent paper [Pfeifer A and Brandon EP, Kootstra Neeltje, Gage FH, Verma IM (2001). *Proc Natl Acad Sci U.S.A.* 98: 11450-5], whereby the authors reported cytotoxicity due to prolonged expression of Cre recombinase mediated by infection using a lentiviral vector. In the provided construct, upon production of adequate levels of Cre recombinase to produce excisional activation of $\text{COLL1-IL1}\beta^{\text{XAT}}$ following successful transduction of target cells with FIV(Cre), Cre is anticipated to de-activate the *cre* gene by loxP-directed self excisional recombination.

10. Kits

161. Disclosed herein are kits that are drawn to reagents that can be used in practicing the methods disclosed herein. The kits can include any reagent or combination of reagent discussed herein or that would be understood to be required or beneficial in the practice of the disclosed methods. For example, the kits could include primers to perform the amplification reactions discussed in certain embodiments of the methods, as well as the buffers and enzymes required to use the primers as intended.

D. Methods of making the compositions

162. The compositions disclosed herein and the compositions necessary to perform the disclosed methods can be made using any method known to those of skill in the art for that particular reagent or compound unless otherwise specifically noted.

1. Nucleic acid synthesis

163. For example, the nucleic acids, such as, the oligonucleotides to be used as primers can be made using standard chemical synthesis methods or can be produced using enzymatic methods or any other known method. Such methods can range from standard enzymatic digestion followed by nucleotide fragment isolation (see for example, Sambrook *et al.*,

Molecular Cloning: A Laboratory Manual, 2nd Edition (Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 1989) Chapters 5, 6) to purely synthetic methods, for example, by the cyanoethyl phosphoramidite method using a Milligen or Beckman System 1Plus DNA synthesizer (for example, Model 8700 automated synthesizer of Milligen-Bioscience, Burlington, MA or ABI Model 380B). Synthetic methods useful for making oligonucleotides are also described by Ikuta *et al.*, *Ann. Rev. Biochem.* 53:323-356 (1984), (phosphotriester and phosphite-triester methods), and Narang *et al.*, *Methods Enzymol.*, 65:610-620 (1980), (phosphotriester method). Protein nucleic acid molecules can be made using known methods such as those described by Nielsen *et al.*, *Bioconjug. Chem.* 5:3-7 (1994).

2. Peptide synthesis

164. One method of producing the disclosed proteins, such as SEQ ID NO:5, is to link two or more peptides or polypeptides together by protein chemistry techniques. For example, peptides or polypeptides can be chemically synthesized using currently available laboratory equipment using either Fmoc (9-fluorenylmethyloxycarbonyl) or Boc (*tert*-butyloxycarbonyl) chemistry. (Applied Biosystems, Inc., Foster City, CA). One skilled in the art can readily appreciate that a peptide or polypeptide corresponding to the disclosed proteins, for example, can be synthesized by standard chemical reactions. For example, a peptide or polypeptide can be synthesized and not cleaved from its synthesis resin whereas the other fragment of a peptide or protein can be synthesized and subsequently cleaved from the resin, thereby exposing a terminal group which is functionally blocked on the other fragment. By peptide condensation reactions, these two fragments can be covalently joined via a peptide bond at their carboxyl and amino termini, respectively, to form an antibody, or fragment thereof. (Grant GA (1992) *Synthetic Peptides: A User Guide*. W.H. Freeman and Co., N.Y. (1992); Bodansky M and Trost B., Ed. (1993) *Principles of Peptide Synthesis*. Springer-Verlag Inc., NY (which is herein incorporated by reference at least for material related to peptide synthesis). Alternatively, the peptide or polypeptide is independently synthesized *in vivo* as described herein. Once isolated, these independent peptides or polypeptides can be linked to form a peptide or fragment thereof via similar peptide condensation reactions.

165. For example, enzymatic ligation of cloned or synthetic peptide segments allow relatively short peptide fragments to be joined to produce larger peptide fragments, polypeptides or whole protein domains (Abrahmsen L *et al.*, *Biochemistry*, 30:4151 (1991)). Alternatively, native chemical ligation of synthetic peptides can be utilized to synthetically construct large peptides or polypeptides from shorter peptide fragments. This method consists of a two step

chemical reaction (Dawson et al. Synthesis of Proteins by Native Chemical Ligation. Science, 266:776-779 (1994)). The first step is the chemoselective reaction of an unprotected synthetic peptide--thioester with another unprotected peptide segment containing an amino-terminal Cys residue to give a thioester-linked intermediate as the initial covalent product. Without a change in the reaction conditions, this intermediate undergoes spontaneous, rapid intramolecular reaction to form a native peptide bond at the ligation site (Baggiolini M et al. (1992) FEBS Lett. 307:97-101; Clark-Lewis I et al., J.Biol.Chem., 269:16075 (1994); Clark-Lewis I et al., Biochemistry, 30:3128 (1991); Rajarathnam K et al., Biochemistry 33:6623-30 (1994)).

166. Alternatively, unprotected peptide segments are chemically linked where the bond formed between the peptide segments as a result of the chemical ligation is an unnatural (non-peptide) bond (Schnolzer, M et al. Science, 256:221 (1992)). This technique has been used to synthesize analogs of protein domains as well as large amounts of relatively pure proteins with full biological activity (deLisle Milton RC et al., Techniques in Protein Chemistry IV. Academic Press, New York, pp. 257-267 (1992)).

3. Processes for making the compositions

167. Disclosed are processes for making the compositions as well as making the intermediates leading to the compositions. There are a variety of methods that can be used for making these compositions, such as synthetic chemical methods and standard molecular biology methods. It is understood that the methods of making these and the other disclosed compositions are specifically disclosed.

168. Disclosed are nucleic acid molecules produced by the process comprising linking in an operative way a promoter element and a nucleic acid element disclosed herein. The nucleic acid element can, for example, encode a ligand binding inhibitor. Thus, disclosed are nucleic acid molecules produced by the process comprising linking in an operative way a promoter element and an IL-1ra element. Also disclosed is a nucleic acid molecule produced by the process comprising linking in an operative way a promoter element and an IL-1R2 element. Also disclosed is a nucleic acid molecules produced by the process comprising linking in an operative way a promoter element and an IL-1R1 fragment element. Also disclosed is a nucleic acid molecules produced by the process comprising linking in an operative way a promoter element and an IL-1 fragment element.

169. Also disclosed are nucleic acid molecules produced by the process comprising linking in an operative way a promoter element and a nucleic acid element wherein the nucleic acid encodes a gene expression inhibitor disclosed herein. As an example, disclosed are nucleic

acid molecules produced by the process comprising linking in an operative way a promoter element and a COX-1 siRNA element. Also disclosed are nucleic acid molecules produced by the process comprising linking in an operative way a promoter element and a COX-2 siRNA element. Also disclosed are nucleic acid molecules produced by the process comprising linking in an operative way a promoter element and a mPGES siRNA element. Also disclosed are nucleic acid molecules produced by the process comprising linking in an operative way a promoter element and cPGES siRNA element.

170. Further disclosed are cells produced by the process of transforming the cell with any of the disclosed nucleic acids. Disclosed are cells produced by the process of transforming the cell with any of the non-naturally occurring disclosed nucleic acids.

171. Disclosed are any of the peptides produced by the process of expressing any of the disclosed nucleic acids. Disclosed are any of the non-naturally occurring disclosed peptides produced by the process of expressing any of the disclosed nucleic acids. Disclosed are any of the disclosed peptides produced by the process of expressing any of the non-naturally disclosed nucleic acids.

172. Disclosed are animals produced by the process of transfecting a cell within the animal with any of the nucleic acid molecules disclosed herein. Disclosed are animals produced by the process of transfecting a cell within the animal any of the nucleic acid molecules disclosed herein, wherein the animal is a mammal. Also disclosed are animals produced by the process of transfecting a cell within the animal any of the nucleic acid molecules disclosed herein, wherein the mammal is mouse, rat, rabbit, cow, sheep, pig, or primate. Also disclosed are mammals wherein mammal is a murine, ungulate, or non-human primate.

173. Also disclosed are animals produced by the process of adding to the animal any of the cells disclosed herein.

E. Methods of using the compositions

1. Methods of using the compositions as research tools

174. The disclosed compositions can be used in a variety of ways as research tools. For example, the disclosed compositions, such as SEQ ID NOs:5 can be used to study the interactions between IL-1 and IL-1R1, by for example acting as inhibitors of binding.

2. Therapeutic Uses

175. Effective dosages and schedules for administering the compositions can be determined empirically, and making such determinations is within the skill in the art. The dosage ranges for the administration of the compositions are those large enough to produce the

desired effect in which the symptoms of the disorder are affected. The dosage should not be so large as to cause adverse side effects, such as unwanted cross-reactions, anaphylactic reactions, and the like. Generally, the dosage will vary with the age, condition, sex and extent of the disease in the patient, route of administration, or whether other drugs are included in the regimen, and can be determined by one of skill in the art. The dosage can be adjusted by the individual physician in the event of any counterindications. Dosage can vary, and can be administered in one or more dose administrations daily, for one or several days. Guidance can be found in the literature for appropriate dosages for given classes of pharmaceutical products.

176. Following administration of a disclosed composition, such as the disclosed constructs, for treating, inhibiting, or preventing inflammation, the efficacy of the therapeutic construct can be assessed in various ways well known to the skilled practitioner. For instance, one of ordinary skill in the art will understand that a composition, such as the disclosed constructs, disclosed herein is efficacious in treating inflammation or inhibiting or reducing the effects of inflammation in a subject by observing that the composition reduces the onset of the conditions associated with these diseases. Furthermore, the amount of protein or transcript produced from the constructs can be analyzed using any diagnostic method. For example, it can be measured using polymerase chain reaction assays to detect the presence of construct nucleic acid or antibody assays to detect the presence of protein produced from the construct in a sample (e.g., but not limited to, blood or other cells, such as neural cells) from a subject or patient.

F. Examples

177. The following examples are put forth so as to provide those of ordinary skill in the art with a complete disclosure and description of how the compounds, compositions, articles, devices and/or methods claimed herein are made and evaluated, and are intended to be purely exemplary and are not intended to limit the disclosure. Efforts have been made to ensure accuracy with respect to numbers (e.g., amounts, temperature, etc.), but some errors and deviations should be accounted for. Unless indicated otherwise, parts are parts by weight, temperature is in °C or is at ambient temperature, and pressure is at or near atmospheric.

1. Example 1 - Construction of an inducible Interleukin-1 β transgene - IL-1 β ^{XAT}

178. The human IL-1 β cDNA was cloned from human U937 cells (ATCC, Manassas VA) by polymerase chain reaction (PCR) as follows: Total mRNA was extracted employing the TRIzol® reagent (Invitrogen, Carlsbad CA) per manufacturer's instructions. PCR primers were designed for the amplification of the portion of the cDNA that corresponds to the mature,

secreted IL-1 β protein. The peptide secretion signal (ss) of the human IL-1 receptor antagonist gene (IL1-RA) was incorporated into the upper PCR primer, upstream to the IL-1 β open reading frame (ORF), to ensure proper compartmentalization and secretion of the transgenic IL-1 β peptide. This PCR-synthesized ss-IL1 β fusion construct was cloned directly into the TOPO 2.1 vector (Invitrogen) per manufacturer's instructions. Subsequently, the cell autonomous and gratuitous β -galactosidase reporter gene (lacZ) was inserted down-stream to the IL-1 β ORF, followed by the bovine growth hormone poly A tail (pA) sequence: ssIL-1 β -IRES-lacZ bicistronic gene (Fig. 1). Translation of the second ORF, lacZ, is facilitated by an internal ribosomal entry sequence (IRES). During the initial stages of experimentation, expression of the bicistronic ssIL-1 β -IRES-lacZ transgene was ubiquitously driven by the cytomegalovirus promoter (CMV), the transcription of which was inhibited by a loxP-flanked (floxed) transcriptional termination cassette STOPfl/fl. Transcriptional activation and transgene expression can be turned-on by loxP-directed DNA recombination mediated by the bacteriophage P1 Cre recombinase (Cre/loxP system).

a) Cre-mediated activation of the inducible IL-1 β^{XAT} transgene

179. The function of IL-1 β^{XAT} was tested in vitro by two different experimental strategies. First, IL-1 β^{XAT} regulation by Cre recombinase was evaluated in NIH 3T3 murine fibroblasts (ATCC) in vitro. The IL-1 β^{XAT} gene was transiently co-expressed with the wild type cre gene (cloned into the expression vector pRc/CMV-CreWT; Invitrogen) following transient transfection using the LIPOFECTAMINE 2000 reagent (Invitrogen) per manufacturer's instructions. As anticipated, transient expression of Cre recombinase resulted in loxP-directed DNA recombination of IL-1 β^{XAT} and excision of the "floxed" transcriptional termination signal ►STOP►, ultimately leading to gene activation. Control conditions included co-transfection of IL-1 β^{XAT} with the expression vector pRc/CMV- (lacking any gene), as well as naïve NIH 3T3 cells. IL-1 β expression was assessed at the mRNA level by reverse transcriptase PCR (RT-PCR), and lacZ expression was evaluated by X-gal histochemistry. In brief, no IL-1 β transcript was detected in naïve NIH 3T3 cells; in contrast, IL-1 β^{XAT} + Cre co-transfection resulted in induction of ssIL-1 β and lacZ gene expression (Fig. 2). In addition, IL-1 β^{XAT} function was evaluated in the inducible Cre recombinase cell line, 293HGLVP/CrePr, a stable cell line recently developed for testing the regulation of excisionally-activated genes utilizing the Cre/loxP technology and described in U.S. Patent Application No. 10/978927, herein incorporated by reference). This cell line comprises an inducible, loxP-directed DNA recombination system by placing Cre recombinase under dual transcriptional and post-translational control (Kyrkanides et al., 2003,

herein incorporated by reference). In brief, the system is comprised of two components: (1) The chimeric transcriptional activator GLVP and (2) the CrePr fusion protein, which consists of the bacterial Cre recombinase and the mutated progesterone receptor hPR891 gene, driven by a custom GAL45/TATA minimal promoter. The mutated hPR891 receptor is highly sensitive to the synthetic progesterone compound mifepristone (RU486). Binding of RU486 to hPR891 results in activation of GLVP and subsequent synthesis of CrePr, the activity of which is also turned-on by RU486 at the post-translational level. RU486 administration to 293HGLVP/CrePr cells following IL-1 β^{XAT} transfection resulted in DNA excisional recombination and subsequent expression of human IL-1 β and the bacterial β -galactosidase reporter gene (lacZ). Please refer to Figure 3 for summary of the experiment.

b) IL-1 β^{XAT} activation produces a biologically potent IL-1 β cytokine

180. The ability of murine cells to synthesize and secrete biologically active IL-1 β cytokine was tested in vitro as follows. In an experiment similar to that described in Figure 2, murine NIH 3T3 fibroblasts were transfected with the IL-1 β^{XAT} gene. Concomitantly, Cre recombinase was transiently expressed in these cells (co-transfection of the pRc/CMV-CreWT vector), and the conditioned supernatant media were collected at 72 hours. The presence of human IL-1 β was confirmed by ELISA. The conditioned media were then placed on naïve murine fibroblasts, and levels of the inducible cyclooxygenase COX-2 were evaluated as a measure of cytokine potency by quantitative RT-PCR in total mRNA extracts using protocols previously described [Moore, AH, et al. Journal of Neuroimmunology. 148(1-2):32-40, 2004]. Control experimental conditions included conditioned media derived from cells co-transfected with the pRc/CMV- backbone vector (lacking the cre gene) along with the IL-1 β^{XAT} gene, as well as naïve cells. In brief, murine fibroblasts treated with conditioned medium collected from Cre-activated IL-1 β^{XAT} cells resulted in significant COX-2 induction compared to cells exposed to media derived from pRc/CMV-treated or naïve cells. Please see Figure 4 for a summary of the experiment.

c) IL-1 β induces down-stream inflammation-related genes

181. IL-1 β is a multi-potent pro-inflammatory cytokine, the expression of which is rapidly upregulated following trauma and/or inflammation. Moreover, a plethora of inflammation-related genes are in turn induced by IL-1 β , leading to exacerbation of the inflammatory response. IL-1 β regulates down-stream inflammatory genes, including the inducible isoform of cyclooxygenase (COX-2) and the intercellular adhesion molecule-1 (ICAM-1), the monocyte chemoattractant protein-1 (MCP-1), as well as collagenases A (MMP-2) and B

(MMP-9). ICAM-1 and MCP-1 are molecules associated with the recruitment of circulating immune cells at the site of injury (i.e. neutrophils and monocytes, respectively), whereas MMP-2 and MMP-9 are collagenases associated with tissue destruction during arthritis and injury. Primary rat endothelial cells were employed as a representative rodent model to investigate the effects of IL-1 β on the regulation of ICAM-1, MCP-1, MMP-2 and MMP-9 at the transcriptional level (mRNA) as well as the enzyme activity level (zymography). Figure 5 summarizes the regulation of these genes over time. IL-1 β upregulated the synthesis of COX-2, MCP-1, ICAM-1 and the inducible collagenase B (MMP-9). mRNA levels of the constitutive collagenase B (MMP-2) were not altered by IL-1 β , but interestingly MMP-2 enzyme activity also increased with time, presumably due to post-translational activation from other MMPs.

d) The COL1A1 promoter drives IL-1 β^{XAT} expression to collagen I producing cells

182. Prolonged expression of IL-1 β in the joint can lead to the development of arthrosis similar to that seen in arthritis patients. This can be demonstrated using temporally and spatially controlled expression of IL-1 β in mice, which can be accomplished by targeting IL-1 β^{XAT} transgene expression to chondrocytes, osteocytes and fibroblasts by the 3.6 Kb promoter of the A1 chain of pro-collagen 1 gene. This promoter has been shown to target gene expression in bone and cartilage and was cloned in the IL-1 β^{XAT} gene in place of the CMV promoter (Figure 1): (COL1A1-IL1 β^{XAT}) COL1A1 \Rightarrow \blacktriangleright STOP \blacktriangleright ssIL1 β – IRES – lacZ

183. The collagen 1 promoter was chosen based on the prediction that FIV(Cre) would primarily infect cells located superficially within the joint capsule, including the meniscus, cartilage, and perhaps bone (Kyrkanides et al., 2004). COL2 is another suitable promoter. This transgene has been constructed and tested in a murine NIH 3T3 stable cell line following expression of Cre recombinase by the transient transfection of the pRc/CMV-CreWT expression vector or after infection by the lentiviral vector FIV(Cre). Expression of Cre recombinase led to transgene activation and IL-1 β expression. Please refer to Figure 6 for summary of the experiment.

e) Transgene activation in joints of Col1-IL1 β^{XAT} mice

184. In order to evaluate the effect of transgene activation in the joints of Col1-IL1 β^{XAT} mice, two sets of Col1A1-IL1 β^{XAT} mice received intra-articular FIV(Cre) injections (a total of 10^6 infectious particles) in the right and left knee, as well as the left and right temporomandibular joint (TMJ). The mice were monitored over a period of 8 weeks for changes

in grooming behavior and locomotion. The mice were subsequently sacrificed and their knees and TMJs were histologically analyzed.

185. Behavioral changes were assessed as previously described (Dubuisson, D. and Dennis, S. Pain 1977; 4: 161-74; Abbott FV, et al. Eur J Pharmacol 1986; 126:126-41), which are herein incorporated by reference for teachings related to these methods. In brief, a group of Col1-IL1 β^{XAT} transgenic mice (N=3) received a single intra-articular injection of 10^6 infectious particles of FIV(Cre) in the right and left knees at 2 months of age. In addition, a second group of mice (N=3) received saline injection and served as controls. During a session, each mouse was videotaped for 1 hour. The tape was then transferred digitally to a computer and analyzed in 20 periods of 3 minutes each. The duration of each mouse displaying grooming and licking was recorded and summed as seconds by an investigator who was blind to the animal group assignment. Injection of FIV(Cre) into the knee of Col1-IL1 β^{XAT} transgenic mice resulted in a four-fold increase in the duration of grooming as compared to saline-injected controls (Fig. 9, $P<0.05$).

186. Four groups of mice (N=3) were evaluated in terms of locomotive behavior by the rotorod appliance (Columbus Instruments, Columbus OH) and the lapse time until the mice fell off the rotating cylinder (20 rpm) was recorded. The mice were evaluated over a period of 8 weeks following the intra-articular injections (8 wks – 16 wks of age). As seen in Figure 10, it was demonstrated that FIV(Cre)-injected Col1-IL1 β^{XAT} transgenic mice developed significant locomotive deterioration (Tg+Cre) compared to transgenic mice injected with the control FIV(gfp) vector (TG+gfp), as well as the other control animals groups (WT-Cre & WT-saline).

187. Immunocytochemical detection of the reporter gene β -galactosidase was employed to confirm the activation of the Col1-IL1 β^{XAT} transgene by FIV(Cre) in this mouse model using antibodies raised against β -galactosidase and Cre recombinase. Shown in Figure 11 is FITC-conjugated immunodetection of β -galactosidase (Fig. 11A), Texas Red-conjugated immunodetection of Cre recombinase (Fig. 11B), B/W image of the same microscopic field (Fig. 11C), overlap of panels A+B (Fig. 11D), and overlap of panels A+B+C (Fig. 11E). Demonstrated is the co-expression of β -galactosidase and Cre recombinase *in vivo* (Fig. 11, solid arrows). Note that there are more red cells than green cells (Fig. 11, open arrows) indicating that not all infected cells express the transgene Col1A1 \rightarrow IL1 β -IRES-lacZ in the same capacity.

188. H&E staining of a knee section harvested from a 4 month old Col1-IL1 β^{XAT} transgenic mouse injected with FIV(Cre) revealed the formation of fibrillations (Fig. 12A, solid arrow) and of an articular lip (Fig. 12B, open arrow). In contrast, a transgenic mouse that

received the control vector FIV(GFP) did not develop such anatomic aberrations (Fig. 12B). Alcian blue / orange semi-quantitative evaluation showed a decrease in cartilage (Fig. 12C, less blue stain) and bone (Fig. 12D, less red stain) density in the Col1-IL1 β^{XAT} +FIV(Cre) knees compared to controls (Fig. 12E). Moreover, increased cloning along with thickening of the articular surfaces was observed in the experimental animals (Fig. 12C, indicated by small arrows). These observations indicate the presence of arthritis in the knee following transgene induction by Cre recombinase.

189. Eight weeks after FIV(Cre) injection in the knee and TMJ of Col1-IL1 β^{XAT} mice, the brain was evaluated for activation of microglia and astrocytes by immunocytochemistry. Using a monoclonal antibody raised against the MHC-class II antigen, the presence of activated microglia was detected in the brain (Fig. 13A,C). In contrast, control animals did not display any MHC-II positive cells. Interestingly, there was lack of astrocyte activation in the brains of these animals as assessed by glial fibrillary acidic protein (GFAP) (Fig. 13B,D). In general, control animals (inactive transgenic mice) displayed no signs of brain inflammation by MHC-II or GFAP immunocytochemistry.

190. Eight weeks after FIV(Cre) injection in the TMJ of Col1-IL1 β^{XAT} mice anatomic aberrations of the joint were evaluated by semi-quantitative Alcian blue – orange G histochemistry. Shown in Figures 14A and C are a TMJ section from an inactive Col1-IL1 β^{XAT} mouse depicting the condylar head as well as the meniscus. In comparison, Figures 14B and C depict a TMJ section harvested from a Col1-IL1 β^{XAT} mouse injected with FIV(Cre) in the TMJ. An apparent reorganization of the TMJ cell layers was observed following FIV(Cre) injection, whereby a loss of the most superficial cell layer was noted accompanied by disorganization of the proliferative layer of chondrocytes (Fig. 14, open arrows). In addition, a decrease in cartilage content was observed in the condylar head of FIV(Cre)-treated Col1-IL1 β^{XAT} mice as evaluated semi-quantitatively by Alcian blue – orange G histochemistry (Fig. 14).

2. Example 2 - Development of arthritis in the adult mouse: the IL-1 β somatic mosaic model

a) Development of the IL-1 β somatic mosaic mouse

191. Prolonged, low-level intra-articular expression of IL-1 β in the adult mouse can result in the development of arthritis. This can be demonstrated using the somatic mosaic analysis method for the induction of long-term expression of IL-1 β , due to a permanent change in the genetic constitution of infected cells, at a particular location and during a specific developmental stage. The somatic mosaic analysis model offers significant advantages compared

to traditional transgenic mice, because it avoids compensatory adaptations often encountered in transgenic mice during development and allows regional activation of a gene (Brooks et al., 1997, 1999). The collagen I promoter was chosen based to drive transgene expression based on the prediction that FIV(Cre) would primarily infect cells located superficially within the joint capsule, including the meniscus, cartilage, and perhaps cancellous osteocytes. COLL2 is another choice of suitable promoter.

192. COLL1-IL1 β^{XAT} was microinjected in fertilized C57BL/6 oocytes and subsequently implanted into pseudo-pregnant mothers. One set of micro-injection has already been performed that yielded 8 pups, of which 3 were identified as positive founders by PCR of genomic DNA extracted from tail snips employing primers specifically designed against the IL1 β^{XAT} transgene. The 3 founders have been bred with C57Bl/6 wild type stock mice for analysis of germ-line transmission of a functional transgene (Ngo et al., 2002; Pinkert 2003). In fact, at least two founders have successfully given transgenic pups at the time of grant submission, which were being raised to maturity for further breeding.

b) Characterize the activation of COLL1-IL1 β^{XAT} in vivo

193. COLL1-IL1 β^{XAT} function can be evaluated in transgenic lines after FIV(Cre) injection into the knee joint capsule (approximately 10^7 infectious particles in 50 μ l volume) in 3 month old mice and activation of the dormant COLL1- IL1 β^{XAT} . The ability of FIV(Cre) to activate the dormant COLL1-IL1 β^{XAT} gene has been previously described in U.S. Patent Application No 60/627,604, herein incorporated by reference for this teaching. COLL1-IL1 β^{XAT} activation can be evaluated as follows. First, lacZ expression can be readily assessed in decalcified histology sections by X-gal histochemistry and immunocytochemistry as previously described (Kyrkanides et al., 2001, 2004). ssIL-1 β and lacZ transcript levels can be assessed by semi-quantitative RT-PCR in total mRNA knee extracts from experimental FIV(Cre) intra-articular injection and control FIV(lacZ) intra-articular injection mice. Localization of ssIL-1 β and β -galactosidase can be achieved on histology sections by immunocytochemistry using antibodies raised specifically against bacterial β -galactosidase and human IL-1 β ; the identity of transduced cells can be confirmed by double immunofluorescence employing antibodies raised against the following antigens. Osteocytes/osteoblasts can be confirmed by the expression alkaline phosphatase, osteocalcin, type I collagen. Chondrocytes can be confirmed by detection of collagen II (Scott-Burden et al., 2002). Histologically, ssIL-1 β mRNA localization can be performed by in situ hybridization (ISH); the identity of transduced cells can be confirmed by coupling ISH with immunocytochemistry (ICC), employing aforementioned antibodies. The

Levels of secreted human IL-1 β in joint synovial fluid can be analyzed by ELISA as described in Example 1 (Catalog # DLB50; R&D Systems Inc, Minneapolis MN). 3-5 mouse lines can be analyzed for transgene function at the mRNA, protein and histology levels following gene activation. For this purpose, transgenic mice can be injected intra-articularly with FIV(Cre), FIV(lacZ) or saline at 2 months of age and subsequently analyzed 4 weeks later. Two mouse lines would result, one expressing "high" and another with "moderate" levels of IL-1 β that can be further analyzed.

c) Investigate the long-term effects of IL-1B expression in the knee

194. The effects of IL-1 β expression in the knee can be studied in young adult (3 month old) COLL1-IL1 β^{XAT} transgenic mice over time (4-8-12-16 weeks) after intra-articular injection of FIV(Cre), FIV(lacZ) or saline. Intra-articular transfer of Cre recombinase to the knee of COLL1-IL1 β^{XAT} transgenic mice can result in sustained expression of human IL-1 β by infected cells. In contrast, FIV(lacZ)-injected mice would lack detectable human IL1 β expression. Saline-treated mice can also serve as controls. After intra-articular injections, the animals can be returned to their cages. Subsequently, the effects of FIV(Cre), FIV(lacZ) and saline intra-articular injection can be analyzed in the two COLL1-IL1 β^{XAT} transgenic mouse lines identified above: one characterized by the highest expression of IL-1 β among the mouse lines analyzed (as determined by ELISA in knee homogenates) following FIV(Cre) intra-articular injection ("high"), and a second mouse line with median expression of IL-1 β ("moderate"). The effects of IL-1 β expression can be evaluated over time (4-8-12-16 weeks).

d) Clinical - Behavioral evaluation

195. Arthralgia and joint dysfunction (knee pain) can be measured by (1) Locomotive performance, as evaluated on a rotating cylinder (rotorod appliance, Columbus Instruments, Columbus OH) and (2) Muscle strength, as evaluated by the inverted mesh method. In brief, this method evaluates neuromuscular condition by assessing grip strength. A clear plastic cylinder (20 cm x 20cm x 30 cm) that was covered on the one end by a wire mesh has been constructed. The mesh wire bars were 1 mm in diameter and 1 cm apart. A rectangular area of the screen was taped so that the animals were confined in the center of the mesh. After the mice were placed on the screen, the cylinder was turned up-side-down over bedding: the lapse time until their fall from the mesh was recorded in seconds. If a mouse fell in less than 10s in the first try, this animal was given a second chance. These methods have been adopted from clinical experience and aim at replicating behavioral and somatic events seen in human patients with arthralgia. The total lapse time until the mouse falls off the mesh can thus be recorded.

e) Peripheral evaluation

196. Since IL-1 β is a multipotent cytokine known to induce a number of inflammation-related genes, the expression of cytokines (TNF α , IL-6, murine IL-1 β), adhesion molecules (ICAM-1, VCAM-1), chemokines (MCP-1), and collagenases (MMP-3, MMP-9) can be evaluated at the mRNA and protein level. In addition, the levels of the inducible COX-2, COX-1, mPGES and cPGES can be measured at the mRNA and protein levels as previously described (REF), as well as production of prostaglandin PGE₂. Moreover, joint morphology can be assessed in H&E-stained histology sections as follows. Degenerative changes in the articular cartilage can be evaluated and graded in sagittal sections examined under light microscope, and scored into five categories: grade 0, no apparent changes; grade 1, superficial fibrillation of articular cartilage; grade 2, defects limited to uncalcified cartilage; grade 3, defects extending into calcified cartilage; and grade 4, exposure of subchondral bone at the articular surface. Each joint can be graded according to the highest score observed within the serial sections. The presence of inflammatory cells, including neutrophils, monocytes/macrophages and lymphocytes in the joint can be investigated at the histology level by immunocytochemistry and double immuno-fluorescence in experimental and control mice sacrificed 4-8-12-16 weeks after treatment. In brief, neutrophils can be detected by a rat anti-murine neutrophil antibody (MCA771GA; Serotec, Raleigh, NC); monocytes & macrophages can be stained with a rat anti-mouse CD11b antibody (MC A74; Serotec Inc); activated cells can be immunolocalized by a rat anti-major histocompatibility complex class-II antibody (MHC-II; Bachem, Torrance, CA; clone ER-TR3). Lymphocytes can be detected by a monoclonal antibody raised against CD3 (MCA 1477; Serotec) and CD4 (Serotec) Quantification of the number of cells can be described both in terms of number of positive cells per field, as well as staining profile. Endothelial cells can be detected by antibodies raised against PECAM-1 (CD31) (Kyrkanides et al. 2003).

197. Since the introduction of FIV proteins can elicit an immunologic response in mice treated with FIV vectors, the host's immunologic response can be characterized following FIV intra-articular injection. The presence (titers) of antibodies against viral and transgenic proteins can be quantitatively assessed in blood serum at the different experimental time points. To this end, IgG and IgM titers for the FIV p24 antigen as well as human IL-1 β can be assessed by customized ELISA method. In brief, ELISA plates can be coated with 5 μ g of human IL-1 β (Sigma; St. Louis MO) or p24 recombinant proteins (IDEXX Laboratories Inc.; Westbrook ME). After incubation with the test sera, the plates can be incubated with alkaline phosphatase-conjugated goat anti-mouse IgG and IgM (Southern Biotechnology Associates, Inc; Birmingham

ALJ). Antibody titers can be established as the serum dilution that reached absorbance levels (at 405nm) of saline injected mice assuming linear extrapolation (Kang et al., 2002).

f) Central nervous system evaluation

198. A number of small neuropeptides, such as substance P (SP) and calcitonin-gene related peptide (CGRP), have been implicated in the transmission of pain from the periphery to the central nervous system (CNS). Sustained expression of IL-1 β in the mouse knee could elicit, in addition to a peripheral inflammatory response, changes in the expression of neurotransmitters in the CNS. Therefore, the expression of SP and CGRP can be evaluated in the spinal cord of experimental and control mice adapting methods previously described (Kyrkanides et al. 2002a, 2002b). Particular emphasis can be given to the region of the spinal cord where nociceptive afferents from the knee synapse at the dorsal horn of the spinal cord.

g) Results and alternatives

199. Intra-articular injection of FIV(Cre) can result in expression of IL-1 β : FIV-mediated Cre recombinase expression in the joint can permanently alter the genetic constitution of infected cells in the knee and result in intra-articular expression of IL-1 β . Previous work with FIV demonstrated successful infection of soft and hard articular tissues by the virus following intra-articular injection (Kyrkanides S., et al. Journal of Dental Research. 83(1):65-70, 2004, herein incorporated by reference for this teaching). FIV(Cre) injections can also be repeated to COLL1-IL1 β ^{XAT} transgenic mice, allowing the animals to survive for 26 weeks, at which time they could be sacrificed and analyzed as previously described. The COLL1-IL1 β gene can also be cloned into the FIV backbone vector using established molecular biology methods to develop FIV(COLL1-IL1 β), a virus capable of transducing cells with a COLL1A1-driven ssIL-IL1 β . Moreover, a stronger promoter, such as the chicken β -actin / CMV fusion promoter (Daly et al., 1999) can be employed to drive ssIL-1 β in the knee following intra-articular injection of the new FIV(COLL1-IL1 β) vector. This is a viable alternative to the somatic mosaic model. To this end, expression of the reporter gene β -galactosidase has been observed for up to 5 weeks in the knee (Kyrkanides et al., 2004), and up to 3 months in the liver and brain in vivo. The advantage of the somatic mosaic model is that FIV(Cre) injection will result in a permanent alteration of the cell genome and lead to a chronic low-level inflammation similar to that observe in human patients.

3. Example 3 – Small inhibitory siRNA-based treatment for the management of arthritis

200. IL-1 β is an inducer of cyclooxygenase-2 (COX-2), a key rate-limiting enzyme in the production of prostanoids during inflammation. COX-2 is of particular therapeutic interest

since it is the target of commercially available over-the-counter and prescription drugs often utilized in cases of arthralgia. Small inhibitory RNA (siRNA) constructs have been developed that are capable of attenuating COX-2, as well as other members of the cyclooxygenase-prostaglandin pathway, including mPGES and cPGES. These siRNA constructs can be expressed from a feline immuno-deficiency viral platform, for example, FIV(siRNA), and can be used for gene therapy for the treatment of arthritis. Therefore, FIV(siRNA) transfer vectors can be generated for COX-2, the constitutive isoform COX-1, as well as cPGES and mPGES. To this end, joint pathology and behavior can be investigated in IL-1 β ^{XAT} mice treated with FIV(siRNA) at various time points after induction of arthritis, and compared to mice treated with pharmacologic selective inhibitors for COX-2 and COX-1, as well as a mixed inhibitor (i.e. ibuprofen).

a) Anti-inflammatory regimen in COLL1Pr-IL1 β ^{XAT} transgenic mice

201. It has been established that IL-1 β drives the expression of COX-2 to form prostaglandin E₂ (PGE₂), a principal mediator of inflammation in a number of tissues, including joints. COX-2, as well as the constitutively expressed COX-1, can be temporally (time course) and spatially (sites of expression) characterized at the molecular level, and can be correlated with PGE₂ levels and other inflammatory mediators related to arthritis, as well as neurotransmitter expression and behavioral measures in the IL-1 β ^{XAT} transgenic mice. Transgenic mice of the founder line identified in Example 2 can be treated with FIV(siRNA) for COX-1, COX-2, mPGES and cPGES. In addition, other groups of mice can be given a pharmacologic inhibitor for COX-2 (NS-398) as well as the NSAID ibuprofen in the chow. In brief, knee inflammation can be induced in 8 weeks old COLL1-IL1 β ^{XAT} transgenic mice by intra-articular injection of FIV(Cre). In keeping with the clinical use of anti-inflammatory regimens, anti-inflammatory treatment can be initiated at a time when the FIV(Cre)-injected mice begin to demonstrate knee joint pathology and dysfunction (based on the data derived from Example 2). Alternatively, anti-inflammatory treatment can begin at a set time before or after the FIV(Cre) injection. The mice can be sacrificed at various time points following initiation of anti-inflammatory treatment (4-8-12-16 weeks). Consequently, the effects of therapy can be characterized on knee arthritis (anatomic, histologic, molecular changes) and dysfunction (behavioral changes), as well as on central nervous system changes.

b) FIV(siRNA) development and administration

202. A pseudotyped lentivirus can be used to drive expression of small inhibitory RNA (siRNA) species mouse joints where interleukin-1 driven inflammation has been initiated. These

short double stranded RNAs with sizes of 19-21 base pairs can efficiently mediate gene silencing in mammalian cells by guiding sequence-specific degradation of target mRNA sequences both in vitro and in vivo (Hannon, 2002)., FIV based vectors that contain an RNA polymerase III promoter, which drives expression of single stranded RNA can be used to deliver inhibitory RNA species in vivo. These RNA species contain stem-loop structures that form short hairpin RNAs (shRNA) after intracellular processing (System Biosciences; Paddison et al., 2004). Approaches such as these have been used in a wide variety of in vivo systems (Tiscornia et al., 2003; Robinson et al., 2003) including localized silencing of specific gene expression in brain (Hommel et al., 2003). siRNAs are disclosed herein that effectively mediate gene silencing of a number of key molecules involved in the production of the lipid mediate Prostaglandin E₂. This includes, for example, COX-1 and -2, and the cytosolic and type-1 membrane associated prostaglandin E₂ synthases (PGES). Sequences coding for shRNA's can be sub-cloned into FIV cloning vectors containing green fluorescent protein (GFP) reporter genes. After successful testing of siRNA activity upon transfection of cells in culture, VSV-G pseudotyped viral particles can be packaged by simultaneous expression of the lentiviral expression/cloning vector and packaging vectors in 293T cells. These viral particles can be infection competent but replication incompetent and can be tested and tittered in vitro before being injected into inflamed joints.

c) Pharmacologic anti-inflammatory regimen

203. A COX-2 selective inhibitor (NS-398; Kyrkanides et al., 2002), a COX-1 inhibitor SC-560 (64 ppm in chow) or a mixed inhibitor (ibuprofen at 375 ppm in chow) can be administered to mice via chow. This route of administration simplifies long-term treatment (weeks-months) and the oral doses required for specifically inhibiting these enzymes in vivo have been previously determined (Jantzen et al., 2002; Mueller-Decker et al., 2002).

d) Results & alternatives

204. Anti-inflammatory therapy can attenuate nociception. However, NSAIDs could influence inflammation by COX-independent mechanisms. For example, some NSAIDs are ligands for peroxisome proliferator-activated receptor PPAR- γ and could exert anti-inflammatory effects by this mechanism. In addition, several NSAIDs have been shown to downregulate pro-inflammatory NF- κ B activity by inhibiting I κ B kinase. Another point of potential importance is that drugs targeting COX isoforms could lead to concomitant upregulation of the parallel 5-lipoxygenase pathway. Recent studies on the effectiveness of dual inhibitors of cyclooxygenase and 5-lipoxygenase (ML3000) suggest that simultaneous inhibition may be required to obtain

adequate levels of anti-inflammatory action. In fact, such drugs are currently in Phase III clinical trials in Europe. Such avenues can also be used herein.

205. Interestingly, COX-1 and COX-2, in addition to their roles in peripheral inflammation, both appear to be involved to some degree in the central processing of pain at the level of the central nervous system. Overall, behavioral and pathological benefits are expected from NS-398 administration and COX-2 knockout mice. In some model systems COX-1 has been found to influence inflammation and pain. Thus, results with the COX-1 selective inhibitor and COX-1 knockout mice could also show benefits. Recently, in addition to COX-1 and COX-2, at least two new PGE₂ synthase isoforms have been added to the family of enzymes that result in the production of prostaglandins: the membrane-associated mPGES, which is functionally coupled to COX-2, and the cytosolic cPGES that appears to be linked to COX-1 dependent PGE₂ production. Although cellular localization may play some role, functional coupling is largely a factor of expression patterns: as with COX-2, mPGES is dramatically upregulated by proinflammatory stimuli, whereas cPGES is constitutively expressed in cell systems examined to date. In addition, COX-2 and mPGES are coordinately upregulated in a rat model of adjuvant arthritis. Therefore, mPGES could play a role in IL-1 β -induced arthritis. Thus, the regulation of mPGES is also considered herein. This can be readily accomplished by employing established and routinely used methods. In fact, recent data suggests that COX-2 regulates mPGES at the transcriptional level, at least in an IL-1 β induced brain inflammation model (Moore et al. 2004).

206. It is important to point out that the doses chosen have been previously shown to inhibit COX activity in long-term mouse experiments without evidence of serious toxicity. However, animals fed NSAID chow (and controls) can be weighed each week to assess possible toxic effects of drug treatment.

G. References

Abbott FV, Franklin KBJ, Conel B (1986). The stress of a novel environment reduces formalin pain: possible role of serotonin. *Eur J Pharmacol* 126: 126-41.

Abramowitz M and Stegun IA (1964). *Handbook of Mathematical Functions, Applied Mathematics Series, vol. 55* (Washington: National Bureau of Standards; reprinted 1968 by Dover Publications, New York).

Adamo CT, Mailhot JM, Smith AK, Borke JL (2001) Connexin 43 expression in oral derived human osteoblasts after transforming growth factor-beta and PGE₂ exposure. *J Oral Implantol* 27: 25-31

Agarwal S, Long P, Gassner R, Piesco NP, Buckley MJ (2001). Cyclic tensile strain suppresses catabolic effects of interleukin-1 β in fibrochondrocytes from the temporomandibular joint. *Arthr Rheum* 44: 608-17.

- Ahmadzadeh N, Shingu M, Nobunaga M (1990). The effect of recombinant tumor necrosis factor-alpha on superoxide and metalloproteinase production by synovial cell and chondrocytes. *Clin Exp Rheumatol* 8:387-91.
- Anderson GD, Hauser SD, McGarity KL, Bremer ME, Isakson PC and Gregory SA (1996). Selective inhibition of cyclooxygenase (COX)-2 reverses inflammation and expression of COX-2 and interleukin 6 in rat adjuvant arthritis. *J Clin Invest* 97:2672-79.
- Balkhi KM, Tallents RH, Hutta J, Murphy W, Proskin H (1993). Electromyographic Evaluation of the
- Bellinger DL, Felten DL, Lorton D, Brouxhon SM (2001). Effects of interleukin-2 on the expression of corticotropin-releasing hormone in nerves and lymphoid cells in secondary lymphoid organs from the Fischer 344 rat. *J Neuroimmunol* 119:37-50.
- Breyer RM, Bagdassarian CK, Myers SA and Breyer MD (2001). Prostanoid receptors: subtypes and signaling. *Ann Rev Pharmacol Toxicol* 41:661-90.
- Brooks AI, Halterman MW, Federoff HJ (1999). Focal hippocampal gain of NGF function elicits specific septal cholinergic reorganization. *Neuroreport* 10:337-44.
- Brooks AI, Muhkerjee B, Panahian N, Cory-Slechta D, Federoff HJ (1997). Nerve growth factor somatic mosaicism produced by herpes virus-directed expression of cre recombinase. *Nat Biotech* 15(1):57-62
- Brummelkamp, T.R., R. Bernards and R. Agami. A system for stable expression of short interfering RNAs in mammalian cells. *Science* (2002) 296:550-553.
- Bullough PG, DiCarlo EF (1990). Subchondral avascular necrosis: a common cause of arthritis. *Ann Rheum Dis* 49:412-20
- Burkhardt H, Schwingel M, Menninger H, Macartney HW, Tschesche H (1986). Oxygen radicals as effectors of cartilage destruction. Direct degradative effect on matrix components and indirect action via activation of latent collagenase from polymorphonuclear leukocytes. *Arthritis Rheum* 29:379-87.
- Calvelou P, Dallel R, Orliaguet T, Woda A (1995). The orofacial formalin test in rats: effects of different formalin concentrations. *Pain* 62:295-301.
- Carleson J, Alstergren P, Appelgren A, Appelgren B, Kopp S, Theodorsson E, et al. (1996). A model for the study of experimentally induced temporomandibular arthritis in rats: the effect of human recombinant interleukin-1 alpha on neuropeptide like immunoreactivity. *J Orofac Pain* 10:9-14.
- Chandrasekharan NV, Dai H, Roos KL, Evanson NK, Tomsik J, Elton TS, Simmons DL (2002). COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: cloning, structure, and expression. *Proc Natl Acad Sci U S A*. 99:13926-31.
- Chang JS, Gillman SC, Lewis AJ (1986). Interleukin 1 activates phospholipase A2 in rabbit chondrocytes: a possible signal for IL-1 action. *J Immunol* 136:1283-87.
- Choi HS, Lee HJ, Juan CY, Ju JS, Park JS, Ahn DK (2003). Central cyclooxygenase-2 participates in interleukin- β -induced hyperalgesia in the orofacial formalin test of freely moving rats. *Neurosci Letters* 352: 187-90.

Crombie IK, Croft PR, Linton SJ, LeResche L, Von Korff M (eds). *Epidemiology of Pain: A report of the Task Force on epidemiology of the International Association for the Study of Pain*. Seattle: IASP, 1999.

Daly TM, Vogler C, Levy B, Haskins ME, Sands MS (1999) Neonatal gene transfer leads to widespread correction of pathology in a murine model of lysosomal disease. *Proc Natl Acad Sci USA* 96: 2296-3000.

de Bont LG, Boering G, Liem RS, Eulderink F, Westesson PL (1986). Osteoarthritis and internal derangement of the temporomandibular joint: a light microscopic study. *J Oral & Maxillofac Surg* 44:634-43.

Dubuisson D, Dennis S. The formalin test: A quantitative study of the analgesic effects of morphine, meperidine, and brainstem stimulation in rats and cats. *Pain* 1977; 4: 161-74.

Dijkgraaf LC, de Bont LG, Boering G, Liem RS (1995). The structure, biochemistry, and metabolism of osteoarthritic cartilage: a review of the literature. *J Oral Maxillofac Surg* 53:1182-92.

Dijkgraaf LC, Liem RS, de Bont LG (1997). Synovial membrane involvement in osteoarthritic temporomandibular joints: a light microscopic study. *Oral Surg Oral Med Oral Pathol Oral Radiol & Endodont* 83:373-86.

Dijkgraaf LC, Spijkervet FK, de Bont LG (1999). Arthroscopic findings in osteoarthritic temporomandibular joints. *J Oral & Maxillofac Surg* 57:255-68.

Dinchuk JE, Liu RQ, Trzaskos JM (2003) COX-3: in the wrong frame in mind. *Immunol Lett*. 86:121.

Elbashir, S.M., J. Harborth, W. Lendeckel, A. Yalcin, K. Weber and T. Tuschl. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. *Nature* (2001) 411:494-498.

Fernandes JC, Caron JP, Martel-Pelletier J, Javanovic D, Mineau F, Tardif G, Otterness IG, Pelletier JP (1997). Effects of tenidap on the progression of osteoarthritic lesions in a canine experimental model. Suppression of metalloprotease and interleukin-1 activity. *Arthritis & Rheum* 40:284-94.

Fiorucci S, Meli R, Bucci M, Cirino G (2001) Dual inhibitors of cyclooxygenase and 5-lipoxygenase. A new avenue in anti-inflammatory therapy? *Biochem Pharmacol* 62: 1433-8.

Fitzgerald GA and Patrono C (2001). The coxibs, selective inhibitors of cyclooxygenase-2. *N Engl J Med* 345:433-42.

Futaki N, Arai I, Hamasaka Y, Takahashi S, Higuchi S and Otomo S (1993). Selective inhibition of NS-398 on prostanoid production in inflamed tissue in rat carrageenan-air-pouch inflammation. *J Pharmacol* 45:753-55.

Gillman SC, Chang J, Zeigler PR, Uhl J, Mochan E (1988). Interleukin 1 activates phospholipase A2 in human synovial cells. *Arthritis Rheum* 31:126-30.

Gilroy DW, Colville-Nash PR, McMaster S, Sawatzky DA, Willoughby DA, Lawrence T (2003). Inducible cyclooxygenase-derived 15-deoxy(Delta)12-14PGJ2 brings about acute inflammatory resolution in rat pleurisy by inducing neutrophil and macrophage apoptosis.

FASEB 17:2269-71.

Gilroy DW, Colville-Nash PR, Willis D, Chivers J, Paul-Clark MJ, Willoughby DA (1999). Inducible cyclooxygenase may have anti-inflammatory properties. *Nat Med* 5:698-701.

Greenwald RA, Moy WW (1997). Inhibition of collagen gelation by action of the superoxide radical. *Arthritis Rheum* 22:251-59.

Han R, Tsui S and Smith TJ (2002). Up-regulation of prostaglandin E2 synthesis by interleukin-1 β in human orbital fibroblasts involves coordinate induction of prostaglandin H synthase-2 and glutathione-dependent prostaglandin E2 synthase expression. *J Biol Chem* 277:163555-64.

Hannon, G. J. (2002). RNA interference. *Nature* 418, 244-251

Havenga MJ, Vogels R, Braakman E, Kroos N, Valerio D, Hagenbeek A, van Es HH (1998). Second gene expression in bicistronic constructs using short synthetic intercistrons and viral IRES sequences. *Gene*. 222:319-27.

Helminen HJ, Kiraly K, Pelttari A, Tammi M, Vandenberg P, Pereira R, et al. (1993). An inbred line of transgenic mice expressing an internally deleted gene for type II procollagen (COL2A1). *J Clin Invest* 92:582-95.

Hommel, J. D., Sears, R. M., Georgescu, D., Simmons, D. L., and DiLeone, R. J. (2003). Local gene knockdown in the brain using viral-mediated RNA interference. *Nat Med* 9, 1539-1544.

Hutchins B, Patel H, Spears R (2002). Attenuation of pro-inflammatory neuropeptide levels produced by a cyclooxygenase-2 inhibitor in an animal model of chronic temporomandibular joint inflammation. *J Orofac Pain* 16:312-6.

Irwin, M.H., W.D. Pogozeleski, and CA Pinkert (2002). PCR optimization for detection of transgene integration, p. 475-484. In C.A. Pinkert (ed.), *Transgenic animal technology: a laboratory handbook*. 2nd ed. Academic Press, Inc., San Diego.

Jakobsson PJ, Thorén S, Morgenstern R, Samuelsson B (1999). Identification of human prostaglandin E synthase: a microsomal, glutathione-dependent, inducible enzyme, constituting a potential novel drug target. *Proc Natl Acad Sci USA* 96:7220-25.

Jantzen PT, Connor KE, DiCarlo G, Wenk GL, Wallace JL, Rojiani AM, Coppola D, Morgan D, Gordon MN (2002). Microglial Activation and β -Amyloid Deposit Reduction Caused by a Nitric Oxide-Releasing Nonsteroidal Anti-Inflammatory Drug in Amyloid Precursor Protein Plus Presenilin-1 Transgenic Mice. *J Neurosci* 22:2246-54.

Jiao Y, Ma X, Zhang Z (2001). Interleukin-1 increase nitric oxide synthesis through up-regulation of inducible nitric-oxide synthase by rabbit mandibular condylar cartilage cells in vitro. *Chin J Stomatol* 36:345-7.

Johansson A-S, Isacson G, Isberg A, et al. (1986) Distribution of substance P-like immunoreactive nerve fibers in temporomandibular joint soft tissues of monkey. *Scand J Dent Res* 94:225-30.

Jonakait GM, Schotland S (1990). Conditioned medium from activated splenocytes increases substance P in sympathetic ganglia. *J Neurosci Res* 26:24-30.

Jonakait GM, Schotland S, Hart RP (1991). Effects of lymphokines on substance P in injured

ganglia of the peripheral nervous system. *Ann NY Acad Sci* 632:19-30.

Jonakait GM, Schotland S, Hart RP (1991). Interleukin-1 specifically increases substance P in injured sympathetic ganglia. *Ann NY Acad Sci* 594:222-30.

Joosten LA, Helsen MM, Saxne T, van De Loo FA, Heinegard D, van Den Berg WB (1999). IL-1 alpha beta blockade prevents cartilage and bone destruction in murine type II collagen-induced arthritis, whereas TNF-alpha blockade only ameliorates joint inflammation. *J Immunol*; 163:5049-55.

Jovanovic DV, Fernandes JC, Martel-Pelletier J, Jolicoeur FC, Reboul P, Laufer S, Tries S, Pelletier JP (2001). In vivo dual inhibition of cyclooxygenase and lipoxygenase by ML-3000 reduces the progression of experimental osteoarthritis: suppression of collagenase 1 and interleukin-1beta synthesis. *Arthr Rheumaton* 44:2320-30.

Jow RW and Clark GT (1989). Endurance and recovery from a sustained isometric contraction of human jaw elevating muscles. *Arch Oral Biol* 34: 857-62.

Kang Y, Stein CS, Heth JA, Sinn PL, Penisten AK, Staber PD, Ratliff KL, Shen H, Barker CK, Martins I, Sharkey CM, Sanders DA, McCray PB Jr., Davidson BL (2002). In vivo gene transfer using a nonprimate lentiviral vector pseudotyped with ross river virus glycoproteins. *J Virol* 76 9378-88.

Kawai Y, Kubota, Okabe E (2000). Reactive oxygen species participation in experimentally induced arthritis of the temporomandibular joint in rats. *J Dent Res* 79:1489-95.

Kawakami M, Okabe E (1998). Superoxide anion radical-triggered Ca²⁺ release from cardiac sarcoplasmic reticulum through ryanodine receptor Ca²⁺ channel. *Mol Pharmacol* 53:497-503.

Kehl LJ, Trempea TM and Hargreaves KM (2000). A new animal model for assessing mechanisms and management of muscle hyperalgesia. *Pain* 85:333-43.

Kirtikara K, SG Morham, R Raghov, SJ Lalederkind, T Kanekura, S Goorhaand, LR Ballou (1998). Compensatory prostaglandin E2 biosynthesis in cyclooxygenase 1 or 2 null cells. *J Exp Med* 187:517-23.

Kis B, Snipes JA, Isse T, Nagy K, Busija DW. (2003) Putative cyclooxygenase-3 expression in rat brain cells. *J Cereb Blood Flow Metab.* 23: 1287-92.

Kitanaka J, Hashimoto H, Gotoh M, Kondo K, Sakata K, Hirasawa Y, Sawada M, Suzumura A, Marunouchi T, Matsuda T and Baba A. (1996) Expression pattern of messenger RNAs for prostanoid receptors in glial cell cultures. *Brain Res* 707:282-87.

Krebsbach PH, Harrison JR, Lichtler AC, Woody CO, Rowe DW, Kream BE (1993). Transgenic expression of COL1A1-chloramphenicol acetyltransferase fusion genes in bone: differential utilization of promoter elements in vivo and in cultured cells. *Mol Cell Biol* 13: 5168-74.

Kubota E, Kubota T, Matsumoto J, Shibata T, Murakami KI (1998). Synovial fluid cytokines and proteinases as markers of temporomandibular joint disease. *J Oral Maxillofac Surg* 56:192-98.

Kyrkanides S, Kambylafkas P, Miller JH, Tallents RH (2004). Non-primate lentiviral vector administration in the TMJ. *J Dental Res* 83: 65-70.

- Kyrkanides S, Miller JH, Bowers WA, Federoff HJ (2003). Transcriptional and post-translational regulation of Cre recombinase by RU486 as the basis for an enhanced inducible expression system. *Mol Ther* 8: 790-95.
- Kyrkanides S, Miller JH, Federoff HJ (2003). Systemic FIV vector administration: Transduction of CNS immune cells and Purkinje neurons. *Mol Brain Res* 119: 1-9.
- Kyrkanides S, Moore AH, Olschowka JA, Williams JP, Hansen JT, O'Banion MK (2002). COX-2 modulates inflammation related genes in CNS radiation injury. *Mol Brain Res* 104: 159-69.
- Kyrkanides S, O'Banion MK, Subtelny JD (2000). Non-steroidal anti-inflammatory drugs in orthodontic tooth movement: Metalloproteinase activity and collagen synthesis by endothelial cells. *Am J Orthod Dentofac Orthop* 118: 203-09.
- Kyrkanides S, Olschowka JA, Whitley P, O'Banion MK (2001). Enhanced glial activation and expression of specific CNS inflammation-related molecules in aged versus young rats following cortical stab injury. *J Neuroimmunol* 119: 269-77.
- Kyrkanides S, Olschowka JA, Williams JP, Hansen JT, O'Banion MK (1999). TNF α & IL-1 β mediate ICAM-1 induction via microglia-astrocyte interaction in CNS radiation injury. *J Neuroimmunol* 95:95-106.
- Kyrkanides S, Tallents RH, Macher DJ, Olschowka JA, Stevens SY (2002). Temporomandibular joint nociception: effects of capsaicin on substance P-like immunoreactivity in the rabbit brain stem. *J Orofac Pain* 16:229-35.
- Lane NE (1997). Pain management in osteoarthritis: the role of COX-2 inhibitors. *J Rheumatol* 24 Suppl. 49:20-24.
- Langenbach R, Morham SG, Tiano HF, Loftin CD, Ghanayem BI, Chulada PC, Mahler JF, Lee CA, Goulding EH, Kluckman KD, Kim HS, Smithies O (1995). Prostaglandin Synthase 1 Gene Disruption in Mice Reduces Arachidonic Acid-Induced Inflammation and Indomethacin-Induced Gastric Ulceration. *Cell* 83:483-92.
- Lavigne P, Shi Q, Jolicoeur FC, Pelletier, Martel-Pelletier J, Fernandes JC (2002). Modulation of IL-1 β , IL-6, TNF- α and PGE(2) by pharmacological agents in explants of membranes from failed total hip replacement. *Osteoarthritis & Cartilage* 10:898-904.
- Lehmann, J.M., J.M. Lenhard, B.B. Oliver, G.M. Ringold and S.A. Kleiwer (1997). Peroxisome proliferator-activated receptors alpha and gamma are activated by indomethacin and other non-steroidal anti-inflammatory drugs. *J Biol Chem* 272:3406-10.
- Lipsky PE and Isakson PC (1997). Outcome of specific COX-2 inhibition in rheumatoid arthritis. *J Rheumatol* 24:9-14.
- Lipton JA, Ship JA, Larach-Luchini S, Merskey H (1993). Estimated prevalence and distribution of reported orofacial pain in the United States. *JADA* 124:115-21.
- Liu F, Malaval L, Aubin JE (1997). The mature osteoblasts phenotype is characterized by extensive plasticity. *Exp Cell Res* 232: 97-105.
- Macher DJ, Westesson PL, Brooks SL Hicks D and Tallents RH (1992). Temporomandibular joint surgically created disc displacement causes arthrosis in the rabbit. *Oral Surg Oral Med Oral*

Pathol 73:645-49.

Maguire-Zeiss KA, Bowers WJ, Federoff HJ (2002). Somatic mosaic approaches and the aging brain. *Neurobiol Aging* 23:977-84.

Malmberg AB and Yaksh TL (1995). Cyclooxygenase inhibition and the spinal release of prostaglandin E2 and amino acids evoked by paw formalin injection: a microdialysis study in unanesthetized rats. *J Neurosci* 15:2768-76.

Mancini JA, Blood K, Guay J, Gordon R, Claveau D, Chan CC and Riendeau R (2001). Cloning, expression, and up-regulation of inducible rat prostaglandin synthase during lipopolysaccharide-induced pyresis and adjuvant-induced arthritis. *J Biol Chem* 276:4469-75.

Martel-Pelletier J, Pelletier JP, Fahmi H (2003). Cyclooxygenase-2 and prostaglandins in articular tissues. *Semin Arthritis Rheum* 33:155-67.

Masaki M, Matsushita M and Wakitani K. Inhibitory effects of JTE-522, a novel prostaglandin H synthase-2 inhibitor, on adjuvant-induced arthritis and bone changes in rats. *Inflamm Res* 47:187-92.

Matsubara T, Ziff M (1986). Increased superoxide anion release from human endothelial cells in response to cytokines. *J Immunol* 137:3295-98.

McCord JM (1974). Free radicals and inflammation: protection of synovial fluid by superoxide dismutase. *Science* 185:529-31.

Mizukawa H, Okabe E (1997). Inhibition by singlet molecular oxygen of the vascular reactivity in rabbit mesenteric artery. *Br J Pharmacol* 121:63-70.

Molin C (1972). Vertical isometric muscle forces of the mandible. A comparative study of subjects with and without manifest mandibular pain dysfunction syndrome. *Acta Odontol Scand* 30:485-99.

Moore AH, Olschowka JA, O'Banion MK (2004). Intraparenchymal administration of interleukin-1 β induces cyclooxygenase-2-mediated expression of membrane- and cytosolic-associated prostaglandin synthases in mouse brain. *J Neuroimmunol* 148: 32-40.

Moos V, Fickert S, Muller B, Weber U, Sieper J (1999). Immunohistological analysis of cytokine expression in human osteoarthritic and healthy cartilage. *J Rheumatol* 26:870-9.

Morham SG, Langenbach R, Loftin CD, Tian HF, Vouloumanos N, Jennette JC, Mahler JF, Kluckman KD, Ledford A, Lee CA, Smithies O (1995). Prostaglandin Synthase 2 Gene Disruption Causes Severe Renal Pathology in the Mouse. *Cell* 83:472-82.

Mueller-Decker K, Hirschner W, Marks F, Fuerstenberger G (2002). The Effects of Cyclooxygenase Isozyme Inhibition on Incisional Wound Healing in Mouse Skin. *J Invest Dermatol* 119: 1189-95.

Murakami M, Naraba H, Tanioka T, Semmyo N, Nakatani Y, Kojima F, Ikeda T, Fueki M, Ueno A, Oh-ishi S and Kudo I (2000). Regulation of prostaglandin E2 biosynthesis by inducible membrane-associated prostaglandin synthase that acts in concert with cyclooxygenase-2. *J Biol Chem* 275:32783-92.

Murray R and Spiegel S (1988). *Theory and Problems of Statistics*, 2nd ed. Schaum's Outline

Series, McGraw-Hill Publishing, New York, Chapter 5, p110-21.

Myers SL, Flusser D, Brandt KD, Heck DA (1992). Prevalence of cartilage shards in synovium and their association with synovitis in patients with early and endstage osteoarthritis. *J Rheumatol* 19:1247-51.

Nagy A, Gertsenstein M, Vintersten K, and Behringer R. (2003) *Manipulating the Mouse Embryo: A Laboratory Manual*. 3rd ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York.

Narumiya A and FitzGerald GA (2001). Genetic and pharmacological analysis of prostanoid receptor function. *J Clin Invest* 108:25-30.

Narumiya S, Sugimoto Y, Ushikuni F (1999). Prostanoid receptors: structures, properties and functions. *Physiol. Rev.* 79:1193-1226.

Ngo L, Jay G (2002). Analysis of transgene expression, p. 486-513. In CA Pinkert (ed.), *Transgenic animal technology: a laboratory handbook*. 2nd ed. Academic Press, Inc., San Diego.

Norisue M, Todoki K, Okabe E (1997). Inhibition by hydroxyl radicals of calcitonin gene-related peptide-mediated neurogenic vasorelaxation in isolated canine lingual artery. *J Pharmacol Exp Ther* 280:492-500.

Nordsenskiold UM and Grimby G (1993). Grip force in patients with rheumatoid arthritis and fibromyalgia and in healthy subjects: a study with the Grippit instrument. *Scand J Rheumatol* 22: 14-9.

O'Banion MK (1999). Cyclooxygenase-2: molecular biology, pharmacology, and neurobiology. *Crit Rev Neurobiol* 13: 45-82.

O'Banion MK, Sadowski HB, Winn V, Young DA (1991). A serum- and glucocorticoid-regulated 4-kilobase mRNA encodes a cyclooxygenase-related protein. *J Biol Chem* 266: 23261-7.

O'Banion MK, Winn VD, Young DA (1992). cDNA cloning and functional activity of a glucocorticoid-regulated inflammatory cyclooxygenase. *Proc Natl Acad Sci U.S.A.* 89:4888-92.

O'Byrne EM, Blancuzzi VJ, Wilson DE, et al. (1990). Increased intra-articular substance P and prostaglandin E2 following injection of interleukin-1 in rabbits. *Int J Tissue React* 12:11-4.

Ochi T, Ohkubo Y, Mutoh S (2003). Role of cyclooxygenase-2, but not cyclooxygenase-1, on type II collagen-induced arthritis in DBA/1J mice. *Biochem Pharmacol* 66:1055-60.

Ogura N, Tobe M, Sakamaki H, Kujiraoka H, Akiba M, Abiko Y, Nagura H (2002). Interleukin-1 beta induces interleukin-6 mRNA expression and protein production in synovial cells from human temporomandibular joint. *J Oral Pathol Med* 31:353-60.

Overbeek PA (2002). DNA microinjection and transgenic animal production, p.72-112. In C.A. Pinkert (Ed.), *Transgenic animal technology: a laboratory handbook*. 2nd ed. Academic Press, Inc., San Diego.

Paddison, P. J., Caudy, A. A., Sachidanandam, R., and Hannon, G. J. (2004). Short hairpin activated gene silencing in mammalian cells. *Methods Mol Biol* 265, 85-100.

Paddison, P.J., A.A. Caudy and G.J. Hannon. Stable suppression of gene expression by RNAi in mammalian cells. *Proc. Natl. Acad. Sci. USA* (2002) 99:1443-1448.

Pfeifer A, Brandon EP, Kootstra Neeltje, Gage FH, Verma IM (2001). Delivery of the Cre recombinase by a self-deleting lentiviral vector: Efficient gene targeting in vivo. *Proc Natl Acad Sci U.S.A.* 98: 11450-5.

Pinkert C. A. (2002) *Transgenic Animal Technology: A Laboratory Handbook* 2nd ed., Academic Press, San Diego.

Pinkert CA (2003). *Transgenic animal technology: Alternatives in genotyping and phenotyping.* *Comp Med* 53:116-29.

Polites HG, Pinkert CA (2002). DNA microinjection and transgenic animal production, p. 15-70. In C.A. Pinkert (ed.), *Transgenic animal technology: a laboratory handbook*. 2nd ed. Academic Press, Inc., San Diego.

Portanova JP, Zhang Y, Anderson GD, Hauser SD, Masferrer JL, Seibert K, Gregory SA, Isakson PC. (1996) Selective neutralization of prostaglandin E2 blocks inflammation, hyperalgesia, and interleukin 6 production in vivo. *J. Exp. Med* 184:883-91.

Ratcliffe A, Billingham ME, Saed-Nejad F, Muir H, Hardingham TE (1992). Increased release of matrix components from articular cartilage in experimental canine osteoarthritis. *J Ortho Res* 10:350-8.

Revell PA, Mayston V, Lalor P, Mapp P (1988). The synovial membrane in osteoarthritis: a histological study including the characterisation of the cellular infiltrate present in inflammatory osteoarthritis using monoclonal antibodies. *Ann Rheum Dis* 47:300-7.

Ricote M, Li AC, Willson TM, Kelly CJ and Glass CK (1998). The peroxisome proliferator-activated receptor- α is a negative regulator of macrophage activation. *Nature* 391:79-82.

Ritchlin CT, Haas-Smith SA, Li P, Hicks DG, Schwarz EM (2003). Mechanisms of TNF α and RANKL-mediated osteoclastogenesis and bone resorption in psoriatic arthritis. *J Clin Invest* 111:821-31.

Roberts CR, Roughley PJ, Mort JS (1989). Degradation of human proteoglycan aggregate induced by hydrogen peroxide. Protein fragmentation, amino acid modification and hyaluronic acid cleavage. *Biochem J* 259:805-11.

Rubinson, D. A., Dillon, C. P., Kwiatkowski, A. V., Sievers, C., Yang, L., Kopinja, J., Rooney, D. L., Ihrig, M. M., McManus, M. T., Gertler, F. B., et al. (2003). A lentivirus-based system to functionally silence genes in primary mammalian cells, stem cells and transgenic mice by RNA interference. *Nat Genet* 33, 401-406.

Salvemini D, Misko TP, Masferrer JL (1993). Nitric oxide activates cyclooxygenase enzymes. *Proc Natl Acad Sci* 90:7240-44.

Schwarz EM, Looney RJ, O'Keefe RJ (2000). Anti-TNF-alpha therapy as a clinical intervention for periprosthetic osteolysis. *Arthr Res* 2:165-8.

Scott-Burden T, Bosley JP, Rosenstrauch D, Henderson KD, Clubb FJ, Eichstaedt HC, Eya K, Gregoric I, Myers TJ, Radovancevic B, Frazier OH (2002). Use of autologous auricular chondrocytes for lining artificial surfaces: A feasibility study. *Ann Thorac Surg* 73: 1528-33.

- Sessle BJ, Hu JW (1991). Mechanisms of pain arising from articular tissues. *Can J Physiol Pharmacol* 69: 617-626.
- Shafteel SS, Olschowka JA, Hurley SD, Moore AH, O'Banion MK (2003). COX-3: a splice variant of cyclooxygenase-1 in mouse neural tissue and cells. *Brain Res Mol Brain Res*. 119: 213-5.
- Shin S-j, Fermor B, Weinberg JB, Pisetsky DS, Guilak F (2003). Regulation of matrix turnover in meniscal explants: role of mechanical stress, interleukin-1, and nitric oxide. *J Appl Physiol*; 95:308-13.
- Siqueira-Junior JM, Peters RR, Brum-Fernandes AJ, Ribeiro-do-Valle RM (2003). Effects of valeryl salicylate, a COX-1 inhibitor, on models of acute inflammation in mice. *Pharmacol Res* 48:437-43.
- Smith MD, Triantafillou S, Parker A, Youssef PP, Coleman M (1997). Synovial membrane inflammation and cytokine production in patients with early osteoarthritis. *J Rheumatol* 24:365-71.
- Smith, WL, DeWitt DL, Garavito RM (2000). Cyclooxygenases: structural, cellular, and molecular biology. *Annu Rev Biochem* 69:145-82.
- Srinivas S, Watanabe T, Lin C-S, Williams C, Tanabe Y, Jessell T, Costantini F (2002). Cre reporter strains produced by targeted insertion of EYFP and ECFP into the ROSA26 locus. *BMC Develop Biol* 1:4-11.
- Stegenga B, de Bont LG, Boering G (1989). Osteoarthrosis as the cause of craniomandibular pain and dysfunction: a unifying concept. *J Oral Maxillofacial Surg* 47:249-56.
- Stegenga B, de Bont LG, Boering G, Van Willigen JD (1991). Tissue responses to degenerative changes in the temporomandibular joint: a review. *J Oral Maxillofacial Surg* 49:1079-88.
- Sternberg N, Hamilton D (1981). Bacteriophage P1 site-specific recombination. Recombination between loxP sites. *J Mol Biol* 150: 467-86.
- Stichtenoth DO, Thoren S, Bian H, Peters-Golden M, Jakobsson PJ and Crofford L (2001). Microsomal prostaglandin E synthase is regulated by proinflammatory cytokines in primary rheumatoid synovial cells. *J. Immunol.* (2001) 167:469-74.
- Sugimoto Y, Narumiya S and Ichikawa A (2000). Distribution and function of prostanoid receptors: studies from knockout mice. *Prog Lipid Res* 39:289-314.
- Surnii H, Inoue H, Onoue J, Mori A, Oda T, Tsubokura T (1996). Superoxide dismutase activity in arthropathy: its role and measurement in the joints. *Hiroshima J Med Sci* 45:51-55.
- Suzuki T, Segami N, Nisimura M, Nojima T (2002). Co-expression of interleukin-1beta and tumor necrosis factor alpha in synovial tissues and synovial fluids of temporomandibular joint with internal derangement: comparison with histological grading of synovial inflammation. *J of Oral Pathology Med* 31:549-57.
- Tallents RH, Macher DJ, Rivoli P, Scapino R, Puzas JE, Katzberg RW (1990). An animal model for meniscus displacement in the rabbit. *J Craniomandib Disord Facial Oral Pain* 4:233-40.

Tanaka A, Hase S, Miyazawa T, Ohno R, Takeuchi K (2002). Role of cyclooxygenase (COX)-1 and COX-2 inhibition in nonsteroidal anti-inflammatory drug-induced intestinal damage in rats: relation to various pathogenic events. *J Pharmacol Exp Ther* 303: 1248-54.

Tanioka T, Nakatani Y, Semmyo N, Murakami M and Kudo I (2000). Molecular identification of cytosolic prostaglandin E2 synthase that is functionally coupled with cyclooxygenase-1 in immediate prostaglandin E2 biosynthesis. *J Biol Chem* 275:32775-82.

Tawara T, Shingu M, Nobunaga M, Naono T (1991). Effects of recombinant human IL-1 β on production of prostaglandin E2, leukotriene B4, NAG, and superoxide by human synovial cells and chondrocytes. *Inflammation* 15:145-57.

Tiku ML, Liesch JB, Robertson FM (1990). Production of hydrogen peroxide by rabbit articular chondrocytes. Enhancement by cytokines. *J Immunol* 145:690-96.

Tilley SL, Coffman TM and Koller BH (2001). Mixed messages: modulation of inflammation and immune response by prostaglandins and thromboxanes. *J Clin Invest* 108:15-23

Tinkle BT, Jay G (2002). Analysis of transgene integration, p. 459-474. In CA Pinkert (ed.), *Transgenic animal technology: a laboratory handbook*. 2nd ed. Academic Press, Inc., San Diego.

Tiscornia, G., Singer, O., Ikawa, M., and Verma, I. M. (2003). A general method for gene knockdown in mice by using lentiviral vectors expressing small interfering RNA. *Proc Natl Acad Sci U S A* 100, 1844-1848.

Tuschl, T. RNA interference and small interfering RNAs. *Chembiochem* (2001) 2:239-245.

Vane JR, Bakhle YS, Botting RM(1998). Cyclooxygenases 1 and 2. *Annu. Rev. Pharmacol. Toxicol.* 38:97-120.

Wada S, Okabe E (1997). Susceptibility of caffeine and INS(1,4,5)P3 induced contractions to oxidants in permeabilized vascular smooth muscle. *Eur J Pharmacol* 320:51-59.

Webb GR. Westacott CI. Elson CJ (1998). Osteoarthritic synovial fluid and synovium supernatants up-regulate tumor necrosis factor receptors on human articular chondrocytes. *Osteoarthr & Cartil* 6:167-76.

Wilhelmi G, Faust R (1976). Suitability of the C57 black mouse as an experimental animal for the study of skeletal changes due to ageing, with special reference to osteo-arthritis and its response to tribenoside. *Pharmacol* 14:289-96.

Wingren AG, Bjorkdahl O, Labuda T, Bjork L, Andersson U, Gullberg U, Hedlund G, Sjogren HO, Kalland T, Widegren B, Dohlsten M (1996). Fusion of a signal sequence to the interleukin-1 beta gene directs the protein from cytoplasmic accumulation to extracellular release. *Cell Immunol* 169:226-37.

Woodruff T, Blake DR, Freeman J, Andrews FJ, Salt P, Lunec J (1986). Is chronic synovitis an example of reperfusion injury? *Ann Rheum Dis* 45:608-11.

Yaksh TL, Dirig DM, Conway CM, Svensson C, Luo ZD, Isakson PC (2001). The acute antihyperalgesic action of nonsteroidal, anti-inflammatory drugs and release of spinal prostaglandin E2 is mediated by the inhibition of constitutive spinal cyclooxygenase-2 (COX-2) but not COX-1. *J Neurosci* 21:5847-53.

Yamamoto Y, Yin MJ, Lin KM and Gaynor RB (1999). Sulindac inhibits activation of the NF- κ B pathway. *J Biol Chem* 274:27307-314.

Yang, D., F. Buchholz, Z. Huang, A. Goga, C.-Y. Chen, F.M. Brodsky and J.M. Bishop. Short RNA duplexes produced by hydrolysis with *Escherichia coli* RNase III mediate effective RNA interference in mammalian cells. *Proceedings of the National Academy of Sciences* (2002) 99:9942-994.

Yin MJ, Yamamoto Y and Gaynor RB (1998). The anti-inflammatory agents aspirin and salicylate inhibit the activity of I κ B kinase- β . *Nature* 396:77-80.

Yoshida H, Fukumura Y, Fujita S, Nishida M, Iizuka T (2002). The expression of cyclooxygenase-2 in human temporomandibular joint samples: an immunohistochemical study. *J Oral Rehab* 29:1146-52.

Zhang J, S Goorha, R Raghowand, LR Ballou (2002). The tissue-specific, compensatory expression of cyclooxygenase-1 and -2 in transgenic mice. *Prostaglandin Other Lipid Mediat* 67:121-35.

Zhu J, Musco ML, Grace MJ (1999). Three-color flow cytometry analysis of tricistronic expression of eBFP, eGFP, and eYFP using EMCV-IRES linkages. *Cytometry* 37: 51-9.

Zhu X, Conklin D, Eisenach JC (2003). Cyclooxygenase-1 in the spinal cord plays an important role in postoperative pain. *Pain* 104:15-23.

H. Sequences

SEQ ID NO:1

human IL-1 α mRNA (Accession No. NM_000575)

```

1 accaggcaac accattgaag gctcatatgt aaaaatccat gccttccttt ctcccaatct
61 ccattcccaa acttagccac tggcttctgg ctgaggcctt acgcatacct cccgggggctt
121 gcacacaccc tcttctacag aagacacacc ttgggcatat cctacagaag accaggcttc
181 tctctgggtcc ttggtagagg gctactttac tgtaacaggg ccagggtgga gaggttctctc
241 ctgaagctcc atcccctcta taggaaatgt gttgacaata ttcagaagag taaggaggatc
301 aagacttctt tgtgctcaaa taccactggt ctcttctcta ccctgcccta accaggagct
361 tgtcacccca aactctgagg tgatttatgc cttaatcaag caaacttccc tcttcagaaa
421 agatggctca ttttccctca aaagttgcca ggagctgcca agtattctgc caattcaccc
481 tggagcaca tcaacaaatt cagccagaac acaactacag ctactattag aactattatt
541 attaataaat tcctctccaa atctagcccc ttgacttcgg atttcacgat ttctcccttc
601 ctctagaaa cttgataagt ttccgcgcgt tccctttttc taagactaca tgtttgcat
661 cttataaagc aaaggggtga ataaatgaac caaatcaata acttctggaa tatctgcaaa
721 caacaataat atcagctatg ccatctttca ctatttttagc cagtatcgag ttgaatgaac
781 atagaaaaat acaaaactga attcttccct gtaaatccc cgttttgacg acgcacttgt
841 agccacgtag ccacgcctac ttaagacaat tacaaaaggc gaagaagact gactcaggct
901 taagctgcca gccagagagg gagtcatttc attggcgttt gagtcagcaa agaagtcaag
961 atggccaaag ttccagacat gtttgaagac ctgaagaact gttacagtga aaatgaagaa
1021 gacagttcct ccattgatca tctgtctctg aatcagaaat ccttctatca tgtaagctat
1081 ggccactccc atgaaggctg catggatcaa tctgtgtctc tgagtatctc tgaacacctc
1141 aaaacatcca agcttacctt caaggagagc atgggtgtag tagcaacca cgggaagggtt
1201 ctgaagaaga gacggttgag tttaagccaa tccatcactg atgatgacct ggaggccatc
1261 gccaatgact cagaggaaga aatcatcaag cctaggtcag caccttttag ctctctgagc
1321 aatgtgaaat acaactttat gaggatcatc aaatacgaat tcactctgaa tgacgccttc
1381 aatcaaagta taattcgagc caatgatcag tacctcacgg ctgctgcatt acataatctg
1441 agtaagcag tgaaatttga catgggtgct tataagtcac caaaggatga tgctaaaatt
1501 accgtgattc taagaatctc aaaaactcaa ttgtatgtga ctgccaaga tgaagaccaa
1561 ccagtgtctg tgaaggagat gcctgagata cccaaaacca tcacaggtag tgagaccaac
1621 ctctcttctc tctgggaaac tcacggcact aagaactatt tcacatcagt tgcccatcca
1681 aacttgttta ttgccacaaa gcaagactac tgggtgtgct tggcaggggg gccaccctct
1741 atcactgact ttcagatact ggaaaaccag gcgtaggtct ggagtctcac ttgtctcact

```

```

1801 tgtgcagtg tgcagttca tatgtaccat gtacatgaag aagctaaatc ctttactgtt
1861 agtcatttgc tgagcatgta ctgagccttg taattctaaa tgaatgttta cactccttgt
1921 aagagtggaa ccaacactaa catataatgt tgttatttaa agaaccacct atattttgca
1981 tagtaccatt cattttaatt attattcttc ataacaattt taggaggacc agagctactg
2041 actatggcta ccaaaaagac tctaccata ttacagatgg gcaaattaag gcataagaaa
2101 actaagaaat atgcacaata gcagttgaaa caagaagcca cagacctagg atttcatgat
2161 ttcatttcaa ctgtttgcct tctactttta agttgctgat gaactcttaa tcaaatagca
2221 taagtttctg ggacctcagt tttatcattt tcaaaatgga ggggaataata cctaagcctt
2281 cctgccgcaa cagtttttta tgctaactcag ggaggtcatt ttggtaaaaat acttcttgaa
2341 gccagcctc aagatgaagg caaagcacga aatgttattt ttaattattt atttatatat
2401 gtatttataa atatatttaa gataattata atatactata tttatgggaa ccccttcac
2461 ctctgagtg gaccaggcat cctccacaat agcagacagt gttttctggg ataagtaagt
2521 ttgatttcat taatacaggg cattttgggt caagttgtgc ttatcccata gccaggaaac
2581 tctgcattct agtacttggg agacctgtaa tcatataata aatgtacatt aattaccttg
2641 agccagtaat tgggtccgat tttgactcct ttgccattaa acttacctgg gcattcttgt
2701 ttcaattcca cctgcaatca agtctcataa gctaaaatta gatgaactca actttgacaa
2761 ccatgagacc actgttatca aaactttctt ttctggaatg taatcaatgt ttcttctagg
2821 ttctaaaaat tgtgatcaga ccataatgtt acattattat caacaatagt gattgataga
2881 gtgttatcag tcataactaa ataaagcttg caacaaaatt ctctgacaaa aaaaaaaaaa
2941 aaa

```

SEQ ID NO:2**Human IL-1beta mRNA (Accession No. NM_000576)**

```

1 accaaacctc ttogaggcac aaggcacaaac aggtgctctt gggattctct tcagccaatc
61 ttcattgtct aagtgtctga agcagccatg gcagaagtac ctgagctcgc cagtgaatg
121 atggcttatt acagtggcaa tgaggatgac ttgttctttg aagctgatgg ccctaaacag
181 atgaagtgtc ccttccagga cctggacctc tgccctctgg atggcgcat ccagctacga
241 atctccgacc accactacag caagggtctc aggcaggccg cgtcagttgt tgtggccatg
301 gacaagctga ggaagatgct ggtcccttgc ccacagacct tccaggagaa tgacctgagc
361 accttcttct ccttcattct tgaagaagaa cctatcttct tcgacacatg ggataacgag
421 gcttatgtgc acgatgcacc tgtacgatca ctgaactgca cgctccggga ctcacagcaa
481 aaaagcttgg tgatgtctgg tccatataaa ctgaaagctc tccacctcca gggacaggat
541 atggagcaac aagtgggtgt ctccatgtcc tttgtacaag gagaagaaag taatgacaaa
601 ataccttgg ccttgggctc caaggaaaag aatctgtacc tgtcctgcgt gttgaaagat
661 gataagccca ctctacagct ggagagtgtg gatcccaaaa attaccctaa gaagaagatg
721 gaaaagcgat ttgtcttcaa caagatagaa atcaataaca agctggaatt tgagctctgcc
781 cagttcccca actggtacat cagcacctct caagcagaaa acatgcccggt cttcctggga
841 gggaccacaa gcggccagga tataactgac ttcaccatgc aatttgtgtc ttcctaaaga
901 gagctgtacc cagagagtcc tgtgctgaat gtggactcaa tccctagggc tggcagaaag
961 ggaacagaaa ggtttttgag tacggctata gcctggactt tcctgttgtc tacaccaatg
1021 cccaactgcc tgccttaggg tagtgctaag aggatctcct gtccatcagc caggacagtc
1081 agctctctcc tttcaggggc aatccccagc ccttttgttg agccaggcct ctctcacctc
1141 tctactcac ttaaagcccg cctgacagaa accacggcca catttggttc taagaaaccc
1201 tctgtcattc gctccacat tctgatgagc aaccgcttcc ctatttattt atttatttgt
1261 ttgtttgttt tattcattgg tctaatttat tcaaaggggg caagaagtag cagtgtctgt
1321 aaaagagcct agtttttaat agctatggaa tcaattcaat ttggactggg gtgctctctt
1381 taaatcaagt cctttaatta agactgaaaa tatataagct cagattattt aaatgggaat
1441 atttataaat gagcaaatat catactgttc aatggttctg aaataaactt cactgaag

```

SEQ ID NO:3**Human IL-1beta open reading frame – mature form**

Gcaactgtacgatcactgaactgcacgctccgggactcacagcaaaaaagcttggtgatgtctggtccatatagaact
gaaagctctccacctccagggacaggatatggagcaacaagtggtgttctccatgtcctttgtacaaggagaagaaa
gtaatgacaaaatacctgtggccttgggctcaaggaaaagaatctgtacctgtcctgcgtgttgaaagatgataag
cccactctacagctggagagtgtagatcccaaaaattaccctaaagaagaagatggaaaagcgatttgtcttcaacaa
gatagaaatcaataacaagctggaatttgagtctgccagttcccaactggtacatcagcacctctcaagcagaaa
acatgcccgctcttctggggagggaacaaaggcgccaggatataactgacttcaccatgcaatttgtgtcttctctaa
ag

SEQ ID NO:4**IL-1β, Sequence of ssIL-1β (539 BP)**

atggaaatctgcagaggcctccgcagtcacctaatactctcctccttctcctgttccattcagagacgatctgcgc
acctgtacgatcactgaactgcacgctccgggactcacagcaaaaaagcttggtgatgtctggtccatatagaactga
aagctctccacctccagggacaggatatggagcaacaagtggtgttctccatgtcctttgtacaaggagaagaaagt
aatgacaaaatacctgtggccttgggctcaaggaaaagaatctgtacctgtcctgcgtgttgaaagatgataagcc

cactctacagctggagagctgtagatcccaaaaattacccaaagaagaagatggaaaagcgatttgtcttcaacaaga
tagaaatcaataacaagctggaatttgagtctgccagttccccaactggtacatcagcacctctcaagcagaaaac
atgcccgtcttctctgggagggaacaaaggcgccaggatataactgacttcaccatgcaatttgtgtcttctctaaag

SEQ ID NO:5**Human IL1-RA mRNA (Accession No. NM_173842)**

1 atttctttat aaaccacaac tctgggcccg caatggcagt ccactgcctt gctgcagtca
61 cagaatggaa atctgcagag gcctccgcag tcacctaatc actctcctcc tcttctgtt
121 ccattcagag acgatctgcc gacctcttgg gagaaaatcc agcaagatgc aagccttcag
181 aatctgggat gttaaccaga agaccttcta tctgaggaac aaccaactag ttgctggata
241 ctgcaagga ccaaatgtca atttagaaga aaagatagat gtggtaccca ttgagcctca
301 tgctctgttc ttgggaatcc atggagggaa gatgtgcctg tcctgtgtca agtctgggtga
361 tgagaccaga ctccagctgg aggcagttaa catcactgac ctgagcgaga acagaaagca
421 ggacaagcgc ttgccttca tccgctcaga cagcggcccc accaccagtt ttgagtctgc
481 cgcctgcccc gggttggttc tctgcacagc gatggaagct gaccagcccg tcagcctcac
541 caatatgcct gacgaaggcg tcatgggtcac caaattctac ttccaggagg acgagtagta
601 ctgcccagge ctgcctgttc ccattcttgc atggcaagga ctgcaggggac tgccagtccc
661 cctgccccag ggctcccggc tatgggggca ctgaggacca gccattgagg ggtggaccct
721 cagaaggcgt cacaagaacc tggtcacagg actctgcctc ctcttcaact gaccagcctc
781 catgctgcct ccagaatggt ctttctaatt tgtgaatcag agcacagcag cccctgcaca
841 aagcccttcc atgtcgcttc tgcattcagg atcaaacccc gaccacctgc ccaacctgct
901 ctctcttgc cactgcctct tcctccctca ttccaccttc ccatgccttg gatccatcag
961 gccacttgat gacccccaac caagtggctc ccacacctg ttttcaaaaa aagaaaagac
1021 cagtcctatga gggaggtttt taagggtttg tggaaaatga aaattaggat ttcattgattt
1081 ttttttttca gtccccgtga aggagagccc ttcatttggg gattatgttc tttcggggag
1141 aggtcgagga cttaaaatat tcttgcattt gtgaaatgat ggtgaaagta agtggtagct
1201 tttcccttct ttttcttctt tttttgtgat gtcccaactt gtaaaaaatta aaagttagtg
1261 tactatgcta gcccataat ttttttttct cttttaaaac acttccataa tctggactcc
1321 tctgtccagg cactgctgcc cagcctccaa gctccatctc cactccagat tttttacagc
1381 tgcttgagct actttacctc ctatcagaag tttctcagct cccaaggctc tgagcaaatg
1441 tggctcctgg gggttctttc ttctctgtct gaaggataaa attgctcctt gacattgtag
1501 agcttctggc acttgagac ttgtatgaaa gatggctgtg cctctgcctg tctccccac
1561 cgggctggga gctctgcaga gcaggaaaca tgaactgtat atgtctcagg tccctgcagg
1621 cccaagcacc tagctcgct ctggcagggt actcagcgaa tgaatgctgt atatgttggg
1681 tgcaaaagtt cctacttctt gtgacttcag ctctgtttta caataaaatc ttgaaaatgc
1741 ctaaaaaaaaa aaaaaaaaaa

SEQ ID NO:6**Human IL1-RA open reading frame**

atggaaatctgcagaggcctccgcagtcacctaatactctctctcttcttctgttccattcagagacgatctgccg
accctctgggagaaaatccagcaagatgcaagccttcagaatctgggatgttaaccagaagaccttctatctgagga
acaaccaactagttgctggatacttgcaaggaccaaattgtcaatttagaagaaaagatagatgtggtacccattgag
cctcatgctctgttcttgggaatccatggagggaagatgtgcctgtcctgtgtcaagtctggtgatgagaccagact
ccagctggaggcagttaacatcactgacctgagcgagaacagaaagcaggacaagcgcttcgccttcatccgctcag
acagcggccccaccaccagttttgagtctgccgcctgccccggttggttctctgcacagcgatggaagctgaccag
cccgtcagcctcaccaatatgcctgacgaaggcgctatggtcaccaaattctacttccaggaggacgagtag

SEQ ID NO:7 IL-1RA, Sequence of hIL-1RA (534 BP, note silent T→C mutation at position 390)

atggaaatctgcagaggcctccgcagtcacctaatactctctctcttcttctgttccattcagagacgatctgccg
accctctgggagaaaatccagcaagatgcaagccttcagaatctgggatgttaaccagaagaccttctatctgagga
acaaccaactagttgctggatacttgcaaggaccaaattgtcaatttagaagaaaagatagatgtggtacccattgag
cctcatgctctgttcttgggaatccatggagggaagatgtgcctgtcctgtgtcaagtctggtgatgagaccagact
ccagctggaggcagttaacatcactgacctgagcgagaacagaaagcaggacaagcgcttcgccttcatccgctcag
acagcggccccaccaccagttttgagtctgccgcctgccccggttggttctctgcacagcgatggaagctgaccag
cccgtcagcctcaccaatatgcctgacgaaggcgctatggtcaccaaattctacttccaggaggacgagtag

SEQ ID NO:8 human IL-1R1 mRNA (Accession No. NM_000877)

1 tagacgcacc ctctgaagat ggtgactccc tctgagaag ctggaccctt tggtaaaaga
61 caaggccttc tccaagaaga atatgaaagt gttactcaga cttatttgtt tcatagctct
121 actgatttct tctctggagg ctgataaatg caaggacgt gaagaaaaaa taattttagt
181 gtcatactgca aatgaaattg atgttcgtcc ctgtcctctt aacccaaatg aacacaaagg
241 cactataact tggataaaag atgacagcaa gacacctgta tctacagaac aagcctccag
301 gattcatcaa cacaaagaga aactttgggt tgttctgtct aagggtggagg attcaggaca

361	ttactatttgc	gtggtaagaa	attcatctta	ctgcctcaga	attaaaaataa	gtgcaaaatt
421	tgtggagaat	gagcctaact	tatgttataa	tgcaaacgcc	atattttaagc	agaaactacc
481	cgttgacgga	gacggaggac	ttgtgtgccc	ttatatggag	ttttttaaaa	atgaaaaataa
541	tgagttacct	aaattacagt	ggtataagga	ttgcaaacct	ctacttcttg	acaatataca
601	ctttagtggg	gtcaaagata	ggctcatcgt	gatgaatgtg	gctgaaaagc	atagagggaa
661	ctatacttgt	catgcacctc	acacatactt	gggcaagcaa	tatcctatta	cccgggtaat
721	agaattttatt	actctagagg	aaaacaaacc	cacaaggcct	gtgattgtga	gcccagctaa
781	tgagacaatg	gaagtagact	tgggatccca	gatacaattg	atctgtaatg	tcaccggcca
841	gttgagtgc	attgcttact	ggaagtggaa	tgggtcagta	attgatgaag	atgaccaggt
901	gctaggggaa	gactattaca	gtgtggaaaa	tcctgcaaac	aaaagaagga	gtaccctcat
961	cacagtgcct	aatatatcgg	aaattgaaag	tagattttat	aaacatccat	ttacctgttt
1021	tgccaagaat	acacatggta	tagatgcagc	atatatccag	ttaatatatc	cagtcactaa
1081	tttccagaag	cacatgattg	gtatatgtgt	cacgttgaca	gtcataattg	tgtgttctgt
1201	ttttctccca	ataaaagctt	cagatggaaa	gacctatgac	gcatatatac	tgtatccaaa
1261	gactgttggg	gaagggtcta	cctctgactg	tgatatTTTT	gtgtttaaag	tcttgccctga
1321	ggtcttggaa	aaacagtggt	gatataagct	gttcattttat	ggaagggatg	actacgttgg
1381	ggaagacatt	gttgaggtca	ttaatgaaaa	cgtaaagaaa	agcagaagac	tgattatcat
1441	tttagtcaga	gaaacatcag	gcttcagctg	gctgggtggg	tcactctgaag	agcaaatagc
1501	catgtataat	gctcttggtc	aggatggaat	taaagttgtc	ctgcttgagc	tggagaaaaat
1561	ccaagctcat	gagaaaaatg	cagaatcgat	taaatttcatt	aagcagaaac	atggggctat
1621	ccgctgggtca	ggggacttta	cacagggacc	acagctctgca	aagacaaggt	tctggaagaa
1681	tgtaagggtac	cacatgccag	tcagcgacg	gtcaccttca	tctaaacacc	agttactgtc
1741	accagccact	aaggagaaac	tgcaaaagaga	ggctcacgtg	cctctcgggt	agcatggaga
1801	agttgccaag	agttctttag	gtgcctcctg	tcttatggcg	ttgcaggcca	ggttatgcct
1861	catgtcgtct	tgtagagttc	atggaaatgta	actatatcat	cctttatccc	tgaggtcacc
1921	tggaatcaga	ttattaaggg	aataagccat	gacgtcaata	gcagcccagg	gcacttcaga
1981	gtagagggct	tggaagatc	ttttaaaaag	gcagtaggcc	cgggtgtggtg	gctcacgcct
2041	ataatcccag	cactttggga	ggctgaagtg	gggtggatcac	cagaggtcag	gagttcgaga
2101	ccagcccagc	caacatggca	aaaccccatc	tctactaaaa	atacaaaaat	gagctaggca
2161	tggtggcaca	cgctctgaat	ccagctaca	cctgaggtcg	aggcaggaga	attgcttgaa
2221	ccggggagac	ggaggttgca	gtgagccgag	tttgggccac	tgcaactctag	cctggcaaca
2281	gagcaagact	ccgtctcaaa	aaaagggcaa	taaatgccct	ctctgaatgt	ttgaactgcc
2341	aagaaaaggc	atggagacag	cgaactagaa	gaaagggcaa	gaaggaaata	gccaccgtct
2401	acagatggct	tagttaagtc	atccacagcc	caagggcggg	gctatgcctt	gtctggggac
2461	cctgatgact	cactgaccct	ggagcggctc	tcctgagagg	tgctgcaggc	aaagtgcagc
2521	tgacacctca	ctgaggaagg	gagacatatt	cctggagaac	tttccatctg	cctgtatttt
2581	ccatacacat	cccagccag	aagttagtg	ccgaagaccg	aattttattt	tacagagctt
2641	gaaaactcac	ttcaatgaac	aaagggattc	tccaggattc	caaagttttg	aagtcattct
2701	agctttccac	aggagggaga	gaacttaaaa	aagcaacagt	agcagggaaat	tgatccactt
2761	cctagtctct	tccctcctgg	catgaccatc	ctgtcctttg	ttattatcct	gcatttttacg
2821	tccttggagg	aacagctccc	tagtggtctc	ctccgtctgc	aatgtccctt	gcacagccca
2881	cacatgaacc	atccttccca	tgatgcgct	cctctgtcat	cccgtcctg	ctgaaacacc
2941	tcccaggggc	tccacctggt	caggagctga	agcccattgt	ttcccaccag	catgtcactc
3001	ccagaccacc	tccttgccct	gtcctccagc	ttcccctcgc	tgtcctgctg	tgtgaattcc
3061	caggttggcc	tgggtggccat	gtgcctgccc	cccagcactc	ctctgtctct	gctcttgccct
3121	cgacccttcc	tcctcctttg	cctaggaggc	cctctcgcac	tttctctagc	tgatcagaat
3181	tttaccaaaa	ttcagaacat	cctccaattc	cacagtctct	gggagacttt	ccctaagagg
3241	cgacttctct	tccagccttc	tctctctggt	caggcccaact	gcagagatgg	tgggtgagcac
3301	atctgggagg	ctggtctccc	tccagctgga	attgtctgct	tctgagggag	aggctgtggt
3361	ggctgtctct	gtccctcact	gccttccagg	agcaatttgc	acatgtaaca	tagattttatg
3421	taatgcttta	tgtttaaaaa	cattcccca	ttatcttatt	taatttttgc	aattatttcta
3481	attttatata	tagagaaagt	gacctatttt	ttaaaaaat	cacactctaa	gttctattga
3541	acctaggact	tgagcctcca	tttctggctt	ctagtctggt	gttctgagta	cttgatttca
3601	ggtcaataac	ggccccccct	cactccacac	tggcacgttt	gtgagaagaa	atgacatttt
3661	gctaggaagt	gaccgagtc	aggaatgctt	ttattcaaga	caccaaattc	caaacttcta
3721	aatgttggaa	ttttcaaaaa	ttgtgtttag	attttatgaa	aaactcttct	actttcatct
3781	attctttccc	tagaggcaaa	catttcttaa	aatgtttcat	tttcattaaa	aatgaaagcc
3841	aaatttatat	gccaccgatt	gcaggacaca	agcacagttt	taagagttgt	atgaacatgg
3901	agaggacttt	tgggtttttat	atttctcgta	tttaatatgg	gtgaacacca	acttttattt
3961	ggaataataa	ttttcctcct	aaacaaaaac	acattgagtt	taagtctctg	actcttgccct
4021	ttccacctgc	tttctcctgg	gcccgttttg	cctgcttgaa	ggaacagtgc	tgttctggag
4081	ctgctgttcc	aacagacagg	gcctagcttt	catttgacac	acagactaca	gccagaagcc
4141	catggagcag	ggatgtcacg	tcttgaaaag	cctattagat	gttttacaaa	tttaattttg
4201	cagattattt	tagtctgtca	tccagaaaaat	gtgtcagcat	gcatagtgtc	aagaaagcaa
4261	gccaatttgg	aaacttaggt	tagtgacaaa	attggccaga	gagtgggggt	gatgatgacc
4321	aagaattaca	agtagaatgg	cagctggaat	ttaaggaggg	acaagaatca	atggataagc
4381	gtgggtggag	gaagatccaa	acagaaaagt	gcaagtttat	tccccatctt	ccaaggggtg

```

4441 aattcttggag gaaagaagaca cattcctagt tccccgtgaa cttcctttga cttattgtcc
4501 ccactaaaac aaaacaaaaa acttttaatg ccttccacat taattagatt ttcttgcaat
4561 ttttttatgg cattttttta aagatgccct aagtgttgaa gaagagtttg caaatgcaac
4621 aaaatatttta attaccggtt gttaaaactg gtttagcaca atttatattt tccctctctt
4681 gcctttcttta tttgcaataa aagggtattga gccatttttt aaatgacatt tttgataaat
4741 tatgttttgta ctagttgatg aaggagtttt ttttaacctg tttatataat tttgcagcag
4801 aagccaaatt ttttgtatat taaagcacca aattcatgta cagcatgcat cacggatcaa
4861 tagactgtac ttattttcca ataaaatttt caaactttgt actgttaaa

```

SEQ ID NO:9 human IL-1R2 mRNA (Accession No. NM_173343)

```

1 gggatgggag atactgttgt ggtcacctct ggaaaataca ttctgtctact cttaaaaaact
61 agtgacgctc atacaaatca acagaaagag cttctgaagg aagactttta agctgcttct
121 gccacgtgct gctgggtctc agtcctccac ttcccggtgc ctctggaagt tgtcaggagc
181 aatgttgccg ttgtacgtgt tggtaatggg agtttctgccc ttcaccttc agcctgcggc
241 acacacaggg gctgccagaa gctgccggtt tcgtgggagg cattacaagc gggagttcag
301 gctggaaggg gagcctgtag cctgaggtg ccccgagggt ccctactggt tgtgggctc
361 tgtcagcccc cgcatacaac tgacatggca taaaaatgac tctgttagga cgggtcccagg
421 agaagaagag acacggatgt gggcccagga cgggtgctctg tggcttctgc cagccttgca
481 ggaggactct ggcacctacg tctgcactac tagaaatgct tcttactgtg acaaaatgtc
541 cattgagctc agagtttttg agaatacaga tgctttcctg ccgttcatct catacccgca
601 aatttttaac ttgtcaacct ctgggggtatt agtatgcctt gacctgagtg aattcaccgg
661 tgacaaaact gacgtgaaga ttcaatggta caaggattct cttcttttgg ataaagacaa
721 tgagaaatth ctaagtgtga gggggaccac tcacttactc gtacacgatg tggccctgga
781 agatgctggc tattaccgct gtgtcctgac atttgcccac gaaggccagc aatacaacat
841 cactagaggt attgagctac gcatcaagaa aaaaaaagaa gagaccattc ctgtgatcat
901 ttccccctc aagaccatct cagcttctct ggggtcaaga ctgacaatcc cgtgtaagg
961 gtttctggga accggcacac ccttaaccac catgctgtgg tggacggcca atgacacca
1021 catagagagc gcctaccggg gaggccgctg gaccgagggg ccacgccagg aatattcaga
1081 aaataatgag aactacattg aagtgccatt gatttttgat cctgtcacia gagaggattt
1141 gcacatggat tttaaatgtg ttgtccataa taccctgagt tttcagacac tacgcaccac
1201 agtcaaggaa gcctctcca cgttctctct gggcattgtg ctggcccccac tttcattggc
1261 cttcttggtt ttgggggaa tatggatgca cagacgggtg aaacacagaa ctggaaaagc
1321 agatggtctg actgtgctat ggctcatca tcaagacttt caatcctatc ccaagtgaag
1381 taaatggaat gaaataattc aaacacaaaa aaaaaaaaaa aaaaaaaaaa aaaaaa

```

SEQ ID NO:10 human COX1 mRNA (Accession No. M59979)

```

1 gcgcatagag ccggagtctc ttgtccgggt tcttgtctgt cctgctcctg ctcccgcgcg
61 tccccgtcct gctcgggac ccaggggcgc ccacgccagt gaatccctgt tgttactatc
121 catgccagca ccagggcac ttgttccgct tcggccttga ccgctaccag tgtgactgca
181 cccgcacggg ctattccggc cccaactgca ccatccctgg cctgtggacc tggctccgga
241 attcactgag gccagcccc tctttcacc acttctctgt cactcacggg cgctggttct
301 gggagtttgt caatgccacc ttcacccag agatgctcat gcgcctggtg ctacagtgct
361 gctccaaact tatcccagtt cccccacct acaactcagc acatgactac atcagctggg
421 agtctttctc caacgtgagc tattacactc gtattctgct ctctgtgctt aaagattggc
481 ccacacccat gggaacaaaa gggaagaagc agttgccaga tgcccagctc ctggcccgcc
541 gcttctctgt caggaggaag ttcatacctg accccaagg caccaacctc atgtttgcct
601 tctttgcaca acacttcacc caccagttct tcaaaacttc tggcaagatg ggtcctggct
661 tcaccaaggg cttggggcct ggggtagacc tcggccacat ttatggagac aatctggagc
721 gtcagtatca actgcggtc tttaaggatg ggaactcaa gtaccaggtg ctggatggag
781 aaatgtaccc gccctcggta gaagaggcgc ctgtgttgat gcactacccc cgaggcatcc
841 cgcgccagag ccagatggct gtgggcccag aggtgtttgg gctgcttctt gggctcatgc
901 tgtatgccac gctctggcta cgtgagcaca accgtgtgtg tgacctgtgt aaggctgagc
961 accccacctg gggcgatgag cagcttttcc agacgacccg cctcatcctc ataggggaga
1021 ccatcaagat tgtcatcgag gactacgtgc agcagctgag tggctatttc ctgcagctga
1081 aatttgaccc agagctgctg ttccgtgtcc agttccaata ccgcaaccgc attgccatgg
1141 agttcaacca tctctaccac tggcaccccc tcatgcctga ctcttcaag gtgggctccc
1201 aggagtacag ctacgagcag ttcttgttca acacctccat gttgggtggc tatgggggtg
1261 agggcctggg ggatgccttc tctgcgcaga ttgctggccg gatcgggtgg ggcaggaaca
1321 tggaccacca catcctgcac gtggctgtgg atgtcatcag ggagctctcg gagatcgggc
1381 tgcagccctt caatgagtac cgcaagaggt ttggcatgaa accctacacc tccctccagg
1441 agctcgtagg agagaaggag atggcagcag agttggagga attgtatgga gacattgatg
1501 cgttggagtt ctaccctgga ctgcttcttg aaaagtggca tccaaactct atctttgggg
1561 agagtatgat agagattggg gctccctttt ccctcaaggg tctcctaggg aatcccctct
1621 gttctccgga gtagtgaag ccgagcacat ttggcggcga ggtgggcttt aacattgtca
1681 agacggccac actgaagaag ctggtctgcc tcaacaccaa gacctgtccc tacgttctct
1741 tccgtgtgcc ggatgccagt caggatgatg ggcctgtgtg ggagcgacca tccacagagc

```



```

1801 tctgaggggc äggäaägcäg cattctggag gggagagctt tgtgcttgtc attccagagt
1861 gctgagggcca gggctgatgg tcttaaattgc tcattttctg gtttggcatg gtgagtgttg
1921 gggttgacat ttagaacttt aagtctcacc cattatctgg aatattgtga ttctgtttat
1981 tcttcagaa tgctgaactc cttgttagcc cttcagattg ttaggagtgg ttctcatttg
2041 gtctgccaga atactgggtt cttagttagac aacctagaat gtcagatttc tggttgattt
2101 gtaacacagt cattctagga tgtggagcta ctgatgaaat ctgctagaaa gttaggggggt
2161 tcttattttg cattccagaa tcttgacttt ctgattgggtg attcaaagtg ttgtgttccc
2221 tggctgatga tccagaacag tggtctgtat cccaaatctg tcagcatctg gctgtctaga
2281 atgtggattt gattcatttt cctgttcagt gagatatcat agagacggag atccctaaagt
2341 ccaacaagaa tgcattccct gaatctgtgc ctgactgag agggcaagga agtgggggtgt
2401 tcttcttggg accccacta agaccctggt ctgaggatgt agagagaaca ggtgggctgt
2461 attcacgcca ttgggttgaa gctaccagag ctctatcccc atccaggtct tgactcatgg
2521 cagctgtttc tcatgaagct aataaaattc gcc

```

SEQ ID NO:11 human COX2 mRNA (Accession No. NM_000963)

```

1 caattgtcat acgacttgca gtgagcgtca ggagcacgtc caggaactcc tcagcagcgc
61 ctccttcagc tccacagcca gacgcctca gacagcaaag cctacccccg cgccgcgccc
121 tgcccgccgc toggatgtct gcccgcgccc tgctgctgtg cgcggtcctg gcgctcagcc
181 atacagcaaa tcttgtctgt tcccacccat gtcaaaaccg aggtgtatgt atgagtgtgg
241 gatttgacca gtataagtgc gattgtaccc ggacaggatt ctatggagaa aactgctcaa
301 caccggaatt tttgacaaga ataaaattat ttctgaaacc cactccaaac acagtgcact
361 acatacttac ccacttcaag ggattttgga acgttgtgaa taacattccc ttccttcgaa
421 atgcaattat gagttatgtc ttgacatcca gatcacattt gattgacagt ccaccaactt
481 acaatgctga ctatggctac aaaagctggg aagccttctc taacctctcc tattatacta
541 gagcccttcc tctgtgcct gatgattgcc cgactccctt ggggtgtcaa ggtaaaaagc
601 agcttcttga ttcaaatgag attgtggaaa aattgtctct aagaagaaag ttcatccctg
661 atccccaggg tcacaacatg atgtttgcat tctttgcca gcacttcacg catcagtttt
721 tcaagacaga tcataagcga gggccagctt tcaccaacgg gctgggcat ggggtggact
781 taaatcatat ttacggtgaa actctggcta gacagcgtaa actgcgcctt tcaaggatg
841 gaaaaatgaa atatcagata attgatggag agatgtatcc tcccacagtc aaagatactc
901 aggcagagat gatctaccct cctcaagtc ctgagcatct acggtttgct gtgggcagg
961 aggtccttgg tctgtgtcct ggtctatgta tgtatgccac aatctggctg cggaacaca
1021 acagagtatg cgatgtgctt aaacaggagc atcctgaatg ggggtgatgag cagtgttcc
1081 agacaagcag gctaatactg ataggagaga ctattaagat tgtgattgaa gattatgtgc
1141 aacacttgag tggctatcac ttcaaaactga aatttgacc agaactactt ttcaacaaac
1201 aattccagta ccaaaactgt attgctgtcg aatttaacac cctctatcac tggcatcccc
1261 ttctgcttga cacctttcaa attcatgacc agaaatacaa ctatcaacag tttatctaca
1321 acaactctat attgctggaa catggaatta cccagtttgt tgaatcattc accaggcaaa
1381 ttgctggcag ggttgcctgg gtaggaatg ttccaccgc agtacagaaa gtatcacagg
1441 cttccattga ccagagcagg cagatgaaat accagtcctt taatgagtac cgcaaacgct
1501 ttatgtgaa gccctatgaa tcatttgaag aacttacagg agaaaaggaa atgtctgcag
1561 agttggaagc actctatggt gacatcgatg ctgtggagct gtatcctgcc cttctggtag
1621 aaaagcctcg gccagatgcc atctttgggt aaaccatggt agaagtggga gcaccattct
1681 ccttgaaagg acttatgggt aatgttatat gttctcctgc ctactggaag ccaagcactt
1741 ttggtggaga agtgggtttt caaatcatat acactgcctc aattcagctc ctcatctgca
1801 ataactgaa gggctgtccc tttacttcat tcagtgttcc agatccagag ctcatataaa
1861 cagtcaccat caatgcaagt tctcccgtc cggactaga tgatatcaat cccagctac
1921 tactaaaaga acgttcgact gaactgtaga agtctaata tcatatttat ttatttatat
1981 gaaccatgtc tattaattta attatttaat aatatttata ttaaactcct tatgttactt
2041 aacatcttct gtaacagaag tcagtactcc tgttgcggag aaaggagtca tacttgtgaa
2101 gacttttatg tcaactactc aaagatattg ctggtgtgt taagtttgga aaacagtttt
2161 tattctgttt tataaaccag agagaaatga gttttgacgt ctttttactt gaatttcaac
2221 ttatattata agaacgaaag taaagatggt tgaatactta aacactatca caagatggca
2281 aaatgctgaa agttttttaca ctgtcgatgt ttccaatgca tcttccatga tgcattagaa
2341 gtaactaatg tttgaaatth taaagtactt ttggttattt ttctgtcatc aaacaaaaac
2401 aggtatcagt gcattattaa atgaatattt aaattagaca ttaccagtaa tttcatgtct
2461 actttttaa atcagcaatg aaacaataat ttgaaatttc taaattcata ggttagaatc
2521 acctgtaaaa gcttgtttga tttcttaaag ttattaaact tgtacatata ccaaaagaa
2581 gctgtcttgg atttaaactc gtaaaatcag atgaaatttt actacaattg cttgttaaaa
2641 tattttataa gtgatgttcc tttttcacca agagtataaa cttttttagt gtgactgtta
2701 aaacttcctt ttaaatacaa atgcccattt tattaagggt gtggagccac tgcagtgtta
2761 tctcaaaata agaataattt gttgagatat tccagaattt gtttatatgg ctggtaacat
2821 gtaaaatcta tatcagcaaa aggtcttacc tttaaaataa gcaataacaa agaagaaac
2881 caaattattg ttcaaattta ggtttaaact tttgaagcaa actttttttt atccttgtgc
2941 actgcaggcc tggtagctag attttgtctat gaggttaatg aagtaccaag ctgtgcttga
3001 ataacgatat gttttctcag attttctgtt gtacagttta atttagcagt ccatatcaca
3061 ttgcaaaagt agcaatgacc tcataaaata cctcttcaaa atgcttaaat tcatttcaca

```

```

3121 cattaattccc atctcagctc cgaagccaat tcagtaggtg cattggaatc aagcctggct
3181 acctgcatgc tgttcccttt cttttctctt tttagccatt ttgctaagag acacagctct
3241 ctcatcactt cgtttctcct attttgtttt actagtttta agatcagagt tcactttctt
3301 tggactctgc ctatatttct ttacctgaac ttttgcaagt tttcaggtaa acctcagctc
3361 aggactgcta tttagctcct ctttaagaaga ttaaaagaga aaaaaaagg cccttttaaa
3421 aatagtatac acttatttta agtgaaaagc agagaatttt atttatagct aatttttagct
3481 atctgtaacc aagatggatg caaaggaggc agtgcctcag agagaactgt acgggggttg
3541 tgactggaaa aagttacgtt cccattctaa ttaatgcctt ttcttattta aaaacaaaac
3601 caaatgatat ctaagtagtt ctcagcaata ataataatga cgataatact tctttccac
3661 atctcattgt cactgacatt taatggtagt gtatattact taatttattg aagattatta
3721 tttatgtctt attaggacac tatgggtata aactgtgttt aagcctacaa tcattgattt
3781 ttttttgtta tgtcacaaac agtatatttt ctttgggggt acctctctga atattatgta
3841 aacaatccaa agaaatgatt gtattaagat ttgtgaataa atttttagaa atctgattgg
3901 catattgaga tatttaaggc tgaatgtttg tccttaggat aggcctatgt gctagccac
3961 aaagaatatt gtctcattag cctctaagtg ccataagact gaccttttaa aatgttttga
4021 gggatctgtg gatgcttctg taatttgttc agccacaatt tattgagaaa atattctgtg
4081 tcaagcactg tgggttttaa tttttttaa tcaaacgctg attacagata atagtattta
4141 tataaataat tgaaaaaaat tttcttttgg gaagagggag aaaatgaaat aaatatcatt
4201 aaagataact caggagaatc ttctttacaa ttttacgttt agaattgtta aggttaagaa
4261 agaaatagtc aatatgtctg tataaaacac tgttcactgt tttttttaa aaaaaaactt
4321 gatgtgttat taacattgat ctgctgacaa aacctgggaa tttgggtgtg gtatgcgaat
4381 gtttcagtgc ctcagacaaa tgtgtattta acttatgtaa aagataagtc tggaaataaa
4441 tgtctgttta ttttgtact attta

```

SEQ ID NO:12 human mPGES mRNA (Accession No. NM_004878)

```

1 gctgctctc tgtcagctg atcacacca cagttgagct gcgctggcca gagatgcctg
61 cccacagcct ggtgatgag agcccgcccc tcccgccctt cctgctctgc agcacgctgc
121 tggatcatca gatgtacgtg gtggccatca tcacgggcca agtgaggctg cggaagaagg
181 cctttgccaa ccccgaggat gccctgagac acggaggccc ccagtattgc aggagcgacc
241 ccgacgtgga acgctgcctc agggcccacc ggaacgacat ggagaccatc tacccttcc
301 ttttctggg cttcgtctac tcctttctgg gtccaaacc ttttgcgc tggatgcact
361 tcctgggtct cctcgtgggc cgtgtggcac acaccgtggc ctacctgggg aagctgcggg
421 caccatccg ctccgtgacc tacaccctgg cccagctccc ctgcgcctcc atggctctgc
481 agatcctctg ggaagcggcc cgccacctgt gaccagcagc tgatgcctcc ttggccacca
541 gaccatgggc caagagccgc cgtggctata cctggggact tgatgttctt tccagattgt
601 ggtgggccc gagtctgggt ttctctggcag cctgctgcgc gtgtgggtct ctgggcacag
661 tgggcctgtg tgtgtgccc gtgtgtgtga tgtgtgtgtg tatgtttctt agcccttgg
721 attcctgcac gaagtggctg atgggaacca tttcaagaca gattgtgaag attgatagaa
781 aatccttcag ctaaagtaac agagcatcaa aaacatcact ccctctccct ccctaacagt
841 gaaaagagag aaggagagct ctattttaaga ttcccaaacc taatgatcat ctgaatcccg
901 ggtaagaat gcagactttt cagactgacc ccagaaattc tggccagacc aatctaagg
961 caagcctggc catctgtatt ttttttttcc caagacagag tcttgcctgc ttgcccagc
1021 tggagtgaag tggtaacaac tggctcactg cagcctccgc ctcccgggtt caagcgattc
1081 tccgcctca gcctcctgag tagctgggat tacaggcgcg tatcaccata cccagctaatt
1141 ttttgtattt ttagtagaga cgggttcacc atgttgccca ggagggtctc gaactcctgg
1201 cctcaagtga tccaccggcc tcggcctccc aaagtgcctg gatgacaggc atgaactcact
1261 gtgctcagcc accatctgga gttttaaaag gctcccattg gattccctgt gatggccagg
1321 ccaggggacc cctgccagtt ctctgtggaa gcaaggctgg ggtcttgggt tctgtatgg
1381 tggaaagctg gtgagccaag gacagggtct gctcctctgc ccccgctgac gcttcccttg
1441 cggttggtt tggatgtctt tgcctcagtc ttctctctgg ctccaggtgtg ggtgggaggg
1501 gcccacagga agctcagcct tctcctccca aggtttgagt ccctccaaag ggcagtgggt
1561 ggaggaccgg gagctttggg tgaccagcca ctcaaaggaa ctttctgggt ccttcagtat
1621 cttcaagggt tggaaactgc aaatgtcccc ttgatgggga atccgtgtgt gtgtgtgtgt
1681 gtgtgtgtgt gtgtgtgtgt gtgtgtgttt tctcctagac ccgtgacctg agatgtgtga
1741 tttttagtc ttaaagtgaa gtgtctgcca gctgggcccc gcacctaaaa aaaaaaaaaa
1801 aaaaa

```

SEQ ID NO:13 human cPGES/p23 mRNA (Accession No. L24804)

```

1 ggattcgggc tacactttcc tcttctcccc gaccggagag ccgctcttcc cgcgcgggtgc
61 attctggggc ccgaggtcga gcccgccgct gccgcccctg cctgagggaa gcgagaagag
121 gccgcgacc agagaaaaag cggagtgcga ccggagagaa gtcgactccc tagcagcagc
181 cgcgcgcaga gagcccgccc accagttcgc ccgtccccc gcccgttca caatgcagcc
241 tgcttctgca aagtggtagt atcgaaggga ctatgtcttc attgaatttt gtgtgaaga
301 cagtaaggat gttaatgtaa attttgaaaa atccaaactt acattcagtt gtcctcagg
361 aagtgataat ttaagcatt taaatgaaat tgatcttttt cactgtattg atccaaatga
421 ttccaagcat aaaagaacgg acagatcaat tttatgttgt ttacgaaaag gagaatctgg

```

481 ccagtcattg ccaagggtta caaaagaaag ggcaaagctt aattggctta gtgtcgactt
 541 caataattgg aaagactggg aagatgattc agatgaagac atgtctaatt ttgatcggtt
 601 ctctgagatg atgaacaaca tgggtggtga tgaggatgta gatttaccag aagtagatgg
 661 agcagatgat gattcacaag acagtgtatg tgaaaaaatg ccagatctgg agtaaggaat
 721 attgtcatca cctggatttt gagaaagaaa aataacttct ctgcaagatt tcataattga
 781 ga

SEQ ID NO:14 Secretion Signal sequence of human IL-1ra: (75 bp)

atggaaatctgcagaggcctccgcagtcacctaatactctctctctctctctgttccattcagagacgatctgc

SEQ ID NO:15 CMV sequence

Cgatgtacggggccagatatacggttgacattgattattgactagttattaatagtaatacaattacgggggtcattag
 ttcatagcccatatatggagttccgcgttacataacttacggtaaatggccgcctgggtgaccgcccacgacccc
 cgccattgacgtcaataatgacgtatgttcccatagtaacgccaatagggactttccattgacgtcaatgggtgga
 ctatttacggtaaaactgccactttggcagtagatcaagtgtatcatatgccaaagtagcccccctattgacgtcaatg
 acggtaaatggccgcctggcattatgccagtagatgaccttatgggactttcctacttggcagtagatctacgta
 ttatgcatcgctattaccatggtagtgcgggttttggcagtagatcaatggcggtggatagcgggttgactcacggggg
 atttccaagtctccacccattgacgtcaatgggagtttgttttggcaccaaaatcaacgggactttccaaaatgtc
 gtaacaactccgccccattgacgcaaatggcggttagcggtgtacgggtgggaggtctatataagcagagctctctgg
 ctaactagagaacccactgcttactggcttatcgaaatt

SEQ ID NO:16 Chicken Beta Actin promoter

tcgaggtgag	ccccacgttc	tgcttcaactc	tccccatctc	ccccccctcc	ccacccccaa	60
ttttgtat	at	tttttttt	taattat	tttt	gtgcagcgat	120
cgcgccag	g	cgggggcg	g	cgggggcg	ggg	180
gcgcagcca	atcagagcgg	cgcgctccga	aagtttcctt	ttatggcgag	gcggcgccgg	240
cgggggccct	ataaaaagcg	aagcgcgcg	cgggcgggag	tcgctgcgtt	gccttcgccc	300
cgtgccccgc	tccgcgcgc	ctcgcgccgc	ccgccccggc	tctgactgac	cgcgttactc	360
ccacaggtga	g	cgggcgga	cgcccttct	cctccgggct	gtaattagcg	420
tgacggctcg	tttcttttct	gtggctgcgt	gaaagcctta	aagggtccg	ggagggccct	480
ttgtgcgggg	gggagcggtc	cggggggtgc	gtgcgtgtgt	gtgtgcgtgg	ggagcgccgc	540
gtgcggcccg	cgctgcccgg	cggtgtgag	cgctgcgggc	gcggcgccgg	gctttgtgcg	600
ctccgcgtgt	gcgcgagggg	agcgcgccg	ggggcggtgc	ccgcgggtgc	gggggggctg	660
cgaggggaac	aaaggtcg	tcgggggtgt	gtgcgtgggg	gggtgagcag	gggggtgtggg	720
cgcggcggtc	gggtgtaac	ccccccctgc	acccccctcc	ccgagttgct	gcgcacggcc	780
cggcttcggg	tcgggggctc	cgtgcggggc	gtggcgcggg	gtcgcgcgtg	ccgggcgggg	840
gggtggcgga	gggtgggggtg	ccgggcgggg	cggggcggcc	tcgggcgggg	gagggctcgg	900
gggagggggc	cggcggcccc	ggagcgccgg	cggtgtcga	ggcgcgccga	gccgcagcca	960
ttgcctttta	tggtaatcgt	gcgagagggc	gcagggactt	cctttgtccc	aaatctggcg	1020
gagccgaaat	ctgggagggc	ccgcgcgacc	ccctctagcg	ggcgcgggcg	aagcggtgcg	1080
gcgcggcgag	gaaggaaatg	ggcggggagg	gccttcgtgc	gtcgcgcgcg	cgccgtcccc	1140
ttctccatct	ccagcctcgg	ggctgcgcga	gggggacggc	tgccctcggg	ggggacgggg	1200
cagggcgggg	ttcggttctt	ggcgttgtac	cggcgggggtt	tatatcttcc	cttctctggt	1260
cctccgcagc	cagccatg					1278

SEQ ID NO:17 E06566 Accession # Promoter gene of human beta-actin gene

cccggggcca	gcacccaag	gcggccaacg	ccaaaactct	ccctcctcct	cttctctaat	60
ctcgctctcg	ctcttttttt	ttttcgcaaa	aggaggggag	aggggggtaaa	aaaatgctgc	120
actgtgcggc	gaagccgggtg	agtgcgcggc	gcggggccaa	tcagcgtgcg	ccgttccgaa	180
agttgccttt	tatggctcga	gcggcccgcg	cggcgccta	taaaaccag	cggcgcgacg	240
cggccaccac	gccgagaccg	cgtccgcccc	gcgagcacag	agcctcgcc	ttgccgatcc	300
gccgcccgtc	cacaccgcgc	gccaggtaa	ccgggccagc	cgaccggggc	atgcggccgc	360
ggcccttcg	cccgtgcaga	gccgcgctct	gggcccgcagc	ggggggcgca	tgggggggga	420
accggaccgc	cgtggggggc	gcgggagaag	cccctggggc	tccggagatg	ggggacaccc	480
cacgccagtt	cggaggcgcg	aggccgcgct	cgggaggcgc	gctccggggg	tgccgctctc	540
ggggcggggg	caaccggcg	ggtctttgtc	tgagccgggc	tcttgccaat	ggggatcgca	600
gggtggcgcg	ggcgtagccc	ccgccaaggc	cggtgggggc	tggggcgcca	ttgccggtgc	660
gcgctggtcc	tttgggcgct	aactgcgtgc	gcgctgggaa	ttggcgctaa	ttgcgcgtgc	720
gcgctgggac	tcaaggcgct	aattgcgcgt	gcgttctggg	gcccgggggtg	ccgcggcctg	780
ggctggggcg	aaggcgggct	cgcccggaag	gggtggggtc	gccgcggctc	ccgggcgctt	840
gcgcgacctt	cctgcccgag	ccgctggccg	cccagggtg	tggccgctgc	gtgcgcgcgc	900
gccgaccggg	cgctgtttga	accgggcgga	ggcgggcggtg	gcgcccggtt	gggagggggg	960
tggggcctgg	cttctctgcc	cgcgcccgcg	ggacgcctcc	gaccagtgtt	tgccctttat	1020

ggtaataacg	cggccgccc	gggttccttt	gtccccaatc	tgggcgcgcg	cgggcgcccc	1080
ctggcggcct	aaggactcgg	cgcgccggaa	gtggccaggg	cgggggcgac	ttcggctcac	1140
agcgcgcccc	gctattctcg	cagctcacca	tgatg			1176

SEQ ID NO:18 CMV-Beta actin promoter

gaattcggtg	ccctagttat	taatagtaat	caattacggg	gtcattagtt	catagcccat	60
atatggagtt	cgcggttaca	taacttacgg	taaatggccc	gcctggctga	ccgcccacg	120
accccgccc	attgacgtca	ataatgacgt	atgttcccat	agtaacgcca	atagggactt	180
tccattgacg	tcaatgggtg	gactatttac	ggtaaaactgc	ccacttgcca	gtacatcaag	240
tgtatcatat	cccaagtacg	ccccctattg	acgtcaatga	cggtaaatgg	cccgcctggc	300
attatgcccc	gtacatgacc	ttatgggact	ttcctacttg	gcagtacatc	tacgtattag	360
tcacgctat	taccatggtc	gaggtgagcc	ccacgttctg	cttcaactctc	cccatctccc	420
ccccctcccc	accccccaatt	ttgtattttat	ttatttttta	attattttgt	gcagcgatgg	480
ggggcggggg	gggggggggg	cgcgcgccag	gcggggcggg	gcggggcgag	gggcggggcg	540
gggcgagggc	gagaggtgcg	gcggcagcca	atcagagcgg	cgcgctccga	aagtttccct	600
ttatggcgag	gcggcgggcg	cggcgccct	ataaaaagcg	aagcgcgcgg	cgggcgggag	660
tcgctgcgac	gctgccttcg	ccccgtgccc	cgcctccgcg	ccgcctcgcg	ccgcccgcgc	720
cggctctgac	tgaccgcgtt	actcccacag	gtgagcgggc	gggacggccc	ttctcctccg	780
ggctgtaatt	agcgccttgg	ttaatgacgg	cctgtttctt	ttctgtggct	gcgtgaaagc	840
cttgagggcg	tccgggaggg	ccctttgtgc	gggggggagc	ggctcggggg	gtgcgtgcgt	900
gtgtgtgtgc	gtggggagcg	ccgcgtgccc	cccgcgctgc	ccggcggtcg	tgagcgctgc	960
gggcgcggcg	cggggctttg	tgcgctccgc	agtgtgcgcg	aggggagcgc	ggccgggggc	1020
ggtgccccgc	ggtgcggggg	gggtgcgag	gggaacaaag	gctgcgtgcg	gggtgtgtgc	1080
gtgggggggt	gagcaggggg	tgtgggcgcg	gcggtcgggc	tgtaaccccc	ccctgcaccc	1140
ccctccccga	gttgcagagc	acggcccggc	ttcgggtgcg	gggctccgta	cggggcggtg	1200
cgcggggctc	gccgtgccc	gcgggggggtg	gcggcaggtg	gggggtgccc	gcggggcggg	1260
gccgcctcgg	gccggggagg	gctcggggga	ggggcgcggc	ggcccccgga	gcgccggcgg	1320
ctgtcgaggg	gcggcgagcc	gcagccattg	ccttttatgg	taatcgtgcg	agagggcgca	1380
gggacttcct	ttgtcccaaa	tctgtgcgga	gccgaaatct	gggaggcgcc	gccgcacccc	1440
ctctagcggg	cgcggggcga	agcgggtgcg	gcgccggcag	aaggaaatgg	gcggggaggg	1500
ccttcgtgcg	tcgcgcggcc	gccgtccct	tctccctctc	cagcctcggg	gctgtccgcg	1560
gggggacggc	tgcccttcggg	ggggacgggg	cagggcgggg	ttcggcttct	ggcgtgtgac	1620
cggcggtctc	agagcctctg	ctaaccatgt	tcatgccttc	ttctttttcc	tacagctcct	1680
gggcaacgtg	ctgggtattg	tgctgtctca	tcattttggc	aaagaattc		1729

SEQ ID NO:19 Chicken beta-actin with CMV enhancer elements promoter sequence

cgatgtacggccagatatacgcgttgacattgattattgactagttattaatagtaatacaattacgggggtcattag
 ttcatagcccatatatggagttccgcgttacataacttacggtaaatggccgcctggctgaccgcccacgacccc
 cgcccatgtacgtcaataatgacgtatgttcccatagtaacgccaatagggactttccattgacgtcaatgggtgga
 ctattttacggtaaaactgcccacttgccaggtacatcaagtgtatcatatgccaaagtacgccccctattgacgtcaatg
 acggtaaatggccgcctggcattatgccagtagacacattatgggactttcctacttgccagtagacatctacgta
 ttatgtcatcgctattaccatgggtgatgcgggttttggcagtagacatcaatggggcggtgtagcggtttgactcacgggg
 atttccaagtctccacccattgacgtcaatggggagttgttttggcaccacaaatcaacgggactttccaaaatgtc
 gtaacaactccgccccattgacgcaaatgggcggtaggcgtgtacgggtgggaggtctatataagcagagctctctgg
 ctaactagagaacccactgcttactggttatcgaaatt

SEQ ID NO:20 Fusion promoter-CMV portion

tagttattaa	tagtaataca	ttacggggtc	attagttcat	agcccatata	tggagttccg	60
cgttacataa	cttacggtaa	atggcccgcc	tggctgacgg	cccaacgacc	cccggccatt	120
gacgtcaata	atgacgtatg	ttcccatagt	aacgccaata	gggactttcc	attgacgtca	180
atgggtggac	tattttacgg	aaactgcccc	cttggcagta	catcaagtgt	atcatatgcc	240
aagtacgccc	cctattgacg	tcaatgacgg	taaatggccc	gcctggcatt	atgccagta	300
catgacctta	tgggactttc	ctacttgcca	gtacatctac	gtattagtca	tcgctattac	360
catggt						366

SEQ ID NO:21 Fusion promoter - beta actin portion

ccaattttgt	atttatttat	tttttaatta	ttttgtgcag	cgatgggggc	gggggggggg	60
ggggggcgcg	cgccaggcgg	ggcgggcgcg	ggcgaggggc	ggggcggggc	gaggcgagga	120
ggtgcggcgg	cagccaatca	gagcggcgcg	ctccgaaagt	ttccttttat	ggcgaggcgg	180
cggcgggcgg	ggccctataa	aaagcgaaag	gcgcggcggg	cgggagtcgc	tgcgacgctg	240
ccttcgcccc	gtgccccgct	ccgcgcggcg	ctcgcgcggc	ccgccccggc	tctgactgac	300
cgcgttactc	ccacaggtga	gcgggcggga	cggcccttct	cctccgggct	gtaattagcg	360
cttgggttaa	tgacggcgtg	tttcttttct	gtgggtcgct	gaaagccttg	aggggctccg	420

ggaggggcccct	ttgtgctgggg	gggagcgggct	cgggggggtgc	gtgcgtgtgt	gtgtgcgtgg	480
ggagcgccgc	gtgcggcccg	cgctgcccgg	cggctgtgag	cgctgcgggc	gcggcgccgg	540
gctttgtgcg	ctccgcagtg	tgcgcgaggg	gagcgcggcc	ggggcggtg	ccccgcggtg	600
cggggggggc	tgcgagggga	acaaaggctg	cgtgcggggt	gtgtgcgtgg	gggggtgagc	660
agggggtgtg	ggcgcgccgg	tgggctgta	acccccccct	gcacccccct	ccccgagttg	720
ctgagcacgg	cccggcttcg	ggtgcggggc	tccgtacggg	gcgtggcgcg	gggctcgccg	780
tgcggggcgg	gggggtggcg	caggtggggg	tgcggggcgg	ggcggggccc	cctcgggcgg	840
gggagggctc	gggggagggg	cgcggcgccc	cccggagcgc	cggcggtgt	cgaggcgcg	900
cgagccgcag	ccattgcctt	ttatggtaat	cgtgcgagag	ggcgagggga	cttcctttgt	960
cccaaactctg	tgcggagccg	aaatctggga	ggcgccgcgg	cacccccctc	agcgggcgcg	1020
gggcgaagcg	gtgcggcgcc	ggcaggaagg	aaatggcgcg	ggagggcctt	cgtgcgtcgc	1080
cgcgcgcggc	tccccctctc	cctctccagc	ctcggggctg	tccgcggggg	gacggctgcc	1140
ttcggggggg	acggggcagg	gcgggggttcg	gcttctggcg	tgtgaccggc	ggctctagag	1200
cctctgctaa	ccatgttcat	gccttcttct	tttctctaca	gctcctgggc	aacgtgctgg	1260
ttattgtgct	gtctcatcat	tttgcaaaag	aattc			1295

SEQ ID NO:22 Accession # BD136067. promoter element for sustained gene expression from CMV promoter

gtattagtca	tgcgtattac	catgggtgatg	cggtttttggc	agtacatcaa	tgggcgtgga	60
tagcggtttg	actcacgggg	atttccaagt	ctccacccca	ttgacgtcaa	tgggagtttg	120
ttttggcacc	aaaatcaacg	ggactttcca	aaatgtcgta	acaactccgc	cccattgacg	180
caaatgggcg	gtaggcgtgt	acgggtgggag	gtctatataa	gcagagctc		229

SEQ IDNO:23 BD136066 Accession # promoter element for sustained gene expression from CMV promoter

tggcattatg	ccagtagcat	gaccttatgg	gactttccta	cttggcagta	catctacgta	60
ttagtcatcg	ctattaccat	ggtgatgcgg	ttttggcagt	acatcaatgg	gcgtggatag	120
cggtttgact	cacggggatt	tccaagtctc	caccccatgg	acgtcaatgg	gagtttgttt	180
tggcaccaaa	atcaacggga	ctttccaaaa	tgtcgtaaaca	actccgcccc	attgacgcaa	240
atggggcggtg	ggcgtgtacg	gtggggaggtc	tatataagca	g		281

SEQ ID NO:24 BD136065 Accession # promoter element for sustained gene expression from CMV promoter

attatgcccc	gtacatgacc	ttatgggact	ttcctacttg	gcagtacatc	tacgtattag	60
tcacgcgtat	taccatgggtg	atgcgggtttt	ggcagtacat	caatgggcgt	ggatagcggt	120
ttgactcacg	gggatttcca	agtctccacc	ccattgacgt	caatgggagt	ttgttttggc	180
acaaaaatca	acgggacttt	ccaaaatgtc	gtaacaactc	cgccccattg	acgcaaatgg	240
gcggtaggcg	tgtacgggtg	gaggtctata	taagcagagc	tc		282

SEQ ID NO:25 BD136064 Accession # promoter element for sustained gene expression from CMV promoter

ttgcgttaca	taacttacgg	taaatggccc	gcctggctga	cgcaccaacg	acccccgccc	60
attgacgtca	ataatgacgt	atgttcccat	agtaacgcca	atagggactt	tccattgacg	120
tcaatgggtg	gactatttac	ggtaaaactgc	ccacttgcca	gtacatcaag	tgtatcatat	180
gccaagtacg	ccccctattg	acgtcaatga	cggtaaatgg	cccgccctggc	attatgcccc	240
gtacatgacc	ttatgggact	ttcctacttg	gcagtacatc	tacgtattag	tcacgcgtat	300
taccatgggtg	atgcgggtttt	ggcagtacat	caatgggcgt	ggatagcggt	ttgactcacg	360
gggatttcca	agtctccacc	ccattgacgt	caatgggagt	ttgttttggc	acaaaaatca	420
acgggacttt	ccaaaatgtc	gtaacaactc	cgcgccattg	acgcaaatgg	gcggtaggcg	480
tgtacgggtg	gaggtctata	taagcagagc	tc			512

SED ID NO:26 L77202 Accession # Murine Cytomegalovirus early (E1) gene, promoter region

tcggcggaagc	ctcgcgcggc	cggccaggac	gaggagcgcc	actaggttga	acatccgcac	60
gagccgcggc	gccaggtctc	ggacgggctc	tgcgagactcg	atctcgtgca	tgtcggcggt	120
ccgcgggtgag	gttatagacc	atctgtctagg	cgggtccggg	gagacaggca	cattactggc	180
ctcggcgccc	agcctaggcg	tgtctagagc	tcgaccgcgc	gtccggagcg	ccattcgacc	240
ggcgggtagc	gagaagaacg	ccggagaccg	caggttataa	caacgtcatg	cataaattaa	300
gaatgggc						308

SEQ ID NO:27 X03922 Accession # Human cytomegalovirus (HCMV) IE1 gene promoter**region**

ctgcagtgaa	taataaaatg	tgtgtttgtc	cgaaatacgc	gtttgagatt	tctgtcccga	60
ctaaattcat	gtcgcgcgat	agtgggtgtt	atcgccgata	gagatggcga	tattggaaaa	120
atcgatattt	gaaaatatgg	catattgaaa	atgtcgccga	tgtgagtttc	tgtgtaactg	180
atatcgccat	ttttccaaaa	gttgattttt	gggcatacgc	gatatctggc	gatacgctta	240
tatcgtttac	gggggatggc	gatacagccc	tttggtgact	tgggcgattc	tgtgtgtcgc	300
aaatatcgca	gtttcgatat	aggtgacaga	cgatatgagg	ctatatcgcc	gatacagggc	360
acatcaagct	ggcacatggc	caatgcatac	cgatctatac	attgaatcaa	tattggccat	420
tagccatatt	attcattggg	tatatagcat	aaatcaatat	tggctattgg	ccattgcata	480
cgttgtatcc	atatcataat	atgtacattt	atattgggtc	atgtccaaca	ttaccgccat	540
gttgacattg	attattgact	agttattaat	agtaatcaat	tacgggggtc	ttagttcata	600
gcccataat	ggagttccgc	gtacataaac	ttacggtaaa	tggcccgcct	ggctgaccgc	660
ccaacgaccc	ccgcccattg	acgtcaataa	tgacgtatgt	tcccatagta	acgccaatag	720
ggactttcca	ttgacgtcaa	tgggtggagt	atttacggta	aactgcccac	ttggcagtac	780
atcaagtgt	tcatatgcc	agtacgcccc	ctattgacgt	caatgacggg	aaatggcccc	840
cctggcatta	tgcccagtac	atgaccttat	gggactttcc	tacttggcag	tacatctacg	900
tattagtcat	cgctattacc	atggtgatgc	ggttttggca	gtacatcaat	gggcgtggat	960
agcggtttga	ctcacgggga	ttccaagtc	tccaccctat	tgacgtcaat	gggagtttgt	1020
tttggcacca	aaatcaacgg	gactttccaa	aatgtcgtaa	caactccgcc	ccattgacgc	1080
aaatgggcgg	taggcgtgt	cggtgggagg	tctatataag	cagagctcgt	ttagtgaacc	1140
gtcagatcgc	ctggagacgc	catccacgct	gttttgacct	ccatagaaga	caccgggacc	1200
gatccagcct	ccgcggccgg	gaacgggtga	ttggaacgcg	gattccccgt	gccaagagtg	1260
acgtaagtac	cgcctataga	gtctataggc	ccaccctctt	ggcttcttat	gcatgctata	1320
ctgttttttg	cttgggggtc	atacaccctc	gcttctctcat	gttatagggt	atggatatagc	1380
ttagcctata	ggtgtgggtt	attgaccatt	attgaccact	cccctattgg	tgacgatact	1440
ttccattact	aatccataac	atggctcttt	gcacaactct	ctttattggc	tatatgccaa	1500
tacactgtcc	ttcagagact	gacacggact	ctgtattttt	acaggatggg	gtctcattta	1560
ttattttacaa	attcacatat	acaacaccac	cgtccccagt	gcccgcagtt	ttatttaaac	1620
ataacgtggg	atctccagcg	aatctcgggt	acgtgttccg	gacatggggc	tcttctccgg	1680
tagcggcgga	gcttctacat	ccagccctgc	tcccatcctc	ccactcatgg	tcctcggcag	1740
ctccttgctc	ctaacagtgg	aggccagact	taggcacagc	acgatgccca	ccaccaccag	1800
tgtgccca	aggccgtggc	ggtaggggat	gtgtctgaaa	atgagctc		1848

SEQ ID NO:28 E02198 Accession # Dna encoding 3'end region of beta-actin gene promoter

cttctggcgt	gtgaccggcg	gggtttatat	cttcccttct	caagcttgg	49
------------	------------	------------	------------	-----------	----

SEQ ID NO:29 E02197 Accession # DNA encoding 3'end region of beta-actin gene promoter

cttctggcgt	gtgaccggcg	gggtttatat	cttcccttct	ctgttcctcc	gcagccccaa	60
gcttgg						66

SEQ ID NO:30 E02196 Accession # DNA encoding 3'end region of beta-actin gene promoter

cttctggcgt	gtgaccggcg	gggtttatat	cttcccttct	ctgttcctcc	gcagccagcc	60
aagcttgg						68

SEQ ID NO:31 E02195 Accession # DNA encoding 3'end region of beta-actin gene promoter

cttctggcgt	gtgaccggcg	gggtttatat	cttcccttct	ctgttcctcc	gcagccagcc	60
atggatgat						

69

SEQ ID NO 32 E03011 Accession # DNA encoding hybrid promoter that is composed of chicken beta-actin gene promoter and rabbit beta-globin gene promoter

tgcaggtgag	ccccagttc	tgttcaactc	tccccatctc	ccccccctcc	ccacccccaa	60
ttttgtattt	atttattttt	taattatttt	gtgcagcgat	gggggcgggg	gggggggggg	120

cgcgccag	gcgggg	g ³ ggg	ggcg	ggcg	gagaggtgcg	180
gcgccagcca	atcagagcgg	cgcgctccga	aagtttccct	ttatggcgag	gcggcgccg	240
cggcgccct	ataaaaagcg	aagcgcgcg	cggcgggag	tcgctgcgtt	gccttcgcc	300
cgtgccccgc	tcgcgcgcgc	ctcgccgcgc	ccgcccgcgc	tctgactgac	cgcgttactc	360
ccacaggtga	gcgggcgga	cgcccttct	cctccgggct	gtaattagcg	cttggtttaa	420
tgacggctcg	tttcttttct	gtggctgcgt	gaaagcctta	aagggctccg	ggagggccct	480
ttgtgcgggg	gggagcggt	cggggggtgc	gtgcgtgtgt	gtgtgcgtgg	ggagcgccgc	540
gtgcggcccg	cgctgcccg	cggtgtgag	cgctgcgggc	gcggcgccgg	gctttgtgcg	600
ctccgctgt	gcgcgagggg	agcgcgccg	ggggcggtgc	ccgcggtgc	gggggggctg	660
cgaggggaac	aaaggctgcg	tcgggggtgt	gtgcgtgggg	gggtgagcag	ggggtgtggg	720
cgcgcggtc	gggtgtaac	ccccccctgc	acccccctcc	ccgagttgct	gagcacggcc	780
cggcttcggg	tcgggggctc	cgctcggggc	gtggcgccgg	gctcgccgtg	ccggcgggg	840
ggtggcgga	ggtgggggtg	ccggcgggg	cggggccgc	tcggggccgg	gagggctcgg	900
gggaggggg	cggcgccccc	ggagcgccg	cggtgtcga	ggcgccgca	gccgcagcca	960
ttgcctttta	tggtaatcgt	gcgagagggc	caggagactt	cctttgtccc	aaatctggcg	1020
gagccgaat	ctgggagggc	ccgcgcacc	ccctctagcg	ggcgcgggcg	aagcgggtgcg	1080
gcgcggcag	gaaggaaatg	ggcggggagg	gccttcgtgc	gtcgccgcgc	cgccgtcccc	1140
ttctccatct	ccagcctcgg	ggctgcgcga	gggggacggc	tgccctcggg	ggggacgggg	1200
cagggcgggg	ttcggttct	ggcgtgtgac	cggcggtct	agagcctctg	ctaaccatgt	1260
tcatgccttc	ttcttttcc	tacagctcct	gggcaacgtg	ctggttgttg	tgctgtctca	1320
tcattttggc	aaagaattca	agctt				1345

SEQ ID NO:33 BD015377 Accession # Baculovirus containing minimum CMV promoter

tcaatattgg	ccattagcca	tattattcat	tggttatata	gcataaatca	atattggcta	60
ttggccattg	catacggtgt	atctatatca	taatatgtac	atattatattg	gctcatgtcc	120
aatatgaccg	ccatggtggc	attgattatt	gactagttat	taatagtaat	caattacggg	180
gtcattagtt	catagcccat	atatggagtt	ccgcgttaca	taacttacgg	taaattggccc	240
gcctggctga	ccgcccacg	acccccgcgc	attgacgtca	ataatgacgt	atgttcccat	300
agtaacgcca	ataggagctt	tcatttgacg	tcaatgggtg	gagtatttac	ggtaaactgc	360
ccacttggca	gtacatcaag	tgtatcatat	gccaaagtccg	ccccctattg	acgtcaatga	420
cggtaaatgg	ccgcctggc	attatgccc	gtacatgacc	ttacgggact	ttcctacttg	480
gcagtacatc	tacgtattag	tcacgctat	taccatggtg	atgcggtttt	ggcagtacac	540
caatgggcgt	ggatagcgg	ttgactcacg	gggatttcca	agtctccacc	ccattgacgt	600
caatgggagt	ttgttttggc	accaaataca	acgggacttt	ccaaaatgtc	gtaataaacc	660
cgccccgttg	acgcaaatgg	gcgg				684

SEQ ID NO:34 Mouse GFAP promoter sequence

aattccatacctgcttgatccacatatgaactacagggggacatgatgaggtccagtcctaaagggtcactggcaacct
ctctcaagatctccctcactatgccattatcaggattgggggaagatgtggctggagccctaaagggtccttcccttc
cctatggtgggactcattaggagaacctcagcaagcagtcactgtaagctcaaacaataaccatgtcgctggtag
gagtaaggctgttgctatgacaggaactcaggggtcttaactggcttgagcgctgggaggggcagcagccaggcct
tgtctgtaagctgaagacctggcagtgctgagctgggtcaccgccagggactccttttgtgcccacagtgactca
ccttgggcatagacataatggtcaggggtgggcacgcagcctgcttccgctgtgctccaggcctccttcgatgctt
tccgagaagtctattgagctgggagcttgactgcaccggggctgacatcctggcatcctgggataaaagcagccc
acggggtgccttgccatagctcactggcgccagagaacaaggctctattcagcaagtgccctggagtagacac
cagaagcccaagcatgggcagagggaaggcaggggttgggggagcagagctgtctgtgtccagaagcccaaggaca
cagatggctaaggcgccctgggagggacctgagtggaagagatagatgggctgaagtctcaagcagcaacagcctcc
tccccgccattggtgaggggtggggtttgggttcccgacctacatatccctcagaggcctgggtgttaggaatttaa
aggaggtaaatctcctgagagaatcaggggtacccaggaagacggggtgttacagaaagactccagcatgcacagcc
aactcactcaaaactactctgtcaggggtgcgggggcccaggctcgggggtgggggtgggggggcaagagaagct
ggaccagggagaaatggcccactaggctggatatgagggccacagaggggctcaggaagggaagcctgctgtcttacc
tattaggatctgcgtgcataccttctgctgtgcactctaaacacacagccagaggctcaagttgacctggagtcac
agagagggtccaaccttagccctcactcctgaactccaggaatgagaagatagagttggagcgattcaggggaga
ggactctgttgagaatgggggtcacaggaactgtaatataggttgatcccgagggaagggaataggttcttcaagt
tcttagcatctcagagcccccagagaaggacagagtggggtgggtcctggcttaacaggctctaagaactggaagctg
attaccaccaagctgtcactctctgtctctgtctctgtgtgtgtgcgcgctcgtgcacacttatcacaaa
atgttctatgtgtgtgcacatagatgagttgacacagaggtcaacctcaggcactgttgcttgggtttctgagaga
gcatttctctctggacctggaactcgccaattagtgagagccaggaagtctgctgattttcactgccagcactgga
gtttacaagtatgcactgtcaaccaggccttttgtatttctctgcagctagaacttgggtgggtcttcatgcttg
acaggcaagcaatttatggactaagctgtttcctcgccctctcttgaccatttaccagaaaggggttccttgat
caatggcgcaagcagggtgtgtcccaagaaagccttgactctgggtacagtgcactcagtggggtgagaggagttc
tcccttagctgggtgggcccagctccaccctcagcttattcaatgggggtgcttccaggaagtcaggggcag
atttagtccaaacccgttctccataaaggccctgacatccaggagccagcagaggcagggcaggatggagcggaga
cgcatacctctgcgcgcgctcctatgcctccgagacggtgggtcaggggctcggctcctagtcgac

SEQ ID NO:35 Rat COL1a1 promoter sequence

tctagaatatagaagccaaggatttcaagggtttccttttctctcttctcttttttttcttttttcttttctga
gatggagtttcttctttagtaccctgactgtcctggaattcactctatagaccaggctagcctcacacttagtgatct
gcctgcctctgcctcttgggtgcctcaggattcaaggcatgaaccaccactaccgcaccagggtatttcttacacact
tctgactggactaaccagggaagcagagaggagacaggaagaaatgctcagaaggaaggataggattggagggtg
agctgggggaaccagactgagccgtgcagaagacaaggaagaagaaagccaccacacacactaggatccaccaca
gattttgtctctgggtaccctgtctggagactgtagggtttgtgatggagggtggggtagtctcatgccccgtgc
cctttactccagacctaaatgccacccccacatacagctgctcgtctctctctccctgccttctcccaagaga
ccagttctccatccctgggtctgcagccaaggctgggggcagaagaactttctggaggatttgatgagaaaagcaag
agagctcaagtagggactggaacctctgggaaggagtgacagaggagaccgggtatgtgcctacctggtagatt
tatacctgggcagctctgctcctgttccagacttcagagcccagacgggtcctctccctccctcatgaggggaaac
atltggggaaatttggagagagacagaactcagagctcagcactttcctctttctgtttttcttcttgaggaaat
ttcccccaactgctgatgactttaccattcttgggggtgggggggtggagattctggcttttgctccctacactc
caagtgcgggacaaagccctacattccacaagaagccagggttcagagtttccctaaagatgaggtggcgtggcgag
tctcctcctctccagctccaactccccctccccagcttcagccctagcctggccaggaggccccgcaggct
gggaggagaccccaagcacattcttctcgtctgctgctgcagaaattaaagacacatctctgagctgggtacc
cgccaatcgtttcaagttgagaagtggcagaggaggtcccgagcttcagctcatgccagtgtaaggaagcttgga
accactgcccacaactcctggggcaaaaacctggagtcagacatggggtgaaggctgtcacacggcacagacacgt
caagcaccctcccaattctagtagtctcctagcctccaccagaaccacagaccttgatgtggcagtcaccagtc
acacctgttaggtcttctctcttctccagatgagcctggggggcgtgggggtgcttagatcaggagcagggaagga
tagcttggataagtgcttttcccaatacaaaaacccaacaaagagttggcagatcacactgtgtgcttctgga
accctaccctagacaactgccttgaacacctattccctctgatgtacaccatccccgtccactgttagggagtgggc
atcctttggaactgaccactgtggaaggcaggactttactgagttccggaactaccatctcagcttctcagccccag
ccttaccctacaggcactggcataggcgggggcagatcctgggcccagaagtcactgccacatgggtgggataattga
tgaagtcctgtccttccattgtctgtctccagttcgtctctctggaactctataattttccctttaaataatagct
ctgacatctcctctgcccaccccccgccgcttagccttaactgccacggccagcagctgtgctcctccctt
ctgctcccttggtcttttttttttttttcttgccttcggtgcacaaaactagctcaggaggggcgtgaaggggg
ggggagcaatggaatcttggttggttggaggaggcgggactccttgcttccacgtttacagctctgaagacggctg
tgggggaagtgtacaggacgtctatgggcccctgagaggagaccctatgcttccctgccacccacacagtttaaca
aaatgaagttcctaagtagagtgggggtcaggcagagcacctttgcagggttgatgggagcccagggaagaaagga
cactgtcttttaggggacacatttaataataagccacttttcttgggggacgacaaatgacctttcctgattgcaga
gggtggggaacaatggctgagattttcagcaaagaagcgaggacatgaggagtagccttcaaataaagtcactcagct
accaaaaacaagtttctgccacacaccgagttacctagggtgtcccagaccagatccaagtacagtaaggaaagcag
gttctctacagagagaacacggctctatggccaatgccttctacctgctctttctggattgatactgctaocaaaga
gggctctaaaccaattcctggctgttagccacagctgacacaagaccttttctaaagacatccctggtcacaggcctc
ctgtagcaaatccagccctgggatggaggtggtcaggaagagtttatacaagaagaccaggccacagctttaag
gactcagaaacccccctgccacacggctgcccataacgcagaagggttcttctggaaggacaaggatgtcaaa
cttctcccccaagcctaactcctcagagatgtctccctctgttacacctggggctggagaaaggtgggtcttctcatgga
gccacattcatggcagaacagatagccacccactcctttcaaacacacacatatctgactcttagtatctgtgaag
agatgtctaatttgttcccaaatattcctaccctgcatacctgggcccacacacatgaggtattctcctccctctaac
agtcatctctgttagctgctggttcttctgatttgagagatgcttgcttaacttattcttctccttaggttctcc
aaggatgccagaagactatgagacatggcgaaggagacctttcccaattgtgctgacactgaacctttgtaaat
gttcccccaactcagattcccaattctacatcttctgatttgaggtcccagaaggaaagtgcaaggggcatccctta
cccacaatcagtatatcgaggcccagccacactcagtgatagcacctctggcccatgtagatctgggggacaagggt
ggcagaattgcaaaggggggagggggctgggtggactccttcccttcccttccctcctccctccttcttcttcaa
attggggggcgggccaaggcaggttctgattggctgggggcggggtgctgggtcccccctctccaagagggcaggggtcc
tccagccctcctccatcaggatggtataaaagggggccaggcagtcgctggagcagacgggagttccactccgg
acggagcaggaggcacagggagtggggccacgcatgagccgaagctaacccccacccagccgcaaagagctctaca
tgtctaggggtctag

SEQ ID NO:36 Rat COL2a1 promoter sequence

tgggtggtgggacacataggaactctggcgctttctcctccccctcacaaaactgagtcagctggagccgcctcc
agactctctggccaggggcctcagagtgggtcaacagtcctctggccagcggttgctctctccaggctaaaggccaccact
ccccggagattcctgaacctgggcccaggaagagccgaattagacaagtgtctccaatccggctgcgtgaggat
gttgcggtgtccctcggttgctgagttcctttagtcccttccctggcctgccccttacacctccacacagggtccc
cctctgtgtaggaatacaccagacctctcttagccacacacacctccagtcocccgtctacctagattttttcat
agctagttggtggggatgggttagggaggctgggtttgcgagcctccagggtgggagttcaccgacaggtatactccg
caaaggagctggaaagcaggtctggaaaactgtccccagatttaggattctgggcagcttccatcagcttatactt
tggctcccccgccccaaactccccatccccactcctttctccgttacttctgctcctccctcgcttccagcctc
gagtcctaaagctccatgcttatgcctctgcaaacacccccctcccttctaaccacagcagaactccgaggaaagggg
ccggaggccctctctcgctgtggttagagggggcagtggtggcagtcaccaagtggggggcgaccggaggccgtctcg
gtgccccgcccagatcaggccactgggacatcgggggcggggaagcgggctcaccaaagggggcagctggccttggcag
gtgtgggtctgtgctcgactgggacaggtccggggcggggtctcaggttacaacgccacggggggctggggcg
cccggttgggttgggttgggttggagcggcgggagcatataaccggagcctctgctgaggaagcgag
ggcgcgctgggtgcccgggtctcctgcctcctcctcctgctccgagagcctcctgcatgagggcgaggtagagacc
cggaccgcctccggtctctgcccgcctcgccgagcttcgcccgggccaaggctctgcgggcctcgcggtgagccatga

ttcgccctcggggctccccagtcgcttgggtgctgctgacgctgctcatcgccacgggtcctacaatgtcagggccaggat
 gcccgtaggtcgcccaccacccctgcctgcttccctgacttgccagcccttctcttcttccctccgctccgagttaggc
 gccaaagtccctaggcgctgtagtgacacaggagaacactgatcctaatacttaattctgctagtggaggattctgtcgcag
 catcctcagtcagagtgc

SEQ ID NO:37 FIV(LacZ) construct 12750 bp

atgcgggtttt	ggcagtagcat	caatgggctg	ggatagcggg	ttgactcacg	gggattttcca	60
agtctccacc	ccattgacgt	caatgggagt	ttgttttggc	acccaaatca	acgggactttt	120
ccaaaatgtc	gtaacaactc	cgccccattg	acgcaaattg	gcggtagggc	tgtacgggtgg	180
gaggtctata	taagcagagc	tctgtgaaac	ttcgaggagt	ctctttgttg	aggacttttg	240
agttctccct	tgaggtccct	acagatacaa	taaataattg	agattgaacc	ctgtcgagta	300
tctgtgtaat	cttttttacc	tgtgaggtct	cggaaatccg	gccgagaact	tcgcagttgg	360
cgcccgaaca	gggacttgat	tgagagtgat	tgaggaagt	aagctagagc	aatagaaagc	420
tggttaagcag	aactcctgct	gacctaaata	gggaagcagt	agcagacgct	gctaacagtg	480
agtatctcta	gtgaagcggg	ctcgagctca	taatcaagtc	attgttttaa	ggcccagata	540
aattacatct	ggtagctctt	cgcggacctt	caagccagga	gattcgccga	gggacagtca	600
acaaggtagg	agagattcta	cagcaacatg	gggaatcgac	aggggcgaga	ttggaaaatg	660
gccattaaga	gatgtagtaa	tggtgctgta	ggagtagggg	ggaagagtaa	aaaatttgga	720
gaagggaatt	tcagatgggc	cattagaatg	gctaattgat	ctacaggacg	agaacctggg	780
gatataccag	agacttttag	tcaactaagg	ttgggtattt	gcgatttaca	agaaagaaga	840
gaaaaatttg	gatctagcaa	agaaattgat	attgcaattg	tgacattaaa	agtctttgcg	900
gtagcaggac	tttttaaatat	gacgggtgtc	tactgtgctg	gcagctgaaa	atatgtattc	960
tcaaattggga	ttagacacta	ggccatctat	gaaagaagca	ggtggaaaag	aggaaggccc	1020
tccacaggca	tatcctattc	aaacagtaaa	tggagtacca	caatatgtag	cacttgaccc	1080
aaaaatgggtg	tccatttttta	tggaaaaggc	aagagaagga	ctaggagggtg	aggaagtcca	1140
actatgggtt	actgcctttt	ctgcaaattt	aacacctact	gacatggcca	cattaataat	1200
ggccgcacca	gggtgcgctg	cagataaaga	aatatgtgat	gaaagcttaa	agcaactgac	1260
agcagaatat	gatcgcacac	atccccctga	tgctcccaga	ccattaccct	attttactgc	1320
agcagaaatt	atgggtatag	gattaactca	agaacaacaa	gcagaagcaa	gatttgcacc	1380
agctaggatg	cagtgtagag	catgggtatc	cgaggcatta	ggaaaatttg	ctgccataaa	1440
agctaagtc	cctcgagctg	tgcatgtaag	acaaggagct	aaggaagatt	attcatcctt	1500
tatatagaca	ttgtttggcc	aaatagatca	agaacaaaat	acagctgaag	ttaagttata	1560
tttaaaacag	tcattgagca	tagctaattg	taatgcagac	tgtaaaaagg	caatgagcca	1620
ccttaagcca	gaaagtaccc	tagaagaaaa	gttgagagct	tgtcaagaaa	taggctcacc	1680
aggatataaaa	atgcaactct	tggcagaagc	tcttacaaaa	gttcaagtag	tgcaatcaaa	1740
aggatcagga	ccagtgtggt	ttaattgtaa	aaaaccagga	catctagcaa	gacaatgtag	1800
agaagtga	aaatgtaata	aatgtggaaa	acctggctat	gtagctgcca	aatgttggca	1860
aggaaataga	aagaattgta	caagggaaga	aagggatata	acaattacaa	aagtgggaag	1920
attgggtagg	atggatagga	aatattccac	aatattttaa	gggactattg	ggaggtatct	1980
tgggaatagg	attaggagt	ttattattga	ttttatgttt	acctacattg	gttgattgta	2040
taagaaattg	tatccacaag	atactaggat	acacagtaat	tgcaatgcct	gaagtagaag	2100
gagaagaaat	acaaccacaa	atgggaattg	ggagaaatgg	taggcaatgt	ggcatgtctg	2160
aaaaagagga	ggaatgatga	agtatctcag	acttattttt	taaggagagat	actgtgctga	2220
gttcttccct	ttgaggaagg	tatgtcatat	gaatccattt	cgaatcaaat	caaactaata	2280
aagtatgtat	tgtaaggtaa	aaggaaaaga	caaagaagaa	gaagaaagaa	gaaagccttc	2340
agtacattta	tattggctca	tgtccaatat	gaccgccatg	ttgacattga	ttattgacta	2400
gttattaata	tgtaatcaatt	acgggtcat	taggtctatg	cccatatatg	gagttccgcg	2460
ttacataact	tacggtaatt	ggccgcctg	ctgaccgccc	aacgaccccc	gcccattgac	2520
gtcaataatg	acgtatgttc	ccatagtaac	gccaataggg	actttccatt	gacgtcaatg	2580
gggtggagtat	ttacggtaaa	ctgcccactt	ggcagtagat	caagtgtatc	atatgccaa	2640
tccggccccc	tattgacgtc	aatgacggta	aatggcccgc	ctggcattat	gcccagtaca	2700
tgaccttacg	ggactttggt	acttggcagt	acatctacgt	attagtcac	gctattacca	2760
tggtgatg	gttttggcag	tacaccaatg	ggcgtggata	gcggtttgac	tcacggggat	2820
ttccaagtct	ccacccattt	gacgtcaatg	ggagtttgtt	ttggcaccac	aatcaacggg	2880
actttccaaa	atgtcgtaat	aaccccgccc	cgttgacgca	aatgggcggt	aggcgtgtac	2940
gggtgggagg	ctatataagc	agagctcggt	tagtgaaccg	tcagatcgcc	tggagacgcc	3000
atccacgctg	ttttgacctc	catagaagac	accgggaccg	atccagcctc	cgcggccggg	3060
aacgggtcat	tgggaacggg	attccccgtg	ccaagagtga	cgtaagtacc	gcctatagac	3120
tctataggca	cacccctttg	gctcttatgc	atgctatact	gtttttggct	tggggcctat	3180
acaccccgcc	tccttatgct	ataggtgatg	gtatagctta	gcctatagg	gtgggttatt	3240
gaccattatt	gaccactccc	ctattgggtg	cgatactttc	cattactaat	ccataacatg	3300
gctctttg	acaactatct	ctattgggta	tatgccaata	ctctgtcctt	cagagactga	3360
cacggagctc	gtatctttac	aggatgggg	cccatttatt	atttacaata	tcacatatac	3420
aacaacgccg	tcccccgctg	ccgcagtttt	tattaaacat	agcgtgggat	ctccacgcga	3480
atctcgggta	cgtgttccgg	acatgggctc	ttctccggta	gcggcgagac	ttccacatcc	3540
gagccctgg	cccatgcctc	cagcggctca	tggtcgctcg	gcagctcctt	gctcctaaca	3600
gtggaggcca	gacttaggca	cagcacaatg	cccaccacca	ccagtgtg	gcacaaggcc	3660

gtggcggtag	ggtatgtgtc	tga ^{aaa} aatgag	ctcggagatt	gggctcgcac	cgtgacgcag	3720
atggaagact	taaggcagcg	gcagaagaag	atgcaggcag	ctgagttgtt	gtattctgat	3780
aagagtcaga	ggtaactccc	gttgcggttc	tgtaaacggt	ggagggcagt	gtagtctgag	3840
cagtactcgt	tgctgccgcg	cgcgccacca	gacataatag	ctgacagact	aacagactgt	3900
tcctttccat	gggtcttttc	tgacgtcacc	gtcgtcgaag	cttatgacca	tgattacgga	3960
ttcactggcc	gtcgtttttac	aacgtcgtga	ctgggaaaac	cctggcggtta	cccaacttaa	4020
tcgccttgca	gcacatcccc	ctttcgccag	ctggcgtaat	agcgaagagg	cccgcaccga	4080
tcgcccttcc	caacagttgc	gcagcctgaa	tggcgaatgg	cgttttgccct	ggtttccggc	4140
accagaagcg	gtgccggaaa	gctggctgga	gtgcgatctt	cctgaggccg	atactgtcgt	4200
cgtccccctca	aactggcaga	tgacgggtta	cgatgcgccc	atctacacca	acgtaacctta	4260
tcccattacg	gtcaatccgc	cgtttgttcc	cacggagaat	ccgacgggtt	gttactcgct	4320
cacattttaat	gttgatgaaa	gctggctaca	ggaaggccag	acgcgaatta	tttttgatgg	4380
cgttaactcg	gcgttttcac	tgtggtgcaa	cgggcgctgg	gtcggttacg	gccaggacag	4440
tcgtttgcgc	tctgaatttg	acctgagcgc	atttttacgc	gccggagaaa	accgcctcgc	4500
ggtgatgggt	ctgcgttgga	gtgacggcag	ttatctggaa	gatcaggata	tgtggcggat	4560
gagcggcatt	ttcgcgtgacg	tctcgttget	gcataaacgg	actacacaaa	tcagcgattt	4620
ccatgttgcc	actcgtttta	atgatgattt	cagccgcgct	gtactggagg	ctgaagttca	4680
gatgtgcggc	gagttgcgtg	actacctacg	ggtaacagtt	tctttatggc	agggtgaaac	4740
gcaggtcgcc	agcggcaccg	cgcctttcgg	cggtgaaatt	atcgatgagc	gtggtgggta	4800
tgccgatcgc	gtcacactac	gtctgaacgt	cgaaaaccgt	aaactgtgga	gcgccgaaat	4860
cccgaatctc	tatcgtgcgg	tgggtgaact	gcacaccgcc	gacggcacgc	tgattgaagc	4920
agaagcctgc	gatgtcgggt	tcgcgcagg	gcggattgaa	aatggtctgc	tgctgctgaa	4980
cggcaagccg	ttgctgattc	gaggcgttaa	ccgtcacgag	catcatcctc	tgcatggtca	5040
ggtcatggat	gagcagacga	tgggtgcagga	tatctgtctg	atgaagcaga	acaactttaa	5100
cgcgtgctgc	tgttcgcatt	atccgaacca	tcctgtgtgg	tacacgctgt	gcgaccgcta	5160
cggcctgtat	tgggtggatg	aagccaatat	tgaaccacac	ggcatggtgc	caatgaatcg	5220
tctgaccgat	gatccgcgct	ggctaccggc	gatgagcgaa	cgcgtaacgc	gaatggtgca	5280
gcgcgatcgt	aatcacccga	gtgtgatcat	ctggctcgtg	gggaatgaat	caggccacgg	5340
cgctaatac	gacgcgctgt	atcgctggat	caaatctgtc	gatccttccc	gcccggtgca	5400
gstatgaagg	ggcggagccg	acaccacggc	accgatattt	atttgcccga	tgtacgcgcg	5460
cgtggatgaa	gaccagccct	tcccggctgt	gccgaaatgg	tccatcaaaa	aatggctttc	5520
gctacctgga	gagacgcgcc	cgtgatcctt	ttgcgaatac	gcccacgcga	tgggtaacag	5580
tcttggcgg	ttcgctaaat	actggcagcg	gtttcgtcag	tatccccggt	tacagggcgg	5640
cttcgtctgg	gactgggtgg	atcagtcgct	gattaaatat	gatgaaaacg	gcaaccctgtg	5700
gtcgggttac	ggcgggtgatt	ttggcgatag	gccgacgat	cgcagttctt	gtatgaacgg	5760
tctgtctctt	cgccgaccca	cgcgcgcatc	agcgctgacg	gaagcaaaac	accagcagca	5820
gtttttccag	ttcgcgttat	ccgggcaaac	catcgaagtg	accagcgaat	acctgttccg	5880
tcatagcgat	aacgagctcc	tgcaactggat	ggtggcgctg	gatggtaagc	cgctggcaag	5940
cgggtgaagt	cctctggatg	tcgctccaca	aggtaaaccag	ttgattgaac	tgccctgaact	6000
accgcagccg	gagagcgcgc	ggcaactctg	gctcacgata	cgcgtagtgc	aaccgaacgc	6060
gaccgcattg	tcagaagccg	ggcacatcag	cgccctggcag	cagtggcgctc	tggcggaaaa	6120
cctcagtgtg	acgctccccg	ccgcgtccca	cgccatcccg	catctgacca	ccagcgaat	6180
ggatttttgc	atcgagctgg	gtaataagcg	ttggcaat	aaccgccag	caggctttct	6240
ttcacagatg	tggattggcg	ataaaaaaca	actgctgacg	ccgctgcgcg	atcagttcac	6300
ccgtgcaccg	ctggataacg	acattggcgt	aagtgaagcg	accgcatttg	accctaacgc	6360
ctgggtcgaa	cgtgcgaagg	cggcgggcca	gagtgaggcc	gaagcagcgt	tgttgacgtg	6420
cacggcagat	acacttgctg	atgcggtgct	gattacgacc	gctcacgcgt	ggcagcatca	6480
ggggaaaacc	ttatttatca	gccggaanaac	ctaccggatt	gatggtagtg	gtcaaatggc	6540
gattaccgtt	gatgttgaag	tggcgagcga	tacaccgcat	ccggcgcgga	ttggcctgaa	6600
ctgccagctg	gcgcaggtag	cagagcgggt	aaactggctc	ggattagggc	cgcaagaaaa	6660
ctatcccagc	cgccttactg	cgcctgtttt	tgaccgctgg	gatctgccat	tgtcagacat	6720
gtataccccc	tacgtcttcc	cgagcgaaaa	cggctctgcg	tgccgggacgc	gcgaattgaa	6780
ttatggccca	caccagtggc	gcggcgactt	ccagttcaac	atcagccgct	acagtcaaca	6840
gcaactgatg	gaaaccagcc	atcgccatct	gctgcacgcg	gaagaaggca	catggctgaa	6900
tatcgacgg	ttccatagcg	ggattgggtg	cgacgactcc	tggagcccgt	cagtatccgc	6960
ggaattccag	ctgagcgcgc	gtcgctacca	ttaccagttg	gtctggtgtc	aaaaataact	7020
cgatcgacca	gagctgagat	cctacaggag	tccagggctg	gagagaaaa	ctctgaagag	7080
gatgatgaca	gagttagaag	atcgcttcag	gaagctat	ggcacgactt	ctacaacggg	7140
agacagcaca	gtagattctg	aagatgaacc	tcctaaaaaa	gaaaaaagg	tggactggga	7200
tgagtattgg	aaccctgaag	aaatagaaag	aatgcttatg	gactagggac	tgtttacgaa	7260
caaatgataa	aaggaaatag	ctgagcatga	ctcatagtta	aagcgctagc	agctgcctaa	7320
ccgcaaaaacc	acatcctatg	gaaagcttgc	taatgacgta	taagttgttc	cattgtaaga	7380
gtatataacc	agtgttttgt	gaaacttcga	ggagtctctt	tgttgaggac	ttttgagttc	7440
tcctttgagg	ctccacagaa	tacaataaat	atttgagatt	gaaccctgtc	gagtatctgt	7500
gtaatctttt	ttacctgtga	ggtctcggaa	tccgggcccga	gaacttcgca	gcggccgctc	7560
gagcatgcac	ctagagggcc	ctattctata	gtgtcaccta	aatgctagag	ctcgtgatc	7620
agcctcgact	gtgccttcta	gttgcagacc	atctgtgtgt	tgccctccc	ccgtgccttc	7680

cttgaccctg	gaagggtgcca	ctccactgt	cctttcctaa	taaaatgagg	aaattgcatc	7740
gcattgtctg	agtaggtgtc	attctattct	gggggggtgg	gtggggcagg	acagcaaggg	7800
ggaggattgg	gaagacaata	gcaggcatgc	tggggatgcg	gtgggtctta	tggcttctga	7860
ggcggaagga	accagctggg	gctcgagggg	ggatccccac	gcgcctgtta	gcggcgcatc	7920
aagcgcgggc	ggtgtgggtg	ttacgcgcag	cgtgaccgct	acacttgcca	gcgccttagc	7980
gccgcgtcct	ttcgctttct	tcccttctct	tctcgccacg	ttcgccggct	ttccccgtca	8040
agctctaaat	cggggcatcc	ctttaggggt	cggatttagt	gctttacggc	acctcgaccc	8100
caaaaaactt	gattaggggt	atgggtcacg	tagtggggca	tgcctctgat	agacgggttt	8160
tcgccctttg	acgttggagt	ccacgttctt	taatagtggg	ctcttggtcc	aaactgggaa	8220
aacactcaac	cctatctcgg	tctattcttt	tgatttataa	gggatttttg	ggatttcggc	8280
ctattgggtta	aaaaatgagc	tgatttaaca	aaaatttaac	gcgaatttta	acaaaaatatt	8340
aacgtttaca	atttaaataat	ttgcttatac	aatcttctct	tttttggggc	ttttctgatt	8400
atcaaccggg	gtgggtaccg	agctcgaatt	ctgtggaatg	tgtgtcagtt	agggtgtgga	8460
aagtcctccg	gtctcccgag	caggcagaag	atgccatttc	atgcatctca	attagttagc	8520
aaccaggtgt	gcaaagtccc	caggctcccc	agcaggcaga	agtatgcaaa	gcatgcatct	8580
caattagtcg	gcaaccatag	tccgcgccct	aactccgccc	atcccgcccc	taactccgcc	8640
cagttccgcc	cattctccgc	cccatggctg	actaattttt	tttatttatg	cagaggccga	8700
ggccgcctcg	gcctctgagc	tattccagaa	gtagttagga	ggcttttttg	gaggcctagg	8760
cttttgcaaa	aagctcccg	gagcttggat	atccattttc	ggatctgata	aagagacagg	8820
atgaggatcg	tttcgcatga	ttgaacaaga	tggattgcac	gcaggttctc	cggccgcttg	8880
ggtggagagg	ctattcggct	atgactgggc	acaacagaca	atcggtctgt	ctgatgccgc	8940
cgtgttccgg	ctgtcagcgc	aggggcgccc	ggttcttttt	gtcaagaccg	acctgtccgg	9000
tgcctgaat	gaactgcagg	acgaggcagc	gcggctatcg	tggctggcca	cgacggcgct	9060
tccttgcgca	ctgtgtctcg	acgttgtcac	tgaacgggga	agggactggc	tgctattggg	9120
cgaagtgcgc	gggcaggatc	tcctgtcatc	tcacctgtct	cctgcccaga	aagtatccat	9180
catggctgat	gcaatgcggc	ggctgcatac	gcttgatccg	gtacactgcc	cattcgacca	9240
ccaagcgaaa	catcgcacgc	agcgagcacg	tactcggatg	gaagccggct	ttgtcgatca	9300
ggatgatctg	gacgaagagc	atcaggggct	cgcgcacgac	gaactgttct	ccaggctcaa	9360
ggcgcgcatg	cccgaaggcg	aggatctcgt	cgtgaccatc	ggcgatgcct	gcttgccgaa	9420
tatcatgggtg	gaaaatggcc	gcttttctgg	attcatcgac	tgtggccggc	tgggtgtggc	9480
ggaccgctat	caggacatag	cgttggctac	ccgtgatatt	gctgaagagc	ttggcgccga	9540
atgggctgac	cgcttctctg	tgctttacgg	tatcgccgct	cccgatccgc	agcgcatcgc	9600
cttctatcgc	cttcttgacg	agttcttctg	agcgggactc	tggggttcga	aatgaccgac	9660
caaggcgacc	ccaactggcc	atcacgagat	ttcgattcca	ccgcgcctct	ctatgaaagg	9720
ttggcgcttcg	gaatcgtttt	ccgggagccc	ggctggatga	tcctccagcg	cggggatctc	9780
atgctggagt	tcttcgcccc	ccccaaactg	tttattgcag	cttataatgg	ttacaaaata	9840
agcaatagca	tcacaaatct	cacaaaataa	gcattttttt	cactgcattc	tagttgtggt	9900
ttgtccaaac	tcataaatgt	atcttatcat	gtctggatcc	cgctcgacct	gagagcttgg	9960
cgtaatcatg	gtcatagctg	tttctgtgtg	gaaattgtta	tccgctcaca	attccacaca	10020
acatacgagc	cgggaagcata	aagtgtaaag	cctgggggtg	ctaattgagt	agctaactca	10080
cattaattgc	gttgcgctca	ctgcccgtct	tccagtcggg	aaacctgtcg	tgccagctgc	10140
attaatgaat	cggccaacgc	gcggggagag	gcggtttgcg	tattgggcgc	tcttccgctt	10200
cctcgctcac	tgactcgctg	cgctcggtcg	ttcggtcgcg	gcgagcggta	tcagctcact	10260
caaaggcggt	aatacggtta	tcacacagaa	caggggataa	cgcaggaaag	aacatgtgag	10320
caaaaggcca	cgaacccccc	aggaaccgta	aaaaggccgc	gttgctggcg	tttttccata	10380
ggctccgccc	ccctgacgag	catcacaaaa	atcgacgctc	aagtcagagg	tggcgaaacc	10440
cgacaggact	ataaagatac	caggcgtttc	cccctggaag	ctccctcgct	cgctctcctg	10500
ttccgaccct	gcgcgttacc	ggatacctgt	ccgcctttct	cccttcggga	agcgtggcgc	10560
tttctcaatg	ctcacgctgt	aggtatctca	gttcgggtga	ggtcgttcgc	tccaagctgg	10620
gctgtgtgca	cgaacccccc	gttcagccgc	accgctcgcc	cttatccggt	aactatcgct	10680
ttgagtccaa	cccggtaaga	cacgacttat	cgccactggc	agcagccact	ggtaacagga	10740
ttagcagagc	gaggatgtga	ggcgggtgta	cagagttctt	gaagtgggtg	cctaactacg	10800
gctacactag	aaggacagta	tttggtatct	gcgctctgct	gaagccagtt	accttcggaa	10860
aaagagtgtg	tagctcttga	tccggcaaac	aaaccaccgc	tggtagcggg	ggtttttttg	10920
tttgcaagca	gcagattacg	cgcagaaaaa	aaggatctca	agaagatcct	ttgatctttt	10980
ctacggggtc	tgacgctcag	tggaaagaaa	actcacgtta	agggattttg	gtcatgagat	11040
tatcaaaaag	gatcttcacc	tagatccttt	taaattaaaa	atgaagtttt	aatcaatctt	11100
aaagtatata	tgagtaaact	tggtctgaca	gttaccaatg	cttaatcagt	gaggcaccta	11160
tctcagcgat	ctgtctatct	cgttcatcca	tagttgcctg	actccccgtc	gtgtagataa	11220
ctacgatacg	ggagggttca	ccatctggcc	ccagtctgct	aatgataccg	cgagaccac	11280
gctcacccgc	tccagattta	tcagcaataa	accagcagc	cggaaaggcc	gagcgcagaa	11340
gtggtcctgc	aactttatcc	gcctccatcc	agtctattaa	ttggtgcccg	gaagctagag	11400
taagtagttc	gccagttaat	agtttgcgca	acgttggtgc	cattgctaca	ggcatcgtgg	11460
tgtcacgctc	gtcggttggt	atggcttcat	tcagctccgg	ttcccaacga	tcaaggcgag	11520
ttacatgata	ccccatgttg	tgcaaaaaag	cggttagctc	cttcgggtcct	ccgatcgttg	11580
tcagaagtaa	gttgcccgca	gtgttatcac	tctggtttat	ggcagcactg	cataattctc	11640
ttactgtcat	gctatccgta	agatgctttt	ctgtgactgg	tgagtactca	accaagtcat	11700

tctgagaata	gtgtatgagg	cgacgagtt	gctcttgccc	ggcgtcaata	cgggataata	11760
ccgcgccaca	tagcagaact	ttaaaagtgc	tcattcattgg	aaaacgttct	tcggggcgaa	11820
aactctcaag	gatcttaccg	ctgttgagat	ccagttcgat	gtaaccact	cgtgcacca	11880
actgatcttc	agcatctttt	actttcacca	gcgtttctgg	gtgagcaaaa	acaggaaggc	11940
aaaatgccgc	aaaaaaggga	ataaggcgga	cacggaaatg	ttgaatactc	atactcttcc	12000
tttttcaata	ttattgaagc	atztatcagg	gttattgtct	catgagcgga	tacataattg	12060
aatgtattta	gaaaaataaa	caaatagggg	ttccgcgcac	atctcccgga	aaagtgccac	12120
ctgacgtcga	cggatcgggga	gatctcccga	tcccctatgg	tcgactctca	gtacaatctg	12180
ctctgatgcc	gcatagttaa	gccagtatct	gctccctgct	tgtgtgttgg	aggtcgctga	12240
gtagtgcgcg	agcaaaattt	aagctacaac	aaggcaaggc	ttgaccgaca	attgcatgaa	12300
gaatctgctt	agggtttaggc	gttttgcgct	gcttcgcgat	gtacggggcca	gatatacgcg	12360
ttgacattga	ttattgacta	gttattaata	gtaatcaatt	acgggggtcat	tagttcatag	12420
cccatatatg	gagttccgcg	ttacataact	tacggtaa	ggcccgcctg	gctgaccgcc	12480
caacgacccc	cgccattga	cgtcaataat	gacgatgtt	cccatagtaa	cgccaatagg	12540
gactttccat	tgacgtcaat	gggtggacta	tttacggtaa	actgcccact	tggcagtaca	12600
tcaagtgtat	catatgccaa	gtacgcccc	tattgacgtc	aatgacggta	aatggccgcg	12660
ctggcattat	gccagtaga	tgacctatg	ggactttcct	acttggcagt	acatctacgt	12720
attagtcatc	gctattacca	tggtg				12745

SEQ ID NO:38 IL-1ra (IL-1RN)

MEICRGLRSHLITLLLFLFHSETICRPSGRKSSKMQA FRIWDVNQKTFYLRNNQLVAGYL
QGPNVNLEEKIDVVP IEPHALFLGIHGGKMCLSCVKSGDETRLQLEAVNITDLS ENRKQD
KRFAFIRSDSGPTTSFBSAACPGWFLCTAMEADQPVSLTNMPDEGVMVTKFYFQEDE

SEQ ID NO:39 IL-1R1

MKVLLRLICFIALLISSLEADKCKERBEKILVSSANEIDVRPCPLNPNEHKGTITWYKDDS
KTPVSTEQASRIHQHKEKLWFVPAKVEDSGHYCYVVRNSSYCLRIKISAKFVENEPNLC
YNAQAIFKQKLPVAGDGGGLVCPYMEFFKNENNELPKLQWYKDCPKLLLDNIHFSGVKD
RLIVMNVAEKHRGNYTCHASYTYLGKQYPITRVIEFITLEENKPTRPVIVSPANETMEVD
LGSQIQLICNVGTQLSDIAYWKWNGSVI EDDPVLGEDYYSVENPANKRRSTLITVLNIS
BIESRFYKHPFTCFAKNTHGIDAAIQLIYPVTNFQKHMIGICVTLTVIIVCSVFIYKIFKIDI
VLWYRDSCYDFLPIKASDGKTYDAYILYPKTVGEGSTSDCDIFVFKVLPEVLEKQCGYK
LFIYGRDDYVGEDIVEVINENVKKSRRLLLVRETSGFSWLGGSSSEQIAMYNALVQDGI
KVVLLELEKIQDYEKMPESIKFIKQKHGAIRWSGDFTQGPQSAKTRFWKNVRYHMPVQ
RRSPSSKHQLLSPATKEKLQREAHVPLG

SEQ ID NO:40 IL-1R2

MLRLYVLVMGVSAFTLQPA AHTGAARSCRFRGRHYKREFRLEGE PVALRCPQVPYWL
WASVSPRINTLWHKND SARTVPGBEETRMWAQDGALWLLPALQEDSGTYVCTTRNAS
YCDKMSIELRVFENTDAFLPFISYPQILTLSTSGVLVCPDLSEFTRDKTDVKIQWYKDSLL
LDKDNEKFLSVRGTTLLVHDVALEDAGYYRCVLTFAHEGQQYNITRSIELRIKKKKKEE
TIPVIISPLKTISASLGSR LTIPTCKVFLGTGTPLTTLMLWWTANDTHIESA YPGGRVTEGPRQ
EYSENNENYIEVPLIFDPVTREDLHMDFKCVVHNTLSFQTLRTTVKEASSTFSWGIVLAP
LSLAFLVLGGIWMHRRCKHRTGKADGLTVLWPHHQDFQSYPK

SEQ ID NO:41 cPGES_1 siRNA

GGAAGCGAUAAUUAAGCtt

SEQ ID NO:42 cPGES_2 siRNA

GGAGAAUCCGCCAGUCAUtt

SEQ ID NO:43 cPGES_3 siRNA

GGGUUGAUUAUGUACCAUtt

SEQ ID NO:44 cPGES_4 siRNA
GGCUUCACUAAGGGUUGAUtt

SEQ ID NO:45 cPGES_5 siRNA
GGCAGUAUCCUUAUGCAUGtt

SEQ ID NO:46 cPGES_6 siRNA
GCUUUUACAUCUCUUAGCAtt

SEQ ID NO:47 COX-1_1 siRNA
GGGAAGAAACAGUUACCAGtt

SEQ ID NO:48 COX-1_2 siRNA
GGGCACCAACAUCCUGUUUtt

SEQ ID NO:49 COX-1_3 siRNA
GGAUGGGAAACUUAAGUACtt

SEQ ID NO:50 COX-1_4 siRNA
CCUACAACUCAGCGCAUGAtt

SEQ ID NO:51 COX-1_5 siRNA
GCGCAUGACUACAUCAGCUtt

SEQ ID NO:52 COX-1_6 siRNA
GCUACGAGCAGUUUUUAUUtt

SEQ ID NO:53 COX-2_1 siRNA
GGAUUUGACCAGUAUAAGUtt

SEQ ID NO:54 COX-2_2 siRNA
GGGAGUCUGGAACAUUGUGtt

SEQ ID NO:55 COX-2_3 siRNA
GGUUUUUAGUAUCAGAACUtt

SEQ ID NO:56 COX-2_4 siRNA
GCACAGGAUUUGACCAGUAtt

SEQ ID NO:57 COX-2_5 siRNA
GGGAAAUAAAGGAGCUUCCUtt

SEQ ID NO:58 COX-2_6 siRNA

CCCUACAGUACUAAUCAAAt

SEQ ID NO:59 mPGES-1 siRNA
GGCUUUUGCCAACCCGAGtt

SEQ ID NO:60 cPGES_3 shRNA sense
GATCCGGggttgattatgtaccattTTCAAGAGAAatgtacataatcaaccTTTTTG

SEQ ID NO:61 cPGES_3 shRNA antisense
GCCcctaatacatgtgtaaAAGTTCTCTtaccatgtattagttgggaAAAACTTAA

SEQ ID NO:62 mPGES-1shRNA sense
GATCCGGggttttggcaaccccgagTTCAAGAGActcggggttggcaaaagccTTTTTG

SEQ ID NO:63 mPGES-1 shRNA antisense
GCccgaaaacggttggggctcAAGTTCTCTgagccccaaccgttttcggAAAACTTAA

SEQ ID NO:64 COX-1_3 shRNA sense
GATCCGGgatgggaaacttaagtacTTCAAGAGAgacttaagttcccatccTTTTTG

SEQ ID NO:65 COX-1_3 shRNA antisense
GATCCGGgatgggaaacttaagtacTTCAAGAGAgacttaagttcccatccTTTTTG

SEQ ID NO:66 COX-2_1 shRNA sense
GATCCGGgatttgaccagtataagtTTCAAGAGAAacttatactggtcaaatccTTTTTG

SEQ ID NO:67 COX-2_1 shRNA antisense
GCcctaactggtcatattcaAAGTTCTCTtgaatatgaccagtttaggAAAACTTAA

SEQ ID NO:68 Secretion Signal sequence of human IL-1ra
MEICRGLRSHLITLLLFLFHSETIC

SEQ ID NO:69 Human CD11b (Mac-1) gene, 5' flank (Accession No. M82856)

```

1 ggttcaagtg attctgctgc ctcagcctcc caggcgggat tacagggtgcc tgccaccacg
61 cctggctaatt ttttttgtct ttttagtaaa gatgaggttt caccatggtg ggcaggctgg
121 tttcaattgc tgacctcaag tgagccaccc cgctcagcc tccaaaatgc taggattaca
181 ggcattagcc accgcaccca gccagtttg tacatatatt ttgactaca cttcttaact
241 attcttagga taaattacta gaagtgaata ttcttgggtg aagagcttga ggcctttaca
301 cacacacaca cacacacaca cacacacaca caaataggct ggatcgagtg gctcacacct
361 gtaatctcag cagtttggga ggctgaggaa ggaggatcac ttgagtccag gaggttgaga
421 atagcctgaa caacatagca agatcttgct tctacaaaaa agtttaaaaa aaattagctg
481 gccatggcag catgtgcctg tagtaccagc tactcggaag gctgaggtag gaggatcgct
541 tgagcccagg aggtgattga agctgcagtg agctgtgatt acaccactgc actccagcct
601 gggcaacaga gctagactct gtctctaaaa aaaggcacaa aataatattt aaaaagcacc
661 aggtatgcct gtacttgagt tgtctttggt gatggctaca aatgagacag ctctggctga
721 agggcggcct ccatttccat gggctggagg aggacatttt gcaaagtgtg ttttcaggaa
781 gacacagagt tttacctcct acacttggtt gatctgtatt aatgtttgct tatttattta
841 ttttaattttt tttttgagac agagtctcac tctgtcacct gggctggagt gcagtggcat
901 tattgaggct cattgcagtc tcagactcct gagctcaaac aatcctcctg cctcagcctc
961 tggagtagct aggactacag gcatgtgcca ccatgcctgg ctaatttttt aaatgtattt
1021 tttttagtag tcgggggtctc cctatgttgc ccaggctgga gtgcagtggg gtgatccatg
1081 ctactgcag cctggacctc gggctcaaga aattctcaca cctcagcctg tccagtagca
1141 ggggctacag gcgcgcacca ccatcccagc taattaaaaa tatttttttg tagagacagg
1201 gtctctctat gttgcccagg ctggtttcaa actcccaggc tcaagcaatc ctctgcctt

```

1261 gccctcccaaa cgacacggg ttacaggcgt gagccactga gcctggcccg tattaatgtt
1321 tagaacacga attccaggag gcaggctaag tctattcagc ttgttcatat gcttgggcca
1381 acccaagaaa caagtgggtg acaaattggca ccttttggat agtggattg actttgaaag
1441 tttgggtcag gagctgggga ggaagggtgg gcaggctgtg ggcagtcctg ggcggaagac
1501 caggcagggc tatgtgtcga ctgagcctcc gccctcttcc tttgaatctc tgatagactt
1561 ctgcctccta cttctccttt tctgcccttc tttgctttgg tggcttcctt gtggttcctc
1621 agtgggtgct gcaaccctgg ttcactcttc caggttctgg ctccctccag ccatggctct
1681 cagagtcctt ctgttaacag gtgcatgggg gtgggggtgg ggactctggg tggggaggag
1741 ggtaactttt ggtctgtca taaatagagg gccc

SEQ ID NO:70 IL-1beta antisense

GTTCCCTTTCTGCCAGCCCT

SEQ ID NO:71 IL-1alpha antisense

GTGCCGTGAGTTTCCCAGA

SEQ ID NO:72 COX-1 antisense

CCCACTTCCTTGCCCTCTCA

SEQ ID NO:73 COX-2 antisense

ACTCTGTTGTGTTCCCGCA

SEQ ID NO:74 cPGES antisense

CCTCTTCTCGCTTCCCTCA

SEQ ID NO:75 mPGES antisense

GTTCCCATCAGCCACTTCGT

SEQ ID NO:76 IL-1alpha Hammerhead Ribozyme

ATCCTTTGATCUGAUGAGUCCGUGAGGACGAAAGTTATAAGCAC

SEQ ID NO:77 IL-1beta Hammerhead Ribozyme

TCTTTAGAACUGAUGAGUCCGUGAGGACGAAAGACAAATTGCA

SEQ ID NO:78 COX-1 Hammerhead Ribozyme

GGCCGAAGCGCUGAUGAGUCCGUGAGGACGAAAGACAGATGCCC

SEQ ID NO:79 COX-2 Hammerhead Ribozyme

TGGATGTCAACUGAUGAGUCCGUGAGGACGAAAGATAACTCATA

SEQ ID NO:80 mPGES Hammerhead Ribozyme

AGGAGTTCGACUGAUGAGUCCGUGAGGACGAAAGCCTCCTGGGC

SEQ ID NO:81 cPGES Hammerhead Ribozyme

TCTCCGGTGCCUGAUGAGUCCGUGAGGACGAAAGTCCGCTTTTT

SEQ ID NO:82

CUGAUGAGUCCGUGAGGACGAAAG

VI. CLAIMS

What is claimed is:

1. A composition comprising a viral vector, wherein delivery of the vector to a cell inhibits a mediator of inflammation.
2. The composition of claim 1, wherein the vector comprises a nucleic acid operably linked to an expression control sequence and wherein the nucleic acid inhibits expression of the mediator of inflammation.
3. The composition of claim 2, wherein the nucleic acid is an siRNA.
4. The composition of claim 3, wherein the siRNA inhibits gene expression of COX-1.
5. The composition of claim 4, wherein the siRNA comprises the nucleic acid sequence SEQ ID NO:49.
6. The composition of claim 3, wherein the siRNA inhibits gene expression of COX-2.
7. The composition of claim 6, wherein the siRNA comprises the nucleic acid sequence SEQ ID NO:53.
8. The composition of claim 3, wherein the siRNA inhibits gene expression of mPGES.
9. The composition of claim 8, wherein the siRNA comprises the nucleic acid sequence SEQ ID NO:59.
10. The composition of claim 3, wherein the siRNA inhibits gene expression of cPGES.
11. The composition of claim 10, wherein the siRNA comprises the nucleic acid sequence SEQ ID NO:43.
12. The composition of claim 1, wherein the vector comprises a nucleic acid that encodes a polypeptide that inhibits the binding of the mediator of inflammation to its receptor.
13. The composition of claim 12, where the polypeptide inhibits the binding of IL-1 β to an IL-1 receptor.
14. The composition of claim 12, where the polypeptide is IL-1ra.
15. The composition of claim 14, where the polypeptide is human IL-1ra.
16. The composition of claim 12, where the nucleic acid has the sequence set forth in SEQ ID NO:5.
17. The composition of claim 12, where the nucleic acid encodes a polypeptide with at least 70%, 75%, 80%, 85%, 90%, 95% identity to the sequence set forth in SEQ ID NO:38.
18. The composition of claim 17, wherein any change is a conservative change.
19. The composition of claim 12, where the nucleic acid hybridizes to SEQ ID NO:5 under stringent conditions.
20. The composition of claim 2, wherein the expression control sequence is a constitutive

promoter.

21. The composition of claim 20, wherein the promoter is a CMV promoter.
22. The composition of claim 21, wherein the CMV promoter comprises the nucleic acid sequence set forth in SEQ ID NO:15.
23. The composition of claim 20, wherein the promoter is a beta actin promoter.
24. The composition of claim 23, wherein the beta actin promoter comprises the nucleic acid sequence set forth in SEQ ID NO:16.
25. The composition of claim 2, wherein the expression control sequence is a tissue-specific promoter.
26. The composition of claim 2, wherein the expression control sequence is an inducible promoter.
27. The composition of claim 2, wherein the vector further comprises a marker sequence.
28. The composition of claim 2, wherein the vector comprises a lentivirus.
29. The composition of claim 28, wherein the vector comprises a feline immunodeficiency virus.
30. The composition of claim 28, wherein the vector comprises a human immunodeficiency virus.
31. The composition of claim 28, wherein the vector can be stably integrated for at least 3 months.
32. A composition comprising a cell, wherein the cell comprises the vector of claim 1.
33. A method of inhibiting inflammation in a subject comprising administering to the subject the vector of claim 1.
34. A method of treating a subject with arthritis comprising administering to the subject the vector of claim 1.
35. The method of claim 34, wherein the subject has Osteoarthritis, Rheumatoid arthritis, Gout, Ankylosing spondylitis, Juvenile arthritis, Systemic lupus erythematosus (lupus), Scleroderma, or Fibromyalgia.
36. A method of treating a subject with a central nervous system disorder resulting from neuroinflammation comprising administering to the subject the vector of claim 1.
37. The method of claim 36, wherein the subject has Alzheimer's disease.




FIG. 1




FIG. 2




FIG. 3




FIG. 4




FIG. 5




FIG. 6

L c 3 4 11 12 13 14 +





FIG. 7



Western Immunoblotting







FIG. 8




FIG. 9




FIG. 10




FIG. 11




FIG. 12




FIG. 13



FIG. 14




FIG. 15




FIG. 16




FIG. 17

SEQUENCE LISTING

<110> UNIVERSITY OF ROCHESTER, et al.
KYRKANIDES, Stephanos

<120> COMPOSITIONS AND METHODS FOR STUDYING
AND TREATING INFLAMMATORY DISEASES AND DISORDERS

<130> 21108/0054P1

<140> NEW

<141> 2006-01-20

<150> 60/646,098

<151> 2005-01-20

<150> 60/646,099

<151> 2005-01-20

<160> 82

<170> FastSEQ for Windows Version 4.0

<210> 1

<211> 2943

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequences; note =
synthetic construct

<400> 1

accaggcaac	accattgaag	gtcatatgt	aaaaatccat	gccttccttt	ctcccaatct	60
ccattcccaa	acttagccac	tggttctgg	ctgaggcctt	acgcatacct	cccggggctt	120
gcacacacct	tcttctacag	aagacacacc	ttgggcatat	cctacagaag	accaggcttc	180
tctctgggtcc	ttggtagagg	gctactttac	tgtaacaggg	ccagggtgga	gagttctctc	240
ctgaagctcc	atccccctcta	taggaaatgt	gttgacaata	ttcagaagag	taagaggatc	300
aagacttctt	tgtgtcctcaa	taccactgtt	ctcttctcta	ccctgcccta	accaggagct	360
tgtaacccca	aactctgagg	tgatttatgc	cttaatcaag	caaacttccc	tcttcagaaa	420
agatggctca	ttttccctca	aaagttgcca	ggagctgcca	agtattctgc	caattcaccc	480
tggagcacia	tcaacaaatt	cagccagaac	acaactacag	ctactattag	aactattatt	540
attaataaat	tcctctccaa	atctagcccc	ttgacttcgg	atttcacgat	ttctcccttc	600
ctcctagaaa	cttgataagt	ttcccgcgct	tccctttttc	taagactaca	tgtttgtcat	660
cttataaagc	aaaggggtga	ataaatgaac	caaatacaata	acttctggaa	tatctgcaaa	720
caacaataat	atcagctatg	ccatctttca	ctatttttagc	cagtatcgag	ttgaatgaac	780
atagaaaaat	acaaaactga	attcttccct	gtaaattccc	cgttttgacg	acgcacttgt	840
agccacgtag	ccacgcctac	ttaagacaat	tacaaaaggc	gaagaagact	gactcaggct	900
taagctgcca	gccagagagg	gagtcatttc	attggcggtt	gagtcagcaa	agaagtcaag	960
atggccaaag	ttccagacat	gtttgaagac	ctgaagaact	gttacagtga	aaatgaagaa	1020
gacagttcct	ccattgatca	tctgtctctg	aatcagaaat	ccttctatca	tgtaagctat	1080
ggcccactcc	atgaaggctg	catggatcaa	tctgtgtctc	tgagtatctc	tgaaacctct	1140
aaaacatcca	agcttacctt	caaggagagc	atggttggtg	tagcaacca	cgggaagggt	1200
ctgaagaaga	gacggttgag	tttaagccaa	tccatcactg	atgatgacct	ggaggccatc	1260
gccaatgact	cagaggaaga	aatcatcaag	cctaggtcag	caccttttag	cttcctgagc	1320
aatgtgaaat	acaactttat	gaggatcatc	aaatacgaat	tcacccctgaa	tgacgccttc	1380
aatcaaagta	taattcgagc	caatgatcag	tacctcacgg	ctgctgcatt	acataatctg	1440
gatgaagcag	tgaaatttga	catgggtgct	tataagtcac	caaaggatga	tgctaaaatt	1500

accgtgattc	taagaatctc	aaaaactcaa	ttgtatgtga	ctgcccaga	tgaagaccaa	1560
ccagtgtgc	tgaaggagat	gcctgagata	cccaaaacca	tcacaggtag	tgagaccaac	1620
ctcctcttct	tctgggaaac	tcacggcact	aagaactatt	tcacatcagt	tgcccatcca	1680
aacttgttta	ttgccacaaa	gcaagactac	tgggtgtgct	tggcaggggg	gccaccctct	1740
atcactgact	ttcagatact	ggaaaaccag	gcgtaggctc	ggagtctcac	ttgtctcact	1800
tgtgcagtgt	tgacagttca	tatgtacat	gtacatgaag	aagctaaatc	ctttactgtt	1860
agtcatttgc	tgagcatgta	ctgagccttg	taattctaaa	tgaatgttta	cactctttgt	1920
aagagtggaa	ccaacactaa	catataatgt	tgttatttaa	agaacaccct	atattttgca	1980
tagtaccaat	cattttaatt	attattcttc	ataacaattt	taggaggacc	agagctactg	2040
actatggcta	ccaaaaagac	tctaccata	ttacagatgg	gcaaattaag	gcataagaaa	2100
actaagaaat	atgcacaata	gcagttgaaa	caagaagcca	cagacctagg	atctcatgat	2160
ttcattttca	ctgtttgcct	tctactttta	agttgctgat	gaactcttaa	tcaaatagca	2220
taagttttctg	ggacctcagt	tttatcattt	tcaaaatgga	gggaataata	cctaagcctt	2280
cctgccgcaa	cagtttttta	tgctaactag	ggaggtcatt	ttggtaaaat	acttcttgaa	2340
gccgagcctc	aagatgaagg	caaagcacga	aatgttattt	tttaattatt	atztatatat	2400
gtatttataa	atatatttaa	gataattata	atatactata	tttatgggaa	ccccttcac	2460
ctctgagtgt	gaccaggcat	cctccacaat	agcagacagt	gttttctggg	ataagtaagt	2520
ttgatttcat	taatacaggg	cattttggtc	caagttgtgc	ttatcccata	gccaggaaac	2580
tctgcattct	agtacttggg	agacctgtaa	tcataataa	aatgtacatt	aattaccttg	2640
agccagtaat	tgttccgac	tttgactctt	ttgccattaa	acttacctgg	gcattcttgt	2700
ttcaattcca	cctgcataca	agtcctacaa	gctaaaatta	gatgaactca	actttgacaa	2760
ccatgagacc	actgttatca	aaactttctt	ttctggaatg	taatcaatgt	ttcttctagg	2820
ttctaaaaat	tgtgatcaga	ccataatgtt	acattattat	caacaatagt	gattgataga	2880
gtgttatcag	tcataactaa	ataaagcttg	caacaaaatt	ctctgacaaa	aaaaaaaaaa	2940
aaa						2943

<210> 2

<211> 1498

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequences; note =
synthetic construct

<400> 2

accaaactc	ttcgaggcac	aaggcacaac	aggtgtctct	gggattctct	tcagccaatc	60
ttcattgtct	aagtgtctga	agcagccatg	gcagaagtac	ctgagctcgc	cagtgaatg	120
atggcttatt	acagtggcaa	tgaggatgac	ttgttctttg	aagctgatgg	ccctaaacag	180
atgaagtgt	ccttcocagga	cctggacctc	tgccctctgg	atggcggcat	ccagctacga	240
atctccgacc	accactacag	caagggtctc	aggcaggccg	cgtcagttgt	tgtggccatg	300
gacaagtga	ggaagatgct	ggttccctgc	ccacagacct	tccaggagaa	tgacctgagc	360
acctcttttc	ccttcattct	tgaagaagaa	cctatcttct	tcgacacatg	ggataacgag	420
gcttatgtgc	acgatgcacc	tgtacgatca	ctgaactgca	cgtccgggga	ctcacagcaa	480
aaaagcttgg	tgatgtctgg	tccatatgaa	ctgaaagctc	tccacctcca	gggacaggat	540
atggagcaac	aagtgggtgt	ctccatgtcc	ttgtgacaag	gagaagaaag	taatgacaaa	600
atacctgtgg	ccttgggccc	caaggaaaag	aatctgtacc	tgtcctgcgt	gttgaaagat	660
gataagccca	ctctacagct	ggagagtgt	gatcccaaaa	attacccaaa	gaagaagatg	720
gaaaagcgat	ttgtcttcaa	caagatagaa	atcaataaca	agctggaatt	tgagtctgcc	780
cagttcccca	actggtagat	cagcacctct	caagcagaaa	acatgcccg	cttcctggga	840
gggaccaaag	gcggccagga	tataactgac	ttcaccatgc	aatttgtgtc	ttcctaaaga	900
gagctgtacc	cagagagtcc	tgtgtctgaat	gtggactcaa	tccctagggc	tggcagaaag	960
ggaacagaaa	ggtttttgag	tacggctata	gcctggactt	tcctgttgtc	tacaccaatg	1020
cccaactgcc	tgccctaggg	tagtgctaag	aggatctcct	gtccatcagc	caggacagtc	1080
agctctctcc	tttcaggggc	aatccccagc	ccttttgttg	agccaggcct	ctctcacctc	1140
tcctactcac	ttaaaagccc	cctgacagaa	accacggcca	catttgggtc	taagaaaccc	1200
tctgtcattc	gctccacat	tctgatgagc	aaccgcttcc	ctatttattt	atttatttgt	1260
ttgttttttt	tattcattgg	tctaatttat	tcaaaggggg	caagaagtag	cagtgtctgt	1320
aaaagagcct	agtttttaat	agctatggaa	tcaattcaat	ttggactggg	gtgctctctt	1380
taaatcaagt	cctttaatta	agactgaaaa	tatataagct	cagattattt	aaatgggaat	1440
atttataaat	gagcaaatat	catactgttc	aatggttctg	aaataaactt	cactgaag	1498

<210> 3
 <211> 464
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequences; note =
 synthetic construct

<400> 3
 gcacctgtac gatcactgaa ctgcacgctc cgggactcac agcaaaaaag cttggtgatg 60
 tctggtccat atgaactgaa agctctccac ctccaggac aggatatgga gcaacaagtg 120
 gtgttctcca tgtcctttgt acaaggagaa gaaagtaatg acaaaatacc tgtggccttg 180
 ggctcaagg aaaagaatct gtacctgtcc tgcgtgttga aagatgataa gcccactcta 240
 cagctggaga gtgtagatcc caaaaattac ccaaagaaga agatggaaaa gcgatttgtc 300
 ttcaacaaga tagaaatcaa taacaagctg gaatttgagt ctgccagtt cccaactgg 360
 tacatcagca cctctcaagc agaaaacatg cccgtcttcc tgggaggagc caaaggcggc 420
 caggatataa ctgacttcac catgcaattt gtgtcttctt aaag 464

<210> 4
 <211> 539
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequences; note =
 synthetic construct

<400> 4
 atggaaatct gcagaggcct cgcagtcac ctaatcactc tcctcctctt cctgttccat 60
 tcagagacga tctgcgcacc tgtacgatca ctgaactgca cgctccggga ctcacagcaa 120
 aaaagcttgg tgatgtctgg tccatatgaa ctgaaagctc tccacctcca gggacaggat 180
 atggagcaac aagtgggtgtt ctccatgtcc tttgtacaag gagaagaaaag taatgacaaa 240
 atacctgtgg ccttggggcct caaggaaaag aatctgtacc tgtcctgctg gttgaaagat 300
 gataagccca ctctacagct ggagagtgtg gatcccaaaa attaccctaaa gaagaagatg 360
 gaaaagcgt ttgtcttcaa caagatagaa atcaataaca agctggaatt tgagtctgcc 420
 cagttcccca actggtacat cagcacctct caagcagaaa acatgcccggt cttcctggga 480
 gggaccaaag gcggccagga tataactgac ttcaccatgc aatttgtgtc ttcctaaag 539

<210> 5
 <211> 1760
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequences; note =
 synthetic construct

<400> 5
 atttctttat aaaccacaac tctgggcccg caatggcagt ccactgcctt gctgcagtca 60
 cagaatggaa atctgcagag gcctccgcag tcacctaatc actctcctcc tcttctgtt 120
 ccattcagag acgatctgcc gaccctctgg gagaaaatcc agcaagatgc aagccttcag 180
 aatctgggat gttaaccaga agaccttcta tctgaggaaac aaccaactag ttgtctggata 240
 cttgcaagga ccaaatgtca atttagaaga aaagatagat gtggtaccca ttgagcctca 300
 tgctctgttc ttgggaatcc atggagggaa gatgtgcctg tcctgtgtca agtctggtga 360
 tgagaccaga ctccagctgg aggaggttaa catcactgac ctgagcgaga acagaaagca 420
 ggacaagcgc ttgccttca tccgctcaga cagcggcccc accaccagtt ttgagtctgc 480
 cgcctgcccc ggttggttcc tctgcacagc gatggaagct gaccagcccg tcagcctcac 540
 caatatgcct gacgaaggcg tcatgggtcac caaattctac ttccaggagg acgagtagta 600
 ctgcccaggc ctgcctgttc ccattcttgc atggcaagga ctgcagggac tgccagtccc 660

cctgccccag	ggctccccgc	tatgggggca	ctgaggacca	gccattgagg	ggtggaccct	720
cagaaggcgt	cacaagaacc	tggtcacagg	actctgcctc	ctcttcaact	gaccagcctc	780
catgctgcct	ccagaatggt	ctttctaatt	tgtgaatcag	agcacagcag	ccccgcaca	840
aagcccttcc	atgtgcctc	tgcattcagg	atcaaacc	gaccacctgc	ccaacctgct	900
ctectcttgc	cactgcctct	tcctccctca	ttccaccttc	ccatgccttg	gatccatcag	960
gccacttgat	gacccccaac	caagtggctc	ccacaccctg	ttttacaaaa	aagaaaagac	1020
cagtcctatga	gggagggtttt	taagggtttg	tggaaaatga	aaattaggat	ttcatgattt	1080
ttttttttca	gtccccgtga	aggagagccc	ttcatttggg	gattatgttc	tttcggggag	1140
aggctgagga	cttaaaatat	tcctgcattt	gtgaaatgat	ggtgaaagta	agtggtagct	1200
tttcccttct	ttttcttctt	tttttgtgat	gtcccaactt	gtaaaaatta	aaagtatatg	1260
tactatgtta	gccccataat	tttttttttc	cttttaaaac	acttccataa	tctggactcc	1320
tctgtccagg	cactgctgcc	cagcctccaa	gctccatctc	cactccagat	ttttacagc	1380
tgcttgcagt	actttacctc	ctatcagaag	tttctcagct	cccaaggctc	tgagcaaatg	1440
tggctctctg	gggttctttc	ttcctctgct	gaaggaataa	attgctcctt	gacattgtag	1500
agcttctggc	acttggagac	ttgtatgaaa	gatggctgtg	cctctgcctg	tctccccac	1560
cgggctggga	gctctgcaga	gcaggaaaca	tgactcgtat	atgtctcagg	tccttgcagg	1620
gccaaagcacc	tagcctcgct	cttggcaggt	actcagcgaa	tgaatgctgt	atatgttggg	1680
tgcaaagtcc	cctacttctt	gtgacttcag	ctctgtttta	caataaaatc	ttgaaaatgc	1740
ctaaaaaaa	aaaaaaaaa					1760

<210> 6

<211> 534

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequences; note =
synthetic construct

<400> 6

atggaaatct	gcagaggcct	ccgcagtcac	ctaatactc	tcctcctctt	cctgttccat	60
tcagagacga	tctgccgacc	ctctgggaga	aaatccagca	agatgcaagc	cttcagaatc	120
tgggatgtta	accagaagac	cttctatctg	aggaacaacc	aactagttgc	tggatacttg	180
caaggaccaa	atgtcaattt	agaagaaaag	atagatgtgg	taccattga	gcctcatgct	240
ctgttcttgg	gaatccatgg	agggaagatg	tgctgtcct	gtgtcaagtc	tggatgatgag	300
accagactcc	agctggaggc	agttaacatc	actgacctga	gcgagaacag	aaagcaggac	360
aagcgcttcg	ccttcatccg	ctcagacagc	ggccccacca	ccagttttga	gtctgccgcc	420
tgccccgggt	ggttcctctg	cacagcgatg	gaagctgacc	agcccgtcag	cctcaccaat	480
atgcctgacg	aaggcgctcat	ggtcaccaa	ttctacttcc	aggaggacga	gtag	534

<210> 7

<211> 534

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequences; note =
synthetic construct

<400> 7

atggaaatct	gcagaggcct	ccgcagtcac	ctaatactc	tcctcctctt	cctgttccat	60
tcagagacga	tctgccgacc	ctctgggaga	aaatccagca	agatgcaagc	cttcagaatc	120
tgggatgtta	accagaagac	cttctatctg	aggaacaacc	aactagttgc	tggatacttg	180
caaggaccaa	atgtcaattt	agaagaaaag	atagatgtgg	taccattga	gcctcatgct	240
ctgttcttgg	gaatccatgg	agggaagatg	tgctgtcct	gtgtcaagtc	tggatgatgag	300
accagactcc	agctggaggc	agttaacatc	actgacctga	gcgagaacag	aaagcaggac	360
aagcgcttcg	ccttcatccg	ctcagacagc	ggccccacca	ccagttttga	gtctgccgcc	420
tgccccgggt	ggttcctctg	cacagcgatg	gaagctgacc	agcccgtcag	cctcaccaat	480
atgcctgacg	aaggcgctcat	ggtcaccaa	ttctacttcc	aggaggacga	gtag	534

<210> 8

<211> 4849
 <212> DNA
 <213> Artificial Sequence

<220>

<223> Description of Artificial Sequences; note =
 synthetic construct

<400> 8

tagacgcacc	ctctgaagat	ggtagactccc	tcctgagaag	ctggacccct	tggtaaaaga	60
caaggccttc	tccaagaaga	atatgaaagt	gttactcaga	cttatttggt	tcatagctct	120
actgatttct	tctctggagg	ctgataaatg	caaggaacgt	gaagaaaaaa	taatttttagt	180
gtcatctgca	aatgaaattg	atgttcgtcc	ctgtcctctt	aacccaaatg	aacacaaagg	240
cactataaact	tggatataaag	atgacagcaa	gacacctgta	tctacagaac	aagcctccag	300
gattcatcaa	cacaaagaga	aactttgggt	tggtcctgct	aagggtggagg	attcaggaca	360
ttactattgc	gtggtaagaa	attcatctta	ctgcctcaga	attaaaataa	gtgcaaaatt	420
tgtggagaat	gagcctaact	tatgttataa	tgcacaagcc	atatttaagc	agaaactacc	480
cgttgccagga	gacggaggac	ttgtgtgccc	ttatatggag	ttttttaaaa	atgaaaataa	540
tgagttacct	aaattacagt	ggtataagga	ttgcaaacct	ctacttcttg	acaatatata	600
cttttagtgga	gtcaaagata	ggctcatcgt	gatgaatgtg	gctgaaaagc	atagagggaa	660
cttactattgt	catgcatact	acacataact	gggcaagcaa	tatcctatta	cccgggtaat	720
agaattttatt	actctagagg	aaaacaaaacc	cacaaggcct	gtgattgtga	gcccagctaa	780
tgagacaatg	gaagtagact	tgggatccca	gatacaattg	atctgtaatg	tcaccggcca	840
gttgagtgc	attgcttact	ggaagtggaa	tgggtcagta	attgatgaag	atgaccaggt	900
gctaggggaa	gactattaca	gtgtggaaaa	tcctgcaaac	aaaagaagga	gtaccctcat	960
cacagtgcct	aatatatcgg	aaattgaaag	tagattttat	aaacatccat	ttacctgttt	1020
tgccaagaat	acacatggta	tagatgcagc	atatatccag	ttaatatatc	cagtcactaa	1080
tttccagaag	cacatgattg	gtatatgtgt	cacgttgaca	gtcataattg	tgtgttctgt	1140
ttttctccca	ataaaagctt	cagatggaaa	gacctatgac	gcataataac	tgtatccaaa	1200
gactgttggg	gaagggtcta	cctctgactg	tgatattttt	gtgtttaaag	tcttgccctga	1260
ggtccttgaa	aaacagtgtg	gatataagct	gttcattttat	ggaagggatg	actacgttgg	1320
ggaagacatt	gttgagggtca	ttaatgaaaa	cgtaaagaaa	agcagaagac	tgattatcat	1380
tttagtcaga	gaaacatcag	gcttcagctg	gctgggtggt	tcactctgaag	agcaaatagc	1440
catgtataat	gctcttggtc	aggatggaat	taaagttgtc	ctgcttgagc	tggagaaaaat	1500
ccaagactat	gagaaaaatgc	cagaatcgat	taaattcatt	aagcagaaac	atggggctat	1560
ccgctggtca	ggggacttta	cacaggggacc	gacctctgca	aagacaaggt	tctggaagaa	1620
tgtcagggtac	cacatgccag	tccagcgcag	gtcaccttca	tctaaacacc	agttactgtc	1680
accagccact	aaggagaaac	tgcaaaagaga	ggctcacgtg	cctctcgggt	agcatggaga	1740
agttgccaa	agttcttttag	gtgcctcctg	tcttatggcg	ttgcaggcca	ggttatgcct	1800
catgctgact	tgcagagttc	atggaatgta	actatatcat	ccttttatccc	tgaggtcacc	1860
tggaatcaga	ttattaagggt	aataagccat	gacgtcaata	gcagcccagg	gcacttcaga	1920
gtagagggtc	tgggaagatc	ttttaaaaag	gcagtaggcc	cgggtgtggtg	gctcacgcct	1980
ataatcccag	cacttttggga	ggctgaagtg	ggtggatcac	cagaggtcag	gagttcgaga	2040
ccagcccagc	caacatggca	aaaccccac	tctactaaaa	atacaaaaat	gagctaggca	2100
tgggtggcaca	cgctgtaat	cccagctaca	cctgaggctg	aggcaggaga	attgcttgaa	2160
ccggggagac	ggagggttgca	gtgagccgag	tttggggccac	tgcactctag	cctggcaaca	2220
gagcaagact	ccgtctcaaa	aaaagggcaa	taaatgccct	ctctgaatgt	ttgaaactgcc	2280
aagaaaaggc	atggagacag	cgaactagaa	gaaagggcaa	gaaggaaata	gccaccgtct	2340
acagatggct	tagttaagtc	atcccacagcc	caagggcggg	gctatgcctt	gtctggggac	2400
cctgtagagt	cactgacctc	ggagcggctc	tcctgagagg	tgctgcaggc	aaagtgcagc	2460
tgacacctca	ctgaggaagg	gagacataat	ccttgagaaac	tttccatctg	cttgatattt	2520
ccatacacat	ccccagccag	aagttagtg	ccgaagaccg	aattttattt	tacagagctt	2580
gaaaactcac	ttcaatgaac	aaagggatcc	tccaggatcc	caaagttttg	aagtcatctt	2640
agctttccac	aggagggaga	gaacttaaaa	aagcaacagt	agcaggggaat	tgatccactt	2700
cttaatgctt	tcctccctgg	catgaccatc	ctgtcctttg	ttattatcct	gcattttacg	2760
tctttggagg	aacagctccc	tagtggtctc	ctcctgtctg	aatgtccctt	gcacagccca	2820
ccatgaacc	atccttccca	tgatgccgct	cttctgtcat	cccgtcctctg	ctgaaacacc	2880
tcccaggggc	tccactgttt	caggagctga	agccactgtc	ttcccaccag	catgtcactc	2940
ccagaccacc	tcctctccct	gtcctccagc	ttccctctgc	tgtcctgtctg	tgtgaattcc	3000
cagggtggcc	tgggtggccat	gtcgcctgcc	cccagcactc	ctctgtctct	gctcttgcc	3060
cgacccttcc	tcctcctttg	cctaggaggc	cttctctcat	tttctctagc	tgatcagaat	3120

tttaccaaaa	ttcagaacat	cctccaattc	cacagtctct	gggagacttt	ccctaagagg	3180
cgacttcctc	tccagccttc	tctctctggg	caggccact	gcagagatgg	tggtaggcac	3240
atctgggagg	ctgggtctcc	tccagctgga	attgctgctc	tctgagggag	aggctgtggg	3300
gggtgtctct	gtccctcact	gccttccagg	agcaatttgc	acatgtaaca	tagattttatg	3360
taatgcttta	tgtttaaaaa	cattcccca	ttatcttatt	taatttttgc	aattattcta	3420
atcttatata	tagagaaagt	gacctatttt	ttaaaaaat	cacactctaa	gttctattga	3480
acctaggact	tgagcctcca	tttctggctt	ctagtctggg	gttctgagta	cttgatttca	3540
gggtcaataac	gggtccccct	cactccacac	tggcacgttt	gtgagaagaa	atgacatttt	3600
gctaggaagt	gaccgagtct	aggaatgctt	ttattcaaga	caccaaattc	caaacttcta	3660
aatgtttgaa	ttttcaaaaa	ttgtgtttag	atcttatgaa	aaactcttct	actttcatct	3720
attctttccc	tagaggcaaa	catttcttaa	aatgtttcat	tttcattaaa	aatgaaagcc	3780
aaatttatat	gccaccgatt	gcaggacaca	agcacagtct	taagagtgtg	atgaacatgg	3840
agaggacttt	tgggtttttat	atttctcgta	tttaatatgg	gtgaacacca	acttttattt	3900
ggaataataa	ttttcctcct	aaacaaaaac	acattgagtt	taagtctctg	actcttgcc	3960
ttccacctgc	tttctcctgg	gcccgttttg	cctgcttgaa	ggaacagtgc	tgttctggag	4020
ctgctgttcc	aacagacagg	gcctagcttt	catttgacac	acagactaca	gccagaagcc	4080
catggagcag	ggatgtcacg	tcttgaaaag	cctattagat	gttttacaaa	tttaattttg	4140
cagattattt	tagtctgtca	tccagaaaaa	gtgtcagcat	gcatagtgct	aagaaagcaa	4200
gccaatttgg	aaacttaggt	tagtgacaaa	attggccaga	gagtgggggt	gatgatgacc	4260
aagaatttga	agtagaatgg	cagctggaat	ttaaggaggg	acaagaatca	atggataagc	4320
gtgggtggag	gaagatccaa	acagaaaagt	gcaaagttaa	tcccatctt	ccaaggggtg	4380
aattctggag	gaagaagaca	cattcctagt	tcccctgtaa	cttcttttga	cttattgtcc	4440
ccactaaaac	aaaacaaaaa	acttttaatt	ccttccacat	taattagatt	ttcttgcagt	4500
ttttttatgg	cattttttta	aagatgccct	aagtgttgaa	gaagagtttg	caaatgcaac	4560
aaaatattta	attaccggtt	gttaaaactg	gtttagcaca	atttatattt	tccctctctt	4620
gcctttctta	tttgcaataa	aaggatttga	gccatttttt	aaatgacatt	tttgataaat	4680
tatgttttga	ctagttgatg	aaggagtttt	ttttaacctg	tttatataat	tttgagcag	4740
aagccaaatt	ttttgtatat	taaagcacca	aattcatgta	cagcatgcat	cacggatcaa	4800
tagactgtac	ttattttcca	ataaaatttt	caaactttgt	actgttaaa		4849

<210> 9

<211> 1436

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequences; note =
synthetic construct

<400> 9

gggatgggag	atactgttgt	ggtcacctct	ggaaaataca	ttctgtctact	cttaaaaaact	60
agtgcgctc	atacaaatca	acagaaagag	cttctgaagg	aagacttta	agctgcttct	120
gccacgtgct	gctgggtctc	agtcctccac	ttcccgtgtc	ctctggaagt	tgtcaggagc	180
aatgttgcgc	ttgtacgtgt	tggtaatggg	agtttctgcc	ttcacccttc	agcctgcggc	240
acacacaggg	gctgccagaa	gctgccggtt	tcgtgggagg	cattacaagc	gggagttcag	300
gctggaagg	gagcctgtag	ccctgagggtg	cccccagggtg	ccctactggg	tgtgggcctc	360
tgtcagcccc	cgcatacaacc	tgacatggca	taaaaatgac	tctgctagga	cgggtcccagg	420
agaagaagag	acacggatgt	gggcccagga	cgggtgctctg	tggcttctgc	cagccttgca	480
ggaggactct	ggcacctacg	tctgcactac	tagaaatgct	tcttactgtg	acaaaatgtc	540
cattgagctc	agagtttttg	agaatacaga	tgctttcctg	ccgttcatct	catacccgca	600
aattttaacc	ttgtcaacct	ctgggttatt	agtatgccct	gacctgagtg	aattcacccg	660
tgacaaaact	gacgtgaaga	ttcaatggta	caaggattct	cttcttttgg	ataaagacaa	720
tgagaaat	ctaagtgtga	gggggaccac	tcacttactc	gtacacgatg	tggccctgga	780
agatgctggc	tattaccgct	gtgtcctgac	atttgcccat	gaaggccagc	aatacaacat	840
cactaggagt	attgagctac	gcatcaagaa	aaaaaaagaa	gagaccattc	ctgtgatcat	900
ttccccctc	aagaccatat	cagcttctct	ggggtcaaga	ctgacaatcc	cgtgtaaggt	960
gtttctggga	accggcacac	ccttaaccac	catgctgtgg	tggacggcca	atgacacca	1020
catagagagc	gcctaccg	gaggccgctg	gaccgagg	ccacgccagg	aattattcga	1080
aaataatgag	aactacattg	aagtgccatt	gatttttgat	cctgtcacaa	gagaggattt	1140

gcacatggat tttaaagtgt ttgtccataa taccctgagt tttcagacac tacgcaccac 1200

agtcaaggaa gcctcctcca cggtctcctg gggcattgtg ctggccccac tttcactggc 1260
 cttcttgggt ttggggggaa tatggatgca cagacgggtc aaacacagaa ctggaaaagc 1320
 agatggctcg actgtgctat ggctcatca tcaagacttt caatcctatc ccaagtgaag 1380
 taaatggaat gaaataattc aaacacaaaa aaaaaaaaaa aaaaaaaaaa aaaaaa 1436

<210> 10

<211> 2554

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequences; note =
 synthetic construct

<400> 10

gcgccatgag ccggagtctc ttgctccggt tcttgctgtt cctgctcctg ctccccccgc 60
 tccccgtcct gctcggcgac ccaggggcgc ccacgccagt gaatccctgt tgttactatc 120
 catgccagca ccagggcacg tgtgtccgct tgggccttga ccgctaccag tgtgactgca 180
 cccgcacggg ctattccggc cccaactgca ccattccctgg cctgtggacc tggctccgga 240
 attcaatggc gctcagcccc tctttcaccc acttccctgt cactcacggg cgctgggtct 300
 gggagtgtgt caatgccacc ttcattccgag agatgctcat gcgcctggta ctcacagtgc 360
 gctccaacct tatccccagt cccccacct acaactcagc acatgactac atcagctggg 420
 agtctttctc caacgtgagc tattacactc gtattctgcc ctctgtgcct aaagattgcc 480
 ccacacccat gggaacaaaa gggaagaagc agttgccaga tgcccagctc ctggcccggc 540
 gcttcctgct caggaggaag ttcataacctg accccaagg caccaacctc atgtttgcct 600
 tctttgcaca acacttcacc caccagtctt tcaaaacttc tggcaagatg ggtcctggct 660
 tcaccaaggc cttggcgacc ggggtagacc toggccacat ttatggagac aatctggagc 720
 gtcagtatca actgcggctc tttaaggatg ggaaactcaa gtaccagggtg ctggatggag 780
 aaatgtaccc gccctcggtg gaagaggcgc ctgtgttgat gcactacccc cgaggcatcc 840
 cgccccagag ccagatggct gtgggcccagg aggtgttttg gctgcttcc tgggtccatgc 900
 tgtatgccac gctctggcta cgtgagcaca accgtgtgtg tgacctgctg aaggctgagc 960
 accccacctg gggcgatgag cagcttttcc agacgacccg cctcatcctc ataggggaga 1020
 ccatcaagat tgtcatcgag gactacgtgc agcagctgag tggctatttc ctgcagctga 1080
 aatttgaccc agagctgctg ttcggtgtcc agttccaata ccgcaaccgc attgccatgg 1140
 agttcaacca tctctaccac ttgcaccccc tcatgcctga ctcttcaag gtgggctccc 1200
 aggagtacag ctacgagcag ttcttgttca acacctccat gttggtggac tatggggttg 1260
 agggcctggt ggatgccttc tctcgccaga ttgctggccg gatcggtggg ggcaggaaca 1320
 tggaccacca catctgcat gtggctgtgg atgtcatcag ggagtctcgg gagatgcggc 1380
 tgcagccctt caatgagtag cgcaagaggt ttggcatgaa accctacacc tcttccagg 1440
 agctcgtagg agagaaggag atggcagcag agttggagga attgtatgga gacattgatg 1500
 cgttggaggt ctaccctgga ctgcttcttg aaaagtgcc tccaaactct atctttgggg 1560
 agagtatgat agagattggg gctccctttt cctcaaggg tctcctaggg aatcccatct 1620
 gttctccgga gtactggaag ccgagcacat ttggcggcga ggtgggcttt aacattgtca 1680
 agacggccac actgaagaag ctggtctgcc tcaacaccaa gacctgtccc tacgtttcct 1740
 tccgtgtgcc ggatgccagt caggatgatg ggcctgctgt ggagcgacca tccacagagc 1800
 tctgaggggc aggaagcag cattctggag gggagagctt tgtgcttgtc attccagagt 1860
 gctgaggcca gggctgatgg tcttaaagtgc tcattttctg gtttggcatg gtgagtgttg 1920
 gggttgacat ttagaacttt aagtctcacc cattatcttg aatattgtga ttctgtttat 1980
 tcttccagaa tgtgaactc cttgttagcc ctccagattg ttaggagtgg ttctcatttg 2040
 gtctgccaga atactgggtt cttagttagc aacctagaat gtcagatttc tgggtgattt 2100
 gtaacacagt cattctagga tgtggagcta ctgatgaaat ctgctagaaa gttagggggg 2160
 tcttattttg cattccagaa tcttgacttt ctgattgggt attcaaagtg ttgtgttccc 2220
 tggctgatga tccagaacag tggctcgtat cccaaatctg tcagcatctg gctgtctaga 2280
 atgtggattt gattcatttt cctgttcagt gagatatcat agagacggag atcctaagg 2340
 ccaacaagaa tgcattccct gaatctgtgc ctgcactgag agggcaagga agtgggggtg 2400
 tcttcttggg accccacta agacctgggt ctgaggatgt agagagaaca ggtgggctgt 2460
 attcacgcca ttggttggaa gctaccagag ctctatcccc atccaggtct tgactcatgg 2520
 cagctgtttc tcatgaagct aataaaattc gccc 2554

<210> 11
 <211> 4465
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequences; note =
 synthetic construct

```

<400> 11
caattgtcat acgacttgca gtgagcgtca ggagcacgtc caggaactcc tcagcagcgc      60
ctccttcagc tccacagcca gacgccctca gacagcaaag cctacccccg cgccgcgccc      120
tgcccgcgcg tcggatgctc gcccgcgccc tgctgctgtg cgcggctcctg gcgctcagcc      180
atacagcaaa tccttgctgt tcccaccat gtcaaaaccg aggtgtatgt atgagtgtgg      240
gatttgacca gtataagtgc gattgtaccc ggacaggatt ctatggagaa aactgctcaa      300
caccggaatt tttgacaaga ataaaattat ttctgaaacc cactccaaac acagtgcact      360
acatacttac ccacttcaag ggattttgga acgtttgtgaa taacattccc ttccttcgaa      420
atgcaattat gagttatgtc ttgacatcca gatcacattt gattgacagt ccaccaactt      480
acaatgctga ctatggctac aaaagctggg aagccttctc taacctctcc tattatacta      540
gagcccttcc tcctgtgcct gatgattgcc cgactccctt ggggtgtcaaa ggtaaaaagc      600
agcttcctga ttcaaatgag atttgtgaaa aattgcttct aagaagaaag ttcacccctg      660
atccccaggg ctcaaacatg atgtttgcat tctttgccc gacttcacg catcagtttt      720
tcaagacaga tcataagcga gggccagctt tcaccaacgg gctgggccat ggggtggact      780
taaatacatat ttacggtgaa actctggcta gacagcgtaa actgcgcctt ttcaaggatg      840
gaaaaatgaa atatcagata attgatggag agatgtatcc tcccacagtc aaagatactc      900
aggcagagat gatctaccct cctcaagtcc ctgagcatct acggtttgct gtggggcagg      960
aggtcttttg tctggtgcct ggtctgatga tgtatgccac aatctggctg cgggaaacaca      1020
acagagattg cgatgtgctt aaacaggagc atoctgaatg gggatgatgag cagttgttcc      1080
agacaagcag gctaatactg ataggagaga ctattaagat tgtgattgaa gattatgtgc      1140
aacacttgag tggctatcac ttcaaaactga aatttgaccc agaactactt ttcaacaaac      1200
aattccagta ccaaaatcgt attgctgctg aatttaacac cctctatcac tggcatcccc      1260
ttctgcctga cacttttcaa attcatgacc agaaatacaa ctatcaacag tttatctaca      1320
acaactctat attgctggaa catggaatta cccagtttgt tgaatcattc accaggcaaa      1380
ttgtggcag ggttgctggt ggtaggaatg ttccaccgc agtacagaaa gtatcacagg      1440
cttcattatg ctagagcagg cagatgaaat accagtcttt taatgagtac cgcaaacgct      1500
ttatgctgaa gcctatgaa tcatttgaag aacttacagg agaaaaggaa atgtctgcag      1560
agttggaagc actctatggt gacatcgatg ctgtggagct gtatcctgcc cttctggtag      1620
aaaagcctcg gccagatgcc atctttggtg aaaccatggt agaagtggga gcaccattct      1680
ccttgaaagg acttatgggt aatgttatat gttctcctgc ctactggaag ccaagcactt      1740
ttggtggaga agtggggttt caaatcatca aactgcctc aattcagttc ctcatctgca      1800
ataacgtgaa gggctgtccc tttacttcat tcagtgttcc agatccagag ctcatataaa      1860
cagtcaccat caatgcaagt tcttcccgcg cggcagtaga tgatatcaat ccacagtag      1920
tactaaaaga acgttcgact gaactgtaga agtctaata tcatatttat ttatttatat      1980
gaaccatgtc tattaattta attatttaat aatatttata ttaaactcct tatgttactt      2040
aacatcttct gtaacagaag tcagtactcc tgttgccggag aaaggagtca tacttgtgaa      2100
gacttttatg tcaactactc aaagattttg ctggtgctgt taagtttggg aaacagtttt      2160
tattctgttt tataaaccag agagaaatga gttttgacgt ctttttactt gaatttcaac      2220
ttatattata agaacgaaag taaagatggt tgaatactta aacactatca caagatggca      2280
aaatgctgaa agtttttaca ctgtcgatgt ttccaatgca tcttccatga tgcattagaa      2340
gtaactaatg tttgaaattt taaagtactt ttgggtattt ttctgtcatc aaacaaaaac      2400
aggatcagtg cattatttaa atgaatattt aaattagaca ttaccagtaa tttcatgtct      2460
actttttaaa atcagcaatg aaacaataat ttgaaatttc taaattcata gggtagaatc      2520
acctgtaaaa gcttggttga tttcttaaag ttattaaact tgtacatata ccaaaaagaa      2580
gctgtcttgg atttaaatct gtaaaatcag atgaaatttt actacaattg cttgttaaaa      2640
tattttataa gtgatgttcc tttttcacca agagtataaa cttttttagt gtgactgtta      2700
aaacttcctt ttaaatcaaa atgccaaatt tattaagggt gtggagccac tgcagtgtta      2760
tctcaaaaaa agaataatat gttgagatat tccagaattt gtttatatgg ctggtaacat      2820
gtaaaatcta tatcagcaaa agggctcacc tttaaaaata gcaataacaa agaagaaaac      2880
caaattattg ttcaaattta ggtttaaact tttgaagcaa actttttttt atccttgtgc      2940
actgcaggcc tggtagtcag attttgctat gaggttaatg aagtaccaag ctgtgcttga      3000
ataacgatat gttttctcag attttctggt gtacagttta atttagcagt ccatatcaca      3060

```

ttgcaaaagt	agcaatgacc	tcataaaata	cctcttcaaa	atgcttaa	tcatttcaca	3120
cattaat	atctcagtc	tgaagcca	tcagtaggtg	cattggaatc	aagcctggct	3180
acctgcatgc	tgctcctttt	cttttcttct	tttagccatt	ttgctaagag	acacagtcct	3240
ctcatcactt	cgtttctcct	attttgtttt	actagtttta	agatcagagt	tcactttctt	3300
tggaactctgc	ctatat	ttacctgaac	ttttgcaagt	tttcaggtaa	acctcagctc	3360
aggactgtcta	tttagctcct	cttaagaaga	ttaaaagaga	aaaaaaaagg	ccctttttaa	3420
aatagtatac	acttat	agtga	agagaat	at	aatttttagct	3480
atctgtaacc	aagatggatg	caaagaggct	agtgcctcag	agagaactgt	acgggggttg	3540
tgactggaaa	aagttacgtt	cccattctaa	ttaatgcctt	ttcttat	aaaacaaaac	3600
caa	atgat	ctcagcaata	ataataatga	cgataa	tcttttccac	3660
atctcattgt	cactgacatt	taatgg	gtatattact	taatttattg	aagattatta	3720
tttatgtcct	attaggacac	tatggttata	aactgtgttt	aagcctacaa	tcattgattt	3780
ttttttgtta	tgtcacaatc	agtata	ctttgggggt	acctctctga	atattatgta	3840
aacaatccaa	agaaatgatt	gtattaagat	ttgtgaataa	at	atctgattgg	3900
catattgaga	tatttaagg	tgaatgtttg	tccttaggat	aggcctatgt	gctagccac	3960
aaagaatatt	gtctcattag	cctgaatgtg	ccataagact	gaccttttaa	aatgttttga	4020
gggatctgtg	gatgcttcgt	taatttgttc	agccacaatt	tattgagaaa	atattctgtg	4080
tcaagcactg	tgggttttaa	tattttttaa	tcaaacgctg	attacagata	atagtattta	4140
tataaataat	tga	tttcttttgg	gaagaggag	aaaatgaa	aaatatcatt	4200
aaagataact	caggagaatc	ttctttacaa	ttttacgttt	agaatgttta	agggttaagaa	4260
agaaatagtc	aatatgtctg	tataaaacac	ttttcactgt	tttttttaa	aaaaaaactt	4320
gatttgttat	taacattgat	ctgctgacaa	aaacctggga	tttgggttgt	gtatgcgaat	4380
gtttcagtcg	ctcagacaaa	tgtgtattta	acttatgtaa	aagataagtc	tggaaataaa	4440
tgtctgttta	tttttgtact	attta				4465

<210> 12

<211> 1805

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequences; note =
synthetic construct

<400> 12

gctgctctc	tgctgagctg	atcacaccca	cagttgagct	gcgctggcca	gagatgcctg	60
cccacagcct	ggtgatgagc	agcccggccc	tccggcctt	cctgctctgc	agcacgctgc	120
tggtcatcaa	gatgtacgtg	gtggccatca	tcacgggcca	agtgaggctg	cggaagaagg	180
cctttgcca	ccccgaggat	gccctgagac	acggaggccc	ccagtattgc	aggagcgacc	240
ccgacgtgga	acgctgcctc	agggcccacc	ggaacgacat	ggagaccatc	taccccttcc	300
ttttcctggg	cttcgtctac	tcctttctgg	gtcctaacc	ttttgtcgcc	tgatgcact	360
tccgtgctct	cctcgtgggc	cgtgtggcac	acaccgtggc	ctacctgggg	aagctgcggg	420
cacccatccg	ctccgtgacc	tacaccctgg	cccagctccc	ctgcgcctcc	atggctctgc	480
agatcctctg	ggaagcggcc	cgccacctgt	gaccagcagc	tgatgcctcc	ttggccacca	540
gaccatgggc	caagagccgc	cgtggctata	cctggggact	tgatgttctt	tccagattgt	600
ggtgggccc	gagtcctggt	ttcctggcag	cctgctgcgc	gtgtgggtct	ctgggcacag	660
tgggcctgtg	tgtgtgccc	tgtgtgtgta	tgtgtgtgtg	tatgtttctt	agccccttgg	720
attcctgcac	gaagtggctg	atgggaacca	tttcaagaca	gattgtgaag	attgatagaa	780
aatccttcag	ctaaagtaac	agagcatcaa	aaacatcact	ccctctccct	ccctaacagt	840
gaaaagagag	aagggagact	ctatttaaga	ttcccaaac	taatgatcat	ctgaatccc	900
ggctaagaat	gcagactttt	cagactgacc	ccagaaattc	tggcccagcc	aatctagagg	960
caagcctggc	catctgtatt	tttttttttc	caagacagag	tcttgcctctg	ttgcccgaagc	1020
tggagtgaag	tggtacaatc	tggtcactg	cagcctccgc	ctcccgggtt	caagcgattc	1080
tcccgctca	gcctcctgag	tagctgggat	tacaggcgcg	tatcaccata	cccagcta	1140
ttttgtattt	ttagtagaga	cgggttcacc	atgttgccca	ggagggtctc	gaactcctgg	1200
cctcaagtga	tccaccggcc	tggcctccc	aaagtgtctg	gatgacaggc	atgaatcact	1260
gtgctcagcc	accatctgga	gttttaaaag	gctcccatgt	gagtcctgt	gatggccagg	1320
ccaggggacc	cctgccagtt	ctctgtggaa	gcaaggctgg	ggtcttgggt	tctgtatgg	1380
tgggaagctgg	gtgagccaa	gacagggtg	gctcctctgc	cccgcctgac	gcttcccttg	1440
ccgttggcct	tggatgtctt	tgctgcagtc	ttctctctgg	ctcaggtgtg	ggtgggagg	1500
gccacagga	agctcagcct	tctcctccca	aggttttagt	ccctccaaag	ggcagtggtg	1560

ggaggaccgg	gagctttggg	tgaccagcca	ctcaaaggaa	ctttctgggc	ccttcagtat	1620
cttcaaggtt	tggaaactgc	aatgtccccc	ttgatgggga	atccgtgtgt	gtgtgtgtgt	1680
gtgtgtgtgt	gtgtgtgtgt	gtgtgtgttt	tctcctagac	ccgtgacctg	agatgtgtga	1740
tttttagtca	ttaaattggaa	gtgtctgcc	gctggggcca	gcacctaaaa	aaaaaaaaaa	1800
aaaaa						1805

<210> 13

<211> 782

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequences; note =
synthetic construct

<400> 13

ggattcgggc	tacactttcc	tcttctcccc	gaccggagag	ccgctctttc	cgcgcggtgc	60
attctggggc	ccgaggtcga	gcccgccgct	gccgccgtcg	cctgagggaa	gcgagaagag	120
gccgcgaccg	agagaaaaag	cggagtcgca	ccggagagaa	gtcgactccc	tagcagcagc	180
cgccgccaga	gagcccgccc	accagttcgc	ccgtccccc	gccccgttca	caatgcagcc	240
tgcttctgca	aagtgggtacg	atcgaaggga	ctatgtcttc	attgaatttt	gtgttgaaga	300
cagtaaggat	gttaatgtaa	attttgaaaa	atccaaactt	acattcagtt	gtctcggagg	360
aagtgataat	tttaagcatt	taaatgaaat	tgatcttttt	cactgtattg	atccaaatga	420
ttccaagcat	aaaagaacgg	acagatcaat	tttatgttgt	ttacgaaaag	gagaatctgg	480
ccagtcattg	ccaagggttaa	caaaagaaa	ggcaaagctt	aattggctta	gtgtcgactt	540
caataattgg	aaagactggg	aagatgattc	agatgaagac	atgtctaatt	ttgatcgttt	600
ctctgagatg	atgaacaaca	tgggtgggtga	tgaggatgta	gatttaccag	aagtagatgg	660
agcagatgat	gattcacaag	acagtgatga	tgaaaaaatg	ccagatctgg	agtaaggaat	720
attgtcatca	cctggatttt	gagaaagaaa	aataacttct	ctgcaagatt	tcataattga	780
ga						782

<210> 14

<211> 75

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequences; note =
synthetic construct

<400> 14

atggaaatct	gcagaggcct	ccgcagtcac	ctaatacttc	tcctcctctt	cctgttccat	60
tcagagacga	tctgc					75

<210> 15

<211> 655

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequences; note =
synthetic construct

<400> 15

cgatgtacgg	gccagatata	cgcggttgaca	ttgattattg	actagttatt	aatagtaatc	60
aattacgggg	tcattagttc	atagcccata	tatggagttc	cgcgttacat	aacttacggg	120
aaatggcccc	cctgggtgac	cgcccaacga	cccccgccca	ttgacgtcaa	taatgacgta	180
tgttcccata	gtaacgccaa	tagggacttt	ccattgacgt	caatgggtgg	actattttacg	240
gtaaaactgcc	cacttggcag	tacatcaagt	gtatcatatg	ccaagtacgc	cccctattga	300
cgtcaatgac	ggtaaatggc	ccgcctggca	ttatgcccag	tacatgacct	tatgggactt	360

tccctacttgg	cagtacatct	acgtattagt	catcgctatt	accatggtga	tgcggttttg	420
gcagtacatc	aatgggcggtg	gatagcggtt	tgactcacgg	ggatttccaa	gtctccaccc	480
cattgacgtc	aatgggagtt	tgttttggca	ccaaaatcaa	cgggactttc	caaaatgtcg	540
taacaactcc	gccccattga	cgcaaattgg	cggtaggcgt	gtacggtggg	aggtctatat	600
aagcagagct	ctctggctaa	ctagagaacc	cactgcttac	tggttatctg	aaatt	655

<210> 16

<211> 1278

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequences; note =
synthetic construct

<400> 16

tgcaggtgag	ccccacgttc	tgcttcactc	tccccatctc	ccccccctcc	ccacccccaa	60
ttttgtatatt	atttattttt	taattatttt	gtgcagcgat	gggggcgggg	gggggggggg	120
cgcgcgccag	gcggggcggg	gcggggcgag	gggcggggcg	gggcgaggcg	gagaggtgcg	180
gcggcagcca	atcagagcgg	cgcgctccga	aagtttcctt	ttatggcgag	gcggcgcgcg	240
cggcgggccct	ataaaaagcg	aagcgcgcg	cggcggggag	tcgctgctgt	gccttcgccc	300
cgtgccccgc	tccgcgccgc	ctcgcgccgc	ccgccccggc	tctgactgac	cgcgttactc	360
ccacaggtga	gcgggcggga	cggcccttct	cctccgggct	gtaattagcg	cttggtttta	420
tgacggctcg	tttcttttct	gtggctgctg	gaaagcctta	aagggctccg	ggagggccct	480
ttgtgcgggg	gggagcggtc	cggggggtgc	gtgcgtgtgt	gtgtgcgtgg	ggagcgccgc	540
gtgcggcccg	cgctgcccg	cggctgtgag	cgctgcgggc	gcggcgcggg	gctttgtgcg	600
ctcccgctgt	gcgcgagggg	agcgcgcccg	ggggcggtgc	cccgcggtgc	gggggggctg	660
cgaggggaac	aaaggctcgc	tgcggggtgt	gtgcgtgggg	gggtgagcag	gggggtgtgg	720
cgcgcggttc	gggctgtaac	ccccccctgc	acccccctcc	ccgagttgct	gcgcacggcc	780
cggcttcggg	tgcggggctc	cgtgcggggc	gtggcgcggg	gctcgccgtg	ccgggcgggg	840
ggtggcgcca	ggtgggggtg	ccgggcgggg	cggggccgcc	tcgggcccgg	gagggctcgg	900
gggagggggc	cggcgccccc	ggagcgcccg	cggctgtcga	ggcgcgccga	gccgcagcca	960
ttgcctttta	tggtaatcgt	gcgagagggc	gcagggactt	cctttgtccc	aaatctggcg	1020
gagccgaaat	ctgggagggc	ccgccgcacc	ccctctagcg	ggcgcgggcg	aagcggtgcg	1080
gcgcgggcag	gaaggaaatg	ggcggggagg	gccttcgtgc	gtcgccgcgc	cgccgtcccc	1140
ttctccatct	ccagcctcgg	ggctgcccga	gggggacggc	tgccctcggg	ggggacgggg	1200
cagggcgggg	ttcggttctt	ggcggtgtac	cggcgggggt	tatatcttcc	cttctctgtt	1260
cctccgcagc	cagccatg					1278

<210> 17

<211> 1176

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequences; note =
synthetic construct

<400> 17

ccggggccca	gcaccccaag	gcggccaacg	ccaaaactct	ccctcctcct	cttcctcaat	60
ctcgctctcg	ctcttttttt	ttttcgcaaa	aggaggggag	agggggtaaa	aaaatgctgc	120
actgtgcggc	gaagccgggtg	agtgcgcggc	gcggggccaa	tcagcggtgc	ccgttccgaa	180
agttgccttt	tatggctcga	gcggcccgcg	cggcgcccta	taaaaccag	cggcgcgacg	240
cgccaccacc	gccgagaccg	cgcccgcccc	gcgagcacag	agcctcgcc	ttgccgatcc	300
gccgcccgtc	cacacccgcc	gccaggtgag	cccggccagc	cgaccggggc	atgcggccgc	360
ggcccccttc	ccggtgcaga	gccgccgtct	ggggccgcag	ggggggcgca	tgggggggga	420
accggaccgc	cgtggggggc	gcgggagaag	cccctggggc	tccggagatg	ggggacaccc	480
cacgccagtt	cggaggcgcg	aggccgcgct	cgggagggcg	gctccggggg	tgccgctctc	540
ggggcggggg	caaccggcgg	ggtctttgtc	tgagccgggc	tcttgccaat	ggggatcgca	600
gggtggggcg	ggcgtagccc	ccgccaggcc	cgggtggggc	tggggcgcca	ttgccggtgc	660
gcgctggtcc	tttgggcgct	aactgcgtgc	gcgctgggaa	ttggcgctaa	ttgcgcgtgc	720

gcgctgggac	tcaaggcgct	aattgcgcgt	gcgttctggg	gcccgggggtg	ccgcggcctg	780
ggctggggcg	aaggcgggct	cggccggaag	gggtggggtc	gccgcggctc	ccgggcgctt	840
gcgcgcaactt	cctgcccag	ccgctggccg	cccaggggtg	tggccgctgc	gtgcgcgcgc	900
gccgaccggg	cgctgtttga	accggggcgga	ggcggggctg	gcgcccgggt	gggaggggggt	960
tggggcctgg	cttcctgccg	cgcgcgcgcg	ggacgcctcc	gaccagtgtt	tgccttttat	1020
ggtaataacg	cggccggccc	ggcttccttt	gtccccaatc	tgggcgcgcg	ccggcgcccc	1080
ctggcgccct	aaggactcgg	cgcgcgcgaa	gtggccaggg	cgggggcgac	ttcggtctac	1140
agcgcgcccc	gctattctcg	cagctcacca	tggatg			1176

<210> 18

<211> 1729

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequences; note =
synthetic construct

<400> 18

gaattcggta	ccctagttat	taatagtaat	caattacggg	gtcattagtt	catagcccat	60
atatggagtt	ccgcgttaca	taacttacgg	taaatggccc	gcctggctga	ccgccaacg	120
acccccgccc	attgacgtca	ataatgacgt	atgttcccat	agtaacgcca	atagggactt	180
tccattgacg	tcaatgggtg	gactattttac	ggtaaacgtc	ccacttggca	gtacatcaag	240
tgtatcatat	gccaaagtacg	ccccctattg	acgtcaatga	cggtaaatgg	ccgcctggc	300
attatgcccc	gtacatgacc	ttatgggact	ttcctacttg	gcagtacatc	tacgtattag	360
tcacgcctat	taccatggtc	gagggtgagcc	ccacgttctg	cttactcttc	cccatctccc	420
ccccctcccc	accccccaatt	ttgtatttat	ttatttttta	attattttgt	gcagcgatgg	480
gggcggggggg	ggggggggggg	cgcgcgcagc	gcggggcggg	gcggggcgag	gggcggggcg	540
gggcgagggcg	gagaggtgcg	gcggcgacca	atcagagcgg	cgcgctccga	aagtttcctt	600
ttatggcgag	gcggcgcgcg	cggcgggcct	ataaaaagcg	aagcgcgcgg	cgggcgggag	660
tcgctgcgac	gctgccttcg	ccccgtgccc	cgctccgcgg	ccgcctcgcg	ccgcccgcgc	720
cggctctgac	tgaccgcggt	actcccacag	gtgagcgggc	gggacggccc	ttctcctccg	780
ggctgtaatt	agcgcttggt	ttaatgacgg	cttggtttctt	ttctgtgggt	gcgtgaaagc	840
cttgagggggc	tccgggaggg	ccctttgtgc	ggggggggagc	ggctcggggg	gtgcgtgcgt	900
gtgtgtgtgc	gtggggagcg	cgcgcgtgcg	cccgcgctgc	ccggcggtcg	tgagcgctgc	960
gggcgcggcg	cggggcctttg	tgcgctccgc	agtgtgcgcg	aggggagcgc	ggccgggggc	1020
gggtccccgc	ggtgcggggg	gggctgcgag	gggaacaaag	gctgcgtgcg	gggtgtgtgc	1080
gtgggggggt	gagcaggggg	tgtgggcgcg	gcggtcgggc	tgtaaccccc	ccctgcaccc	1140
ccctccccga	gttgctgagc	acggcccggc	ttcgggtgcg	gggctccgta	cggggcggtg	1200
cgcggggctc	gccgtgcggg	gcgggggggtg	gcggcgaggtg	ggggtgccgg	gcggggcggg	1260
gcgcctctgg	gccggggagg	gctcggggga	ggggcgcggc	ggcccccgga	gcgcgggcgg	1320
ctgtcgagcg	cggcgagacc	gcagccattg	ccttttatgg	taatcgtgcg	agagggcgca	1380
gggacttcct	ttgtcccaaa	tctgtgcgga	gccgaaatct	gggagggcgc	gccgcacccc	1440
ctctagcggg	cgcggggcga	agcgggtgcg	cgccggcagg	aaggaaatgg	gcggggaggg	1500
ccttcgtgcg	tcgcccgcgc	gccgtcccct	tctccctctc	cagcctcggg	gctgtccgcg	1560
gggggacggc	tgccctcggg	ggggacgggg	cagggcgggg	ttcggttctt	ggcgtgtgac	1620
cggcggtctt	agagcctctg	ctaaccatgt	tcatgccttc	ttctttttcc	tacagtcctt	1680
gggcaacgtg	ctggttattg	tgctgtctca	tcattttggc	aaagaattc		1729

<210> 19

<211> 655

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequences; note =
synthetic construct

<400> 19

cgatgtacgg	gccagatata	cgcgttgaca	ttgattattg	actagttatt	aatagtaatc	60
aattacgggg	tcattagttc	atagcccata	tatggagttc	cgcgttacat	aacttacggt	120

aaatggcccg	cctggctgac	cgcccaacga	ccccgcca	ttgacgtcaa	taatgacgta	180
tggtcccata	gtaacgcaa	tagggacttt	ccattgacgt	caatgggtgg	actatttacg	240
gtaaaactgcc	cacttggcag	tacatcaagt	gtatcatatg	ccaagtacgc	cccctattga	300
cgtcaatgac	ggtaaattggc	ccgcctggca	ttatgccag	tacatgacct	tatgggactt	360
tcctacttgg	cagtacatct	acgtattagt	catcgctatt	accatgggtga	tgcggttttg	420
gcagtacatc	aatgggcgtg	gatagcggtt	tgactcacgg	ggatttccaa	gtctccaccc	480
cattgacgtc	aatgggagtt	tgttttggca	ccaaaatcaa	cgggactttc	caaaatgtcg	540
taacaactcc	gccccattga	cgcaaattggg	cggtaggcgt	gtacgggtggg	aggtctatat	600
aagcagagct	ctctggctaa	ctagagaacc	cactgcttac	tggcttatcg	aaatt	655

<210> 20

<211> 366

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequences; note =
synthetic construct

<400> 20

tagttattaa	tagtaatcaa	ttacggggtc	attagttcat	agcccatata	tggagttccg	60
cgttacataa	cttacggtaa	atggcccgcc	tggtgaccg	cccaacgacc	cccggccatt	120
gacgtcaata	atgacgtatg	ttcccatagt	aacgccata	gggactttcc	attgacgtca	180
atgggtggac	tatttacggt	aaactgccc	cttggcagta	catcaagtgt	atcatatgcc	240
aagtacgcc	cctattgacg	tcaatgacgg	taaatggccc	gcctggcatt	atgccagta	300
catgacctta	tgggactttc	ctacttggca	gtacatctac	gtattagtca	tcgctattac	360
catggt						366

<210> 21

<211> 1295

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequences; note =
synthetic construct

<400> 21

ccaattttgt	atattattat	tttttaatta	ttttgtgcag	cgatgggggc	gggggggggg	60
ggggggcgcg	cgccaggcgg	ggcggggcgg	ggcgaggggc	ggggcggggc	gaggcggaga	120
ggtgcgggcg	cagccaatca	gagcggcgcg	ctccgaaagt	ttccttttat	ggcgaggcgg	180
cggcgggcgg	ggccctataa	aaagcgaagc	gcgcggcggg	cgggagtcgc	tgcgacgctg	240
ccttcgcccc	gtgcgccgct	ccgcgccgcg	ctgcgcgcgc	ccgccccggc	tctgactgac	300
cgcgttactc	ccacagggtga	gcgggcggga	cggcccttct	cctccgggct	gtaattagcg	360
cttggtttaa	tgacggcttg	tttcttttct	gtggctgcgt	gaaagccttg	aggggctccg	420
ggagggccct	ttgtgcgggg	gggagcggct	cgggggggtgc	gtgctgtgtg	gtgtgcgtgg	480
ggagcgccgc	gtgcggcccc	cgtgcgccgg	cggctgtgag	cgtgcggggc	gcggcgcggg	540
gctttgtgcg	ctccgcagtg	tgcgcgaggg	gagcgcggcc	gggggcggtg	ccccgcggtg	600
cggggggggc	tgcgagggga	acaaaggctg	cgtgcggggg	gtgtgcgtgg	gggggtgagc	660
aggggggtgtg	ggcgcgggcg	tcgggctgta	acccccccct	gcacccccct	ccccgagttg	720
ctgagcacgg	cccggcttcg	ggtgcggggc	tccgtacggg	gcgtggcgcg	gggctcgccg	780
tgcggggcgg	ggggtggcgg	cagggtggggg	tgcggggcgg	ggcggggccc	cctcggggccg	840
gggagggctc	gggggagggg	cgcggcgggc	cccggagcgc	cggcggtgtg	cgaggcgcg	900
cgagccgcag	ccattgcctt	ttatggtaat	cgtgcgagag	ggcgagggga	cttcctttgt	960
cccaaactctg	tgcggagccg	aaatctggga	ggcgccgcgc	cacccccctc	agcgggcgcg	1020
gggcgaagcg	gtgcggcgcc	ggcaggaagg	aaatgggcgg	ggagggcctt	cgtgcgtcgc	1080
cgcgcgcgcg	tcccttctct	cctctccagc	ctcggggctg	tccgcggggg	gacggctgcc	1140
tccggggggg	acggggcgag	gcgggggttcg	gcttctggtg	tgtgaccggc	ggctctagag	1200
cctctgctaa	ccatgttcct	gccttcttct	ttttcctaca	gctcctgggc	aacgtgctgg	1260
ttattgtgct	gtctcatcat	tttggcaaa	aatc			1295

<210> 22
 <211> 229
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequences; note =
 synthetic construct

<400> 22
 gtattagtca tgcctattac catgggtgatg cggttttggc agtacatcaa tgggcgtgga 60
 tagcgggtttg actcacgggg atttccaagt ctccacccca ttgacgtcaa tgggagtttg 120
 ttttggcacc aaaatcaacg ggactttcca aaatgtcgta acaactccgc cccattgacg 180
 caaatgggag gtaggcgtgt acggtgggag gtctatataa gcagagctc 229

<210> 23
 <211> 281
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequences; note =
 synthetic construct

<400> 23
 tggcattatg cccagtacat gaccttatgg gactttccta cttggcagta catctacgta 60
 ttagtcatcg ctattacat ggtgatgcgg ttttggcagt acatcaatgg gcgtggatag 120
 cggtttgact caggggatt tccaagtctc caccocattg acgtcaatgg gagtttggtt 180
 tggcaccaaa atcaacggga ctttccaaa tgctgtaaca actccgccc attgacgcaa 240
 atgggcggta ggcgtgtacg gtgggaggtc tatataagca g 281

<210> 24
 <211> 282
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequences; note =
 synthetic construct

<400> 24
 attatgccca gtacatgacc ttatgggact ttcctacttg gcagtacatc tacgtattag 60
 tcatcgctat taccatgggtg atgcggtttt ggcagtacat caatgggcgt ggatagcgg 120
 ttgactcacg gggatttcca agtctccacc ccattgacgt caatgggagt ttgttttggc 180
 accaaaatca acgggacttt ccaaaatgtc gtaacaactc cgccccattg acgcaaatgg 240
 gcggtagggc tgtacggtgg gaggtctata taagcagagc tc 282

<210> 25
 <211> 512
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequences; note =
 synthetic construct

<400> 25
 ttgcgttaca taacttacgg taaatggccc gcctggctga ccgccaacg acccccgccc 60
 attgacgtca ataatgacgt atgttcccat agtaacgcca atagggactt tccattgacg 120
 tcaatgggtg gactatttac ggtaaactgc ccacttgga gtacatcaag tgtatcatat 180
 gccaaagtac cccctattg acgtcaatga cggtaaattg cccgcctggc attatgccca 240

gtacatgacc	ttatgggact	ttcctacttg	gcagtacatc	tacgtattag	tcacgcgtat	300
taccatgggtg	atgcgggtttt	ggcagtagcat	caatgggctg	ggatagcggg	ttgactcacg	360
gggatttcca	agtctccacc	ccattgacgt	caatgggagt	ttgttttggc	acccaaatca	420
acgggacttt	ccaaaatgtc	gtaacaactc	cgccccattg	acgcaaattg	gcggtagggc	480
tgtacggtgg	gaggtctata	taagcagagc	tc			512

<210> 26

<211> 308

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequences; note =
synthetic construct

<400> 26

tcggcgaagc	ctcgcgcggc	cggccaggac	gaggagcgcc	actaggttga	acatccgcac	60
------------	------------	------------	------------	------------	------------	----

gagccgcggg	gccaggtctc	ggacggggctc	tcgagactcg	atctcgtgca	tgtcggcggt	120
ccgcgggtgag	gttatagacc	atctgctagg	cgggtccggg	gagacaggca	cattactggc	180
ctcggcgccc	agcctaggcg	tgtctagagc	tcgaccgcgc	gtccggagcg	ccattcgacc	240
ggcgggtagc	gagaagaacg	ccggagaccg	caggttataa	caacgtcatg	cataaattaa	300
gaatgggc						308

<210> 27

<211> 1848

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequences; note =
synthetic construct

<400> 27

ctgcagtga	taataaaatg	tgtgtttgtc	cgaaatacgc	gtttgagatt	tctgtcccga	60
ctaaattcat	gtcgcgcgat	agtgggtgtt	atcgccgata	gagatggcga	tattggaaaa	120
atcgatat	gaaaatatgg	catattgaaa	atgtcgccga	tgtgagtttc	tgtgtaactg	180
atcgcgcat	ttttccaaaa	gttgattttt	gggcatacgc	gatatctggc	gatacgctta	240
tatcgtttac	gggggatggc	gatagacgcc	tttgggtgact	tgggcgatc	tgtgtgtcgc	300
aaatatcgca	gtttcgatat	aggtgacaga	cgatatgagg	ctatatcgcc	gatagaggcg	360
acatcaagct	ggcacatggc	caatgcatat	cgatctatac	attgaatcaa	tattggccat	420
tagccatatt	attcattggg	tatatagcat	aaatcaatat	tggctattgg	ccattgcata	480
cgttgtatcc	atatcataat	atgtacattt	atattggctc	atgtccaaca	ttaccgccat	540
gttgacattg	attattgact	agttattaat	agtaatcaat	tacgggggtca	ttagttcata	600
gccatatat	ggagttccgc	gttacataac	ttacggtaaa	tggcccgcc	ggctgaccgc	660
ccaacgaccc	ccgcccattg	acgtcaataa	tgacgtatgt	tcccatagta	acgccaatag	720
ggactttcca	ttgacgtcaa	tgggtggagt	atttacggta	aactgcccac	ttggcagtag	780
atcaagtgt	tcatatgcca	agtagcggcc	ctattgacgt	caatgacggg	aaatggcccg	840
cctggcatta	tgcccagtag	atgaccttat	gggactttcc	tacttggcag	tacatctacg	900
tattagtcat	cgctattacc	atggtgatgc	ggttttggca	gtacatcaat	gggcgtggat	960
agcgggttga	ctcacgggga	tttccaagtc	tccaccccat	tgacgtcaat	gggagtttgt	1020
tttggcacca	aaatcaacgg	gactttccaa	aatgtcgtaa	caactccgcc	ccattgacgc	1080
aaatgggcgg	taggcgtgta	cgggtggagg	tctatataag	cagagctcgt	ttagtgaacc	1140
gtcagatcgc	ctggagacgc	catccacgct	gttttgacct	ccatagaaga	caccgggacc	1200
gatccagcct	ccgcggccgg	gaacggtgca	ttggaacgcg	gattccccgt	gccaaagagt	1260
acgtaagtac	cgcctataga	gtctataggc	ccacccctt	ggcttcttat	gcattgctata	1320
ctgttttttg	cttgggggtc	atacaccctt	gcttcctcat	gttatagggt	atgggtatagc	1380
ttagcctata	ggtgtgggtt	attgaccatt	attgaccatt	cccctattgg	tgacgatact	1440
ttccattact	aatccataac	atggctcttt	gcacaactct	ctttattggc	tatatgccaa	1500
tacactgtcc	ttcagagact	gacacggact	ctgtattttt	acaggatggg	gtctcattta	1560
ttattttaca	attcacatat	acaacaccac	cgccccagct	gcccgcagtt	tttattaaac	1620

```

ataacgtggg atctccagcg aatctcgggt acgtgttccg gacatggggc tcttctccgg 1680
tagcggcgga gcttctacat ccagccctgc tcccatcctc ccactcatgg tcctcggcag 1740
ctccttgctc ctaacagtgg aggccagact taggcacagc acgatgcca ccaccaccag 1800
tgtgcccaca aggccgtggc ggtagggtat gtgtctgaaa atgagctc 1848

```

<210> 28
 <211> 49
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequences; note =
 synthetic construct

```

<400> 28
cttctggcgt gtgaccggcg gggtttatat cttcccttcc caagcttgg 49

```

<210> 29
 <211> 66
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequences; note =
 synthetic construct

```

<400> 29
cttctggcgt gtgaccggcg gggtttatat cttcccttct ctgttcctcc gcagcccaa 60
gcttgg 66

```

<210> 30
 <211> 68
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequences; note =
 synthetic construct

```

<400> 30
cttctggcgt gtgaccggcg gggtttatat cttcccttct ctgttcctcc gcagccagcc 60
aagcttgg 68

```

<210> 31
 <211> 69
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequences; note =
 synthetic construct

```

<400> 31
cttctggcgt gtgaccggcg gggtttatat cttcccttct ctgttcctcc gcagccagcc 60
atggatgat 69

```

<210> 32
 <211> 1345
 <212> DNA
 <213> Artificial Sequence

<220>

<223> Description of Artificial Sequences; note =
synthetic construct

<400> 32

tcgaggtgag	ccccacgttc	tgcttcactc	tccccatctc	ccccccctcc	ccacccccaa	60
ttttgtat	ttttat	taattat	gtgcagcgat	gggggcggg	ggggggggg	120
cgcgccag	gcgggcg	gcgggcg	gggcgggg	gggcgagcg	gagaggtgc	180
gcgccagca	atcagagcg	cgcgctccga	aagtctcctt	ttatggcgag	gcgggcgcg	240
cgggcgccct	ataaaaagcg	aagcgcgcg	cgggcgggag	tcgctgcgtt	gccttcgccc	300
cgtgccccgc	tccgcgcgc	ctcgcgccgc	ccgccccggc	tctgactgac	cgcgttactc	360
ccacaggtga	gcgggcg	cgcccttct	cctccgggct	gtaattagcg	cttggtttaa	420
tgacggctcg	tttcttttct	gtggctgcgt	gaaagcctta	aagggtccg	ggagggccct	480
ttgtgcgggg	gggagcggt	cgggggggtgc	gtgcgtgtgt	gtgtgcgtgg	ggagcgccgc	540

gtgcggcccg	cgctgcccgg	cggctgtgag	cgctgcgggc	gcggcgccgg	gctttgtgcg	600
ctcccggtgt	gcgcgagggg	agcgcgcccg	ggggcggtgc	cccgcggtgc	gggggggctg	660
cgaggggaac	aaaggctgcg	tcgggggtgt	gtgcgtgggg	gggtgagcag	ggggtgtggg	720
cgcgccggtc	gggctgtaac	ccccccctgc	acccccctcc	ccgagttgct	gagcacggcc	780
cggcttcggg	tcgggggctc	cgtgcggggc	gtggcgccgg	gctcgccgtg	ccgggcgggg	840
ggtggcgcca	ggtgggggtg	ccgggcgggg	cggggccgccc	tcgggcccgg	gagggctcgg	900
gggaagggcg	cggcgccccc	ggagcgccgg	cggctgtcga	ggcgcgccga	gccgcagcca	960
ttgcctttta	tggtaatcgt	gcgagagggc	gcagggaactt	cctttgtccc	aaatctggcg	1020
gagccgaat	ctgggagggc	ccgcgcacc	ccctctagcg	ggcgcgggcg	aagcgggtgcg	1080
gcgcggcgag	gaaggaaatg	ggcggggagg	gccttcgtgc	gtcgccgcgc	cgccgtcccc	1140
ttctccatct	ccagcctcgg	ggctgccgca	gggggacggc	tgccctcggg	ggggacgggg	1200
cagggcgggg	ttcggttctt	ggcgtgtgac	cggcggtctt	agagcctctg	ctaaccatgt	1260
tcatgccttc	ttctttttcc	tacagctcct	gggcaacgtg	ctgggtgttg	tgctgtctca	1320
tcattttggc	aaagaattca	agctt				1345

<210> 33

<211> 684

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequences; note =
synthetic construct

<400> 33

tcaatattgg	ccattagcca	tattattcat	tggttatata	gcataaatca	atattggcta	60
ttggccattg	catacggtgt	atctatatca	taatatgtac	atztatattg	gctcatgtcc	120
aatatgaccg	ccatggtggc	attgattatt	gactagttat	taatagtaat	caattacggg	180
gtcattagtt	catagcccat	atatggagtt	ccgcgttaca	taacttacgg	taaatggccc	240
gcctggctga	ccgcccacg	acccccgccc	attgacgtca	ataatgacgt	atgttcccat	300
agtaacgcca	atagggaactt	tccattgacg	tcaatgggtg	gagtattttac	ggtaaactgc	360
ccacttgcca	gtacatcaag	tgtatcatat	gccaagtccg	ccccctattg	acgtcaatga	420
cggtaaattg	cccgcctggc	attatgccca	gtacatgacc	ttacgggact	ttcctacttg	480
gcagtacatc	tacgtattag	tcacgctat	taccatgggtg	atgcggtttt	ggcagtagac	540
caatgggcgt	ggatagcggg	ttgactcacg	gggatttcca	agctccacc	ccattgacgt	600
caatggggagt	ttgttttggc	accaaaatca	acgggacttt	ccaaaatgtc	gtaataaacc	660
cgccccgttg	acgcaaatgg	gcgg				684

<210> 34

<211> 2069

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequences; note =
synthetic construct

<400> 34

aattccatac	ctgcttgatc	cacatatgaa	ctacaggggg	acatgatgag	gtccagtcta	60
aaggctcactg	gcaacctctc	tcaagatctc	cctcactatg	ccattattca	ggattgggga	120
agatgtggct	ggagcctaag	gggctcttcc	cttccctatg	gtgggactca	ttaggagaac	180
ctcagcaagc	agtccactgt	aagctcaaac	aaataccatg	tcgctgggat	ggagtaaggc	240
tgttgctatg	acaggaactc	aggggtctta	actggcttga	gcgctgggag	ggggcagcag	300
ccaggccttg	tctgtaagct	gaagacctgg	cagtgtctgag	ctggtcaccc	cccaggacct	360
ccttttgtgc	ccaacgagtg	actcaccttg	ggcatagaca	taatggtcag	gggtgggcac	420
gcagcctgct	tcccgtctgt	ctccaggcct	ccttcgatgc	tttccgagaa	gtctattgag	480
ctgggagctt	gtactgcacc	cggggctgac	atcctggcat	cctgggataa	aagcagccca	540
cggggctgcc	cttgccatat	gcctcactgg	cggcagagaa	caaggctcta	ttcagcaagt	600
gccctggagt	agacaccaga	agcccaagca	tgggcagagg	aaggcagggg	ttggggggag	660
cagagctgtc	tgtgttccag	aagcccaagg	acacagatgg	ctaaggcgcc	tgggagggac	720
ctgagtggaa	gagatagatg	ggcctgaagt	ctcaagcagc	aacagcctcc	tcccgcccat	780
tgggtgaggg	ggggtttggg	ttcccggacc	tacatatccc	tcagaggcct	gggtgttagg	840
aatttaaaag	aggtaaatct	cctgagagaa	tcaggggtac	ccaggaagac	gggtgtttac	900
agaaagactc	cagcatgcac	agccaactca	ctcaaaaacta	ctctgtcagg	ggctgccggg	960
ggccaggctc	gggggtggggg	gtgggggggg	aaagagaagc	tggaccaggg	agaaatggcc	1020
cactaggctg	gatatgaggg	cacagagggg	ctcaggaagg	aagcctgctg	tcttacccta	1080
ttagcatctg	cgtgcatacc	ttctgtctgt	cactctaaac	acacagccag	aggctcaagt	1140
tgaccctgga	gtccacagaga	gggctccaac	cttagccctc	cactcctgaa	ctccaggaat	1200
gagaagatag	agttggagcg	attcagggga	gaggactctg	ttgagaatgg	gggtcacagg	1260
aaactgtaat	ataggttgat	cccggaggaa	gggaataggt	tcttcaagtt	cctagcatct	1320
cacaggcccc	agagaaggac	agagtggggg	ggctcctggc	taacaggctc	taagaactgg	1380
aagctgatta	ccccaccaag	ctgtcactct	ctgtctctgt	ctctgtctct	gtgtgtgcgc	1440
gctcgtgcac	acttatcaca	caaattgtta	tgtgtgtgca	catagatgag	ttgacaccag	1500
aggtcaacct	caggcactgt	tgcttgggtt	ttctgagaga	gcatttctct	ctggacctgg	1560
aactcgccaa	ttagtgagag	ccaggaagtc	tgctgatttt	cactgcccag	cactggagtt	1620
tacaagtatg	cactgtcaac	ccaggccttt	tgtattcatt	ctgcagctag	aacttgggtg	1680
ggctcttcag	cttgacaggc	aagcaattta	tggactaagc	tgtttctctg	gccctctctt	1740
gaccatttta	ccagaaaggg	ggttccttga	tcaatggcga	acgcaggctg	gtgtcccaag	1800
aaagccttga	ctctgggtac	agtgaacctca	gtgggggtgag	aggagttctc	cccttagctg	1860
ggctggggcc	cagctccacc	ccctcaggct	attcaatggg	gggtgcttcca	ggaagtacag	1920
ggcagattta	gtccaacccg	ttcctccata	aaggccctga	catcccagga	gccagcagag	1980
gcagggcagg	atggagcgga	gacgcatcac	ctctgcgcgc	cgctcctatg	cctccgagac	2040
gggtggtcagg	ggcctcggtc	ctagtgcac				2069

<210> 35

<211> 3633

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequences; note =
synthetic construct

<400> 35

tctagaatat	agaagccaag	gatttcaagg	gtttcctttt	ctctcttctt	cttttttttt	60
ctttttcttt	ttcctgagat	ggagtcttct	ttttagccc	tgactgtcct	ggaattcact	120
ctatagacca	ggctagcctc	acacttagtg	atctgcctgc	ctctgcctct	tgggtgcctc	180
aggattcaag	gcatgaacca	ccactaccgc	accagggatt	tcttacacac	ttctgactgg	240
actaaccagg	aaagcagaga	gggagacagg	aagaaaatgc	tcagaaggaa	ggagtaggat	300
tggaggtgag	ctgggggaac	ccagactgag	ccgtgcagaa	gacaagggaag	aagaaagcca	360
cccacacacc	taggatccac	ccacagattt	tgtctgggtt	acccctgtct	ggagactgta	420
gggctttgtg	atggaggggtg	gggtagtctt	catgcccctg	gccctttact	ccagacctaa	480
atgcccaccc	ccacatacag	ctgctcgctc	tctctctccc	ctgcccttct	cccaagagac	540
cagttctcca	ttcctgggtc	gcagccaagg	ctggggggag	aagaactttc	tggaggattt	600
gagttagaaa	agcaagagag	cctcaagtag	ggactgggaac	ctctgggaag	ggagtgcaga	660
ggagacccgg	gtatgtgccc	tacctggtac	atttatacct	gggcagcctc	tgctcctgtt	720
ccagacttca	gagcccagac	gggtcctctc	cctccctcat	gaggggaaac	atttggggaa	780

atttggagag	agacagaact	cagagctcag	cactttcctc	tttctgtttt	tcttcttgag	840
gaatTTTTTc	ccccaaactgc	tgatgacttt	accattcttg	ggggtggggg	ggtggagatt	900
ctggcttttg	ctccccctac	actccaagtg	cgggacaaag	ccctacattc	cacaagaagc	960
cagggtcttc	gagtttcccta	aagatgaggt	ggcgtggcga	gtctcctccc	tctcccagct	1020
ccaactcccc	ctccccagtc	ctccagccct	agcctggcca	gggaggcccc	gccaggctgg	1080
gaggagaccc	caagcacatt	cttctctctg	ctgtcatgct	gcagaaatta	aagacacatc	1140
tctgagctgg	gtaccgcgca	atcgtttcaa	gttgagaagt	ggcagaggag	gtcccagact	1200
tcagctcatg	ccacgtgtaa	aggaagcttg	gaacccactg	cccacaactc	ctggggcaaa	1260
aacctggagt	cagacatggg	gtgaaggctg	tcacacggca	cagacacgtc	aagcaccccc	1320
cccaattctc	gtagtctcct	agcctccacc	agaaccccag	acccttgatg	tggcagtcac	1380
cagtcacac	ctgttaggct	cttgtctctt	cttcagatg	agcctggggg	gcgtgggggt	1440
gctagatcag	gagcaggga	aagtagcttt	ggataagtgc	ttttcccaat	acaaaaccca	1500
acaaagagt	ggcagatcac	actgtgtagt	gcttcgtgga	accctaccct	agacaactgc	1560
cttgaacacc	tattccctct	gatgtacacc	atccccgtcc	actgttaggg	agtgggcac	1620
ctttggaact	gaccactgtg	gaaggcagga	ctttactgag	ttccggaact	accatctcag	1680
cttctcagcc	ccagccttac	cctacaggca	ctggcatagg	cgggggcaga	tcctgggcca	1740
caagtcactg	ccacatgggt	gggataattg	atgaagtcct	gtccttccat	tgctgtctcc	1800
agttctgctt	ctctggaaac	tctatatttt	tccctttaat	tatagcctct	gcagtctccc	1860
tctgccaccc	caccgcgacc	gcttagccta	actggcccag	gccagcgacg	tggtccctc	1920
ccctctgtgt	cccttggctc	tttttatttt	tttctctttg	ccttcgttgc	acaaaactag	1980
ctcaggggag	gcttgaagg	ggggggagca	atggaatctt	ggatgggttg	gaggaggcgg	2040
gactccttgc	ttccacgttt	acagctctga	agacggctgt	gggggaagtg	atacaggacg	2100
tctatgggccc	ctgagaggag	acccctatgc	ttccctgcca	cccacacagt	ttaacaaaat	2160
gaagttccta	agtagagtgg	gggtcaggca	gagcaccttt	gcagggttga	tgggagccca	2220
gggaaagaaa	ggacactgtc	ttttagggac	acattttaa	ataagccact	tttcttgggg	2280
gacgacaaat	gaccctttcc	tgattgcaga	ggtggggaa	aatggctgag	attttcagca	2340
aagaagcgag	gacatgagga	gtagccttca	aataaagtca	ctcagctacc	aaaaacaagt	2400
ttctgaccaca	caccgagtta	cctaggtgtc	cccagaccag	atccaagtac	agtaaggaaa	2460
gcagggttctc	tacagagaga	acacggctct	atggccaatg	ccttctacct	gctctttctg	2520
gattgatact	gctacctaag	agggcctcta	accaattcct	ggctgtagcc	acagctgaca	2580
caagaccttt	ttctaagaca	tccctgggtc	caggcctcct	gtagcaaatt	ccagccctgg	2640
gatggagggtg	gtcaggaaag	agtttatata	agaagaccca	ggccacagct	ttaaggactc	2700
agaaaccccc	ctgcccacac	ggctgcccac	cataacgcag	aaggtttctt	ctggaaggac	2760
aaggatgtca	aacttctccc	caagccta	cctcagagat	gtctccctct	gttacacctg	2820
gggctgggaga	aagggtgggtc	tttcatggag	ccacattcat	ggcagaacag	atagccaccc	2880
cactcctttc	aaacaaccac	atatctgact	cttagtatct	gtgaagagat	gtctaatttg	2940
ttcccaaata	ttcctacctc	gcatacctgg	gcccacacca	tgaggatttc	tcctccctct	3000
aacagtcaca	tctgcttagc	tgcttggttc	ttcggatttg	gagagatgct	tgcttaactt	3060
attcttcctt	aggtcttccc	aaggatgcca	gaaagactat	gagacatggc	caagaggacc	3120
ttttcccaat	tgtgcctgac	actgaaccct	ttgtaatgtt	ccccaaactca	gattcccaat	3180
tctacatcct	tctgatttga	gggtcccagaa	ggaaagtgc	aggggcatcc	cctaccacaa	3240
atcagtatat	cgaggcccag	ccacactcag	tgatagcacc	tctggcccat	gtagatctgg	3300
gggacaagg	tggcagaatt	gcaaaggggg	gagggggctg	ggtggactcc	tttcccttcc	3360
tttccctcct	ccccctctt	cgttccaaat	tggggggcgg	gccaggcagt	tctgattggc	3420
tggggggcgg	gctgctggct	ccccctctcc	aagaggcagg	gttctcccca	gccctcctcc	3480
atcaggatgg	tataaaagg	gcccaggcca	gtcgtcggag	cagacgggag	tttcacctcc	3540
ggacggagca	ggaggcacac	ggagtgaggc	cacgcgatg	ccgaagctaa	ccccccaccc	3600
cagccgcaaa	gagtcctacat	gtctagggtc	tag			3633

<210> 36

<211> 1404

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequences; note =
synthetic construct

<400> 36

tggtgggtggg ggacaactag gaaactctgg cgctttctcc tcccctcaca aaactgagtc

60

cagctggagc	cgccctccaga	ctctctggcc	agggcctcag	agtgggtcaac	agtcctctggc	120
cagcgttgct	ctctccaggc	taagggcacc	cactcccctg	gagattcctg	aacctggggcc	180
aggaagagcc	gaattagaca	agtgtctcca	atccggctgc	gtgcggattt	tgttcgggtg	240
tccctcggtt	gtctgcagtt	ccttttagtcc	cttccctggc	ctgcccctta	cacctccaca	300
caggtcccc	tctgtgtagg	aatacaccag	accctctctt	agccacacac	acctccagtc	360
ccccgtctac	ctagattttt	ttcatagcta	gttggatggg	ggatgggtta	gggaggctgg	420
gtttgcgagc	ctccagggtg	gagttcaccg	acaggctact	cgcaaaggag	ctggaaggca	480
ggtctggaaa	actgtcccc	agatttagga	ttctgggcag	cttccatcag	cttatacttt	540
ggctcccccg	cccctaaact	ccccatcccc	acctcctttc	tcccgttact	tcgtcctccc	600
tcgcctttcc	agcctcgagt	ctaaagctcc	atgcttatgc	ctctgcaaac	aacccccctc	660
cttctaacc	cagcagaact	ccgaggaaag	gggcgcggag	ccctcttctc	gcctgtgggt	720
agagggggca	gtgtggcagt	cccaagtggg	ggcgaccgga	ggcgtctctg	gtgccccgcc	780
cgatcaggcc	actgggcaca	tcggggcgcg	gaagcgggct	caccaaaggg	gcgactggcc	840
ttggcagggt	tgggctctgg	tccgacctgg	gcaggctccg	ggggcggggt	ctcaggttac	900
aacgccacgg	ggggctgggg	gcggcccgcg	gtttgggttg	tttgccagcc	tttggagcga	960
ccgggagcat	ataaccggag	cctctgctgg	gagaagcgca	gggcgcgcgt	gggctgccgg	1020
gtctcctgcc	tcctcctcct	gctccgagag	cctcctgcat	gagggcgagg	tagagaccgc	1080
gaccgcctcc	ggtctctgcc	gcctcgccga	gcttcgcccc	ggccaaggct	ctgcgggcct	1140
cgcggtgagc	catgattcgc	ctcggggctc	cccagtcgct	ggtgctgctg	acgctgctca	1200
tcgccacggg	cctacaatgt	cagggccagg	atgcccgtag	gtcgcccacc	acctctgcct	1260
gcttccttga	cttgcgaccc	ttctcttctt	ccctccgctc	gagttaggcg	ccaagtctta	1320
ggcgcgtagt	gcacaggaga	acactgatcc	taatccta	tctgctagtg	aggagtctctg	1380
tcgcagcatc	ctcagtcaga	gtcg				1404

<210> 37

<211> 12745

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequences; note =
synthetic construct

<400> 37

atgcgggtttt	ggcagtagcat	caatgggcgt	ggatagcggg	ttgactcacg	gggattttcca	60
agtctccacc	ccattgacgt	caatgggagt	ttgttttggc	acaaaaatca	acgggactttt	120
ccaaaatgtc	gtaacaactc	cgccccattg	acgcaaattg	gcggtaggcg	tgtacgggtg	180
gaggtctata	taagcagagc	tctgtgaaac	ttcgaggagt	ctctttgttg	aggacttttg	240
agttctccct	tgaggctccc	acagatacaa	taaatatattg	agattgaacc	ctgtcgagta	300
tctgtgtaat	cttttttacc	tgtgaggtct	cggaaatccg	gccgagaact	tcgcagttgg	360
cgcccgaaca	gggacttgat	tgagagtgat	tgaggaagtg	aagctagagc	aatagaaagc	420
tgtaagcag	aactcctgct	gacctaaata	gggaagcagt	agcagacgct	gctaacagt	480
agtatctcta	gtgaagcgga	ctcgagctca	taatcaagtc	attgtttaaa	ggcccagata	540
aattacatct	ggtgactctt	cgcggacctt	caagccagga	gattcgccga	gggacagtca	600
acaaggtagg	agagattcta	cagcaacatg	gggaatggac	aggggcgaga	ttggaaaatg	660
gccattaaga	gatgtagtaa	tgttgctgta	ggagtagggg	ggaagagtaa	aaaatttgga	720
gaagggaatt	tcagatgggc	cattagaatg	gctaattgat	ctacaggacg	agaacctggt	780
gatataccag	agactttaga	tcaactaagg	ttggttattt	gcgatttaca	agaaagaaga	840
gaaaaatttg	gatctagcaa	agaaattgat	atggcaattg	tgacattaaa	agtctttgctg	900
gtagcaggac	ttttaaatat	gacgggtgtc	tactgctgct	gcagctgaaa	atatgtattc	960
tcaaatggga	ttagacacta	ggccatctat	gaaagaagca	ggtggaaaag	aggaaggccc	1020
tccacaggca	tatcctattc	aaacagtaaa	tggagtacca	caatatgtag	cacttgaccc	1080
aaaaatgggtg	tccattttta	tggaaaaggc	aagagaagga	ctaggagggtg	aggaagttca	1140
actatgggtt	actgccttct	ctgcaaattt	aacacctact	gacatggcca	cattaataat	1200
ggccgcacca	gggtgcgctg	cagataaaga	aatattggat	gaaagcttaa	agcaactgac	1260
agcagaatat	gatcgacac	atccccctga	tgctcccaga	ccattaccct	attttactgc	1320
agcagaaatt	atgggtatag	gattaactca	agaacaacaa	gcagaagcaa	gatttgcacc	1380
agctaggatg	cagtgtagag	catggatatc	cgaggcatta	ggaaaattgg	ctgccataaa	1440
agctaagtct	cctcgagctg	tgcagttaag	acaaggagct	aagggaagatt	attcatcctt	1500
tatagacaga	ttgtttgccc	aaatagatca	agaacaaaat	acagctgaag	taaagttata	1560
tttaaaacag	tcattgagca	tagctaattgc	taatgcagac	tgtaaaaagg	caatgagcca	1620

ccttaagcca	gaaagtaccc	tagaagaaaa	gttgagagct	tgcaagaaa	taggctcacc	1680
aggatataaa	atgcaactct	tggcagaagc	tcttacaaaa	gttcaagtag	tgcaatcaaa	1740
aggatcagga	ccagtgtgtt	ttaattgtaa	aaaaccagga	catctagcaa	gacaatgtag	1800
agaagtgaaa	aaatgtaata	aatgtgga	acctgggtcat	gtagctgcca	aatgttgcca	1860
aggaaataga	aagaattgta	caagggaaga	aagggaataca	acaattacaa	aagtgggaag	1920
attgggtagg	atggatagga	aatattccac	aatatttaaa	gggactattg	ggaggtagct	1980
tgggaatagg	attaggagtg	ttattattga	ttttatgttt	acctacattg	gttgattgta	2040
taagaaattg	tatccacaag	atactaggat	acacagtaat	tgcaatgcct	gaagtagaag	2100
gagaagaaat	acaaccacaa	atggaattga	ggagaaatgg	taggcaatgt	ggcatgtctg	2160
aaaaagagga	ggaatgatga	agtatctcag	acttattttta	taaggagat	actgtgctga	2220
gttcttccct	ttaggaagg	tatgtcatat	gaatccattt	cgaatcaaat	caaactaata	2280
aagtatgtat	tgtaaagtaa	aaggaaaaga	caaagaagaa	gaagaaagaa	gaaagccttc	2340
agtacattta	tattggctca	tgtccaatat	gaccgccatg	ttgacattga	ttattgacta	2400
gttatttaata	gtaaatcaatt	acgggggtcat	tagttcatag	cccatatatg	gagttccgcg	2460
ttacataact	tacggtaatt	ggcccgctg	ctgaccgccc	aacgaccccc	gccattgac	2520
gtcaataatg	acgtatgttc	ccatagtaac	gccaataggg	actttccatt	gacgtcaatg	2580
ggtggagtat	ttacggtaaa	ctgcccactt	ggcagtacat	caagtgtatc	atatgccaa	2640
tccggccccc	tattgacgtc	aatgacggta	aatggcccg	ctggcattat	gccagtaga	2700
tgaccttacg	ggactttggg	acttggcagt	acatctacgt	attagtcac	gctattacca	2760
tggtagtgcg	gttttggcag	tacaccaatg	ggcgtggata	gcggtttgac	tcacggggat	2820
ttccaagtct	ccacccatt	gacgtcaatg	ggagtttgtt	ttggcaccaa	aatcaacggg	2880
actttccaaa	atgtcgtaat	aaccccgccc	cgttgacgca	aatgggcggt	aggcgtgtac	2940
ggtgggaggt	ctatataagc	agagctcggt	tagtgaaccg	tcagatcgcc	tggagacgcc	3000
atccacgctg	ttttgacctc	catagaagac	accgggaccg	atccagcctc	cgcgcccg	3060
aacgggtgcat	tggaaacggg	attccccgtg	ccaagagtga	cgtaagtacc	gcctatagac	3120
tctataggca	cacccctttg	gctcttatgc	atgtctatact	gtttttgggt	tggggcctat	3180
acacccccgc	tctttatgct	ataggtgatg	gtatagctta	gcctataggt	gtgggttatt	3240
gaccattatt	gaccactccc	ctattgggtg	cgatactttc	cattactaat	ccataacatg	3300
gctctttgcc	acaaatatct	ctattggcta	tatgccaaata	ctctgtcctt	cagagactga	3360
caaggactct	gtatttttac	aggatggggg	cccatattat	atttacaat	tcacatatac	3420
aacaacggcg	tccccgtg	ccgcagttt	tattaaacat	agcgtgggat	ctccacgcga	3480
atctcgggta	cgtgttccgg	acatgggctc	ttctccggta	gcggcgagc	ttccacatcc	3540
gagccctggt	cccatgcctc	cagcggctca	tggctcgtcg	gcagctcctt	gctcctaaca	3600
gtggaggcca	gacttaggca	cagcacaatg	cccaccacca	ccagtgtgcc	gcacaaggcc	3660
gtggcggtg	ggtatgtgtc	tgaaaatgag	ctcgagagat	gggctcgac	cgtgacgcag	3720
atggaagact	taaggcagcg	gcagaagaag	atgcaggcag	ctgagttgtt	gtattctgat	3780
aagagtcaga	ggtaactccc	gttgcggttc	tgtaaacggg	ggagggcagt	gtagtctgag	3840
cagtactcgt	tgtgcgcgcg	cgcgccacca	gacataatag	ctgacagact	aacagactgt	3900
tcttttccat	gggtcttttc	tgcagtcacc	gtcgtcgaag	cttatgacca	tgattacgga	3960
ttcactggcc	gtcgttttac	aacgtcgtga	ctgggaaaac	cctggcggtta	cccaacttaa	4020
tcgccttgca	gcacatcccc	ctttcgccag	ctggcgtaat	agcgaagagg	cccgcaccga	4080
tcgcccctcc	caacagttgc	gcagcctgaa	tggcgaaatg	cgctttgcct	ggtttccggc	4140
accagaagcg	gtgcccggaa	gctggctgga	gtgcgatctt	cctgaggccg	atactgtcgt	4200
cgtccctcca	aactggcaga	tgcacgggta	cgatgcgcgc	atctacacca	acgtaacctta	4260
tcccattacg	gtcaatccgc	cgtttgttcc	cacggagaat	ccgacgggtt	gttactcgtc	4320
cacatttaat	gttgatgaaa	gctggctaca	ggaaggccag	acgcgaatta	tttttgatgg	4380
cgttaaactcg	gcgtttcatc	tgtgggtgcaa	cgggcgctgg	gtcggttacg	gccaggacag	4440
tcgtttgcgc	tctgaatttg	acctgagcgc	atttttacgc	gccggagaaa	accgcctcgc	4500
ggtgatggtg	ctgcgttgga	gtgacggcag	ttatctggaa	gatcaggata	tgtggcggat	4560
gagcggcatt	ttccgtgacg	tctcgttgct	gcataaaccg	actacacaaa	tcagcgattt	4620
ccatggtgcc	actcgcttta	atgatgattt	cagccgcgct	gtactggagg	ctgaagttca	4680
gatgtgcggc	gagttgcgtg	actacctacg	ggtaacagtt	tctttatggc	agggtgaaac	4740
gcaggctgcc	agcggcaccg	cgcctttcgg	cggtgaaatt	atcgatgagc	gtgggtggta	4800
tgccgatcgc	gtcacactac	gtctgaacgt	cgaaaaccgc	aaactgtgga	gcgccgaaat	4860
cccgaatctc	tatcgtgcgg	tgggtgaact	gcacaccgcc	gacggcacgc	tgattgaagc	4920
agaagcctgc	gatgtcgggt	tccgcgaggt	gcggattgaa	aatggtctgc	tgctgctgaa	4980
cggcaagccg	ttgctgattc	gaggcggtta	ccgtcacgag	catcatcctc	tgcatggtca	5040
ggctatggat	gagcagcaga	tgggtgcagga	tatcctgctg	atgaagcaga	acaacttta	5100
gcgcgtgcgc	gtttcgcatt	atccgaacca	tcctgctggt	tacacgctgt	gcgaccgcta	5160
cggcctgtat	gtgggtggatg	aagccaatat	tgaaaccac	ggcatgggtgc	caatgaatcg	5220

tctgaccgat	gatccgcgct	ggctaccggc	gatgagcgaa	cgcgtaacgc	gaatgggtgca	5280
gcgcgatcgt	aatcaccgca	gtgtgatcat	ctggtcgctg	gggaatgaat	caggccacgg	5340
cgtaatcac	gacgcgctgt	atcgctggat	caaatctgtc	gatccttccc	gcccggtgca	5400
gtatgaaggc	ggcggagccg	acaccacggc	caccgatatt	atttgcgcca	tgtacgcgcg	5460
cgtggatgaa	gaccagccct	tcccggctgt	gccgaaatgg	tccatcaaaa	aatggctttc	5520
gctacctgga	gagacgcgcc	cgctgatcct	ttgcgaatac	gcccacgcga	tgggtaacag	5580
tcttggcggg	ttcgctaaat	actggcaggc	gtttcgtoag	tatccccgtt	tacagggcgg	5640
cttcgtctgg	gactgggtgg	atcagtcgct	gattaaatat	gatgaaaacg	gcaaccctgt	5700
gtcggcttac	ggcgggtgatt	ttggcgatac	gccgaacgat	cgccagttct	gtatgaacgg	5760
tctggtcttt	gccgaccgca	cgccgcaccc	agcgtgacg	gaagcaaac	accagcagca	5820
gtttttccag	ttccgtttat	cggggcaaac	catcgaagtg	accagcgaat	acctgttccg	5880
tcatagcgat	aacgagctcc	tgcactggat	ggtggcgctg	gatggttaagc	cgctggcaag	5940
cggatgaagt	cctctggatg	tgcctccaca	aggtaaacag	ttgattgaac	tgcctgaact	6000
accgcagccg	gagacgcgcc	ggcaactctg	gctcacagta	cgcgtagtgc	aaccgaacgc	6060
gaccgcctgg	tcagaagccg	ggcacatcag	cgctggcgag	cagtggcgctc	tggcggaaaa	6120
cctcagtggt	acgctccccg	ccgcgtccca	cgccatcccc	catctgacca	ccagcgaaat	6180
ggatttttgc	atcgagctgg	gtaataagcg	ttggcaattt	aaccgccagt	caggctttct	6240
ttcacagatg	tggattggcg	ataaaaaaca	actgctgacg	ccgctgcgcg	atcagttcac	6300
ccgtgcaccg	ctggataaac	acattggcgt	aagtgaagcg	acccgcattg	accctaacgc	6360
ctgggtcgaa	cgctggaagg	cggcgggcca	ttaccaggcc	gaagcagcgt	tgttgagtg	6420
cacggcagat	acacttgctg	atgcggtgct	gattacgacc	gctcacgcgt	ggcagcatca	6480
ggggaaaaac	ttcattatca	gccggaaaaa	ctaccggatt	gatggtagt	gtcaaatggc	6540
gattaccggt	gatgttgaag	tggcgagcga	tacaccgat	ccggcgcgga	ttggcctgaa	6600
ctgccagctg	gcgaggttag	cagagcgggt	aaactggctc	ggattagggc	cgcaagaaaa	6660
ctatcccagc	cgccttactg	ccgcctgttt	tgaccgctgg	gatctgccat	tgtcagacat	6720
gtataccccg	tacgtcttcc	cgagcgaaaa	cggtctgcgc	tgcgggacgc	gcgaattgaa	6780
ttatggccca	caccagtggc	gcggcgactt	ccagttcaac	atcagccgct	acagtcaaca	6840
gcaactgatg	gaaaccagcc	atcgccatct	gctgcacgcg	gaagaaggca	catggctgaa	6900
tatcgacggt	ggattgggtg	cgacgactcc	cgacgactcc	tggagcccg	cagtatcggc	6960
ggaattccag	ctgagcgccg	gtcgctacca	ttaccagtgt	gtctggtgtc	aaaaataact	7020
cgatcgacca	gagctgagat	cctacaggag	tccagggtcg	gagagaaaac	ctctgaagag	7080
gatgatgaca	gagttagaag	atcgcttcag	gaagctatct	ggcagcactt	ctacaacggg	7140
agacagcaca	gtagattctg	aagatgaacc	tccataaaaa	gaaaaaagg	tggactggga	7200
tgagtatttg	aaccttgaag	aaatagaaag	aatgcttatg	gactagggac	tgtttacgaa	7260
caaatgataa	aaggaatatg	ctgagcatga	ctcatagtta	aagcgctagc	agctgcctaa	7320
ccgcaaaacc	acatcctatg	gaaagcttgc	taatgacgta	taagttgttc	cattgtaaga	7380
gtatataacc	agtgtcttgt	gaaacttcga	ggagtctctt	tgttgaggac	ttttgagttc	7440
tcccttgagg	ctccacagaa	tacaataaat	atcttgagatt	gaacctgttc	gagtatctgt	7500
gtaatctttt	ttacctgtga	ggtctcgga	tccggggccga	gaacttcgca	gcggccgctc	7560
gagcatgcat	ctagagggcc	ctattctata	gtgtcaccta	aatgctagag	ctcgctgatc	7620
agcctcgact	gtgcttctta	gttgccagcc	atctgttgtt	tgccccctcc	ccgtgccttc	7680
cttgaccctg	gaaggtgcc	ctccactgt	cctttcctaa	taaaatgagg	aaattgcac	7740
gcattgtctg	agttaggtgc	attctattct	gggggggtgg	gtggggcagg	acagcaagg	7800
ggaggattgg	gaagacaata	gcaggcatgc	tggggatgcg	gtgggctcta	tggcttctga	7860
ggcggaagaa	accagctggg	gctcgagggg	ggatccccac	gcgcccgtga	gcggcgcatt	7920
aagcgcgccg	ggtgtggtgg	ttacgcgcag	cgtgaccgct	acacttgcca	gcgccttagc	7980
gcccgcctct	ttcgctttct	tcccttcctt	tctcgccacg	ttcgccggct	ttccccgtca	8040
agctctaaat	cggggcatcc	ctttagggtt	ccgatttagt	gctttacggc	acctcgaccc	8100
caaaaaactt	gattagggtg	atggttcacg	tagtgggcca	tgcacctgat	agacggtttt	8160
tgcgcccttg	acgttgagg	ccacgttctt	taatagtga	ctcttggtcc	aaactggaac	8220
aacactcaac	cctatctcgg	tctattcttt	tgatttataa	gggattttcg	ggatttccgc	8280
ctattggtta	aaaaatgagc	tgatttaaca	aaaatttaac	gcgaatttta	acaaaatatt	8340
aacgtttaca	atttaaatat	ttgcttatac	aatcttctct	tttttggggc	ttttctgatt	8400
atcaaccggg	gtgggtaccg	agctcgaatt	ctgtggaatg	tgtgtcagtt	aggggtgtgga	8460
aagtccccag	gctccccagg	caggcagaag	tatgcaaagc	atgcatctca	attagtcagc	8520
aaccagggtg	ggaaagtccc	caggctcccc	agcaggcaga	agtatgcaaa	gcatgcatct	8580
caattagtca	gcaaccatag	tcccgcctct	aactccgcct	atcccgcccc	taactccgpc	8640
cagttccgcc	cattctccgc	cccatggctg	actaattttt	tttattttat	cagaggccga	8700
ggcgcctcgc	gctctcagc	tattccagaa	gtagtgagg	ggcttttttg	gaggcctagg	8760
cttttgcaaa	aagctccccg	gagcttggat	atccattttc	ggatctgatc	aagagacagg	8820
atgaggatcg	tttcgcatga	ttgaacaaga	tggattgcac	gcaggttctc	cggccgcttg	8880

ggtggagagg	ctattcggct	atgactgggc	acaacagaca	atcggctgct	ctgatgccgc	8940
cgtgttccgg	ctgtcagcgc	aggggccc	gggtctttt	gtcaagaccg	acctgtccgg	9000
tgcoctgaat	gaactgcagg	acgaggcagc	gcggtatcgc	tggtggcca	cgacgggcgt	9060
tccttgccga	gctgtgctcg	acgttgtcac	tgaagcggga	agggactggc	tgctattggg	9120
cgaagtgcg	gggcaggatc	tcctgtcatc	tcaccttgct	cctgccgaga	aagtatccat	9180
catggctgat	gcaatgcggc	ggctgcatac	gcttgatccg	gctacctgcc	cattcgacca	9240
ccaagcga	catcgcacgc	agcagcacgc	tactcggatg	gaagccggtc	ttgtcgatca	9300
ggatgatctg	gacgaagagc	atcaggggct	cgcgccagcc	gaactgttcg	ccaggctcaa	9360
ggcgcgcag	cccgcaggcg	aggatctcgt	cgtgacccat	ggcgatgcct	gcttgccgaa	9420
tatcatgggt	gaaaatggcc	gcttttctgg	attcatcgac	tgtggccggc	tggtgtggc	9480
ggaccgctat	caggacatag	cgttgggtac	ccgtgatatt	gctgaagagc	ttggcggcga	9540
atgggctgac	cgttccctcg	tgctttacgg	tatcgccgct	cccgattcgc	agcgcacgc	9600
cttctctcgc	cttcttgacg	agttcttctg	agcgggactc	tggtgttcga	aatgaccgac	9660
caagcgagc	ccaacctgcc	atcacgagat	ttcgattcca	ccgccgcctt	ctatgaaagg	9720
ttgggcttcg	gaatcggttt	ccgggacgcc	ggctggatga	tcctccagcg	cggggatctc	9780
atgctggagt	tcctcgccca	ccccaaactg	tttattgcag	cttataatgg	ttacaaataa	9840
agcaatagca	tcacaaattt	cacaaataaa	gcattttttt	cactgcattc	tagttgtggg	9900
ttgtccaaac	tcataaatgt	atccttatcat	gtctggatcc	cgtcgacctc	gagagcttgg	9960
cgtaatcatg	gtcatagctg	tttccgtgtg	gaaattgtta	tcctgtcaca	attccacaca	10020
acatacagc	cggagcagata	aagtgtaaa	cctgggggtgc	ctaagtgtg	agctaaactca	10080
cattaattgc	gttgccgtca	ctgcccgctt	tcagctcgcc	aaacctgtcg	tgccagctgc	10140
attaatgaat	cggcccaacgc	gcggggagag	gcgggttgcg	tattggggcg	tcctccgctt	10200
cctcgctcac	tgactcgctg	cgtcgggtcg	ttcggctgcg	gcgagcggta	tcagctcact	10260
caaaggcgg	aatacgggta	tcacagaat	caggggataa	cgcaggaaag	aacatgtgag	10320
caaaggccca	gcaaaaggcc	aggaaccgta	aaaaggccgc	gttgctggcg	tttttccata	10380
ggctccgccc	ccctgacgag	catcacaaaa	atcgacgctc	aagtcagagg	tggtcgaaacc	10440
cgacaggact	ataaagatac	caggcggttc	cccctggaag	ctccctcgtg	cgctctcctg	10500
ttccgacctc	gcgcgttacc	ggatacctgt	ccgcctttct	cccttcggga	agcgtggcgc	10560
tttctcaatg	ctcacgctgt	aggtatctca	gttcgggtga	ggtcgttcgc	tcgaagctgg	10620
gctgtgtgca	cgaaccccc	gttcagcccc	accgctgcgc	cttatccggg	aactatcgct	10680
ttgagtccaa	cccggtaaga	cacgacttat	cgccactggc	agcagccact	ggtaacagga	10740
ttagcagagc	gaggtatgta	ggcgggtgta	cagagttctt	gaagtgggtg	cctaactacg	10800
gctacactag	aaggacagta	tttgggtatc	gcgctctgct	gaagccagtt	accttcggaa	10860
aaagagttgg	tagctcttga	tcgggcaaac	aaaccaccgc	tggtagcggg	ggtttttttg	10920
tttgcaagca	gcagattacg	cgcagaaaaa	aaggatctca	agaagatcct	ttgatctttt	10980
ctacggggtc	tcacgctcag	tggaacgaaa	actcacgtta	agggattttg	gtcatgagat	11040
tatcaaaaag	gatcttccac	tagatccttt	taaattaaaa	atgaagtttt	aaatcaatct	11100
aaagtatata	tgagtaaact	tggtctgaca	gttaccaatg	cttaatcagt	gaggcaccta	11160
tctcagcgat	ctgtctatatt	cgttcatcca	tagttgcctg	actccccgtc	gtgtagataa	11220
ctacgatacg	ggagggctta	ccatctggcc	ccagtgtctg	aatgataacc	cgagaccac	11280
gctcacccgc	tcagatttta	tcagcaataa	accagccagc	cggaggggcc	gagcgcagaa	11340
tggtcctg	aactttatcc	gcctccatcc	agtctattaa	ttgttgccgg	gaagctagag	11400
taagtatttc	ccaggttaat	agtttgcgca	catttgctaca	ggcatcgtgg	ggcatcgtgg	11460
tgtcacgctc	gtcgtttggg	atggcttcat	tcagctccgg	ttcccaacga	tcaaggcgag	11520
ttacatgatc	ccccatgttg	tgcaaaaaag	cggttagctc	cttcggctct	ccgatcgttg	11580
tcagaagtaa	gttgcccgca	gtgttatcac	tcatgggtat	ggcagcactg	cataattctc	11640
ttactgtcat	gccatccgta	agatgctttt	ctgtgactgg	tgagtactca	accaagtcac	11700
tctgagaata	gtgtatgcgg	cgaccgagtt	gctcttgccc	ggcgtcaata	cgggataata	11760
ccgcgccaca	tagcagaact	ttaaaagtgc	tcacatttgg	aaaacgttct	tcggggcgaa	11820
aactctcaag	gatcttaccg	ctgttgagat	ccagttcgat	gtaaccact	cgtgcacca	11880
actgatcttc	agcatctttt	actttcacca	gcgtttctgg	gtgagcaaaa	acaggaaggc	11940
aaaatgccgc	aaaaaaggga	ataagggcga	cacggaaatg	ttgaatactc	atactcttcc	12000
tttttcaata	ttattgaagc	atttatcagg	gttattgtct	catgagcgga	tacatatttg	12060
aatgtattta	gaaaaataaa	caaatagggg	ttccgcgcac	atttccccga	aaagtgccac	12120
ctgacgtcga	cggatcggga	gatctcccga	tcccctatgg	tcgactctca	gtacaatctg	12180
ctctgatgcc	gcatagttaa	gccagtatct	gctccctgct	tgtgtgttgg	aggctcgctga	12240
gtagtgccgc	agcaaaaatt	aagctacaac	aaggcaaggc	ttgaccgaca	attgcatgaa	12300
gaatctgctt	aggggttaggc	gttttgcgat	gcttcgcgat	gtacgggcca	gatatacgcg	12360
ttgacattga	ttattgacta	gttatttaata	gtaatcaatt	acgggggtcat	tagttcatag	12420
cccataatg	gagttccgcg	ttacataact	tacggtaaat	ggcccgccctg	gctgaccgcc	12480
caacgacccc	cgcccatgga	cgtcaataat	gacgtatgtt	cccatagtaa	cgccaatagg	12540

```

gacttttccat tgacgtcaat ggggtggacta tttacggtaa actgcccact tggcagtaca 12600
tcaagtgtat catatgccaa gtacgcccc tattgacgtc aatgacggta aatggccgc 12660
ctggcattat gcccagtaca tgaccttatg ggactttcct acttggcagt acatctacgt 12720
attagtcacg gctattacca tgggtg 12745

```

<210> 38
 <211> 177
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequences; note =
 synthetic construct

<400> 38

Met	Glu	Ile	Cys	Arg	Gly	Leu	Arg	Ser	His	Leu	Ile	Thr	Leu	Leu	Leu
1			5					10					15		
Phe	Leu	Phe	His	Ser	Glu	Thr	Ile	Cys	Arg	Pro	Ser	Gly	Arg	Lys	Ser
			20					25				30			
Ser	Lys	Met	Gln	Ala	Phe	Arg	Ile	Trp	Asp	Val	Asn	Gln	Lys	Thr	Phe
		35					40					45			
Tyr	Leu	Arg	Asn	Asn	Gln	Leu	Val	Ala	Gly	Tyr	Leu	Gln	Gly	Pro	Asn
	50				55						60				
Val	Asn	Leu	Glu	Glu	Lys	Ile	Asp	Val	Val	Pro	Ile	Glu	Pro	His	Ala
65					70					75				80	
Leu	Phe	Leu	Gly	Ile	His	Gly	Gly	Lys	Met	Cys	Leu	Ser	Cys	Val	Lys
			85					90					95		
Ser	Gly	Asp	Glu	Thr	Arg	Leu	Gln	Leu	Glu	Ala	Val	Asn	Ile	Thr	Asp
			100					105					110		
Leu	Ser	Glu	Asn	Arg	Lys	Gln	Asp	Lys	Arg	Phe	Ala	Phe	Ile	Arg	Ser
		115					120					125			
Asp	Ser	Gly	Pro	Thr	Thr	Ser	Phe	Glu	Ser	Ala	Ala	Cys	Pro	Gly	Trp
		130				135						140			
Phe	Leu	Cys	Thr	Ala	Met	Glu	Ala	Asp	Gln	Pro	Val	Ser	Leu	Thr	Asn
145					150					155					160
Met	Pro	Asp	Glu	Gly	Val	Met	Val	Thr	Lys	Phe	Tyr	Phe	Gln	Glu	Asp
			165					170						175	

Glu

<210> 39
 <211> 569
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequences; note =
 synthetic construct

<400> 39

Met	Lys	Val	Leu	Leu	Arg	Leu	Ile	Cys	Phe	Ile	Ala	Leu	Leu	Ile	Ser
1			5					10					15		
Ser	Leu	Glu	Ala	Asp	Lys	Cys	Lys	Glu	Arg	Glu	Glu	Lys	Ile	Ile	Leu
			20					25				30			
Val	Ser	Ser	Ala	Asn	Glu	Ile	Asp	Val	Arg	Pro	Cys	Pro	Leu	Asn	Pro
		35					40					45			
Asn	Glu	His	Lys	Gly	Thr	Ile	Thr	Trp	Tyr	Lys	Asp	Asp	Ser	Lys	Thr
	50				55						60				
Pro	Val	Ser	Thr	Glu	Gln	Ala	Ser	Arg	Ile	His	Gln	His	Lys	Glu	Lys

65					70					75				80
Leu	Trp	Phe	Val	Pro	Ala	Lys	Val	Glu	Asp	Ser	Gly	His	Tyr	Tyr Cys
				85					90					95
Val	Val	Arg	Asn	Ser	Ser	Tyr	Cys	Leu	Arg	Ile	Lys	Ile	Ser	Ala Lys
			100					105						110
Phe	Val	Glu	Asn	Glu	Pro	Asn	Leu	Cys	Tyr	Asn	Ala	Gln	Ala	Ile Phe
		115					120					125		
Lys	Gln	Lys	Leu	Pro	Val	Ala	Gly	Asp	Gly	Gly	Leu	Val	Cys	Pro Tyr
	130					135					140			
Met	Glu	Phe	Phe	Lys	Asn	Glu	Asn	Asn	Glu	Leu	Pro	Lys	Leu	Gln Trp
145					150					155				160
Tyr	Lys	Asp	Cys	Lys	Pro	Leu	Leu	Leu	Asp	Asn	Ile	His	Phe	Ser Gly
				165					170					175
Val	Lys	Asp	Arg	Leu	Ile	Val	Met	Asn	Val	Ala	Glu	Lys	His	Arg Gly
			180					185					190	
Asn	Tyr	Thr	Cys	His	Ala	Ser	Tyr	Thr	Tyr	Leu	Gly	Lys	Gln	Tyr Pro
		195					200					205		
Ile	Thr	Arg	Val	Ile	Glu	Phe	Ile	Thr	Leu	Glu	Glu	Asn	Lys	Pro Thr
	210					215					220			
Arg	Pro	Val	Ile	Val	Ser	Pro	Ala	Asn	Glu	Thr	Met	Glu	Val	Asp Leu
225					230					235				240
Gly	Ser	Gln	Ile	Gln	Leu	Ile	Cys	Asn	Val	Thr	Gly	Gln	Leu	Ser Asp
				245					250				255	
Ile	Ala	Tyr	Trp	Lys	Trp	Asn	Gly	Ser	Val	Ile	Asp	Glu	Asp	Asp Pro
		260					265					270		
Val	Leu	Gly	Glu	Asp	Tyr	Tyr	Ser	Val	Glu	Asn	Pro	Ala	Asn	Lys Arg
	275						280					285		
Arg	Ser	Thr	Leu	Ile	Thr	Val	Leu	Asn	Ile	Ser	Glu	Ile	Glu	Ser Arg
	290					295					300			
Phe	Tyr	Lys	His	Pro	Phe	Thr	Cys	Phe	Ala	Lys	Asn	Thr	His	Gly Ile
305					310					315				320
Asp	Ala	Ala	Tyr	Ile	Gln	Leu	Ile	Tyr	Pro	Val	Thr	Asn	Phe	Gln Lys
				325					330				335	
His	Met	Ile	Gly	Ile	Cys	Val	Thr	Leu	Thr	Val	Ile	Ile	Val	Cys Ser
	340						345					350		
Val	Phe	Ile	Tyr	Lys	Ile	Phe	Lys	Ile	Asp	Ile	Val	Leu	Trp	Tyr Arg
	355						360					365		
Asp	Ser	Cys	Tyr	Asp	Phe	Leu	Pro	Ile	Lys	Ala	Ser	Asp	Gly	Lys Thr
	370					375				380				
Tyr	Asp	Ala	Tyr	Ile	Leu	Tyr	Pro	Lys	Thr	Val	Gly	Glu	Gly	Ser Thr
385					390					395				400
Ser	Asp	Cys	Asp	Ile	Phe	Val	Phe	Lys	Val	Leu	Pro	Glu	Val	Leu Glu
				405					410				415	
Lys	Gln	Cys	Gly	Tyr	Lys	Leu	Phe	Ile	Tyr	Gly	Arg	Asp	Asp	Tyr Val
			420					425				430		
Gly	Glu	Asp	Ile	Val	Glu	Val	Ile	Asn	Glu	Asn	Val	Lys	Lys	Ser Arg
	435						440					445		
Arg	Leu	Ile	Ile	Ile	Leu	Val	Arg	Glu	Thr	Ser	Gly	Phe	Ser	Trp Leu
	450					455					460			
Gly	Gly	Ser	Ser	Glu	Glu	Gln	Ile	Ala	Met	Tyr	Asn	Ala	Leu	Val Gln
465					470					475				480
Asp	Gly	Ile	Lys	Val	Val	Leu	Leu	Glu	Leu	Glu	Lys	Ile	Gln	Asp Tyr
				485					490				495	
Glu	Lys	Met	Pro	Glu	Ser	Ile	Lys	Phe	Ile	Lys	Gln	Lys	His	Gly Ala
			500					505				510		
Ile	Arg	Trp	Ser	Gly	Asp	Phe	Thr	Gln	Gly	Pro	Gln	Ser	Ala	Lys Thr
	515						520					525		
Arg	Phe	Trp	Lys	Asn	Val	Arg	Tyr	His	Met	Pro	Val	Gln	Arg	Arg Ser
	530					535					540			
Pro	Ser	Ser	Lys	His	Gln	Leu	Leu	Ser	Pro	Ala	Thr	Lys	Glu	Lys Leu
545					550					555				560

Gln Arg Glu Ala His Val Pro Leu Gly
565

<210> 40

<211> 398

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequences; note =
synthetic construct

<400> 40

Met	Leu	Arg	Leu	Tyr	Val	Leu	Val	Met	Gly	Val	Ser	Ala	Phe	Thr	Leu
1				5					10					15	
Gln	Pro	Ala	Ala	His	Thr	Gly	Ala	Ala	Arg	Ser	Cys	Arg	Phe	Arg	Gly
			20				25						30		
Arg	His	Tyr	Lys	Arg	Glu	Phe	Arg	Leu	Glu	Gly	Glu	Pro	Val	Ala	Leu
		35				40					45				
Arg	Cys	Pro	Gln	Val	Pro	Tyr	Trp	Leu	Trp	Ala	Ser	Val	Ser	Pro	Arg
	50					55					60				
Ile	Asn	Leu	Thr	Trp	His	Lys	Asn	Asp	Ser	Ala	Arg	Thr	Val	Pro	Gly
65					70				75					80	
Glu	Glu	Glu	Thr	Arg	Met	Trp	Ala	Gln	Asp	Gly	Ala	Leu	Trp	Leu	Leu
			85					90					95		
Pro	Ala	Leu	Gln	Glu	Asp	Ser	Gly	Thr	Tyr	Val	Cys	Thr	Thr	Arg	Asn
			100				105						110		
Ala	Ser	Tyr	Cys	Asp	Lys	Met	Ser	Ile	Glu	Leu	Arg	Val	Phe	Glu	Asn
		115					120					125			
Thr	Asp	Ala	Phe	Leu	Pro	Phe	Ile	Ser	Tyr	Pro	Gln	Ile	Leu	Thr	Leu
	130					135					140				
Ser	Thr	Ser	Gly	Val	Leu	Val	Cys	Pro	Asp	Leu	Ser	Glu	Phe	Thr	Arg
145				150					155					160	
Asp	Lys	Thr	Asp	Val	Lys	Ile	Gln	Trp	Tyr	Lys	Asp	Ser	Leu	Leu	Leu
			165					170					175		
Asp	Lys	Asp	Asn	Glu	Lys	Phe	Leu	Ser	Val	Arg	Gly	Thr	Thr	His	Leu
		180						185					190		
Leu	Val	His	Asp	Val	Ala	Leu	Glu	Asp	Ala	Gly	Tyr	Tyr	Arg	Cys	Val
	195					200					205				
Leu	Thr	Phe	Ala	His	Glu	Gly	Gln	Gln	Tyr	Asn	Ile	Thr	Arg	Ser	Ile
	210				215						220				
Glu	Leu	Arg	Ile	Lys	Lys	Lys	Glu	Glu	Thr	Ile	Pro	Val	Ile	Ile	
225				230					235				240		
Ser	Pro	Leu	Lys	Thr	Ile	Ser	Ala	Ser	Leu	Gly	Ser	Arg	Leu	Thr	Ile
			245					250					255		
Pro	Cys	Lys	Val	Phe	Leu	Gly	Thr	Gly	Thr	Pro	Leu	Thr	Thr	Met	Leu
		260				265					270				
Trp	Trp	Thr	Ala	Asn	Asp	Thr	His	Ile	Glu	Ser	Ala	Tyr	Pro	Gly	Gly
	275				280						285				
Arg	Val	Thr	Glu	Gly	Pro	Arg	Gln	Glu	Tyr	Ser	Glu	Asn	Asn	Glu	Asn
	290				295						300				
Tyr	Ile	Glu	Val	Pro	Leu	Ile	Phe	Asp	Pro	Val	Thr	Arg	Glu	Asp	Leu
305				310				315					320		
His	Met	Asp	Phe	Lys	Cys	Val	Val	His	Asn	Thr	Leu	Ser	Phe	Gln	Thr
			325					330					335		
Leu	Arg	Thr	Thr	Val	Lys	Glu	Ala	Ser	Ser	Thr	Phe	Ser	Trp	Gly	Ile
		340				345					350				
Val	Leu	Ala	Pro	Leu	Ser	Leu	Ala	Phe	Leu	Val	Leu	Gly	Gly	Ile	Trp
	355					360					365				
Met	His	Arg	Arg	Cys	Lys	His	Arg	Thr	Gly	Lys	Ala	Asp	Gly	Leu	Thr
	370					375					380				

Val Leu Trp Pro His His Gln Asp Phe Gln Ser Tyr Pro Lys
385 390 395

<210> 41
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequences; note =
synthetic construct

<400> 41
ggaagcgaua auuuuaagct t 21

<210> 42
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequences; note =
synthetic construct

<400> 42
ggagaaucg gccagucat t 21

<210> 43
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequences; note =
synthetic construct

<400> 43
ggguugauua uguaccat t 21

<210> 44
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequences; note =
synthetic construct

<400> 44
ggcuucacua agguugaut t 21

<210> 45
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequences; note =
synthetic construct

<400> 45
ggcaguaucc uuaugcaugt t 21

<210> 46
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequences; note =
synthetic construct

<400> 46
gcuuuuacau cucuuagcat t 21

<210> 47
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequences; note =
synthetic construct

<400> 47
gggaagaaac aguuaccagt t 21

<210> 48
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequences; note =
synthetic construct

<400> 48
gggcaccaac auccuguuut t 21

<210> 49
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequences; note =
synthetic construct

<400> 49
ggaugggaaa cuuaaguact t 21

<210> 50
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequences; note =
synthetic construct

<400> 50
ccuacaacuc agcgcaugat t 21

<210> 51
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequences; note =
synthetic construct

<400> 51
gcgcaugacu acaucagcut t 21

<210> 52
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequences; note =
synthetic construct

<400> 52
gcuacgagca guuuuuauut t 21

<210> 53
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequences; note =
synthetic construct

<400> 53
ggauuugacc aguauaagut t 21

<210> 54
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequences; note =
synthetic construct

<400> 54
gggagucugg aacauugugt t 21

<210> 55
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequences; note =
synthetic construct

<400> 55

gguuuuuagu aucagaacut t

21

<210> 56

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequences; note =
synthetic construct

<400> 56

gcacaggauu ugaccaguat t

21

<210> 57

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequences; note =
synthetic construct

<400> 57

gggaaauaag gagcuucut t

21

<210> 58

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequences; note =
synthetic construct

<400> 58

cccuacagua cuaaucaaat t

21

<210> 59

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequences; note =
synthetic construct

<400> 59

ggcuuuugcc aaccccagat t

21

<210> 60

<211> 59

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequences; note =
synthetic construct

<400> 60

gatccgggggt tgattatgta ccatttttcaa gagaaatggg acataatcaa cccttttttg 59

<210> 61

<211> 59

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequences; note =
synthetic construct

<400> 61

gccccaaacta atacatggta aaagttctct ttaccatgta ttagttggga aaaacttaa 59

<210> 62

<211> 59

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequences; note =
synthetic construct

<400> 62

gatccggggct tttgccaacc ccgagttcaa gagactcggg gttggcaaaa gccttttttg 59

<210> 63

<211> 59

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequences; note =
synthetic construct

<400> 63

gcccgaacac gggtggggct caagttctct gagccccaac cgttttcgga aaaacttaa 59

<210> 64

<211> 59

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequences; note =
synthetic construct

<400> 64

gatccgggat gggaaactta agtacttcaa gagagtactt aagtttccca tccttttttg 59

<210> 65

<211> 59

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequences; note =
synthetic construct

<400> 65

gatccgggat gggaaactta agtacttcaa gagagtactt aagtttccca tccttttttg 59

<210> 66
 <211> 59
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequences; note =
 synthetic construct

<400> 66
 gatccgggat ttgaccagta taagtttcaa gagaacttat actgggtcaaa tcctttttg 59

<210> 67
 <211> 59
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequences; note =
 synthetic construct

<400> 67
 gccctaaact ggtcatattc aaagttctct tgaatatgac cagtttagga aaaacttaa 59

<210> 68
 <211> 25
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequences; note =
 synthetic construct

<400> 68
 Met Glu Ile Cys Arg Gly Leu Arg Ser His Leu Ile Thr Leu Leu Leu
 1 5 10 15
 Phe Leu Phe His Ser Glu Thr Ile Cys
 20 25

<210> 69
 <211> 1774
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequences; note =
 synthetic construct

<400> 69
 gggttcaagtg attctgctgc ctcagcctcc caggcgggat tacaggtgcc tgccaccacg 60
 cctggctaatt ttttttgtct ttttagtaaa gatgaggttt caccatgttg ggcaggctgg 120
 tttcaattgc tgacctcaag tgagccaccc cgcctcagcc tccaaaatgc taggattaca 180
 ggcattgagcc accgcaccca gccaaagttg tacatatatt tttgactaca cttcttaact 240
 attcttagga taaattacta gaagtgaata ttcttggttg aagagcttga ggcctttaca 300
 cacacacaca cacacacaca cacacacaca caaataggct ggatcgagtg gctcacacct 360
 gtaatctcag cagtttggga ggctgaggaa ggaggatcac ttgagtccag gaggttgaga 420
 atagcctgaa caacatagca agatcttgtc tctacaaaaa agtttaaaaa aaattagctg 480
 gccatggcag catgtgcctg tagtaccagc tactcggaag gctgaggtag gaggatcgct 540
 tgagcccagg aggtgattga agctgcagtg agctgtgatt acaccactgc actccagcct 600
 gggcaacaga gctagactct gtctctaaaa aaaggcacia aataatattt aaaaagcacc 660

aggatatgcct	gtactttgagt	tgtcttttgtt	gatggctaca	aatgagacag	ctctggctga	720
agggcgggctt	ccattttccat	gggctggagg	aggacatttt	gcaaagtgtg	ttttcaggaa	780
gacacagagt	tttacctcct	acacttgttt	gatctgtatt	aatgtttgct	tattttattta	840
tttaattttt	tttttgagac	agagtctcac	tctgtcacct	gggctggagt	gcagtggcat	900
tattgaggct	cattgcagtc	tcagactcct	gagctcaaac	aatcctcctg	cctcagcctc	960
tggagtagct	aggactacag	gcatgtgcca	ccatgcctgg	ctaatttttt	aaatgtattt	1020
ttttgtagag	tcgggggtctc	cctatgttgc	ccaggctgga	gtgcagtggg	gtgatcctag	1080
ctcactgcag	cctggacctc	gggctcaaga	aattctcaca	cctcagcctg	tccagtagca	1140
ggggctacag	gcgcgcacca	ccatcccagc	taattaaana	tatttttttg	tagagacagg	1200
gtctctctat	gttgcccagg	ctggtttcaa	actcccaggc	tcaagcaatc	ctcctgcctt	1260
gcctcccaaa	tgacatcgga	ttacaggcgt	gagccactga	gcctggcccc	tattaatgtt	1320
tagaacacga	attccaggag	gcaggctaag	tctatttcagc	ttgttcatat	gcttggggcca	1380
acccaagaaa	caagtgggtg	acaaatggca	cctttttgat	agtgggtattg	actttgaaag	1440
tttgggtcag	gagctgggga	ggaaggggtg	gcaggctgtg	ggcagtcctg	ggcggaagac	1500
caggcagggc	tatgtgctca	ctgagcctcc	gccctcttcc	tttgaatctc	tgatagactt	1560
ctgcctccta	cttctccttt	tctgcccttc	tttgccttgg	tggtctcctt	gtgggttcctc	1620
agtgggtcct	gcaaccctgg	ttcactcttc	cagggttctg	ctccttccag	ccatggctct	1680
cagagtcctt	ctgttaacag	gtgcatgggg	gtgggggtgg	ggactctggg	tggggaggag	1740
ggtaactttt	gggtctgtca	taaatagagg	gccc			1774

<210> 70

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequences; note =
synthetic construct

<400> 70

gttccctttc tgccagccct

20

<210> 71

<211> 19

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequences; note =
synthetic construct

<400> 71

gtgccgtgag tttccaga

19

<210> 72

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequences; note =
synthetic construct

<400> 72

cccacttcct tgccctctca

20

<210> 73

<211> 19

<212> DNA

<213> Artificial Sequence

<220>
<223> Description of Artificial Sequences; note =
synthetic construct

<400> 73
actctgttgt gttcccgca 19

<210> 74
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequences; note =
synthetic construct

<400> 74
cctcttctcg cttccctca 19

<210> 75
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequences; note =
synthetic construct

<400> 75
gttcccatca gccacttcgt 20

<210> 76
<211> 44
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequences; note =
synthetic construct

<400> 76
atcctttgat cugaugaguc cgugaggacg aaagttataa gcac 44

<210> 77
<211> 43
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequences; note =
synthetic construct

<400> 77
tctttagaac ugaugaguucc gugaggacga aagacaaatt gca 43

<210> 78
<211> 44
<212> DNA
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequences; note =
synthetic construct

<400> 78

ggccgaagcg cugaugaguc cgugaggacg aaagacagat gccc

44

<210> 79

<211> 44

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequences; note =
synthetic construct

<400> 79

tggatgtcaa cugaugaguc cgugaggacg aaagataact cata

44

<210> 80

<211> 44

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequences; note =
synthetic construct

<400> 80

aggagttcga cugaugaguc cgugaggacg aaagcctcct gggc

44

<210> 81

<211> 44

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequences; note =
synthetic construct

<400> 81

tctccggtgc cugaugaguc cgugaggacg aaagtccgct tttt

44

<210> 82

<211> 24

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequences; note =
synthetic construct

<400> 82

cugaugaguc cgugaggacg aaag

24